SMILES,Label,DrugBank ID,Name,Patent_id,Status,NCT_Number,Conditions,Gender,Age_y,Funder_Type,Study Designs,Locations,CPC,Gender_code_0,Gender_code_1,Gender_code_2,Gender_code_3,Age_code_0,Age_code_1,Age_code_2,Age_code_3,Age_code_4,Age_code_5,Allocation_Type_0,Allocation_Type_1,Allocation_Type_2,Allocation_Type_3,Intervention_Model_0,Intervention_Model_1,Intervention_Model_2,Intervention_Model_3,Intervention_Model_4,Intervention_Model_5,Country_0,Country_1,Country_2,Country_3,Country_4,Country_5,Funder_Type_0,Funder_Type_1,Funder_Type_2,Funder_Type_3,Funder_Type_4,Funder_Type_5,claims_#,Duration,Patent_#,PCT_code_0,PCT_code_1,PCT_code_2,CPC_code_0,CPC_code_1,CPC_code_2,CPC_code_3,CPC_code_4,CPC_code_5,logP,MW,PSA,HBA,HBD,Rings,Polarizability,Refractivity,Bond_#,Bioavailability_0,Bioavailability_1,Bioavailability_2,ECFP4.1,ECFP4.2,ECFP4.3,ECFP4.4,ECFP4.5,ECFP4.6,ECFP4.7,ECFP4.8,ECFP4.9,ECFP4.10,ECFP4.11,ECFP4.12,ECFP4.13,ECFP4.14,ECFP4.15,ECFP4.16,ECFP4.17,ECFP4.18,ECFP4.19,ECFP4.20,ECFP4.21,ECFP4.22,ECFP4.23,ECFP4.24,ECFP4.25,ECFP4.26,ECFP4.27,ECFP4.28,ECFP4.29,ECFP4.30,ECFP4.31,ECFP4.32,ECFP4.33,ECFP4.34,ECFP4.35,ECFP4.36,ECFP4.37,ECFP4.38,ECFP4.39,ECFP4.40,ECFP4.41,ECFP4.42,ECFP4.43,ECFP4.44,ECFP4.45,ECFP4.46,ECFP4.47,ECFP4.48,ECFP4.49,ECFP4.50,ECFP4.51,ECFP4.52,ECFP4.53,ECFP4.54,ECFP4.55,ECFP4.56,ECFP4.57,ECFP4.58,ECFP4.59,ECFP4.60,ECFP4.61,ECFP4.62,ECFP4.63,ECFP4.64,ECFP4.65,ECFP4.66,ECFP4.67,ECFP4.68,ECFP4.69,ECFP4.70,ECFP4.71,ECFP4.72,ECFP4.73,ECFP4.74,ECFP4.75,ECFP4.76,ECFP4.77,ECFP4.78,ECFP4.79,ECFP4.80,ECFP4.81,ECFP4.82,ECFP4.83,ECFP4.84,ECFP4.85,ECFP4.86,ECFP4.87,ECFP4.88,ECFP4.89,ECFP4.90,ECFP4.91,ECFP4.92,ECFP4.93,ECFP4.94,ECFP4.95,ECFP4.96,ECFP4.97,ECFP4.98,ECFP4.99,ECFP4.100,ECFP4.101,ECFP4.102,ECFP4.103,ECFP4.104,ECFP4.105,ECFP4.106,ECFP4.107,ECFP4.108,ECFP4.109,ECFP4.110,ECFP4.111,ECFP4.112,ECFP4.113,ECFP4.114,ECFP4.115,ECFP4.116,ECFP4.117,ECFP4.118,ECFP4.119,ECFP4.120,ECFP4.121,ECFP4.122,ECFP4.123,ECFP4.124,ECFP4.125,ECFP4.126,ECFP4.127,ECFP4.128
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,DB00007,__LEUPROLIDE,5728396,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,13.5033573584673,886.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,1209.3983,429.04,16.0,16.0,6.0,126.8,327.24,32.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Completed,NCT01211327,VERNAL KERATOCONJUNCTIVITIS,All,"5 Years and older   (Child, Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Kabgayi Hospital, Gitarama/Muhanga, Rwanda",A61K38/13,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Unknown status,NCT00797030,DRY EYE SYNDROMES|HIV SEROPOSITIVITY,All,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil",A61K38/13,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Completed,NCT04376970,ADENOVIRAL KERATOCONJUNCTIVITIS,All,"9 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Military Hospital of Tunis, Tunis, Illinois, Tunisia",A61K38/13,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Completed,NCT00383396,PTERYGIA,All,"Child, Adult, Older Adult",Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),"Dr. Schechter, Boynton Beach, Florida, United States",A61K38/13,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Not yet recruiting,NCT04127851,DRY EYE|DRY EYE SYNDROMES,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Taejoon Pharmaceutical Co., Ltd., Seoul, Korea, Republic of",A61K38/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Completed,NCT02554981,DRY EYE,All,18 Years to 55 Years   (Adult),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Andover Eye Associates, Inc, Andover, Massachusetts, United States|Total Eye Care, PA, Memphis, Tennessee, United States",A61K38/13,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Completed,NCT00349583,CATARACT|DRY EYE,All,"50 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,"Ophthalmic Consultants of Long Island, Rockville Centre, New York, United States",A61K38/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Completed,,CATARACT,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/13,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,1,DB00115,__CYANOCOBALAMIN,7229636,Completed,,DIABETIC MACULAR EDEMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/186,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,39.49157066880221,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1355.3652,477.85,18.0,9.0,8.0,138.79,337.48,27.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,1,DB00115,__CYANOCOBALAMIN,7229636,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/186,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,39.49157066880221,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1355.3652,477.85,18.0,9.0,8.0,138.79,337.48,27.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,1,DB00115,__CYANOCOBALAMIN,7229636,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/186,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,39.49157066880221,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1355.3652,477.85,18.0,9.0,8.0,138.79,337.48,27.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0
NCCCC[C@H](N)C(=O)O,1,DB00123,__L-LYSINE,,Completed,NCT02178293,PHARYNGITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.8,146.1876,89.34,4.0,3.0,0.0,15.84,37.81,5.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1
Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C,1,DB00140,__RIBOFLAVIN,3936272,Completed,NCT03245853,"KERATOCONUS|KERATOCONUS, UNSTABLE",All,"14 Years to 40 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Comprehensive EyeCare of Central Ohio, Westerville, Ohio, United States",G01N15/042,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,11.8606131542742,4111.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,376.3639,155.05,9.0,5.0,3.0,37.5,96.27,5.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0
Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C,1,DB00140,__RIBOFLAVIN,3936272,Not yet recruiting,NCT04097730,KERATITIS BACTERIAL,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kaiser Permanente Northern California, Redwood City, California, United States|Francis I. Proctor Foundaiton, San Francisco, California, United States|Aravind Eye Care System, Madurai, Tamil Nadu, India",G01N15/042,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,14.0,11.8606131542742,4111.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,376.3639,155.05,9.0,5.0,3.0,37.5,96.27,5.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0
Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C,1,DB00140,__RIBOFLAVIN,3936272,Completed,NCT01485211,PROGRESSIVE KERATOCONUS|THIN CORNEAS,All,18 Years to 35 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,G01N15/042,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,11.8606131542742,4111.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,376.3639,155.05,9.0,5.0,3.0,37.5,96.27,5.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0
Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C,1,DB00140,__RIBOFLAVIN,3936272,Recruiting,NCT04427956,PROGRESSIVE KERATOCONUS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Skåne University Hospital, Lund, Skåne, Sweden",G01N15/042,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,11.8606131542742,4111.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,376.3639,155.05,9.0,5.0,3.0,37.5,96.27,5.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0
N[C@@H](CS)C(=O)O,1,DB00151,__CYSTEINE,10478453,Not yet recruiting,NCT04226456,"OTOTOXIC HEARING LOSS|OTOTOXIC HEARING LOSS, BILATERAL|OTOTOXICITY|TINNITUS",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,11.0,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.6,121.15799999999999,63.32,3.0,3.0,0.0,11.41,28.22,2.0,0.0,1.0,0.0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,1,DB00158,__FOLIC_ACID,3960757,Unknown status,NCT01921192,NON PROLIFERATIVE DIABETIC RETINOPATHY|PROLIFERATIVE DIABETIC RETINOPATHY,All,"40 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Catania, Cannizzaro Hospital, Catania, Italy",A61K9/1694,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,6253.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.04,441.3975,208.99,12.0,6.0,3.0,42.06,111.01,9.0,1.0,0.0,0.0,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/CO)C(C)(C)CCC1,1,DB00162,__VITAMIN_A,3932634,Completed,NCT03152474,SEPSIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,13.1090987494609,3344.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.38,286.4516,20.23,1.0,1.0,1.0,36.54,97.92,5.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Completed,NCT02031692,BENIGN PAROXYSMAL POSITIONAL VERTIGO,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Seoul National Universtiy Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,1,DB00178,__RAMIPRIL,5403856,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/556,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.92,416.5106,95.94,5.0,2.0,3.0,44.79,111.19,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
CC(N)Cc1ccccc1,1,DB00182,__AMPHETAMINE,6322819,Completed,,ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,24.0,37.22458366701571,874.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.85,135.2062,26.02,1.0,1.0,1.0,16.17,43.71,2.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CN1CCC[C@H]1c1cccnc1,1,DB00184,__NICOTINE,5656255,Completed,NCT00365508,BLADDER CANCER|CERVICAL CANCER|ESOPHAGEAL CANCER|GASTRIC CANCER|HEAD AND NECK CANCER|KIDNEY CANCER|LEUKEMIA|LIVER CANCER|LUNG CANCER|PANCREATIC CANCER|TOBACCO USE DISORDER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Howard University Cancer Center, Washington, District of Columbia, United States|CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States|Medical College of Georgia Cancer Center, Augusta, Georgia, United States|Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Burlington County, Mount Holly, New Jersey, United States|Hematology Oncology Associates of Central New York, PC - Northeast Center, East Syracuse, New York, United States|Don Monti Comprehensive Cancer Center at North Shore University Hospital, Manhasset, New York, United States|Geisinger Cancer Institute at Geisinger Health, Danville, Pennsylvania, United States|Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States|CCOP - Main Line Health, Wynnewood, Pennsylvania, United States|Nashville General Hospital at Meharry, Nashville, Tennessee, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,22.0,34.4319185198874,1931.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.87,162.2316,16.13,2.0,0.0,2.0,18.59,49.66,1.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1
O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O,1,DB00186,__LORAZEPAM,4028466,Completed,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,14.9161173740733,187.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.98,321.158,61.69,3.0,2.0,3.0,30.33,82.7,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O,1,DB00186,__LORAZEPAM,4028466,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,14.9161173740733,187.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.98,321.158,61.69,3.0,2.0,3.0,30.33,82.7,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0
COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00187,__ESMOLOL,6310094,Completed,NCT02062333,"ANESTHESIA; ADVERSE EFFECT|REFLEX, ABNORMAL|TINNITUS, SPONTANEOUS OTO-ACOUSTIC EMISSION",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kayseri Education and Research Hospital, Kayseri, Turkey",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,9.56077126840386,564.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.02,295.374,67.79,4.0,2.0,1.0,33.68,81.05,10.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0
COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00187,__ESMOLOL,6310094,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,9.56077126840386,564.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.02,295.374,67.79,4.0,2.0,1.0,33.68,81.05,10.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O,1,DB00190,__CARBIDOPA,6500867,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,25.0,30.0622189367338,800.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.16,226.2292,115.81,6.0,5.0,1.0,21.81,68.77,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O,1,DB00190,__CARBIDOPA,6500867,Completed,,NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,25.0,30.0622189367338,800.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.16,226.2292,115.81,6.0,5.0,1.0,21.81,68.77,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O,1,DB00190,__CARBIDOPA,6500867,Completed,,STROKE,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,25.0,30.0622189367338,800.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.16,226.2292,115.81,6.0,5.0,1.0,21.81,68.77,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Completed,NCT01267136,TONSILLITIS|PAIN,All,4 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States",A61K9/2081,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Completed,NCT02484859,NASAL POLYPS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Recep Tayyip Erdogan University, Rize, Eastern Blacksea, Turkey",A61K9/2081,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2081,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,1,DB00196,__FLUCONAZOLE,4404216,Completed,NCT00000951,"CANDIDIASIS, ORAL|HIV INFECTIONS",All,"13 Years and older   (Child, Adult, Older Adult)",NIH|Other,Intervention Model: Parallel Assignment|Primary Purpose: Treatment,"Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States|UCLA CARE Ctr, Los Angeles, California, United States|Univ of California / San Diego Treatment Ctr, San Diego, California, United States|San Francisco Gen Hosp, San Francisco, California, United States|Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States|Howard Univ, Washington, District of Columbia, United States|Institute for Clinical Research, Washington, District of Columbia, United States|Univ of Miami School of Medicine, Miami, Florida, United States|Emory Univ, Atlanta, Georgia, United States|Emory Hemo Comp Evaluation Clinic / East TN Comp Hemo Ctr, Atlanta, Georgia, United States|Queens Med Ctr, Honolulu, Hawaii, United States|Univ of Hawaii, Honolulu, Hawaii, United States|Northwestern Univ Med School, Chicago, Illinois, United States|Cook County Hosp, Chicago, Illinois, United States|Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States|Louis A Weiss Memorial Hosp, Chicago, Illinois, United States|Indiana Univ Hosp, Indianapolis, Indiana, United States|Division of Inf Diseases/ Indiana Univ Hosp, Indianapolis, Indiana, United States|Methodist Hosp of Indiana / Life Care Clinic, Indianapolis, Indiana, United States|Univ of Iowa Hosp and Clinic, Iowa City, Iowa, United States|State of MD Div of Corrections / Johns Hopkins Univ Hosp, Baltimore, Maryland, United States|Johns Hopkins Hosp, Baltimore, Maryland, United States|Harvard (Massachusetts Gen Hosp), Boston, Massachusetts, United States|Boston Med Ctr, Boston, Massachusetts, United States|Hennepin County Med Clinic, Minneapolis, Minnesota, United States|Univ of Minnesota, Minneapolis, Minnesota, United States|St Paul Ramsey Med Ctr, St Paul, Minnesota, United States|St Louis Regional Hosp / St Louis Regional Med Ctr, St Louis, Missouri, United States|Univ of Nebraska Med Ctr, Omaha, Nebraska, United States|Albert Einstein College of Medicine, Bronx, New York, United States|SUNY / Erie County Med Ctr at Buffalo, Buffalo, New York, United States|Beth Israel Med Ctr, New York, New York, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Saint Clare's Hosp and Health Ctr, New York, New York, United States|Cornell Univ Med Ctr, New York, New York, United States|Mem Sloan - Kettering Cancer Ctr, New York, New York, United States|St Vincent's Hosp / Mem Sloan-Kettering Cancer Ctr, New York, New York, United States|Mount Sinai Med Ctr, New York, New York, United States|St Mary's Hosp (Univ of Rochester/Infectious Diseases), Rochester, New York, United States|Univ of Rochester Medical Center, Rochester, New York, United States|Univ of North Carolina, Chapel Hill, North Carolina, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Univ of Cincinnati, Cincinnati, Ohio, United States|Univ of Kentucky Lexington, Cincinnati, Ohio, United States|Case Western Reserve Univ, Cleveland, Ohio, United States|MetroHealth Med Ctr, Cleveland, Ohio, United States|Ohio State Univ Hosp Clinic, Columbus, Ohio, United States|Philadelphia Veterans Administration Med Ctr, Philadelphia, Pennsylvania, United States|Univ of Pennsylvania at Philadelphia, Philadelphia, Pennsylvania, United States|Julio Arroyo, West Columbia, South Carolina, United States|Univ of Tennessee / E Tennessee Comprehensive Hemophilia Ctr, Knoxville, Tennessee, United States|Univ of Texas Galveston, Galveston, Texas, United States|Univ of Washington, Seattle, Washington, United States|Univ of Puerto Rico, San Juan, Puerto Rico",C07D249/08,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.0,15.408940635331302,275.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.58,306.2708,81.65,5.0,1.0,3.0,26.52,97.2,5.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0
CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,1,DB00198,__OSELTAMIVIR,5866601,Completed,NCT00593502,INFLUENZA,All,1 Year to 3 Years   (Child),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Turku University Hospital, Turku, Finland",C07D309/28,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,31.0,43.92698002012361,466.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.3,312.4045,90.65,4.0,2.0,1.0,34.65,84.2,8.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00199,__ERYTHROMYCIN,3960757,Unknown status,NCT02354560,FAP-FAMILIAL ADENOMATOUS POLYPOSIS,All,10 Years to 17 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/1694,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,4982.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.37,733.9268,193.91,13.0,5.0,3.0,78.21,186.04,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00199,__ERYTHROMYCIN,3960757,Completed,NCT01478256,BLEPHARITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"George John, M.D., Louisville, Kentucky, United States",A61K9/1694,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,35.0890162015647,4982.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.37,733.9268,193.91,13.0,5.0,3.0,78.21,186.04,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00199,__ERYTHROMYCIN,3960757,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/1694,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,4982.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.37,733.9268,193.91,13.0,5.0,3.0,78.21,186.04,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0
Cn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00201,__CAFFEINE,5972916,Completed,NCT02825199,"VERTIGO|DISEASES, VESTIBULAR|CAFFEINE",All,18 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","Instituto Brasiliense de Otorrinolaringologia (IBORL), Brasilia, Distrito Federal, Brazil",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,2772.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.24,194.1906,58.44,3.0,0.0,2.0,18.95,49.83,0.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
Cn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00201,__CAFFEINE,5972916,Completed,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,2772.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.24,194.1906,58.44,3.0,0.0,2.0,18.95,49.83,0.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
Cn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00201,__CAFFEINE,5972916,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,2772.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.24,194.1906,58.44,3.0,0.0,2.0,18.95,49.83,0.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,1,DB00202,__SUCCINYLCHOLINE,4474752,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/18,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,54.0,16.591716462350302,234.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.5,290.399,52.6,2.0,0.0,0.0,33.15,100.94,11.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Completed,NCT00145483,MENIERE'S DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Pfizer Investigational Site, Bondi Junction, New South Wales, Australia|Pfizer Investigational Site, Brisbane, Queensland, Australia|Pfizer Investigational Site, East Melbourne, Victoria, Australia|Pfizer Investigational Site, Melbourne, Victoria, Australia",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Completed,NCT00251784,BLINDNESS,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Educational/Counseling/Training,,C07D487/04,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Completed,NCT01825408,SINUSITIS,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Otolaryngology-Head and Neck Surgery clinics at UNC Hospitals, Chapel Hill, North Carolina, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Recruiting,NCT03162497,DRY EYE SYNDROMES|MEIBOMIAN GLAND DYSFUNCTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Gerhard Garhofer, Vienna, Austria",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Completed,NCT00803452,BLEPHARITIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kentucky Lions Eye Center, Louisville, Kentucky, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Terminated,NCT00245440,MAXILLARY SINUSITIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Southeastern Researchs Associates,Inc., Taylors, South Carolina, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Completed,NCT00564447,BACTERIAL INFECTIONS|EYE INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,,A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Completed,NCT01202331,TRACHOMA|CHLAMYDIA,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"The Carter Center, Ethiopia, Addis Ababa, Ethiopia",A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Completed,NCT00618449,TRACHOMA|CHLAMYDIA TRACHOMATIS,All,"Child, Adult, Older Adult",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Chlamydia Research Laboratory, San Francisco, California, United States|Programme National de Lutte Contre la Cécité, Niamey, Niger",A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Suspended,NCT03523156,TRACHOMA,All,2 Years to 9 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Amhara, Ethiopia",A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Not yet recruiting,NCT03570814,TRACHOMA|LYMPHATIC FILARIASES,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Withdrawn,NCT01903057,TRACHOMA|LYMPHATIC FILARIASIS,All,"5 Years to 65 Years   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","National Institute of Health, Ministry of Health, Maputo, Mozambique",A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Completed,NCT02307825,CHRONIC RHINOSINUSITIS|HIGH-RISK PATIENT,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Not yet recruiting,NCT03953118,"DRY EYE|NEUROPATHIC EYE PAIN|OCULAR MICROBIOME|DEPRESSION, ANXIETY",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of California San Francisco, San Francisco, California, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Not yet recruiting,NCT04454151,FAMILIAL ADENOMATOUS POLYPOSIS,All,"18 Years to 120 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sourasky medical center (Ichilov), Tel-Aviv, Israel",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Completed,NCT00645112,ACUTE OTITIS MEDIA,All,6 Months to 6 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Columbiana, Alabama, United States|Montgomery, Alabama, United States|Ozark, Alabama, United States|Fresno, California, United States|Fresno, California, United States|Marietta, Georgia, United States|Stone Mountain, Georgia, United States|Dubuque, Iowa, United States|Bardstown, Kentucky, United States|Louisville, Kentucky, United States|Owensboro, Kentucky, United States|Cadillac, Michigan, United States|Kalamazoo, Michigan, United States|Portage, Michigan, United States|Richland, Michigan, United States|Omaha, Nebraska, United States|Columbus, Ohio, United States|Huber Heights, Ohio, United States|Pittsburgh, Pennsylvania, United States|Reading, Pennsylvania, United States|Sellersville, Pennsylvania, United States|Charleston, South Carolina, United States|Kingsport, Tennessee, United States|Lake Jackson, Texas, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|West Jordan, Utah, United States|West Jordan, Utah, United States|Vienna, Virginia, United States|Monroe, Wisconsin, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Completed,NCT01014078,DRY EYE,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Sall Research Medical Center, Inc., Artesia, California, United States|David Wirta, MD, Inc., Newport Beach, California, United States|North Bay Eye Associates, Inc., Petaluma, California, United States|Kentucky Lions Eye Center, Louisville, Kentucky, United States|Tauber Eye Center, Kansas City, Missouri, United States|Ophthalmology Associates, Saint Louis, Missouri, United States|Abrams Eye Center, Cleveland, Ohio, United States|OSU - College of Optometry, Columbus, Ohio, United States|Eye Clinics of South Texas, San Antonio, Texas, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Completed,NCT00347776,TRICHIASIS,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Johns Hopkins University, Baltimore, Maryland, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Completed,NCT01105624,CONTACT LENS DRY EYE,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Ohio State University, College of Optometry, Columbus, Ohio, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
COc1ccnc(CS(=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC,1,DB00213,__PANTOPRAZOLE,4758579,Withdrawn,NCT02123498,EUSTACHIAN TUBE DYSFUNCTION|LARYNGOPHARYNGEAL REFLUX,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"11234 Anderson Street, Loma Linda, California, United States|1895 Orange Tree Lane, Suite 102, Redlands, California, United States",C07D317/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,14.718988069570198,416.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.11,383.37,86.33,6.0,1.0,3.0,35.17,90.05,7.0,0.0,1.0,0.0,1,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,0
COc1ccnc(CS(=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC,1,DB00213,__PANTOPRAZOLE,4758579,Completed,NCT00410592,GASTROESOPHAGEAL REFLUX,All,"18 Years to 69 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Anaheim, California, United States|Research Site, Orange, California, United States|Research Site, San Diego, California, United States|Research Site, Miami, Florida, United States|Research Site, Chicago, Illinois, United States|Research SIte, Chapel Hill, North Carolina, United States|Research Site, Houston, Texas, United States|Research Site, San Juan, Puerto Rico",C07D317/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,14.718988069570198,416.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.11,383.37,86.33,6.0,1.0,3.0,35.17,90.05,7.0,0.0,1.0,0.0,1,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,0
COc1ccnc(CS(=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC,1,DB00213,__PANTOPRAZOLE,4758579,Unknown status,NCT02213887,PSYCHOTIC DISORDERS|GASTROESOPHAGEAL REFLUX,All,"19 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"UBC Hospital - Detwiller Pavilion, Vancouver, British Columbia, Canada",C07D317/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,14.718988069570198,416.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.11,383.37,86.33,6.0,1.0,3.0,35.17,90.05,7.0,0.0,1.0,0.0,1,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,0
COc1ccnc(CS(=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC,1,DB00213,__PANTOPRAZOLE,4758579,Completed,NCT00307944,ACID REFLUX DISEASE|OBSTRUCTIVE SLEEP APNEA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"University Ear, Nose and Throat Specialists, Cincinnati, Ohio, United States",C07D317/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,28.0,14.718988069570198,416.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.11,383.37,86.33,6.0,1.0,3.0,35.17,90.05,7.0,0.0,1.0,0.0,1,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,0
COc1ccnc(CS(=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC,1,DB00213,__PANTOPRAZOLE,4758579,Terminated,NCT00449813,GASTROESOPHAGEAL REFLUX DISEASE|NON-EROSIVE REFLUX DISEASE,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Altana Pharma/Nycomed, BT Oss, Netherlands|Altana Pharma/Nycomed, Den Helder, Netherlands|Altana Pharma/Nycomed, EH Geldrop, Netherlands|Altana Pharma/Nycomed, Basel, Switzerland|Altana Pharma/Nycomed, Basel, Switzerland|Altana Pharma/Nycomed, Biel/Bienne, Switzerland|Altana Pharma/Nycomed, Bülach, Switzerland|Altana Pharma/Nycomed, Locarno, TI., Switzerland|Altana Pharma/Nycomed, Luzern, Switzerland|Altana Pharma/Nycomed, Luzern, Switzerland|Altana Pharma/Nycomed, Reinach BL, Switzerland|Altana Pharma/Nycomed, Sion, Switzerland|Altana Pharma/Nycomed, Thun, Switzerland|Altana Pharma/Nycomed, Winterthur, Switzerland|Altana Pharma/Nycomed, Zürich, Switzerland",C07D317/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,14.718988069570198,416.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.11,383.37,86.33,6.0,1.0,3.0,35.17,90.05,7.0,0.0,1.0,0.0,1,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,0
COc1ccnc(CS(=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC,1,DB00213,__PANTOPRAZOLE,4758579,Completed,NCT00261339,GASTROESOPHAGEAL REFLUX|GERD|GORD,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Altana Pharma/Nycomed, Antrim, United Kingdom|Altana Pharma/Nycomed, Ashford, United Kingdom|Altana Pharma/Nycomed, Aston Clinton, Aylesbury, United Kingdom|Altana Pharma/Nycomed, Atherstone, Warwick, United Kingdom|Altana Pharma/Nycomed, Bangor, Northern Ireland, United Kingdom|Altana Pharma/Nycomed, Barry, Vale of Glamorgan, Cardiff, United Kingdom|Altana Pharma/Nycomed, Barry, United Kingdom|Altana Pharma/Nycomed, Bath, United Kingdom|Altana Pharma/Nycomed, Bath, United Kingdom|Altana Pharma/Nycomed, Belfast, United Kingdom|Altana Pharma/Nycomed, Belfast, United Kingdom|Altana Pharma/Nycomed, Bexhill-on-Sea, Easr Sussex, United Kingdom|Altana Pharma/Nycomed, Blackpool, United Kingdom|Altana Pharma/Nycomed, Bradford on Avon, Wiltshire, United Kingdom|Altana Pharma/Nycomed, Cardiff (Wales), United Kingdom|Altana Pharma/Nycomed, Chesterfield, United Kingdom|Altana Pharma/Nycomed, Chesterfield, United Kingdom|Altana Pharma/Nycomed, Chippenham, Wiltshire, United Kingdom|Altana Pharma/Nycomed, Chippenham, United Kingdom|Altana Pharma/Nycomed, Cookstown, United Kingdom|Altana Pharma/Nycomed, Crawley, West Sussex, United Kingdom|Altana Pharma/Nycomed, Crawley, United Kingdom|Altana Pharma/Nycomed, Downpatrick, Northern Ireland, United Kingdom|Altana Pharma/Nycomed, Dronfield, United Kingdom|Altana Pharma/Nycomed, Ely, United Kingdom|Altana Pharma/Nycomed, Glasgow, United Kingdom|Altana Pharma/Nycomed, Hull, United Kingdom|Altana Pharma/Nycomed, Kent, United Kingdom|Altana Pharma/Nycomed, Keresely End, Coventry, United Kingdom|Altana Pharma/Nycomed, Leigh Lancs, United Kingdom|Altana Pharma/Nycomed, Leigh on Sea, Essex, United Kingdom|Altana Pharma/Nycomed, Lisburn, United Kingdom|Altana Pharma/Nycomed, Middlesex, United Kingdom|Altana Pharma/Nycomed, New Street, Ledbury, United Kingdom|Altana Pharma/Nycomed, Sheffield, United Kingdom|Altana Pharma/Nycomed, Sheffield, United Kingdom|Altana Pharma/Nycomed, Slough, Berks, United Kingdom|Altana Pharma/Nycomed, Somerset, United Kingdom|Altana Pharma/Nycomed, Southdown, Bath, United Kingdom|Altana Pharma/Nycomed, St George's Way, Sunderland, United Kingdom|Altana Pharma/Nycomed, Sunbury on Thames, Middlesex, United Kingdom|Altana Pharma/Nycomed, Trowbridge, Wilts, United Kingdom|Altana Pharma/Nycomed, Trowbridge, United Kingdom|Altana Pharma/Nycomed, Warminster Wiltshire, United Kingdom|Altana Pharma/Nycomed, Watford, United Kingdom",C07D317/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,14.718988069570198,416.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.11,383.37,86.33,6.0,1.0,3.0,35.17,90.05,7.0,0.0,1.0,0.0,1,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,0
CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,1,DB00215,__CITALOPRAM,,Completed,NCT03746691,GASTRO ESOPHAGEAL REFLUX,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.58,324.3919,36.26,3.0,0.0,3.0,35.4,94.02,5.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,1,DB00218,__MOXIFLOXACIN,4990517,Not yet recruiting,NCT04097730,KERATITIS BACTERIAL,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kaiser Permanente Northern California, Redwood City, California, United States|Francis I. Proctor Foundaiton, San Francisco, California, United States|Aravind Eye Care System, Madurai, Tamil Nadu, India",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,14.0,19.220107189059306,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.01,401.4314,82.11,7.0,2.0,5.0,41.24,106.22,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,1,DB00218,__MOXIFLOXACIN,4990517,Terminated,NCT00493038,SINUSITIS|BACTERIAL INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","San Benedetto del Tronto, Ascoli Piceno, Italy|Esine, Brescia, Italy|Lamezia Terme, Catanzaro, Italy|Cesena, Forlì, Italy|Sestri Ponente, Genova, Italy|Monza, Monza-Brianza, Italy|Comiso, Ragusa, Italy|Bari, Italy|Benevento, Italy|Bergamo, Italy|Bologna, Italy|Bolzano, Italy|Caserta, Italy|Catania, Italy|Catania, Italy|Firenze, Italy|Foggia, Italy|Lecce, Italy|Lecco, Italy|Matera, Italy|Milano, Italy|Milano, Italy|Novara, Italy|Pavia, Italy|Perugia, Italy|Pisa, Italy|Roma, Italy|Roma, Italy|Roma, Italy|Siena, Italy|Torino, Italy|Torino, Italy|Treviso, Italy|Udine, Italy",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,19.220107189059306,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.01,401.4314,82.11,7.0,2.0,5.0,41.24,106.22,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,1,DB00218,__MOXIFLOXACIN,4990517,Unknown status,NCT00347828,EYE INFECTION|INFECTION,All,"25 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Prevention,"Ophthalmic Consultants of Boston, Boston, Massachusetts, United States",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,19.220107189059306,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.01,401.4314,82.11,7.0,2.0,5.0,41.24,106.22,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,1,DB00218,__MOXIFLOXACIN,4990517,Completed,NCT00464438,BACTERIAL CONJUNCTIVITIS,All,up to 31 Days   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Sacramento, California, United States|Whitby, Ontario, Canada",C07D401/04,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,19.220107189059306,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.01,401.4314,82.11,7.0,2.0,5.0,41.24,106.22,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,1,DB00218,__MOXIFLOXACIN,4990517,Completed,NCT00407017,CATARACT SURGERY,All,"Child, Adult, Older Adult",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,"The Center for Excellence in Eye Care, Miami, Florida, United States",C07D401/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,19.220107189059306,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.01,401.4314,82.11,7.0,2.0,5.0,41.24,106.22,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,1,DB00218,__MOXIFLOXACIN,4990517,Completed,NCT02515045,CATARACT,All,"50 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Minnesota Eye Consultants, P.A., Bloomington, Minnesota, United States|Associated Eye Care, Stillwater, Minnesota, United States|Ophthalmic Consultants of Long Island, Garden City, New York, United States|Carolina Eyecare Physicians, LLC, Mount Pleasant, South Carolina, United States",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,19.220107189059306,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.01,401.4314,82.11,7.0,2.0,5.0,41.24,106.22,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,1,DB00218,__MOXIFLOXACIN,4990517,Completed,NCT03634852,ENDOPHTHALMITIS POSTOPERATIVE,All,"38 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,19.220107189059306,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.01,401.4314,82.11,7.0,2.0,5.0,41.24,106.22,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,1,DB00218,__MOXIFLOXACIN,4990517,Completed,NCT00564447,BACTERIAL INFECTIONS|EYE INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,,C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,19.220107189059306,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.01,401.4314,82.11,7.0,2.0,5.0,41.24,106.22,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,1,DB00218,__MOXIFLOXACIN,4990517,Completed,NCT04403334,CATARACT SENILE|ENDOPHTHALMITIS|ANTIBIOTIC SIDE EFFECT|SAFETY ISSUES,All,"21 Years to 100 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","Peregrine Eye and Laser Instittute, Makati City, MM, Philippines",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,19.220107189059306,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.01,401.4314,82.11,7.0,2.0,5.0,41.24,106.22,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,1,DB00218,__MOXIFLOXACIN,4990517,Recruiting,NCT03363295,ENDOPHTHALMITIS|MACULA EDEMA|CATARACT,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Hospital das Clínicas da UNICAMP, Campinas, São Paulo, Brazil",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,19.220107189059306,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.01,401.4314,82.11,7.0,2.0,5.0,41.24,106.22,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,1,DB00218,__MOXIFLOXACIN,4990517,Completed,NCT00581542,CONJUNCTIVITIS,All,"1 Year to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"University of Rochester, Rochester, New York, United States",C07D401/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,19.220107189059306,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.01,401.4314,82.11,7.0,2.0,5.0,41.24,106.22,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,1,DB00222,__GLIMEPIRIDE,6150383,Terminated,NCT02985242,"DIABETES MELLITUS, TYPE II",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hannover Medical School, University Eye Hospital and CRC Core Facility Hannover, Hanover, Lower Saxony, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,19.7786402184849,200.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.82,490.62,124.68,5.0,3.0,3.0,53.49,129.8,6.0,0.0,1.0,0.0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,0
O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1,1,DB00252,__PHENYTOIN,3962430,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",A61L2/0023,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,884.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.26,252.268,58.2,2.0,2.0,3.0,25.48,70.18,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Completed,NCT01825408,SINUSITIS,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Otolaryngology-Head and Neck Surgery clinics at UNC Hospitals, Chapel Hill, North Carolina, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,"Active, not recruiting",NCT04167085,EPISTAXIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","100 UCLA Medical Plaza, Los Angeles, California, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Recruiting,NCT03162497,DRY EYE SYNDROMES|MEIBOMIAN GLAND DYSFUNCTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Gerhard Garhofer, Vienna, Austria",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Completed,NCT00803452,BLEPHARITIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kentucky Lions Eye Center, Louisville, Kentucky, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
N[C@@H]1CONC1=O,1,DB00260,__CYCLOSERINE,,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.3,102.0919,64.35,3.0,2.0,1.0,8.87,21.85,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
COCCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00264,__METOPROLOL,9504655,Completed,NCT01458600,GRAVES´ DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Departmenty of Endocrinology, Skane University Hospital, Malmö, Sweden|Department of Endocrinology, Karolinska Hospital, Stockholm, Sweden|Department of Internal Medicine, section of Endocrinology, Sodersjukhuset, Stockholm, Sweden",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,9.92217499332635,777.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.8,267.3639,50.72,4.0,2.0,1.0,31.9,76.7,9.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
COCCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00264,__METOPROLOL,9504655,Completed,NCT02484859,NASAL POLYPS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Recep Tayyip Erdogan University, Rize, Eastern Blacksea, Turkey",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,9.92217499332635,777.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.8,267.3639,50.72,4.0,2.0,1.0,31.9,76.7,9.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
COCCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00264,__METOPROLOL,9504655,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,9.92217499332635,777.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.8,267.3639,50.72,4.0,2.0,1.0,31.9,76.7,9.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,1,DB00273,__TOPIRAMATE,5998380,Recruiting,NCT04404439,"TINNITUS, SUBJECTIVE|TINNITUS",All,"25 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of California, Irvine Medical Center ENT Clinic (Pavilion 2), Orange, California, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,49.8080042711349,138.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.29,339.36199999999997,115.54,8.0,1.0,3.0,32.42,72.3,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0
CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,1,DB00273,__TOPIRAMATE,5998380,Unknown status,NCT00153699,"GLAUCOMA, ANGLE-CLOSURE",All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hong Kong Eye Hospital, Kowloon, Hong Kong|Prince of Wales Hospital, Shatin, Hong Kong",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,49.8080042711349,138.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.29,339.36199999999997,115.54,8.0,1.0,3.0,32.42,72.3,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0
CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,1,DB00273,__TOPIRAMATE,5998380,Completed,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,49.8080042711349,138.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.29,339.36199999999997,115.54,8.0,1.0,3.0,32.42,72.3,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0
Cn1c(=O)c2[nH]cnc2n(C)c1=O,1,DB00277,__THEOPHYLLINE,3935196,Completed,NCT00157937,ASTHMA|ALLERGIC RHINITIS,All,18 Years to 60 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,21.191400234091,1897.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.26,180.16400000000002,69.3,3.0,1.0,2.0,16.86,44.93,0.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Unknown status,NCT02324166,VITREORETINAL SURGERY|ENDOPHTHALMITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant),,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Completed,NCT01990781,"POSTOPERATIVE SORE THROAT, COUGH, HOARSENESS",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","BP Koirala Institute of Health Sciences (BPKIHS), Dharan, Koshi, Nepal",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Completed,NCT01827020,"NOSE DEFORMITIES, ACQUIRED",All,18 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Turgut Ozal Medical Center, Malatya, Turkey",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Unknown status,NCT02952157,SORE THROAT,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention",,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Recruiting,NCT03031808,INTUBATION COMPLICATION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ostfold Hospital Trust, Moss, Grålum, Ostfold, Norway",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Recruiting,NCT03731429,LIDOCAINE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Fernandez, Capital federal, Buenos Aires, Argentina",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Unknown status,NCT01417572,RETINAL DETACHMENT,All,20 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Isfahan University of Medical Sciences, Isfahan, Iran, Islamic Republic of",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Withdrawn,NCT01344252,CATARACT SURGERY ANESTHESIA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospitalitaliano de buenos aires, Caba, Argentina|Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Unknown status,NCT01239498,BLEPHAROPTOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Goldschlager eye institute, Ramat Gan, Israel|Goldschleger institute of ophthalmology, Sheba medical center, Ramat Gan, Israel",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,DB00284,__ACARBOSE,5643874,Unknown status,NCT01175486,DIABETES,All,"30 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Taipei Veterans General Hospital, Taiwan, Taipei, Taiwan",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,35.3190003901517,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.7,645.6080000000002,329.01,19.0,14.0,3.0,60.87,139.02,13.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1
COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1,1,DB00285,__VENLAFAXINE,5916923,Completed,NCT02350985,VESTIBULAR MIGRAINE,All,18 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Haseki Training and Research Hospital, Istanbul, Turkey",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,26.678165876096,374.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.69,277.4018,32.7,3.0,1.0,2.0,32.33,83.02,5.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1cccc(C(F)(F)F)c1,1,DB00287,__TRAVOPROST,5631287,Completed,NCT00966940,GLAUCOMA,All,"21 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,28.9122979937986,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,500.5477,96.22,5.0,3.0,2.0,51.61,127.86,14.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1cccc(C(F)(F)F)c1,1,DB00287,__TRAVOPROST,5631287,Completed,NCT03966560,"GLAUCOMA, OPEN-ANGLE",All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,28.9122979937986,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,500.5477,96.22,5.0,3.0,2.0,51.61,127.86,14.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1cccc(C(F)(F)F)c1,1,DB00287,__TRAVOPROST,5631287,Unknown status,NCT02873806,OPEN-ANGLE GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"S.V. Malayan's Ophtalmology Centre, Yerevan, Armenia",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,28.9122979937986,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,500.5477,96.22,5.0,3.0,2.0,51.61,127.86,14.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1cccc(C(F)(F)F)c1,1,DB00287,__TRAVOPROST,5631287,Completed,NCT00471380,GLAUCOMA|OCULAR HYPERTENSION,All,"40 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"Catania, Catania, Italy",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,28.9122979937986,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,500.5477,96.22,5.0,3.0,2.0,51.61,127.86,14.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1cccc(C(F)(F)F)c1,1,DB00287,__TRAVOPROST,5631287,Completed,NCT01978015,"UVEITIS, ANTERIOR|CYSTOID MACULAR EDEMA",All,"18 Years to 95 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital de Clínicas, UNICAMP, Campinas, São Paulo, Brazil",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,28.9122979937986,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,500.5477,96.22,5.0,3.0,2.0,51.61,127.86,14.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1cccc(C(F)(F)F)c1,1,DB00287,__TRAVOPROST,5631287,Completed,NCT00705757,GLAUCOMA|APPLICATION SITE PIGMENTATION CHANGES,All,"30 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Arlington Eye Physicians, Arlington Heights, Illinois, United States|Summa Health System, Akron, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,28.9122979937986,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,500.5477,96.22,5.0,3.0,2.0,51.61,127.86,14.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1cccc(C(F)(F)F)c1,1,DB00287,__TRAVOPROST,5631287,Completed,NCT00539526,OPEN ANGLE GLAUCOMA|OCULAR HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"San Diego, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,28.9122979937986,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,500.5477,96.22,5.0,3.0,2.0,51.61,127.86,14.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1cccc(C(F)(F)F)c1,1,DB00287,__TRAVOPROST,5631287,Completed,NCT01655758,OCULAR HYPERTENSION,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University Eye Clinic, Parma, Italy",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,28.9122979937986,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,500.5477,96.22,5.0,3.0,2.0,51.61,127.86,14.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1cccc(C(F)(F)F)c1,1,DB00287,__TRAVOPROST,5631287,Completed,NCT01253902,"GLAUCOMA, OPEN-ANGLE|OCULAR HYPERTENSION",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Rogers, Arkansas, United States|Calgary, Alberta, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,28.9122979937986,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,500.5477,96.22,5.0,3.0,2.0,51.61,127.86,14.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1cccc(C(F)(F)F)c1,1,DB00287,__TRAVOPROST,5631287,Completed,NCT00798759,OPEN-ANGLE GLAUCOMA|OCULAR HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,28.9122979937986,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,500.5477,96.22,5.0,3.0,2.0,51.61,127.86,14.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1cccc(C(F)(F)F)c1,1,DB00287,__TRAVOPROST,5631287,Completed,NCT01937299,OCULAR HYPERTENSION|OPEN ANGLE GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,28.9122979937986,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,500.5477,96.22,5.0,3.0,2.0,51.61,127.86,14.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1cccc(C(F)(F)F)c1,1,DB00287,__TRAVOPROST,5631287,Terminated,NCT00758342,INTRAOCULAR PRESSURE,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Alcon Call Center, Fort Worth, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,28.9122979937986,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,500.5477,96.22,5.0,3.0,2.0,51.61,127.86,14.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1cccc(C(F)(F)F)c1,1,DB00287,__TRAVOPROST,5631287,Completed,NCT00372827,PRIMARY OPEN-ANGLE GLAUCOMA|OCULAR HYPERTENSION|PIGMENT DISPERSION GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Mainz Site, Mainz, Germany",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,28.9122979937986,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,500.5477,96.22,5.0,3.0,2.0,51.61,127.86,14.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1cccc(C(F)(F)F)c1,1,DB00287,__TRAVOPROST,5631287,Completed,NCT00762645,ANGLE-CLOSURE GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Alcon Call Center, Fort Worth, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,28.9122979937986,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,500.5477,96.22,5.0,3.0,2.0,51.61,127.86,14.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1cccc(C(F)(F)F)c1,1,DB00287,__TRAVOPROST,5631287,Unknown status,NCT02796560,"GLAUCOMA, PRIMARY OPEN ANGLE|OCULAR HYPERTENSION",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hotel-Dieu de Sherbrooke (CHUS), Sherbrooke, Quebec, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,28.9122979937986,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,500.5477,96.22,5.0,3.0,2.0,51.61,127.86,14.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1cccc(C(F)(F)F)c1,1,DB00287,__TRAVOPROST,5631287,Completed,NCT01464424,GLAUCOMA|OCULAR HYPERTENSION|OPEN-ANGLE GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,28.9122979937986,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,500.5477,96.22,5.0,3.0,2.0,51.61,127.86,14.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1cccc(C(F)(F)F)c1,1,DB00287,__TRAVOPROST,5631287,Completed,NCT01327599,OPEN-ANGLE GLAUCOMA|OCULAR HYPERTENSION|PIGMENT DISPERSION GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,28.9122979937986,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,500.5477,96.22,5.0,3.0,2.0,51.61,127.86,14.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1cccc(C(F)(F)F)c1,1,DB00287,__TRAVOPROST,5631287,Completed,NCT01995136,NORMAL TENSION GLAUCOMA|OCULAR HYPERTENSION,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Alcon Japan, Ltd., Tokyo, Japan",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,28.9122979937986,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,500.5477,96.22,5.0,3.0,2.0,51.61,127.86,14.0,1.0,0.0,0.0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,1
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Completed,NCT01924234,PHARYNGEAL DYSFUNCTION|PHARYNGEAL SWALLOWING,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Örebro University Hospital, Örebro, Sweden",A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Completed,NCT01244126,OTITIS MEDIA,All,6 Months to 6 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Texas Children's Hospital, Houston, Texas, United States",A61K9/5078,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Recruiting,NCT04528173,ANESTHESIA|OPIOID USE|TONSILLITIS|SLEEP DISORDER|SURGERY,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",A61K9/5078,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Not yet recruiting,NCT04292990,PAIN|NASOPHARYNGEAL CARCINOMA|HEAD AND NECK CANCER|RADIATION INDUCED ORAL MUCOSITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Completed,NCT02398474,PATIENTS SCHEDULED FOR ILIAC CREST BONE GRAFT HARVEST DURING UPPER OR LOWER LIMB SURGERY,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CHU de Rennes, Rennes, France",C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Completed,NCT02444533,TONSILLECTOMY|TONSILLITIS|POST-OPERATIVE PAIN,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Recruiting,NCT04549844,STRABISMUS,All,"10 Years to 50 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Faculty of Medicine -Fayoum University, Fayoum, Egypt",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
NC[C@H]1CC[C@H](C(=O)O)CC1,1,DB00302,__TRANEXAMIC_ACID,8273795,Completed,NCT03360045,TRANEXAMIC ACID|EPISTAXIS|NASAL PACKING,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Keçiören Training and Research Hospital, Ankara, Turkey",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12,1,DB00305,__MITOMYCIN,7806265,Completed,NCT00599950,REFRACTIVE DISORDERS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Asociación Para Evitar la Ceguera en Mëxico, Hospital ""Luis Sánchez Bulnes""., Mexico city, Distrito Federal, Mexico",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,50.79365079365071,3420.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.55,334.3272,146.89,7.0,3.0,4.0,32.77,83.27,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0
CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12,1,DB00305,__MITOMYCIN,7806265,Completed,NCT04352660,OPEN ANGLE GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,,A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,50.79365079365071,3420.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.55,334.3272,146.89,7.0,3.0,4.0,32.77,83.27,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0
CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12,1,DB00305,__MITOMYCIN,7806265,Recruiting,NCT03875911,"GLAUCOMA OPEN-ANGLE PRIMARY|GLAUCOMA|OPEN ANGLE GLAUCOMA|GLAUCOMA, OPEN-ANGLE",All,"20 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Doheny Eye Center UCLA (Arcadia), Arcadia, California, United States|Doheny Eye Center UCLA (Fountain Valley), Fountain Valley, California, United States|Stein Eye Institute - UCLA (Westwood), Los Angeles, California, United States|Doheny Eye Center UCLA (Pasadena), Pasadena, California, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,50.79365079365071,3420.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.55,334.3272,146.89,7.0,3.0,4.0,32.77,83.27,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0
CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12,1,DB00305,__MITOMYCIN,7806265,Recruiting,NCT03242317,PRESBYOPIA,All,"41 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Fichte Endl & Elmer Eyecare, Amherst, New York, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,50.79365079365071,3420.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.55,334.3272,146.89,7.0,3.0,4.0,32.77,83.27,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0
CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12,1,DB00305,__MITOMYCIN,7806265,Unknown status,NCT02641132,PTERYGIUM,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Meir medical centre, Kfar saba, Israel|Sackler school of medicine, Tel aviv, Israel",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,50.79365079365071,3420.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.55,334.3272,146.89,7.0,3.0,4.0,32.77,83.27,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0
CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12,1,DB00305,__MITOMYCIN,7806265,Completed,NCT01440751,GLAUCOMA,All,"30 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"VoldVision-Holf Eye Clinic, Rogers, Arkansas, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Institue of Ophthalmology and Visual Science, Newark, New Jersey, United States|Glaucoma Associates of New York, New York, New York, United States|New York Eye and Ear Infirmary, New York, New York, United States|Dean McGee Eye Institue, Oklahoma City, Oklahoma, United States|Wills Eye Institue, Philadelphia, Pennsylvania, United States|Glaucoma Associates of Texas, Dallas, Texas, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,50.79365079365071,3420.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.55,334.3272,146.89,7.0,3.0,4.0,32.77,83.27,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0
CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12,1,DB00305,__MITOMYCIN,7806265,Completed,NCT00564213,HIGH MYOPIA,All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,50.79365079365071,3420.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.55,334.3272,146.89,7.0,3.0,4.0,32.77,83.27,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT00377403,ACUTE RESPIRATORY INFECTIONS|ACUTE RHINOSINUSITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Washington University in St. Louis, St. Louis, Missouri, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Recruiting,NCT03783702,SINUSITIS|OPIOID USE|OPIOID ABUSE|NARCOTIC USE|OTOLARYNGOLOGIC DISEASE|POSTOPERATIVE PAIN|PAIN,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford Health Care, Stanford, California, United States|NorthShore University Health System, Evanston, Illinois, United States|Mayo Clinic, Rochester, Minnesota, United States|Albert Einstein, Bronx, New York, United States|Vanderbilt, Nashville, Tennessee, United States|University of British Columbia, Vancouver, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Recruiting,NCT03323047,TONSILLITIS,All,3 Years to 13 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,"Children's Hospital, London, Ontario, Canada",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT01267136,TONSILLITIS|PAIN,All,4 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT01721486,TONSILLITIS|AIRWAY OBSTRUCTION|DIFFICULTY SWALLOWING,All,5 Years to 13 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Beaumont Health System, Royal Oak, Michigan, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314,1,DB00318,__CODEINE,6383471,Completed,NCT03784105,ESOPHAGEAL MOTILITY DISORDERS,All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","Jan Tack, Leuven, Belgium|UZ Leuven, Leuven, Belgium",A61K47/02,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,114.0,37.0274543625125,1579.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.2,299.3642,41.93,4.0,1.0,5.0,31.95,84.6,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314,1,DB00318,__CODEINE,6383471,Completed,NCT01267136,TONSILLITIS|PAIN,All,4 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States",A61K47/02,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,114.0,37.0274543625125,1579.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.2,299.3642,41.93,4.0,1.0,5.0,31.95,84.6,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00324,__FLUOROMETHOLONE,3962414,Unknown status,NCT02974387,MUST BE PRK CANDIDATE,All,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,,A61F9/0017,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,1087.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.34,376.4617,74.6,4.0,2.0,4.0,40.05,100.87,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,1
CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00324,__FLUOROMETHOLONE,3962414,Completed,NCT02816905,INTRAOCULAR PRESSURE,All,up to 13 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Cairo University Hospitals, Cairo, Egypt",A61F9/0017,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,1087.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.34,376.4617,74.6,4.0,2.0,4.0,40.05,100.87,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,1
CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00324,__FLUOROMETHOLONE,3962414,Not yet recruiting,NCT04149210,TRACHOMATOUS TRICHIASIS (TT)|EYE DISEASES|EYELID DISEASES|TRACHOMATOUS|TRICHIASIS,All,"15 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,A61F9/0017,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,1087.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.34,376.4617,74.6,4.0,2.0,4.0,40.05,100.87,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,1
CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00324,__FLUOROMETHOLONE,3962414,Recruiting,NCT03747614,DRY EYE SYNDROMES|INFLAMMATION|MICROVESSELS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Wan Chen, Guangzhou, Guangdong, China",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,1087.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.34,376.4617,74.6,4.0,2.0,4.0,40.05,100.87,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,1
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,1,DB00327,__HYDROMORPHONE,5968551,Active Not Recruiting,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,52.0,50.7607959095669,1264.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.69,285.3377,49.77,4.0,1.0,5.0,30.02,78.26,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0
COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,1,DB00328,__INDOMETHACIN,8734847,Completed,NCT00904904,CATARACT|INFLAMMATION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,"Bausch & Lomb, Berlin, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,14.981827142241096,3062.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.25,357.788,68.53,4.0,1.0,3.0,36.64,94.81,4.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,1,DB00328,__INDOMETHACIN,8734847,Completed,NCT03261635,MACULAR EDEMA,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,14.981827142241096,3062.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.25,357.788,68.53,4.0,1.0,3.0,36.64,94.81,4.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,1,DB00328,__INDOMETHACIN,8734847,Completed,,CATARACT,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,14.981827142241096,3062.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.25,357.788,68.53,4.0,1.0,3.0,36.64,94.81,4.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Active Not Recruiting,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Active Not Recruiting,,TYPE 1 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Active Not Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",F04B53/125,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,1,DB00333,__METHADONE,3947592,Active Not Recruiting,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,46.2596767900778,1074.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,309.4452,20.31,2.0,0.0,2.0,36.28,97.27,7.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0
CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,1,DB00333,__METHADONE,3947592,Active Not Recruiting,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,46.2596767900778,1074.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,309.4452,20.31,2.0,0.0,2.0,36.28,97.27,7.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0
CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,1,DB00333,__METHADONE,3947592,Completed,,CANCER OF HEAD AND NECK,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,46.2596767900778,1074.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,309.4452,20.31,2.0,0.0,2.0,36.28,97.27,7.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,1,DB00334,__OLANZAPINE,5229382,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D495/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,13.9304708515575,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.61,312.432,30.87,4.0,1.0,4.0,35.37,93.87,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,1,DB00334,__OLANZAPINE,5229382,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D495/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,13.9304708515575,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.61,312.432,30.87,4.0,1.0,4.0,35.37,93.87,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Withdrawn,NCT02123498,EUSTACHIAN TUBE DYSFUNCTION|LARYNGOPHARYNGEAL REFLUX,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"11234 Anderson Street, Loma Linda, California, United States|1895 Orange Tree Lane, Suite 102, Redlands, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Withdrawn,NCT02530879,LARYNGOPHARYNGEAL REFLUX,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Temple Otolaryngology, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Completed,NCT03086070,LARYNGOPHARYNGEAL REFLUX|CHRONIC RHINOSINUSITIS (DIAGNOSIS),All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Recruiting,NCT04028466,GERD|GASTRO ESOPHAGEAL REFLUX,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","St. Luke's Medical Center, Quezon City, National Capital Region, Philippines",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Completed,NCT02685436,GASTROESOPHAGEAL REFLUX,All,6 Months to 2 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,,4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Completed,NCT02505945,GERD GASTROESOPHAGEAL REFLUX DISEASE,All,"21 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of South Alabama, Mobile, Alabama, United States|Bapist Health, Heber Springs, Arkansas, United States|University of Southern California, Los Angeles, California, United States|UCSD, San Diego, California, United States|SurgOne Foregut Institute, Englewood, Colorado, United States|Albany Surgical PC, Albany, Georgia, United States|Esophageal Institute of Atlanta, PC., Atlanta, Georgia, United States|St. Elizabeth Healthcare, Edgewood, Kentucky, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Cuyuna Regional Medical Center, Crosby, Minnesota, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Adirondack Surgical Group, LLC, Saranac Lake, New York, United States|University Hospitals Cleveland Medical Center - Geauga, Cleveland, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|The Oregon Clinic, Portland, Oregon, United States|Albert Einstein Healthcare Network, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Scott and White Memorial Hospital, Round Rock, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Gundersen Lutheran, La Crosse, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Unknown status,NCT02140073,GERD,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Gastroenterology and Nutrition Department. Byelorussian Medical Academy Postgraduate Education, Minsk, Belarus|Mother and Child National Reaserch Centre, Minsk, Belarus",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Terminated,NCT01777854,LARYNGOPHARYNGEAL REFLUX|THROAT PAIN,All,7 Years to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Genesys Regional Medical Center, Grand Blanc, Michigan, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Completed,NCT00492622,GASTROPARESIS|GASTROESOPHAGEAL REFLUX DISEASE,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Digestive Health Center, University of Louisville Hospital, Louisville, Kentucky, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,NCT02932774,"ALLERGIC RHINITIS|HAY FEVER|SAR|RHINITIS, ALLERGIC, SEASONAL",All,6 Years to 11 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,NCT00561717,SEASONAL ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Kingston, Ontario, Canada",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Recruiting,NCT03340740,ALLERGIC RHINITIS|ASTHMA,All,"6 Years to 20 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Jacobi Medical Center, Bronx, New York, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,NCT02543346,ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","Biogenics Research Chamber, San Antonio, Texas, United States|Kingston General Hospital, Kingston, Ontario, Canada",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,NCT01916226,"RHINITIS, ALLERGIC, SEASONAL",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Aventura, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Lenexa, Kansas, United States|GSK Investigational Site, Overland Park, Kansas, United States|GSK Investigational Site, Owensboro, Kentucky, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, North Dartmouth, Massachusetts, United States|GSK Investigational Site, Ypsilanti, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Columbia, Missouri, United States|GSK Investigational Site, Rolla, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Bellevue, Nebraska, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Kerrville, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Waco, Texas, United States|GSK Investigational Site, South Burlington, Vermont, United States|GSK Investigational Site, Greenfield, Wisconsin, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,NCT00794846,SEASONAL ALLERGIC RHINITIS|PERENNIAL ALLERGIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,,PERENNIAL ALLERGIC RHINITIS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,1,DB00343,__DILTIAZEM,5286497,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,9.363641963900688,2015.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.09,414.51800000000003,59.08,4.0,0.0,3.0,43.65,114.37,7.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1
COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC,1,DB00346,__ALFUZOSIN,4661491,Completed,NCT03144596,BENIGN PROSTATIC HYPERPLASIA|PUPIL ANOMALY|CHOROID DISEASE,Male,"45 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,11.039241052177598,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.02,389.4488,111.83,8.0,2.0,3.0,42.71,107.11,8.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,0,0
Nc1ccn(C[C@@H](CO)OCP(=O)(O)O)c(=O)n1,1,DB00369,__CIDOFOVIR,5142051,Completed,NCT01866397,CYTOMEGALOVIRUS RETINITIS|ACUTE RENAL FAILURE,Male,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),"Medical University of Vienna, Vienna, Austria",C07F9/6512,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,61.3072137004866,92.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.1,279.187,145.68,8.0,4.0,1.0,24.44,60.43,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,1,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0
Nc1ccn(C[C@@H](CO)OCP(=O)(O)O)c(=O)n1,1,DB00369,__CIDOFOVIR,5142051,Completed,NCT00000894,CYTOMEGALOVIRUS RETINITIS|HIV INFECTIONS,All,"13 Years and older   (Child, Adult, Older Adult)",NIH,Intervention Model: Parallel Assignment|Primary Purpose: Treatment,"Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States|UCLA CARE Ctr, Los Angeles, California, United States|Univ of Miami / Bascom Palmer Eye Institute, Miami, Florida, United States|Emory Eye Clinic, Atlanta, Georgia, United States|Northwestern Univ / SOCA, Chicago, Illinois, United States|Charity Hosp / Tulane Univ Med School, New Orleans, Louisiana, United States|Johns Hopkins Hosp, Baltimore, Maryland, United States|Cornell Univ Med Ctr, New York, New York, United States|New York Hosp / Cornell Med Ctr, New York, New York, United States|Univ of North Carolina, Chapel Hill, North Carolina, United States|Julio Arroyo, West Columbia, South Carolina, United States|Univ of Texas Galveston, Galveston, Texas, United States",C07F9/6512,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.0,61.3072137004866,92.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.1,279.187,145.68,8.0,4.0,1.0,24.44,60.43,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,1,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,1,DB00373,__TIMOLOL,5231095,Completed,NCT03966560,"GLAUCOMA, OPEN-ANGLE",All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D285/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,1,DB00373,__TIMOLOL,5231095,Completed,NCT00811850,GLAUCOMA,All,"30 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Indianapolis, Indiana, United States",C07D285/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,1,DB00373,__TIMOLOL,5231095,"Active, not recruiting",NCT03323164,GLAUCOMA; DRUGS|NORMAL TENSION GLAUCOMA|PRIMARY OPEN-ANGLE GLAUCOMA,All,"18 Years to 90 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,"Glaucoma Research Center - Wills Eye Hospital, Philadelphia, Pennsylvania, United States",C07D285/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,1,DB00373,__TIMOLOL,5231095,Completed,NCT01170884,GLAUCOMA|OCULAR HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Dallas, Texas, United States",C07D285/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,1,DB00373,__TIMOLOL,5231095,Completed,NCT00822081,OPEN-ANGLE GLAUCOMA|OCULAR HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,"Barrie, Ontario, Canada",C07D285/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,1,DB00373,__TIMOLOL,5231095,Completed,NCT00957190,EYE DISEASE,All,"30 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada",C07D285/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,1,DB00373,__TIMOLOL,5231095,Unknown status,NCT02053298,OPEN ANGLE GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"University Hospitals Leuven, Leuven, Flemish Brabant, Belgium",C07D285/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,1,DB00373,__TIMOLOL,5231095,Completed,NCT00273442,"OCULAR HYPERTENSION|OPEN-ANGLE GLAUCOMA|EXFOLIATION SYNDROME|GLAUCOMA, PIGMENTARY",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Little Rock Eye Clinic, Little Rock, Arkansas, United States|Omni Eye Services, Atlanta, Georgia, United States|Midwest Eye Center, Bourbonnais, Illinois, United States|Mark J. Weiss, MD, Tulsa, Oklahoma, United States|Glaucoma Consultants & Center for Eye Research, Mt. Pleasant, South Carolina, United States",C07D285/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,1,DB00373,__TIMOLOL,5231095,Completed,NCT00545064,OCULAR HYPERTENSION|OPEN ANGLE GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D285/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,1,DB00373,__TIMOLOL,5231095,Completed,NCT01978015,"UVEITIS, ANTERIOR|CYSTOID MACULAR EDEMA",All,"18 Years to 95 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital de Clínicas, UNICAMP, Campinas, São Paulo, Brazil",C07D285/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,1,DB00373,__TIMOLOL,5231095,Recruiting,NCT04412096,GLAUCOMA|OHT - OCULAR HYPERTENSION,All,"30 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|The Ohio State University, Columbus, Ohio, United States",C07D285/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,1,DB00373,__TIMOLOL,5231095,Not yet recruiting,NCT03648229,OPEN-ANGLE GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,,C07D285/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,1,DB00373,__TIMOLOL,5231095,Completed,NCT01677507,GLAUCOMA|HEALTHY,All,"40 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States",C07D285/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,1,DB00373,__TIMOLOL,5231095,Completed,NCT01655758,OCULAR HYPERTENSION,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University Eye Clinic, Parma, Italy",C07D285/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,1,DB00373,__TIMOLOL,5231095,Completed,NCT00330577,PRIMARY OPEN ANGLE GLAUCOMA|OCULAR HYPERTENSION,All,"29 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"Glaucoma Unit, A University Dept of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece",C07D285/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,1,DB00373,__TIMOLOL,5231095,Completed,NCT01415401,GLAUCOMA|OCULAR HYPERTENSION|OPEN-ANGLE GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D285/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,1,DB00373,__TIMOLOL,5231095,Completed,NCT01547598,"GLAUCOMA, OPEN-ANGLE|OCULAR HYPERTENSION",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Vancouver, British Columbia, Canada",C07D285/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,1,DB00373,__TIMOLOL,5231095,Completed,NCT02003391,OPEN ANGLE GLAUCOMA|OCULAR HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D285/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,1,DB00373,__TIMOLOL,5231095,Withdrawn,NCT01927406,THYROID EYE DISEASE|OCULAR HYPERTENSION|GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Stanford Hospital and Clinics, Stanford, California, United States",C07D285/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,1,DB00373,__TIMOLOL,5231095,Unknown status,NCT01446497,NORMAL TENSION GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Seoul National University Hospital, Seoul, Korea, Republic of",C07D285/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,1,DB00373,__TIMOLOL,5231095,Completed,NCT00804648,"GLAUCOMA, OPEN ANGLE|OCULAR HYPERTENSION",All,"21 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Bourbonnais, Illinois, United States|Charlotte, North Carolina, United States",C07D285/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1
CNC[C@H](O)c1cccc(O)c1,1,DB00388,__PHENYLEPHRINE,8173707,Recruiting,NCT03638726,CATARACT|MYDRIASIS|ADVERSE DRUG EVENT,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,"Dar El Oyoun Hospital, Cairo, Giza, Egypt",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,24.1154849175547,908.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.69,167.205,52.49,3.0,3.0,1.0,18.2,47.25,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0
CNC[C@H](O)c1cccc(O)c1,1,DB00388,__PHENYLEPHRINE,8173707,Terminated,NCT02895035,CATARACT,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,24.1154849175547,908.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.69,167.205,52.49,3.0,3.0,1.0,18.2,47.25,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0
CNC[C@H](O)c1cccc(O)c1,1,DB00388,__PHENYLEPHRINE,8173707,Completed,NCT00877175,PRETERM INFANTS,All,1 Month to 4 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","Srinagarind Hospital, Khon Kaen, Thailand",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,24.1154849175547,908.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.69,167.205,52.49,3.0,3.0,1.0,18.2,47.25,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0
CNC[C@H](O)c1cccc(O)c1,1,DB00388,__PHENYLEPHRINE,8173707,Completed,NCT00501878,DIABETES,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","Srinagarind Hospital Eye Clinic, Khon Kaen, Thailand",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,24.1154849175547,908.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.69,167.205,52.49,3.0,3.0,1.0,18.2,47.25,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0
CNC[C@H](O)c1cccc(O)c1,1,DB00388,__PHENYLEPHRINE,8173707,Recruiting,NCT03615508,HORNER SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University of Colorado Hospital, Rocky Mountain Lions Eye Institute, Denver, Colorado, United States|Denver Health, Denver, Colorado, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,24.1154849175547,908.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.69,167.205,52.49,3.0,3.0,1.0,18.2,47.25,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0
CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]21C,1,DB00394,__BECLOMETHASONE_DIPROPIONATE,5776432,Completed,NCT02646904,ALLERGIC RHINITIS,All,6 Years to 16 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council, Palermo, Sicily, Italy|Institute of Biomedicine and Molecular Immunology, IBIM, Palermo, Italy",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,37.22458366701571,676.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.69,521.0419999999998,106.97,5.0,1.0,4.0,54.41,134.79,8.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,1,DB00402,__ESZOPICLONE,6319926,Completed,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,39.754409741473104,25.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.97,388.80800000000005,91.76,6.0,0.0,4.0,37.67,95.89,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1
CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,1,DB00402,__ESZOPICLONE,6319926,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,39.754409741473104,25.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.97,388.80800000000005,91.76,6.0,0.0,4.0,37.67,95.89,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1
Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,1,DB00404,__ALPRAZOLAM,6024981,Completed,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,762.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.23,308.765,43.07,3.0,0.0,4.0,32.22,98.88,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0
C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O,1,DB00410,__MUPIROCIN,6013657,Completed,,CHRONIC RHINOSINUSITIS,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,18.135896014291802,384.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.25,500.6222,146.05,8.0,4.0,2.0,55.5,129.39,17.0,1.0,0.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/22,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/22,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/22,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CCCN[C@H]1CCc2nc(N)sc2C1,1,DB00413,__PRAMIPEXOLE,4886812,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/82,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,13.996180619725196,288.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.18,211.327,50.94,3.0,2.0,2.0,24.47,59.77,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O,1,DB00415,__AMPICILLIN,3931150,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D499/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,17.2488141440275,1774.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.88,349.405,112.73,5.0,3.0,3.0,34.54,87.52,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O,1,DB00415,__AMPICILLIN,3931150,Completed,,PNEUMONIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D499/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,17.2488141440275,1774.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.88,349.405,112.73,5.0,3.0,3.0,34.54,87.52,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O,1,DB00417,__PHENOXYMETHYLPENICILLIN,4046759,Recruiting,NCT04083417,SORE THROAT|TONSILLITIS,All,"15 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vårdcentralen Rosenhälsan, Jönköping, Sweden|Vårdcentralen Kärna, Linköping, Sweden|Vårdcentralen Lundbergsgatan, Malmö, Sweden|Mariehems hälsocentral, Umeå, Sweden|Ålidhems hälsocentral, Umeå, Sweden|Vårdcentralen Skärvet, Växjö, Sweden",C07D499/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,24.411178874309503,110.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.78,350.39,95.94,5.0,2.0,3.0,34.37,85.77,5.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O,1,DB00417,__PHENOXYMETHYLPENICILLIN,4046759,Completed,NCT02712307,TONSILLITIS,All,"6 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Alvesta vårdcentral, Alvesta, Sweden|Närhälsan Bollebygd vårdcentral, Bollebygd, Sweden|Capio Citykliniken Bunkeflo Hyllie, Bunkeflostrand, Sweden|Vårdcentralen Tåbelund, Eslöv, Sweden|Närhälsan Fristad vårdcentral, Fristad, Sweden|Vårdcentralen Lessebo, Lessebo, Sweden|Capio Citykliniken Malmö Limhamn, Limhamn, Sweden|Löddeköpinge vårdcentral, Löddeköpinge, Sweden|Vårdcentralen Sorgenfrimottagningen, Malmö, Sweden|Vårdcentralen Lundbergsgatan, Malmö, Sweden|Närhälsan Sandared vårdcentral, Sandared, Sweden|Vårdcentrlaen Sjöbo, Sjöbo, Sweden|Närhälsan Billingen vårdcentral, Skövde, Sweden|Närhälsan Norrmalm vårdcentral, Skövde, Sweden|Närhälsan Södra Ryd, Skövde, Sweden|Vårdcentrlaen Strandbjörket, Växjö, Sweden|Capio vårdcentralen Hovshaga, Växjö, Sweden",C07D499/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,24.411178874309503,110.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.78,350.39,95.94,5.0,2.0,3.0,34.37,85.77,5.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O,1,DB00417,__PHENOXYMETHYLPENICILLIN,4046759,Recruiting,,SORE THROAT,,,,,"FISABIO, Elche, Alicante, Spain",C07D499/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,24.411178874309503,110.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.78,350.39,95.94,5.0,2.0,3.0,34.37,85.77,5.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,1,DB00419,__MIGLUSTAT,5472969,Recruiting,,"NIEMANN-PICK DISEASE, TYPE C",,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,13.766196431138198,165.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.1,219.278,84.16,5.0,4.0,1.0,23.99,55.74,4.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0
COC(=O)C(c1ccccc1)C1CCCCN1,1,DB00422,__METHYLPHENIDATE,5958446,Completed,,ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY,,,,,"FISABIO, Elche, Alicante, Spain",A61L15/585,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,75.0,52.83065360685021,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,233.3062,38.33,2.0,1.0,2.0,26.21,66.73,4.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,1,DB00425,__ZOLPIDEM,6761910,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,37.158873898848,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.15,307.3895,37.61,2.0,0.0,3.0,35.06,93.58,3.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB00443,__BETAMETHASONE,6126920,Completed,NCT00963573,RHINITIS,All,6 Years to 12 Years   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.6906096634427,1325.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.81,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB00443,__BETAMETHASONE,6126920,Recruiting,NCT02912182,VESTIBULAR DISEASES|VESTIBULAR NEURONITIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Dept OtoRhinoLaryngology, Helsingborg, Sweden|Dept. Otorhinolaryngology, Kristianstad, Sweden|Dept. OtoRhinoLaryngology Head and Neck Surgery, Skane University Hospital, Lund, Sweden",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.6906096634427,1325.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.81,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,1,DB00448,__LANSOPRAZOLE,4628098,Completed,NCT00637845,HEARTBURN|GASTROESOPHAGEAL REFLUX DISEASE,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07D213/68,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,36.0,16.3617322737633,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.361,67.87,4.0,1.0,3.0,34.59,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,1,DB00448,__LANSOPRAZOLE,4628098,Unknown status,NCT02278081,RHINITIS|NASAL OBSTRUCTION|GERD,All,"7 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,C07D213/68,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,36.0,16.3617322737633,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.361,67.87,4.0,1.0,3.0,34.59,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,1,DB00448,__LANSOPRAZOLE,4628098,Terminated,NCT00369265,LARYNGOPHARYNGEAL REFLUX,All,"18 Years to 89 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Henry Ford Hospital, Department of Otolaryngology, Detroit, Michigan, United States|American Institute for Voice and Ear Research, Philadelphia, Pennsylvania, United States|Cornell University, Van Lawrence Voice Center, Houston, Texas, United States",C07D213/68,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,36.0,16.3617322737633,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.361,67.87,4.0,1.0,3.0,34.59,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,1,DB00448,__LANSOPRAZOLE,4628098,Terminated,NCT01404832,GASTROESOPHAGEAL REFLUX DISEASE|EOSINOPHILIC ESOPHAGITIS,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Dallas VA Medical Center, Dallas, Texas, United States",C07D213/68,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,36.0,16.3617322737633,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.361,67.87,4.0,1.0,3.0,34.59,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,1,DB00448,__LANSOPRAZOLE,4628098,Completed,NCT02958046,GASTROESOPHAGEAL REFLUX,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department Of Gastroenterology, Faculty Of Medicine, Ege University, Izmir, Turkey, İzmir, Turkey",C07D213/68,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,36.0,16.3617322737633,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.361,67.87,4.0,1.0,3.0,34.59,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,1,DB00448,__LANSOPRAZOLE,4628098,Completed,NCT01008696,REFLUX ESOPHAGITIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D213/68,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,36.0,16.3617322737633,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.361,67.87,4.0,1.0,3.0,34.59,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,1,DB00448,__LANSOPRAZOLE,4628098,Unknown status,NCT00237068,ASTHMA,All,4 Years to 11 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Emory Children's Center, Atlanta, Georgia, United States|Children's Center for Digestive Healthcare, Atlanta, Georgia, United States|Georgia Pediatric Pulmonology Associates/ CHOA, Atlanta, Georgia, United States",C07D213/68,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,36.0,16.3617322737633,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.361,67.87,4.0,1.0,3.0,34.59,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,1,DB00448,__LANSOPRAZOLE,4628098,Completed,NCT01082029,OTITIS MEDIA WITH EFFUSION,All,1 Year to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Mcmaster University Medical Centre 3V1 Clinic, Hamilton, Ontario, Canada",C07D213/68,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,36.0,16.3617322737633,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.361,67.87,4.0,1.0,3.0,34.59,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,1,DB00448,__LANSOPRAZOLE,4628098,Terminated,NCT00637416,DYSPHONIA,All,"3 Years to 18 Years   (Child, Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Kansas Medical Center, Kansas City, Kansas, United States",C07D213/68,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,36.0,16.3617322737633,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.361,67.87,4.0,1.0,3.0,34.59,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,1,DB00455,__LORATADINE,6132758,Completed,NCT03443843,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kingston General Hospital, Kingston, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,28.5508942688761,219.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.8,382.88300000000004,42.43,2.0,0.0,4.0,41.67,116.98,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,1,DB00455,__LORATADINE,6132758,Completed,NCT03004131,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Inflamax Research, Mississauga, Ontario, Canada",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,28.5508942688761,219.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.8,382.88300000000004,42.43,2.0,0.0,4.0,41.67,116.98,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,1,DB00455,__LORATADINE,6132758,Completed,NCT02932774,"ALLERGIC RHINITIS|HAY FEVER|SAR|RHINITIS, ALLERGIC, SEASONAL",All,6 Years to 11 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,28.5508942688761,219.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.8,382.88300000000004,42.43,2.0,0.0,4.0,41.67,116.98,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,1,DB00455,__LORATADINE,6132758,Completed,NCT02513290,ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,28.5508942688761,219.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.8,382.88300000000004,42.43,2.0,0.0,4.0,41.67,116.98,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,1,DB00455,__LORATADINE,6132758,Completed,NCT01469234,RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,28.5508942688761,219.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.8,382.88300000000004,42.43,2.0,0.0,4.0,41.67,116.98,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,1,DB00455,__LORATADINE,6132758,Completed,NCT00730912,PERENNIAL ALLERGIC RHINITIS,All,"3 Years to 64 Years   (Child, Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,28.5508942688761,219.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.8,382.88300000000004,42.43,2.0,0.0,4.0,41.67,116.98,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0
COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC,1,DB00457,__PRAZOSIN,4130647,Completed,NCT00487032,ALLERGIC RHINITIS|TACHYPHYLAXIS|RHINITIS MEDICAMENTOSA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Perth Royal Infirmary (Tayside NHS Trust), Perth, Perthshire, United Kingdom|Ninewells Hospital and Medical School (Tayside NHS Trust, University of Dundee), Dundee, Tayside, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,17.380233680363,616.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.93,383.4011,106.95,7.0,1.0,4.0,40.49,104.5,4.0,0.0,1.0,0.0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0
C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)O)c(CCC(=O)OC)c4C)[C@@]1(C)C3=CC=C(C(=O)OC)[C@H]1C(=O)OC,1,DB00460,__VERTEPORFIN,5214036,Not yet recruiting,NCT04075136,EXUDATIVE AGE RELATED MACULAR DEGENERATION,All,"50 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,38.57163391445409,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.02,718.7942,173.56,7.0,3.0,6.0,81.29,199.08,12.0,1.0,0.0,0.0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0
C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)O)c(CCC(=O)OC)c4C)[C@@]1(C)C3=CC=C(C(=O)OC)[C@H]1C(=O)OC,1,DB00460,__VERTEPORFIN,5214036,Completed,NCT00135837,AGE-RELATED MACULAR DEGENERATION,All,"50 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis, Basel, Switzerland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,38.57163391445409,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.02,718.7942,173.56,7.0,3.0,6.0,81.29,199.08,12.0,1.0,0.0,0.0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0
C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)O)c(CCC(=O)OC)c4C)[C@@]1(C)C3=CC=C(C(=O)OC)[C@H]1C(=O)OC,1,DB00460,__VERTEPORFIN,5214036,Completed,NCT00331435,AGE RELATED MACULAR DEGENERATION,All,"50 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Nagoya City University Hospital, Aichi, Japan|Nagoya University, Aichi, Japan|Kyushu University, Fukuoka, Japan|Fukushima Medical University School of Medicine, Fukushima, Japan|Gunma University, Gunma, Japan|Kagawa University, Kagawa, Japan|Kyoto University, Kyoto, Japan|Osaka University, Osaka, Japan|Kansai Medical University Takii Hospital, Osaka, Japan|Kansai Medical University Hirakata Hospital, Osaka, Japan|Sapporo City general hospital, Sapporo, Japan|Shiga University of Medical Science, Shiga, Japan|Surugadai Nihon University Hospital, Tokyo, Japan|Kyorin University, Tokyo, Japan|Toho University, Tokyo, Japan|Tokyo University Ohashi Medical Center, Tokyo, Japan|Yamanashi University, Yamanashi, Japan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,38.57163391445409,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.02,718.7942,173.56,7.0,3.0,6.0,81.29,199.08,12.0,1.0,0.0,0.0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0
C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)O)c(CCC(=O)OC)c4C)[C@@]1(C)C3=CC=C(C(=O)OC)[C@H]1C(=O)OC,1,DB00460,__VERTEPORFIN,5214036,Completed,NCT01846273,AGE-RELATED MACULAR DEGENERATION|POLYPOIDAL CHOROIDAL VASCULOPATHY,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Hongkong, Hong Kong|Novartis Investigative Site, Nagoya-city, Aichi, Japan|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Fukuoka city, Fukuoka, Japan|Novartis Investigative Site, Fukushima-city, Fukushima, Japan|Novartis Investigative Site, Maebashi city, Gunma, Japan|Novartis Investigative Site, Amagasaki city, Hyogo, Japan|Novartis Investigative Site, Kobe-city, Hyogo, Japan|Novartis Investigative Site, Kobe-shi, Hyogo, Japan|Novartis Investigative Site, Inashiki-gun, Ibaraki, Japan|Novartis Investigative Site, Kita-gun, Kagawa, Japan|Novartis Investigative Site, Sakyo-ku, Kyoto, Japan|Novartis Investigative Site, Tsu-city, Mie, Japan|Novartis Investigative Site, Okayama-city, Okayama, Japan|Novartis Investigative Site, Hirakata-city, Osaka, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Ohtsu-city, Shiga, Japan|Novartis Investigative Site, Bunkyo ku, Tokyo, Japan|Novartis Investigative Site, Chiyoda-ku, Tokyo, Japan|Novartis Investigative Site, Mitaka-city, Tokyo, Japan|Novartis Investigative Site, Shinjuku ku, Tokyo, Japan|Novartis Investigative Site, Chiba, Japan|Novartis Investigative Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Seocho-gu, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Petaling Jaya, Selangor Darul Ehsan, Malaysia|Novartis Investigative Site, Batu Caves, Selangor, Malaysia|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Taipei, Taiwan, ROC, Taiwan|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Kaohsiung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan|Novartis Investigative Site, Songkla, Hat Yai, Thailand|Novartis Investigative Site, Bangkok, Thailand",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,38.57163391445409,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.02,718.7942,173.56,7.0,3.0,6.0,81.29,199.08,12.0,1.0,0.0,0.0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0
C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)O)c(CCC(=O)OC)c4C)[C@@]1(C)C3=CC=C(C(=O)OC)[C@H]1C(=O)OC,1,DB00460,__VERTEPORFIN,5214036,Completed,NCT00473642,AGE-RELATED MACULOPATHY|CHOROIDAL NEOVASCULARIZATION,All,"50 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Eagle Mountain Vision, Tulsa, Oklahoma, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,38.57163391445409,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.02,718.7942,173.56,7.0,3.0,6.0,81.29,199.08,12.0,1.0,0.0,0.0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Completed,NCT00407017,CATARACT SURGERY,All,"Child, Adult, Older Adult",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,"The Center for Excellence in Eye Care, Miami, Florida, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Completed,NCT00981435,GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Bascom Palmer Eye Institute, Miami, Florida, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Completed,NCT00348244,CATARACT,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single,"Dr. Wittpenn, Stony Brook, New York, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Completed,NCT01542190,"CYSTOID MACULAR EDEMA FOLLOWING CATARACT SURGERY, BILATERAL",All,"50 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Unicamp, Campinas, Sao Paulo, Brazil|Unicamp, Campinas, Sao Paulo, Brazil",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Completed,NCT02646072,"CYSTOID MACULAR EDEMA, POSTOPERATIVE|DIABETES MELLITUS",All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","University of Malaya, Kuala Lumpur, Wilayah Persekutuan, Malaysia",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Completed,NCT00595543,ACUTE PSEUDOPHAKIC CYSTOID MACULAR EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Soll Eye Associates, Philadelphia, Pennsylvania, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Completed,NCT02867176,PAIN,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,,A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Completed,NCT00520260,DRY EYE DISEASE|OCULAR COMFORT,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Florida Eye Microsurgical Institute, Boynton Beach, Florida, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Recruiting,NCT04528173,ANESTHESIA|OPIOID USE|TONSILLITIS|SLEEP DISORDER|SURGERY,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Unknown status,NCT02653742,"PAIN, POSTOPERATIVE|OTITIS MEDIA",All,8 Months to 7 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Albany Medical Center, Albany, New York, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Completed,NCT00347204,MYOPIA|HYPEROPIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Completed,NCT02084576,CYSTOID MACULAR EDEMA|CATARACT,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Oftalmologico de Brasília, Brasilia, DF, Brazil",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Completed,NCT01395069,MACULAR EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Hotel Dieu Hospital, Kingston, Ontario, Canada",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Completed,NCT02060604,WET MACULAR DEGENERATION,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Spedali Civili di Brescia, Brescia, BS, Italy",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Completed,NCT00904904,CATARACT|INFLAMMATION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,"Bausch & Lomb, Berlin, Germany",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Completed,NCT01832311,CATARACT|TYPE 2 DIABETES MELLITUS,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Department of Ophtalmology, General Hospital ""Dr. J. Bencevic"", Slavonski brod, Brodsko-posavska zupanija, Croatia|Department of Physiology and Immunology, University of Zagreb School of Medicine, Zagreb, Grad Zagreb, Croatia",A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O,1,DB00469,__TENOXICAM,4636498,Unknown Status,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,16.953120187272805,1159.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.42,337.37,99.6,5.0,2.0,3.0,31.96,83.93,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,1,DB00470,__DRONABINOL,6703418,Completed,,CHEST PAIN,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,141.17743690835502,1151.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.29,314.4617,29.46,2.0,1.0,3.0,38.96,96.73,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00157937,ASTHMA|ALLERGIC RHINITIS,All,18 Years to 60 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/1623,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00545844,ASTHMA,All,"15 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00380705,ASTHMA|RHINITIS ALLERGIC,All,"6 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Terminated,NCT00119015,"RHINITIS, ALLERGIC, PERENNIAL",All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","The University of Chicago, Chicago, Illinois, United States",A61K9/1623,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Unknown status,NCT00488176,SEASONAL ALLERGIC RHINITIS,All,"6 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Department of Pediatrics and Allergy, Medical University of Lodz Lodz, Poland, Lodz, Poland",A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT02761252,SEASONAL ALLERGIC RHINOCONJUNCTIVITIS|ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cakovec, Croatia|Rijeka, Croatia|Zagreb, Croatia|Brno, Czechia|Ostrava Hrabuvka, Czechia|Teplice, Czechia|Dreieich, Germany|Heidelberg, Germany|Catania, Italy|Florence, Italy|Modena, Italy|Pavia, Italy|Verona, Italy|Riga, Latvia|Bialystok, Poland|Bielsko-Biala, Poland|Gdansk, Poland|Katowice, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Nowy Duninow, Poland|Poznan, Poland|Rzeszow, Poland|Tarnow, Poland|Wroclaw, Poland|Brasov, Romania|Bucharest, Romania|Cluj Napoca, Romania|Ploieşti, Romania|Bardejov, Slovakia|Levice, Slovakia",A61K9/1623,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00295022,"RHINITIS, ALLERGIC, SEASONAL",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kingston, Ontario, Canada",A61K9/1623,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT02551536,ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K9/1623,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Unknown status,NCT02110654,SINUSITIS|NASAL POLYPS|ASTHMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"the first affiliated hospital, Sun Yat-sen University, Guangzhou, Guangdong, China",A61K9/1623,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00189462,ACUTE OTITIS MEDIA|OTITIS MEDIA|EAR INFECTION,All,18 Months to 5 Years   (Child),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Bellevue Pediatric Associates, Bellevue, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States",A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Unknown status,NCT00406094,RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Bernstein Allergy Group, Cincinnati, Ohio, United States",A61K9/1623,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00590772,PERENNIAL ALLERGIC RHINITIS,All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT03380975,ASTHMA AND ALLERGIC RHINITIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dr. Faisal Faiyaz Zuberi, Karachi, Sindh, Pakistan",A61K9/1623,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00559546,SEASONAL ALLERGIC RHINITIS|ALLERGIC CONJUNCTIVITIS|ATOPIC ECZEMA|ASTHMA,All,18 Years to 40 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland",A61K9/1623,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,,ACUTE OTITIS MEDIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/1623,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,,UPPER RESPIRATORY INFECTIONS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/1623,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
C=CCC1(C(C)C#CCC)C(=O)NC(=O)N(C)C1=O,1,DB00474,__METHOHEXITAL,4126684,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,23.425532351793603,204.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.43,262.3043,66.48,3.0,1.0,1.0,27.4,71.51,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Recruiting,NCT03321006,HEARING LOSS|DEPRESSION,All,"60 Years to 99 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","New York State Psychiatric Institute, New York, New York, United States",C07D333/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Completed,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",C07D333/20,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D333/20,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,1,DB00477,__CHLORPROMAZINE,3976763,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",G01N33/539,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,15.8360541284215,1011.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.18,318.8640000000001,6.48,2.0,0.0,3.0,35.1,93.76,4.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,1,DB00479,__AMIKACIN,7718189,Completed,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,79.0,57.95601552393271,878.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-3.2,585.6025,331.94,17.0,13.0,3.0,58.06,129.84,10.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,1
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,DB00481,__RALOXIFENE,5393763,Completed,,COMPLIANCE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,13.5362122425511,440.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.45,473.583,70.0,5.0,2.0,5.0,52.55,135.48,7.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,DB00481,__RALOXIFENE,5393763,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,13.5362122425511,440.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.45,473.583,70.0,5.0,2.0,5.0,52.55,135.48,7.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,DB00481,__RALOXIFENE,5393763,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,13.5362122425511,440.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.45,473.583,70.0,5.0,2.0,5.0,52.55,135.48,7.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Recruiting,NCT04147013,CHRONIC RHINOSINUSITIS WITH NASAL POLYPS|ASPIRIN-EXACERBATED RESPIRATORY DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","St. Joseph's Healthcare London, London, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12,1,DB00484,__BRIMONIDINE,5424078,Not yet recruiting,NCT04007276,"GLAUCOMA|GLAUCOMA, OPEN-ANGLE|GLAUCOMA; DRUGS|DROOPY EYELID|PTOSIS|GLAUCOMA, PRIMARY OPEN ANGLE",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,A61K47/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,49.3808907780447,272.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.27,292.135,62.2,5.0,2.0,3.0,25.74,68.49,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12,1,DB00484,__BRIMONIDINE,5424078,Completed,NCT03966560,"GLAUCOMA, OPEN-ANGLE",All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K47/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,49.3808907780447,272.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.27,292.135,62.2,5.0,2.0,3.0,25.74,68.49,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12,1,DB00484,__BRIMONIDINE,5424078,Recruiting,NCT03782701,EYELID DROOP,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bascom Palmer Eye Institute, Miami, Florida, United States",A61K47/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,49.3808907780447,272.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.27,292.135,62.2,5.0,2.0,3.0,25.74,68.49,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12,1,DB00484,__BRIMONIDINE,5424078,Completed,NCT00811850,GLAUCOMA,All,"30 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Indianapolis, Indiana, United States",A61K47/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,49.3808907780447,272.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.27,292.135,62.2,5.0,2.0,3.0,25.74,68.49,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12,1,DB00484,__BRIMONIDINE,5424078,"Active, not recruiting",NCT03323164,GLAUCOMA; DRUGS|NORMAL TENSION GLAUCOMA|PRIMARY OPEN-ANGLE GLAUCOMA,All,"18 Years to 90 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,"Glaucoma Research Center - Wills Eye Hospital, Philadelphia, Pennsylvania, United States",A61K47/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,49.3808907780447,272.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.27,292.135,62.2,5.0,2.0,3.0,25.74,68.49,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12,1,DB00484,__BRIMONIDINE,5424078,Completed,NCT02863705,"GLAUCOMA, OPEN-ANGLE|NORMAL TENSION GLAUCOMA",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea, Republic of|Yeungnam University Hospital, Yeungnam University College of Medicine, Daegu, Korea, Republic of|Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea, Republic of|Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea, Republic of|Seoul National University Bundang Hospital, Seoul National University College of Medicine, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea, Republic of|Kangbuk Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea, Republic of|Kim's Eye Hospital, Konyang University College of Medicine, Seoul, Korea, Republic of",A61K47/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,49.3808907780447,272.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.27,292.135,62.2,5.0,2.0,3.0,25.74,68.49,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12,1,DB00484,__BRIMONIDINE,5424078,Completed,NCT02003534,"GLAUCOMA, OPEN-ANGLE|OCULAR HYPERTENSION",All,"Child, Adult, Older Adult",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai, China",A61K47/02,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,49.3808907780447,272.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.27,292.135,62.2,5.0,2.0,3.0,25.74,68.49,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12,1,DB00484,__BRIMONIDINE,5424078,Completed,NCT01525173,GLAUCOMA|OCULAR HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Deerfield Beach, Florida, United States",A61K47/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,49.3808907780447,272.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.27,292.135,62.2,5.0,2.0,3.0,25.74,68.49,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12,1,DB00484,__BRIMONIDINE,5424078,Completed,NCT00822081,OPEN-ANGLE GLAUCOMA|OCULAR HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,"Barrie, Ontario, Canada",A61K47/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,49.3808907780447,272.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.27,292.135,62.2,5.0,2.0,3.0,25.74,68.49,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12,1,DB00484,__BRIMONIDINE,5424078,Completed,NCT00675207,PRIMARY OPEN ANGLE GLAUCOMA|OCULAR HYPERTENSION,All,"41 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Northwestern Ophthalmic Institute S.C., Glenview, Illinois, United States",A61K47/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,49.3808907780447,272.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.27,292.135,62.2,5.0,2.0,3.0,25.74,68.49,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12,1,DB00484,__BRIMONIDINE,5424078,Terminated,NCT01151904,"GLAUCOMA, ANGLE-CLOSURE",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bangkok, Thailand",A61K47/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,49.3808907780447,272.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.27,292.135,62.2,5.0,2.0,3.0,25.74,68.49,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12,1,DB00484,__BRIMONIDINE,5424078,Completed,NCT03192826,POSTERIOR CAPSULE OPACIFICATION|OCULAR HYPERTENSION,All,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","University Hospital of Patras, Patra, Achaia, Greece",A61K47/02,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,49.3808907780447,272.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.27,292.135,62.2,5.0,2.0,3.0,25.74,68.49,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12,1,DB00484,__BRIMONIDINE,5424078,Unknown status,NCT01446497,NORMAL TENSION GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Seoul National University Hospital, Seoul, Korea, Republic of",A61K47/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,49.3808907780447,272.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.27,292.135,62.2,5.0,2.0,3.0,25.74,68.49,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12,1,DB00484,__BRIMONIDINE,5424078,Completed,,INTRAOCULAR PRESSURE,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,49.3808907780447,272.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.27,292.135,62.2,5.0,2.0,3.0,25.74,68.49,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12,1,DB00484,__BRIMONIDINE,5424078,Completed,,OCULAR HYPERTENSION,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,49.3808907780447,272.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.27,292.135,62.2,5.0,2.0,3.0,25.74,68.49,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,1,DB00497,__OXYCODONE,5508042,Recruiting,NCT03783702,SINUSITIS|OPIOID USE|OPIOID ABUSE|NARCOTIC USE|OTOLARYNGOLOGIC DISEASE|POSTOPERATIVE PAIN|PAIN,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford Health Care, Stanford, California, United States|NorthShore University Health System, Evanston, Illinois, United States|Mayo Clinic, Rochester, Minnesota, United States|Albert Einstein, Bronx, New York, United States|Vanderbilt, Nashville, Tennessee, United States|University of British Columbia, Vancouver, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,10.3492884864165,1114.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.04,315.3636,59.0,5.0,1.0,5.0,32.79,84.04,1.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,1,DB00497,__OXYCODONE,5508042,Not yet recruiting,NCT04177342,ACHALASIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,10.3492884864165,1114.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.04,315.3636,59.0,5.0,1.0,5.0,32.79,84.04,1.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,1,DB00497,__OXYCODONE,5508042,Not yet recruiting,NCT03639415,CANCER PAIN,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,10.3492884864165,1114.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.04,315.3636,59.0,5.0,1.0,5.0,32.79,84.04,1.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,1,DB00514,__DEXTROMETHORPHAN,5980882,Completed,NCT00377403,ACUTE RESPIRATORY INFECTIONS|ACUTE RHINOSINUSITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Washington University in St. Louis, St. Louis, Missouri, United States",A61K47/6903,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,37.0,30.785026386578693,672.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.75,271.404,12.47,2.0,0.0,4.0,31.86,82.56,1.0,0.0,1.0,0.0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0
CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1,1,DB00518,__ALBENDAZOLE,3956499,Not yet recruiting,NCT03570814,TRACHOMA|LYMPHATIC FILARIASES,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D235/32,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,9.13365777531366,309.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.22,265.33099999999996,67.01,3.0,2.0,2.0,29.3,73.01,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1
CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1,1,DB00518,__ALBENDAZOLE,3956499,Withdrawn,NCT01903057,TRACHOMA|LYMPHATIC FILARIASIS,All,"5 Years to 65 Years   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","National Institute of Health, Ministry of Health, Maputo, Mozambique",C07D235/32,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,9.13365777531366,309.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.22,265.33099999999996,67.01,3.0,2.0,2.0,29.3,73.01,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1
CC(C)(C)NCC(O)COc1cccc2c1CCC(=O)N2,1,DB00521,__CARTEOLOL,4281654,Completed,NCT00972426,GLAUCOMA,All,"20 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tri-Service General Hospital, Taipei, Taiwan",A61K9/0051,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,15.901763896589198,727.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.05,292.3734,70.59,4.0,3.0,2.0,32.79,83.14,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0
O=C(O)P(=O)(O)O,1,DB00529,__FOSCARNET,,Completed,NCT00002125,CYTOMEGALOVIRUS RETINITIS|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Industry,Primary Purpose: Treatment,"Dr Ralph Hansen, Beverly Hills, California, United States|Dr Milan Fiala, Los Angeles, California, United States|Dr G Michael Wool, Los Angeles, California, United States|AIDS Community Research Consortium, Redwood City, California, United States|Ingenix Kern McNeill Decatur, Atlanta, Georgia, United States|Dr John Karedes, Indianapolis, Indiana, United States|Dr Paul Benson, Berkley, Michigan, United States|Dr Ronald Nahass, Somerville, New Jersey, United States|Dr Ronald J Grossman, New York, New York, United States|Community Health Network, Rochester, New York, United States|Austin Infectious Disease Consultants, Austin, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.6,126.0053,94.83,5.0,3.0,0.0,7.89,19.07,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1,1,DB00533,__ROFECOXIB,5474995,Terminated,NCT00140894,ADENOMATOUS POLYPOSIS COLI,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,C07D275/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,25.0,23.0312737427873,348.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.32,314.356,60.44,3.0,0.0,3.0,31.74,84.08,3.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0
C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\O)c3csc(N)n3)[C@H]2SC1,1,DB00535,__CEFDINIR,4935507,Completed,NCT00147914,ACUTE BACTERIAL SINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Chicago, Chicago, Illinois, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,22.3413211770262,724.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.02,395.414,158.21,8.0,4.0,3.0,36.12,94.34,5.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,1
C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\O)c3csc(N)n3)[C@H]2SC1,1,DB00535,__CEFDINIR,4935507,Completed,NCT00644943,ACUTE OTITIS MEDIA,All,6 Months to 6 Years   (Child),Industry,Allocation: Randomized|Masking: Single (Investigator)|Primary Purpose: Treatment,"Birmingham, Alabama, United States|Montgomery, Alabama, United States|Ozark, Alabama, United States|Mesa, Arizona, United States|Scottsdale, Arizona, United States|Little Rock, Arkansas, United States|Clovis, California, United States|Fresno, California, United States|Longmont, Colorado, United States|Fairfield, Connecticut, United States|Marietta, Georgia, United States|Stone Mountain, Georgia, United States|Bardstown, Kentucky, United States|Louisville, Kentucky, United States|Owensboro, Kentucky, United States|Ruston, Louisiana, United States|Shreveport, Louisiana, United States|Kalamazoo, Michigan, United States|Richland, Michigan, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Columbus, Ohio, United States|Medford, Oregon, United States|Pittsburgh, Pennsylvania, United States|Sellersville, Pennsylvania, United States|Charleston, South Carolina, United States|Austin, Texas, United States|Lake Jackson, Texas, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|West Jordan, Utah, United States|Vienna, Virginia, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,22.3413211770262,724.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.02,395.414,158.21,8.0,4.0,3.0,36.12,94.34,5.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,1
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,DB00537,__CIPROFLOXACIN,5286754,Completed,NCT00392275,CATARACT,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,"Indiana University Hospital, Indianapolis, Indiana, United States|Richard L Rodeboush VA Medical Center, Indianapolis, Indiana, United States|Wishard Memorial Hospital, Indianapolis, Indiana, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,64.8883960656276,849.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.57,331.3415,72.88,6.0,2.0,4.0,33.12,87.94,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,DB00537,__CIPROFLOXACIN,5286754,Active Not Recruiting,,ULCERATIVE COLITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,64.8883960656276,849.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.57,331.3415,72.88,6.0,2.0,4.0,33.12,87.94,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0
CN(C)CCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1,1,DB00539,__TOREMIFENE,4696949,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07C43/225,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,19.975769522988106,1776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.65,405.96,12.47,2.0,0.0,3.0,46.49,133.41,9.0,0.0,1.0,0.0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNCCC=C1c2ccccc2CCc2ccccc21,1,DB00540,__NORTRIPTYLINE,4175119,Recruiting,NCT04404439,"TINNITUS, SUBJECTIVE|TINNITUS",All,"25 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of California, Irvine Medical Center ENT Clinic (Pavilion 2), Orange, California, United States",A61K9/209,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,198.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.65,263.3767,12.03,1.0,1.0,3.0,31.87,96.21,3.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CNCCC=C1c2ccccc2CCc2ccccc21,1,DB00540,__NORTRIPTYLINE,4175119,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,198.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.65,263.3767,12.03,1.0,1.0,3.0,31.87,96.21,3.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CNCCC=C1c2ccccc2CCc2ccccc21,1,DB00540,__NORTRIPTYLINE,4175119,Completed,,GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD),,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,198.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.65,263.3767,12.03,1.0,1.0,3.0,31.87,96.21,3.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CNCCC=C1c2ccccc2CCc2ccccc21,1,DB00540,__NORTRIPTYLINE,4175119,Recruiting,,TINNITUS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,198.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.65,263.3767,12.03,1.0,1.0,3.0,31.87,96.21,3.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00541,__VINCRISTINE,6723338,Completed,,RETINOBLASTOMA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O,1,DB00542,__BENAZEPRIL,6162802,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,105.33275837286101,681.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.14,424.4895,95.94,5.0,2.0,3.0,44.98,115.23,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0
O=c1[nH]cc(F)c(=O)[nH]1,1,DB00544,__FLUOROURACIL,6670335,Unknown status,NCT02530801,RECURRENT PTERYGIUM,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K8/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,33.8405306063779,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.58,130.0772,58.2,2.0,2.0,1.0,9.46,26.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
O=c1[nH]cc(F)c(=O)[nH]1,1,DB00544,__FLUOROURACIL,6670335,Completed,,GLAUCOMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K8/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,33.8405306063779,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.58,130.0772,58.2,2.0,2.0,1.0,9.46,26.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
CCCc1cc(=O)[nH]c(=S)[nH]1,1,DB00550,__PROPYLTHIOURACIL,4369172,Unknown status,NCT01056419,GRAVES' OPHTHALMOPATHY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ankara University, Medical School, Ibni Sina Hospital, Endocrinology and Metabolic Diseases Department, Ankara, Turkey",A61K9/2054,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,38.0,13.010534097209305,202.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.53,170.232,41.13,1.0,2.0,1.0,17.79,48.9,2.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0
FC(F)(F)C(F)(F)C(F)(F)F,1,DB00556,__PERFLUTREN,6723303,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K49/223,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,106.482679315797,12.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.96,188.0193,0.0,0.0,0.0,0.0,7.1,17.54,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0
OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00557,__HYDROXYZINE,4175119,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,573.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.43,374.904,35.94,4.0,1.0,3.0,41.99,107.07,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1
OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00557,__HYDROXYZINE,4175119,Terminated,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,573.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.43,374.904,35.94,4.0,1.0,3.0,41.99,107.07,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,1,DB00559,__BOSENTAN,5292740,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D409/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,20.928561161420106,93.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.18,551.614,145.65,9.0,2.0,4.0,57.89,166.66,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Withdrawn,NCT00037115,DEMYELINATING DISORDERS|MULTIPLE SCLEROSIS|OPTIC NEURITIS|MYELITIS|NEURITIS,All,18 Years to 50 Years   (Adult),Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MidAmerica Neuroscience Institute, Kansas City, Missouri, United States",A61M5/2425,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Unknown status,NCT02378298,"OPHTHALMOPATHY, THYROID-ASSOCIATED",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Center for Endocrinology and Metabolism, Sahlgrenska University Hospital, Gothenburg, Sweden|MedTech West, Institute of Neuro Science and Physiology, Department for Clinical Neuro Science and Rehabilitation, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden|Department of Ophthalmology, Sahlgrenska University Hospital/Mölndal, Mölndal, Sweden|Department of Rheumatology, Sahlgrenska University Hospital/Mölndal, Mölndal, Sweden|Department of Radiology, Karolinska University Hospital, Stockholm, Sweden",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Terminated,NCT00918554,SARCOID-ASSOCIATED UVEITIS|OCULAR SARCOIDOSIS|MACULAR EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hôpital Avicenne - Service de Médecine Interne, Bobigny, France|CHU Michallon de Grenoble, Grenoble, France",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CC(C)NCC(O)COc1cccc2ccccc12,1,DB00571,__PROPRANOLOL,6500454,Completed,NCT01458600,GRAVES´ DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Departmenty of Endocrinology, Skane University Hospital, Malmö, Sweden|Department of Endocrinology, Karolinska Hospital, Stockholm, Sweden|Department of Internal Medicine, section of Endocrinology, Sodersjukhuset, Stockholm, Sweden",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,14.8832624899895,1234.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.03,259.3434,41.49,3.0,2.0,2.0,29.98,76.83,6.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0
CC(C)NCC(O)COc1cccc2ccccc12,1,DB00571,__PROPRANOLOL,6500454,Completed,NCT02350985,VESTIBULAR MIGRAINE,All,18 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Haseki Training and Research Hospital, Istanbul, Turkey",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,14.8832624899895,1234.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.03,259.3434,41.49,3.0,2.0,2.0,29.98,76.83,6.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0
CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00572,__ATROPINE,3935303,Completed,NCT03158142,MYOPIA,All,18 Years to 40 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"State University of New York College of Optometry, New York, New York, United States",7,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,38.834472987124904,459.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.19,289.3694,49.77,3.0,1.0,3.0,31.28,80.82,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0
CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00572,__ATROPINE,3935303,Recruiting,NCT03638726,CATARACT|MYDRIASIS|ADVERSE DRUG EVENT,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,"Dar El Oyoun Hospital, Cairo, Giza, Egypt",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,38.834472987124904,459.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.19,289.3694,49.77,3.0,1.0,3.0,31.28,80.82,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0
CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00572,__ATROPINE,3935303,Completed,NCT00094614,AMBLYOPIA,All,3 Years to 7 Years   (Child),Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Wilmer Eye Institute, Baltimore, Maryland, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.0,38.834472987124904,459.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.19,289.3694,49.77,3.0,1.0,3.0,31.28,80.82,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0
CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21,1,DB00577,__VALACICLOVIR,4957924,Recruiting,NCT03134196,HERPES ZOSTER OPHTHALMICUS,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Alabama at Birmingham, Birmingham, Alabama, United States|Mayo Clinic - Arizona, Scottsdale, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Scripps Clinic, La Jolla, California, United States|Loma Linda University Eye Institute, Loma Linda, California, United States|Jules Stein Eye Clinic - UCLA, Los Angeles, California, United States|Byers Eye Institute at Stanford University, Palo Alto, California, United States|UCSF- Francis I. Proctor Foundation, San Francisco, California, United States|Pacific Eye Surgeons, Inc., San Luis Obispo, California, United States|University of Colorado, Aurora, Colorado, United States|Colorado Cornea Consultants P.C., Littleton, Colorado, United States|Medstar Georgetown University Hospital, Washington, District of Columbia, United States|Delray Eye Associates, PA, Delray Beach, Florida, United States|University of Florida, Gainesville, Florida, United States|Florida Eye Specialists, Jacksonville, Florida, United States|University of Miami - Bascom Palmer Eye Institute, Miami, Florida, United States|Eye Consultants of Atlanta, PC, Atlanta, Georgia, United States|University of Illinois, Chicago, Illinois, United States|NorthShore University Health System, Glenview, Illinois, United States|Case Western Reserve University, Cleveland, Indiana, United States|Indiana University - Glick Eye Institute, Indianapolis, Indiana, United States|University of Kansas Medical Center, Prairie Village, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|LSU Health Science Center, New Orleans, Louisiana, United States|Shreveport Eye Clinic, Shreveport, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|The Krieger Eye Institute, Baltimore, Maryland, United States|Wilmer Eye Institute John Hopkins, Bethesda, Maryland, United States|Crossroads Eye Physician, Owings Mills, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Lahey Medical Center, Peabody, Massachusetts, United States|Eye Health Services, Weymouth, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Verdier Eye Center, Grand Rapids, Michigan, United States|Northwest Eye Clinic, Golden Valley, Minnesota, United States|Jennifer Burdick, Minnetonka, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University Opthalmology, Saint Louis, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|EyeCare MD of NJ, Morristown, New Jersey, United States|Albany Stratton VA Medical Center, Albany, New York, United States|Finger Lakes Ophthalmology /The Eye Care Center, Canandaigua, New York, United States|Stony Brook Ophthalmology, East Setauket, New York, United States|Northwell Health, Great Neck, New York, United States|New York Eye and Ear Infirmary, New York, New York, United States|NYU Langone Health, New York, New York, United States|Weill Cornell Ophthalmology, New York, New York, United States|Duke University, Durham, North Carolina, United States|Cincinnati Eye Institute, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Devers Eye Institute, Portland, Oregon, United States|Casey Eye Institute - Oregon Health and Science University, Portland, Oregon, United States|Vantage Eye Care Center, LLC, Bala-Cynwyd, Pennsylvania, United States|Geisinger Eye Clinic, Danville, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Corneal Associates at Wills Eye Hospital, Philadelphia, Pennsylvania, United States|University of Tennessee - Hamilton Eye Institute, Memphis, Tennessee, United States|Cornea and Cataract Consultants of Nashville, Nashville, Tennessee, United States|Vanderbilt Eye Institute, Nashville, Tennessee, United States|Cornea Associates of Texas, Dallas, Texas, United States|University of Texas Southwestern, Dallas, Texas, United States|Cornea Consultants of Texas, Fort Worth, Texas, United States|Alkek Eye Center - Baylor College of Medicine, Houston, Texas, United States|R and R Eye Research, LLC, San Antonio, Texas, United States|University of Utah - Moran Eye Center, Salt Lake City, Utah, United States|Virginia Eye Institute, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|NY Eye Surgeons, Seattle, Washington, United States|University of Wisconsin - Madison, Madison, Wisconsin, United States|Royal Alexandra Hospital, Edmonton, Alberta, Canada|University of British Columbia/Vancouver General Hospital Eye Care Centre, Vancouver, British Columbia, Canada|Kingston Health Sciences Centre-HDH Site and Queen's University, Kingston, Ontario, Canada|Prism Eye Institute, Oakville, Ontario, Canada|Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada|The Research Institute of the McGill University Health Centre/McGill Academic Eye Centre, Montréal, Quebec, Canada|Clinique Axe Visuel, Sherbrooke, Quebec, Canada",C07D473/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,24.0,25.4625351649931,393.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,324.3357,146.85,8.0,3.0,2.0,31.96,80.63,8.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0
CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21,1,DB00577,__VALACICLOVIR,4957924,Recruiting,NCT03626376,HERPES SIMPLEX VIRUS KERATITIS,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"New York University School of Medicine, New York, New York, United States",C07D473/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,25.4625351649931,393.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,324.3357,146.85,8.0,3.0,2.0,31.96,80.63,8.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Unknown status,NCT03458923,DIABETIC MACULAR EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cairo University, Cairo, Egypt",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Completed,NCT01458600,GRAVES´ DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Departmenty of Endocrinology, Skane University Hospital, Malmö, Sweden|Department of Endocrinology, Karolinska Hospital, Stockholm, Sweden|Department of Internal Medicine, section of Endocrinology, Sodersjukhuset, Stockholm, Sweden",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Completed,NCT02229747,PHARYNGITIS,All,2 Years to 8 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Completed,NCT00595543,ACUTE PSEUDOPHAKIC CYSTOID MACULAR EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Soll Eye Associates, Philadelphia, Pennsylvania, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT03443843,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kingston General Hospital, Kingston, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00487032,ALLERGIC RHINITIS|TACHYPHYLAXIS|RHINITIS MEDICAMENTOSA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Perth Royal Infirmary (Tayside NHS Trust), Perth, Perthshire, United Kingdom|Ninewells Hospital and Medical School (Tayside NHS Trust, University of Dundee), Dundee, Tayside, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT03004131,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Inflamax Research, Mississauga, Ontario, Canada",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Unknown status,NCT02402465,ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","The University of Chicago Medicine, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT01439815,ALLERGIC RHINITIS|ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Ora, Inc., Andover, Massachusetts, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00848965,"RHINITIS, ALLERGIC, PERENNIAL|ALLERGIC RHINITIS",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Vienna, Austria",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Terminated,NCT00119015,"RHINITIS, ALLERGIC, PERENNIAL",All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","The University of Chicago, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00903227,ASTHMA|ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Asthma and Allergy Research Group, Ninewells Hospital and University of Dundee, Dundee, Angus, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00296530,ASTHMA,All,"15 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"GSK Investigational Site, Ozark, Alabama, United States|GSK Investigational Site, Tempe, Arizona, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Fountain Valley, California, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Palmdale, California, United States|GSK Investigational Site, Riverside, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Jose, California, United States|GSK Investigational Site, Stockton, California, United States|GSK Investigational Site, Vista, California, United States|GSK Investigational Site, Colorado Springs, Colorado, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Wheat Ridge, Colorado, United States|GSK Investigational Site, Coral Gables, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Sarasota, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Lawrenceville, Georgia, United States|GSK Investigational Site, Lilburn, Georgia, United States|GSK Investigational Site, Marietta, Georgia, United States|GSK Investigational Site, Kenilworth, Illinois, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Covington, Louisiana, United States|GSK Investigational Site, Lafayette, Louisiana, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, Chevy Chase, Maryland, United States|GSK Investigational Site, North Andover, Massachusetts, United States|GSK Investigational Site, Ypsilanti, Michigan, United States|GSK Investigational Site, Rolla, Missouri, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Ocean, New Jersey, United States|GSK Investigational Site, Skillman, New Jersey, United States|GSK Investigational Site, Ithaca, New York, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, North Olmsted, Ohio, United States|GSK Investigational Site, Sylvania, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Lake Oswego, Oregon, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Collegeville, Pennsylvania, United States|GSK Investigational Site, Gibsonia, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, East Providence, Rhode Island, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Greer, South Carolina, United States|GSK Investigational Site, Chattanooga, Tennessee, United States|GSK Investigational Site, Germantown, Tennessee, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Corsicana, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Killeen, Texas, United States|GSK Investigational Site, Plano, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Waco, Texas, United States|GSK Investigational Site, Murray, Utah, United States|GSK Investigational Site, West Jordan, Utah, United States|GSK Investigational Site, South Burlington, Vermont, United States|GSK Investigational Site, Charlottesville, Virginia, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT02338362,"OCULAR HYPERTENSION|GLAUCOMA, OPEN-ANGLE",All,"18 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC,1,DB00590,__DOXAZOSIN,4188390,Completed,NCT01946035,ALLERGIC RHINITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Brian Lipworth, Dundee, United Kingdom",C07D319/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,15.8360541284215,320.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,451.4751,112.27,9.0,1.0,5.0,47.17,121.64,4.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,1
CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB00591,__FLUOCINOLONE_ACETONIDE,6217895,Completed,NCT00543296,UVEITIS,All,"Child, Adult, Older Adult",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duke University Eye Center, Durham, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,21.0,24.871147251483606,542.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.47,452.4882,93.06,6.0,2.0,5.0,44.84,111.41,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC[C@@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,1,DB00602,__IVERMECTIN,6103248,Not yet recruiting,NCT03570814,TRACHOMA|LYMPHATIC FILARIASES,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A01N53/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,26.809585412431396,1324.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.83,1736.1589,170.06,13.0,3.0,14.0,96.87,230.33,15.0,1.0,0.0,0.0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,1,0,1
CC[C@@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,1,DB00602,__IVERMECTIN,6103248,Withdrawn,NCT01903057,TRACHOMA|LYMPHATIC FILARIASIS,All,"5 Years to 65 Years   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","National Institute of Health, Ministry of Health, Maputo, Mozambique",A01N53/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,26.809585412431396,1324.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.83,1736.1589,170.06,13.0,3.0,14.0,96.87,230.33,15.0,1.0,0.0,0.0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,1,0,1
COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@@H]1OC,1,DB00604,__CISAPRIDE,5648093,Terminated,NCT01281553,GASTROESOPHAGEAL REFLUX,All,1 Month to 18 Months   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,A61K8/60,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,57.0,25.7910840058317,205.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,465.945,86.05,6.0,2.0,3.0,49.11,122.93,9.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1
COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@@H]1OC,1,DB00604,__CISAPRIDE,5648093,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K8/60,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,57.0,25.7910840058317,205.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,465.945,86.05,6.0,2.0,3.0,49.11,122.93,9.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1
Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3,1,DB00611,__BUTORPHANOL,4315936,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,26.021068194418696,660.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.65,327.4605,43.7,3.0,2.0,5.0,37.94,95.92,2.0,0.0,1.0,0.0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,1,DB00619,__IMATINIB,5521184,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D409/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,25.002566787819,623.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.47,493.6027,86.28,7.0,2.0,5.0,55.54,148.93,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT03634852,ENDOPHTHALMITIS POSTOPERATIVE,All,"38 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT01154153,"RHINITIS, ALLERGIC, SEASONAL",All,2 Years to 12 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Investigational Site Number 840003, Cypress, California, United States|Investigational Site Number 840006, Stockbridge, Georgia, United States|Investigational Site Number 840007, North Dartmouth, Massachusetts, United States|Investigational Site Number 840010, Plymouth, Minnesota, United States|Investigational Site Number 840001, Omaha, Nebraska, United States|Investigational Site Number 840008, Raleigh, North Carolina, United States|Investigational Site Number 840002, Spartanburg, South Carolina, United States|Investigational Site Number 840005, San Antonio, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Unknown status,NCT02379000,EXUDATIVE RETINAL DETACHMENT|UVEAL MELANOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Charité Universitätsmedizin Berlin, Berlin, Germany",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT02877485,NASAL OBSTRUCTION,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Stanford Hospital and Clinics, Stanford, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Unknown status,NCT02917564,GLAUCOMA|CHOROIDAL EFFUSIONS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Not yet recruiting,NCT04075136,EXUDATIVE AGE RELATED MACULAR DEGENERATION,All,"50 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,"Active, not recruiting",NCT02806752,WET MACULAR DEGENERATION,All,"50 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Beijing Aier Intech Eye Hospital, Beijing, Beijing, China|Guangzhou Aier Eye Hospital, Guanzhou, Guangdong, China|Shenzhen Aier Eye Hospital, Shenzhen, Guangdong, China|Shenzhen Eye Hospital, Shenzhen, Guangdong, China|Harbin Aier Eye Hospital, Harbin, Heilongjiang, China|Wuhan General Hospital of PLA, Wuhan, Hubei, China|The Eye Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Withdrawn,NCT02598869,UVEITIS|CYSTOID MACULAR EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT01420471,SINUSITIS,All,"19 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","E.N.T. Clinic, St. Paul's Hospital, Vancouver, British Columbia, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Unknown status,NCT00566761,MACULAR EDEMA|CENTRAL RETINAL VEIN OCCLUSION,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Asociacion Para Evitar la Ceguera en Mexico, Mexico city, Coyoacan, Mexico",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT01599273,THYROID-ASSOCIATED OPHTHALMOPATHY,All,"19 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Severance hospital, Seoul, Korea, Republic of",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT00737971,DIABETIC MACULAR EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Federal University of Sao Paulo - Dept. of Ophthalmology / Vision Institute, São Paulo, Brazil",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT01995045,RETINAL DETACHMENT|PROLIFERATIVE VITREORETINOPATHY|RETINOSCHISIS,All,"18 Years to 89 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Emory University Eye Center, Atlanta, Georgia, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,,RETINAL DETACHMENT,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,1,DB00623,__FLUPHENAZINE,3993072,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",A61M31/002,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,13.240518285796401,311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.4,437.522,29.95,4.0,1.0,4.0,44.92,117.27,7.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,,AGING,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/7084,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1,1,DB00626,__BACITRACIN,,Withdrawn,NCT00671541,CHRONIC SINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Lahey Clinic, Inc, Burlington, Massachusetts, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.9,1422.693,530.87,20.0,17.0,4.0,149.32,363.14,31.0,1.0,0.0,0.0,1,1,1,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,1,0,1,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,0,0
O=C(O)C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O,1,DB00628,__CLORAZEPIC_ACID,WO-1998022114-A1,Terminated,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,59.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.68,314.723,78.76,4.0,2.0,3.0,30.63,82.68,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0
NCCCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00630,__ALENDRONIC_ACID,5358941,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,22.7355797860325,8.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.3,249.09599999999998,161.31,8.0,6.0,0.0,19.4,47.37,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT01569048,CHRONIC SINUSITIS,All,"20 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Severance Hospital, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT01001429,RETINAL DETACHMENT,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","UMDNJ-University Hospital, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT00786370,CATARACT,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Cooper University Hospital, Camden, New Jersey, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT02062333,"ANESTHESIA; ADVERSE EFFECT|REFLEX, ABNORMAL|TINNITUS, SPONTANEOUS OTO-ACOUSTIC EMISSION",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kayseri Education and Research Hospital, Kayseri, Turkey",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Terminated,NCT03401606,FAILED CONSCIOUS SEDATION DURING PROCEDURE,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT02072083,PREMEDICATION|OCULOCARDIAC REFLEX,All,2 Years to 11 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Erciyes university hospital, Kayseri, Turkey",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT00654511,TONSILLITIS,All,2 Years to 12 Years   (Child),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Children's National Medical Center, Washington, District of Columbia, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Recruiting,NCT04528173,ANESTHESIA|OPIOID USE|TONSILLITIS|SLEEP DISORDER|SURGERY,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT00654329,OTITIS,All,6 Months to 6 Years   (Child),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Children's National Medical Center, Washington, District of Columbia, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT01895023,INHALATIONAL ANESTHETICS ADVERSE REACTION|DELIRIUM ON EMERGENCE|STRABISMUS FOLLOWING OCULAR SURGERY,All,2 Years to 6 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Fujian Provincial Hospital, Fuzhou, Fujian, China",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Terminated,NCT02162433,ADENOTONSILLAR HYPERTROPHY|OBSTRUCTIVE SLEEP APNEA|TONSILLITIS|ADENOIDITIS,All,3 Years to 16 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MEEI, Boston, Massachusetts, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT01901588,STRABISMUS|DELIRIUM ON EMERGENCE|PEDIATRIC DISORDERS,All,1 Year to 7 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","NYU Langone Medical Center, New York, New York, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT03690622,GLAUCOMA|INTRAOCULAR PRESSURE,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Beirut Eye Specialist Hospital, Beirut, Lebanon",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Recruiting,NCT02370550,SJOGREN'S SYNDROME,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Peking University People's Hospital, Beijing, Beijing, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Unknown status,NCT01969019,GRAVES' OPHTHALMOPATHY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Institute of Endocrine and Metabolic Diseases Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai, Shanghai, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT01042145,CROUP,All,1 Year to 8 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Washington University School of Medicine, St. Louis, Missouri, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Not yet recruiting,NCT04501367,VITRECTOMY|MACULAR PUCKER|RETINAL EDEMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Unknown status,NCT02809079,NEUROMYELITIS OPTICA SPECTRUM DISORDERS|MYCOPHENOLATE MOFETIL|EFFICACY AND SAFETY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Withdrawn,NCT02119273,CHRONIC RHINOSINUSITIS WITHOUT NASAL POLYPS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Loma Linda Sinus and Allergy Center, Redlands, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Withdrawn,NCT00841802,CHRONIC SINUSITIS|RHINOSINUSITIS|NASAL POLYPS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Chicago, Illinois, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Enrolling by invitation,NCT01903486,ACHALASIA,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Not yet recruiting,NCT04140201,DIABETIC RETINOPATHY,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D205/08 ,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,1,DB00654,__LATANOPROST,5296504,Completed,NCT01162603,PRIMARY OPEN ANGLE GLAUCOMA|OCULAR HYPERTENSION,All,"45 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Glaucoma Unit, 1st University Department of Ophthalmology, Aristotle University, AHEPA Hospital, Thessaloniki, Greece|USVD ""Centro per lo studio del glaucoma"" Spedali civili di Brescia, Brescia, Italy",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,15.408940635331302,173.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.16,432.5928,86.99,4.0,3.0,2.0,50.71,124.34,14.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,1,DB00654,__LATANOPROST,5296504,Not yet recruiting,NCT04140279,OCULAR HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Bausch Site 001, Rochester, Minnesota, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,15.408940635331302,173.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.16,432.5928,86.99,4.0,3.0,2.0,50.71,124.34,14.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,1,DB00654,__LATANOPROST,5296504,Completed,NCT03966560,"GLAUCOMA, OPEN-ANGLE",All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,15.408940635331302,173.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.16,432.5928,86.99,4.0,3.0,2.0,50.71,124.34,14.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,1,DB00654,__LATANOPROST,5296504,Completed,NCT01525173,GLAUCOMA|OCULAR HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Deerfield Beach, Florida, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,15.408940635331302,173.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.16,432.5928,86.99,4.0,3.0,2.0,50.71,124.34,14.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,1,DB00654,__LATANOPROST,5296504,Completed,NCT00397241,OPEN-ANGLE GLAUCOMA,All,"29 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Glaucoma Unit, A University Dept of Ophthalmology, Thessaloniki, Greece",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,15.408940635331302,173.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.16,432.5928,86.99,4.0,3.0,2.0,50.71,124.34,14.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,1,DB00654,__LATANOPROST,5296504,Completed,NCT00348400,GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single,"Dr. Noecker, Pittsburgh, Pennsylvania, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,15.408940635331302,173.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.16,432.5928,86.99,4.0,3.0,2.0,50.71,124.34,14.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,1,DB00654,__LATANOPROST,5296504,Completed,NCT00273481,OPEN-ANGLE GLAUCOMA|OCULAR HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"Lawson Health Research Insitute, London, Ontario, Canada|University Eye Clinic, Ljubljana, Slovenia",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,15.408940635331302,173.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.16,432.5928,86.99,4.0,3.0,2.0,50.71,124.34,14.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,1,DB00654,__LATANOPROST,5296504,Completed,NCT01978015,"UVEITIS, ANTERIOR|CYSTOID MACULAR EDEMA",All,"18 Years to 95 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital de Clínicas, UNICAMP, Campinas, São Paulo, Brazil",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,15.408940635331302,173.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.16,432.5928,86.99,4.0,3.0,2.0,50.71,124.34,14.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,1,DB00654,__LATANOPROST,5296504,Completed,NCT00913029,"EYE DISEASES|GLAUCOMA, OPEN-ANGLE|GLAUCOMA",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"SV Malayan Ophthalmological Center, Yerevan, Armenia|Allgemeines Krankenhaus Wien, Wien, Austria|CHU de Lyon Hopital Edouard Herriot, Lyon, France|CHNO des Quinze-Vingts, Paris, France|Knapschaftskrankenhaus Bochum Langendreer, Bochum, Germany|Helios Cliniic, Erfurt, Germany|Universitatsklinkum Erlangen, Erlangen, Germany|AHEPA Hospital, Thessaloniki, Greece|Universita'degli Studi di Parma, Parma, Italy|Universita' di Torino/Dipartimento di Fisiopatologia Clinica-Clinica Oculistica, Torino, Italy|Azienda Ospedaliera S. Maria della Misericordia, Udine, Italy|Military Health Service Institute, Warsaw, Poland|Hospital Torrevieja Salud, UTE, Alicante, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Hinchingbrooke Hospital Moorfields, Bedford, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,15.408940635331302,173.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.16,432.5928,86.99,4.0,3.0,2.0,50.71,124.34,14.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,1,DB00654,__LATANOPROST,5296504,Recruiting,NCT04412096,GLAUCOMA|OHT - OCULAR HYPERTENSION,All,"30 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|The Ohio State University, Columbus, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,15.408940635331302,173.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.16,432.5928,86.99,4.0,3.0,2.0,50.71,124.34,14.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,1,DB00654,__LATANOPROST,5296504,Recruiting,NCT04178863,GLAUCOMA; DRUGS,All,"18 Years to 101 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Arizona Eye Consultants, Tucson, Arizona, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,15.408940635331302,173.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.16,432.5928,86.99,4.0,3.0,2.0,50.71,124.34,14.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,1,DB00654,__LATANOPROST,5296504,Recruiting,NCT04098861,PRIMARY OPEN ANGLE GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universiti Kebangsaan Malaysia Medical Centre, Cheras, Wilayah Persekutuan Kuala Lumpur, Malaysia",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,15.408940635331302,173.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.16,432.5928,86.99,4.0,3.0,2.0,50.71,124.34,14.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,1,DB00654,__LATANOPROST,5296504,Completed,NCT01677507,GLAUCOMA|HEALTHY,All,"40 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,15.408940635331302,173.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.16,432.5928,86.99,4.0,3.0,2.0,50.71,124.34,14.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,1,DB00654,__LATANOPROST,5296504,Unknown status,NCT01580254,INTRAOCULAR PRESSURE (IOP)|TEAR BREAK-UP TIME,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Catanzaro - Eye Department, Catanzaro, Italy",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,15.408940635331302,173.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.16,432.5928,86.99,4.0,3.0,2.0,50.71,124.34,14.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,1,DB00654,__LATANOPROST,5296504,Terminated,NCT01151904,"GLAUCOMA, ANGLE-CLOSURE",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bangkok, Thailand",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,15.408940635331302,173.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.16,432.5928,86.99,4.0,3.0,2.0,50.71,124.34,14.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,1,DB00654,__LATANOPROST,5296504,Completed,NCT00705757,GLAUCOMA|APPLICATION SITE PIGMENTATION CHANGES,All,"30 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Arlington Eye Physicians, Arlington Heights, Illinois, United States|Summa Health System, Akron, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,15.408940635331302,173.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.16,432.5928,86.99,4.0,3.0,2.0,50.71,124.34,14.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,1,DB00654,__LATANOPROST,5296504,Completed,NCT00539526,OPEN ANGLE GLAUCOMA|OCULAR HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"San Diego, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,15.408940635331302,173.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.16,432.5928,86.99,4.0,3.0,2.0,50.71,124.34,14.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,1,DB00654,__LATANOPROST,5296504,Completed,NCT01253902,"GLAUCOMA, OPEN-ANGLE|OCULAR HYPERTENSION",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Rogers, Arkansas, United States|Calgary, Alberta, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,15.408940635331302,173.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.16,432.5928,86.99,4.0,3.0,2.0,50.71,124.34,14.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,1,DB00654,__LATANOPROST,5296504,Completed,NCT00541242,OCULAR HYPERTENSION|GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Newport Beach, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,15.408940635331302,173.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.16,432.5928,86.99,4.0,3.0,2.0,50.71,124.34,14.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,1,DB00654,__LATANOPROST,5296504,Completed,NCT00140062,"OCULAR HYPERTENSION|GLAUCOMA, OPEN-ANGLE",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pfizer Investigational Site, Helsinki, Finland|Pfizer Investigational Site, Helsinki, Finland|Pfizer Investigational Site, Kuopio, Finland|Pfizer Investigational Site, Lahti, Finland|Pfizer Investigational Site, Rovaniemi, Finland|Pfizer Investigational Site, Seinajoki, Finland|Pfizer Investigational Site, Tammisaari, Finland|Pfizer Investigational Site, Tampere, Finland|Pfizer Investigational Site, Turku, Finland|Pfizer Investigational Site, JÃ¶nkÃ¶ping, Sweden|Pfizer Investigational Site, Karlstad, Sweden|Pfizer Investigational Site, Kristianstad, Sweden|Pfizer Investigational Site, Linkoping, Sweden|Pfizer Investigational Site, Ludvika, Sweden|Pfizer Investigational Site, Molndal, Sweden|Pfizer Investigational Site, Nacka, Sweden|Pfizer Investigational Site, Norrkoping, Sweden|Pfizer Investigational Site, Norrkoping, Sweden|Pfizer Investigational Site, NykÃ¶ping, Sweden|Pfizer Investigational Site, Orebro, Sweden|Pfizer Investigational Site, Seinajoki, Sweden|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site, Sundsvall, Sweden|Pfizer Investigational Site, TÃ¤by, Sweden|Pfizer Investigational Site, Uppsala, Sweden|Pfizer Investigational Site, Uppsala, Sweden",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,15.408940635331302,173.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.16,432.5928,86.99,4.0,3.0,2.0,50.71,124.34,14.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,1,DB00654,__LATANOPROST,5296504,Completed,NCT01225653,DIABETIC RETINOPATHY,All,20 Years to 36 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Department of Ophthalmology, Århus University Hospital, Århus, Denmark",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,15.408940635331302,173.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.16,432.5928,86.99,4.0,3.0,2.0,50.71,124.34,14.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1
COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,1,DB00661,__VERAPAMIL,5785994,Recruiting,NCT04404439,"TINNITUS, SUBJECTIVE|TINNITUS",All,"25 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of California, Irvine Medical Center ENT Clinic (Pavilion 2), Orange, California, United States",A61K9/0004,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,75.8619273496375,982.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.23,454.6016,63.95,6.0,0.0,2.0,51.7,132.65,13.0,1.0,0.0,0.0,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0
CNC[C@H](O)c1ccc(O)c(O)c1,1,DB00668,__EPINEPHRINE,5665071,Recruiting,NCT03638726,CATARACT|MYDRIASIS|ADVERSE DRUG EVENT,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,"Dar El Oyoun Hospital, Cairo, Giza, Egypt",A61M5/31511,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CNC[C@H](O)c1ccc(O)c(O)c1,1,DB00668,__EPINEPHRINE,5665071,Terminated,NCT02895035,CATARACT,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other",,A61M5/31511,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CNC[C@H](O)c1ccc(O)c(O)c1,1,DB00668,__EPINEPHRINE,5665071,"Active, not recruiting",NCT03228914,ENDOSCOPIC SINUS SURGERY|NASAL POLYPS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"The University of Texas Health Science Center at Houston, Houston, Texas, United States",A61M5/31511,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CNC[C@H](O)c1ccc(O)c(O)c1,1,DB00668,__EPINEPHRINE,5665071,Unknown status,NCT01664507,"CROUP|EPINEPHRINE, ADMINISTRATION, INHALATION",All,6 Months to 5 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Seoul National University Hospital, Seoul, Korea, Republic of",A61M5/31511,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,1,DB00675,__TAMOXIFEN,6127425,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,27.2695537896055,7013.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.93,371.5146,12.47,2.0,0.0,3.0,44.19,128.43,8.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Completed,NCT03054103,PHACOEMULSIFICATION|CATARACT,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Completed,NCT01895023,INHALATIONAL ANESTHETICS ADVERSE REACTION|DELIRIUM ON EMERGENCE|STRABISMUS FOLLOWING OCULAR SURGERY,All,2 Years to 6 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Fujian Provincial Hospital, Fuzhou, Fujian, China",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Completed,,ANAESTHESIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,1,DB00684,__TOBRAMYCIN,5149694,Completed,NCT00705159,CONJUNCTIVITIS,All,up to 6 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pediatric Ophthalmology of Erie, Erie, Pennsylvania, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,34.0048050267972,662.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-3.0,467.5145,268.17,14.0,10.0,3.0,47.18,106.69,6.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,1,DB00684,__TOBRAMYCIN,5149694,Unknown status,NCT02873806,OPEN-ANGLE GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"S.V. Malayan's Ophtalmology Centre, Yerevan, Armenia",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,34.0048050267972,662.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-3.0,467.5145,268.17,14.0,10.0,3.0,47.18,106.69,6.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,1,DB00684,__TOBRAMYCIN,5149694,Completed,,CATARACT,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,34.0048050267972,662.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-3.0,467.5145,268.17,14.0,10.0,3.0,47.18,106.69,6.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,1,DB00684,__TOBRAMYCIN,5149694,Completed,,CHALAZION,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,34.0048050267972,662.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-3.0,467.5145,268.17,14.0,10.0,3.0,47.18,106.69,6.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Unknown status,NCT02809079,NEUROMYELITIS OPTICA SPECTRUM DISORDERS|MYCOPHENOLATE MOFETIL|EFFICACY AND SAFETY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D307/88,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13,1,DB00700,__EPLERENONE,6410524,"Active, not recruiting",NCT03079141,CHRONIC CENTRAL SEROUS CHORIORETINOPATHY,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Academic Medical Center, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,105.0,31.639253372759104,243.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.67,414.4914,82.2,4.0,0.0,6.0,43.79,106.68,2.0,0.0,1.0,0.0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0
CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1,1,DB00706,__TAMSULOSIN,4703063,Completed,NCT03144596,BENIGN PROSTATIC HYPERPLASIA|PUPIL ANOMALY|CHOROID DISEASE,Male,"45 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D203/10,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,27.3024086736894,325.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.05,408.51199999999994,99.88,6.0,2.0,2.0,43.95,108.86,11.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0
CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1,1,DB00708,__SUFENTANIL,8202535,Unknown status,NCT02205580,SLEEP BREATHING DISORDERS|TONSILLITIS|ADENOID HYPERTROPHY,All,5 Years to 8 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,65.4469290950532,1368.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.4,386.551,32.78,3.0,0.0,3.0,43.85,111.42,8.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1,0,1
Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,1,DB00715,__PAROXETINE,5811436,Recruiting,NCT04404439,"TINNITUS, SUBJECTIVE|TINNITUS",All,"25 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of California, Irvine Medical Center ENT Clinic (Pavilion 2), Orange, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,25.692519353580106,485.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.1,329.3654,39.72,4.0,1.0,4.0,34.48,88.02,4.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,1,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,1,DB00736,__ESOMEPRAZOLE,5900424,Completed,NCT00637845,HEARTBURN|GASTROESOPHAGEAL REFLUX DISEASE,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,1,DB00736,__ESOMEPRAZOLE,5900424,Completed,NCT00206180,EROSIVE ESOPHAGITIS|REFLUX ESOPHAGITIS|GASTROESOPHAGEAL REFLUX DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,"Research Site, Alabaster, Alabama, United States|Research Site, Anaheim, California, United States|Research Site, Dinuba, California, United States|Research Site, Fresno, California, United States|Research Site, Orange, California, United States|Research Site, San Diego, California, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Zephyr Hills, Florida, United States|Research Site, Decatur, Georgia, United States|Research Site, Rome, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Oakbrook Terrace, Illinois, United States|Research Site, Urbana, Illinois, United States|Research Site, Louisville, Kentucky, United States|Research Site, Covington, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Chevy Chase, Maryland, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Troy, Michigan, United States|Research Site, Egg Harbor Township, New Jersey, United States|Research Site, Passaic, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, New York, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Jacksonville, North Carolina, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, N Providence, Rhode Island, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Bellevue, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Milwaukee, Wisconsin, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,1,DB00736,__ESOMEPRAZOLE,5900424,Completed,NCT00410592,GASTROESOPHAGEAL REFLUX,All,"18 Years to 69 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Anaheim, California, United States|Research Site, Orange, California, United States|Research Site, San Diego, California, United States|Research Site, Miami, Florida, United States|Research Site, Chicago, Illinois, United States|Research SIte, Chapel Hill, North Carolina, United States|Research Site, Houston, Texas, United States|Research Site, San Juan, Puerto Rico",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,1,DB00736,__ESOMEPRAZOLE,5900424,Withdrawn,NCT02530879,LARYNGOPHARYNGEAL REFLUX,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Temple Otolaryngology, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,1,DB00736,__ESOMEPRAZOLE,5900424,Completed,NCT00628667,CHRONIC POSTERIOR LARYNGITIS (CPL),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,1,DB00736,__ESOMEPRAZOLE,5900424,Unknown status,NCT02277886,GASTROESOPHAGEAL REFLUX DISEASE|HEARTBURN|SLEEP DISTURBANCE,All,"20 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chang Gung Memorial Hospital, Taipei, Taiwan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,1,DB00736,__ESOMEPRAZOLE,5900424,Completed,NCT00628342,GASTROESOPHAGEAL REFLUX DISEASE,All,"18 Years to 85 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,1,DB00736,__ESOMEPRAZOLE,5900424,Completed,NCT00635414,GERD,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,1,DB00736,__ESOMEPRAZOLE,5900424,Completed,NCT00384592,GASTRO-OESOPHAGEAL REFLUX DISEASE,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Allerton, United Kingdom|Research Site, Ashford, United Kingdom|Research Site, Atherstone, United Kingdom|Research Site, Ayrshire, United Kingdom|Research Site, Bath, United Kingdom|Research Site, Blackpool, United Kingdom|Research SIte, Bolton, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Fowey, United Kingdom|Research SIte, Glasgow, United Kingdom|Research Site, Hamilton, United Kingdom|Research Site, Motherwell, United Kingdom|Research Site, Stevenage, United Kingdom|Research Site, Warminster, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,1,DB00736,__ESOMEPRAZOLE,5900424,Completed,NCT01349413,DYSPEPSIA|GASTROESOPHAGEAL REFLUX,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","Prince of Wales Hospital, Hong Kong, Hong Kong",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,1,DB00736,__ESOMEPRAZOLE,5900424,Completed,NCT00472550,GASTROESOPHAGEAL REFLUX|HEARTBURN,Male,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"Dep. Medicine II, University Hospital Mannheim, Mannheim, Germany",4,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,1,DB00736,__ESOMEPRAZOLE,5900424,Completed,NCT00228527,GASTROESOPHAGEAL REFLUX DISEASE (GERD)|EROSIVE ESOPHAGITIS|NON-EROSIVE ESOPHAGITIS,All,1 Year to 11 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Research Site, Mobile, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Wilmington, Delaware, United States|Research Site, Orlando, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Park Ridge, Illinois, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Troy, Michigan, United States|Research Site, Jackson, Mississippi, United States|Research Site, St. Louis, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Morristown, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, Buffalo, New York, United States|Research Site, West Islip, New York, United States|Research Site, Columbus, Ohio, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Burlington, Vermont, United States|Research Site, Norfolk, Virginia, United States|Research Site, Brussels (Jette), Belgium|Research Site, Brussels (Laeken), Belgium|Research Site, Brussels (Woluwé-St-Lambert), Belgium|Research Site, Brussels, Belgium|Research Site, Leuven, Belgium|Research Site, Lille, France|Research Site, Paris, France|Research Site, Tours, France|Research Site, Genova, GE, Italy|Research Site, Parma, PR, Italy|Research Site, Roma, RM, Italy|Research Site, Napoli, Italy",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,1,DB00736,__ESOMEPRAZOLE,5900424,Completed,NCT01397084,GASTROESOPHAGEAL REFLUX DISEASE|GERD|REFLUX ESOPHAGITIS,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,1,DB00736,__ESOMEPRAZOLE,5900424,Completed,NCT01119768,NON EROSIVE REFLUX DISEASE|CHRONIC GASTRITIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Guangzhou, Guangdong, China|Research Site, Wuhan, Hubei, China|Research Site, Nanjing, Jiangsu, China|Research Site, Jinan, Shandong, China|Research Site, Xian, Shanxi, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Beijin, China|Research Site, Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,1,DB00736,__ESOMEPRAZOLE,5900424,Completed,NCT00464308,GASTRO-OESOPHAGEAL REFLUX,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Belconnen, Australia|Bondi Junction, Australia|Brookvale, Australia|Browns Plains, Australia|Campbelltown, Australia|Campsie, Australia|Caringbah, Australia|Castle Hill, Australia|Charlestown, Australia|Dapto, Australia|Darlinghurst, Australia|Dubbo, Australia|Elizabeth, Australia|Fairfield, Australia|Hoppers Crossing, Australia|Ingleburn, Australia|Leichhardt, Australia|Maroubra, Australia|Melton, Australia|Mount Druitt, Australia|Oaklands Park, Australia|Royal Park, Australia|Sydney, Australia|Wentworthville, Australia|Wyoming, Australia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1
OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,DB00742,__MANNITOL,3932678,Unknown status,NCT00677664,DIABETIC RETINOPATHY,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Federal University of Sao Paulo, Sao Paulo, SP, Brazil",A23L27/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,18.628719275549802,9603.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.7,182.1718,121.38,6.0,6.0,0.0,17.04,38.4,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
CCCNC(C)C(=O)Nc1ccccc1C,1,DB00750,__PRILOCAINE,6031007,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,30.785026386578693,1115.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.87,220.3107,41.13,2.0,2.0,1.0,25.98,67.86,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NC1=NCC2c3ccccc3Cc3ccccc3N12,1,DB00751,__EPINASTINE,7429602,Completed,NCT02251613,ALLERGIC CONJUNCTIVITIS,All,"20 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,12.1234522269451,349.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.53,249.3104,41.62,3.0,1.0,4.0,27.33,76.9,0.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1
NC1=NCC2c3ccccc3Cc3ccccc3N12,1,DB00751,__EPINASTINE,7429602,Completed,,HYPERSENSITIVITY,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,12.1234522269451,349.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.53,249.3104,41.62,3.0,1.0,4.0,27.33,76.9,0.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1
NC1=NCC2c3ccccc3Cc3ccccc3N12,1,DB00751,__EPINASTINE,7429602,Completed,,SEASONAL ALLERGIC CONJUNCTIVITIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,12.1234522269451,349.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.53,249.3104,41.62,3.0,1.0,4.0,27.33,76.9,0.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1
NC1CC1c1ccccc1,1,DB00752,__TRANYLCYPROMINE,3961073,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,11.039241052177598,31.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.5,133.194,26.02,1.0,1.0,2.0,15.51,41.7,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12,1,DB00759,__TETRACYCLINE,6350468,Completed,NCT00347776,TRICHIASIS,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Johns Hopkins University, Baltimore, Maryland, United States",A61K9/4808,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,37.0,20.3700281319945,4978.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.56,444.4346,181.62,9.0,6.0,4.0,43.03,114.19,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0
Cn1cc[nH]c1=S,1,DB00763,__METHIMAZOLE,,Completed,NCT01458600,GRAVES´ DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Departmenty of Endocrinology, Skane University Hospital, Malmö, Sweden|Department of Endocrinology, Karolinska Hospital, Stockholm, Sweden|Department of Internal Medicine, section of Endocrinology, Sodersjukhuset, Stockholm, Sweden",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.38,114.169,15.27,0.0,1.0,1.0,11.64,33.23,0.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0
Cn1cc[nH]c1=S,1,DB00763,__METHIMAZOLE,,Completed,NCT00150137,TOXIC NODULAR GOITRE|GRAVES DISEASE,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Endocrinology, Odense University Hospital, Odense, Funen, Denmark",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.38,114.169,15.27,0.0,1.0,1.0,11.64,33.23,0.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0
Cn1cc[nH]c1=S,1,DB00763,__METHIMAZOLE,,Completed,NCT00150124,TOXIC NODULAR GOITRE|GRAVES' DISEASE,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Endocrinology, Odense University Hospital, Odense, Funen, Denmark",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.38,114.169,15.27,0.0,1.0,1.0,11.64,33.23,0.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Unknown status,NCT02557269,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medical University Sofia, University Hospital ""Alexandrovska"", Clinic of Allergy and Asthma, Sofia, Bulgaria",A61M15/0065,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT00817050,ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,A61M15/0065,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT00070707,"RHINITIS, ALLERGIC, SEASONAL|ASTHMA",All,"15 Years to 75 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,A61M15/0065,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT02559440,ADENOIDAL HYPERTROPHY,All,5 Years to 11 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,A61M15/0065,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT03590912,OTITIS MEDIA WITH EFFUSION,All,1 Year to 12 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Lumbini Medical College, Tansen, Palpa, Nepal",A61M15/0065,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT03705793,CHRONIC RHINOSINUSITIS (DIAGNOSIS)|ALLERGIC RHINOSINUSITIS|CHRONIC EOSINOPHILIC RHINOSINUSITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Washington University School of Medicine, Saint Louis, Missouri, United States|Washington University, Saint Louis, Missouri, United States",A61M15/0065,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT00834119,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61M15/0065,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Terminated,NCT00491374,PERENNIAL ALLERGIC RHINITIS,All,18 Years to 45 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61M15/0065,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Unknown status,NCT02110654,SINUSITIS|NASAL POLYPS|ASTHMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"the first affiliated hospital, Sun Yat-sen University, Guangzhou, Guangdong, China",A61M15/0065,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT01118312,ASTHMA|RHINITIS|SINUSITIS,All,"6 Years and older   (Child, Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Arizona, Tucson, Arizona, United States|University of California, San Diego, San Diego, California, United States|National Jewish Health, Denver, Colorado, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Univeristy of Miami School of Medicine, Miami, Florida, United States|University of South Florida College of Medicine, Tampa, Florida, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States|University of Missouri, Kansas City School of Medicine, Kansas City, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|North Shore-Long Island Jewish Health System, New Hyde Park, New York, United States|New York University School of Medicine, New York, New York, United States|New York Medical College, Valhalla, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Davis Heart and Lung Research Institute, Columbus, Ohio, United States|Baylor College of Medicine, Houston, Texas, United States|Vermont Lung Center at the University of Vermont, Burlington, Vermont, United States|Univeristy of Virginia, Charlottesville, Virginia, United States",A61M15/0065,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT00359216,PERENNIAL ALLERGIC RHINITIS|OBSTRUCTIVE SLEEP APNEA|SLEEP DISORDER,All,18 Years to 60 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61M15/0065,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Terminated,NCT00553891,NASAL OBSTRUCTION|ADENOIDS HYPERTROPHY|ADENOIDECTOMY,All,2 Years to 11 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61M15/0065,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT01098071,ADENOIDS,All,2 Years to 11 Years   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61M15/0065,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Terminated,NCT01616160,NASAL POLYPS,All,"21 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Massachusetts General Hospital, Boston, Massachusetts, United States",A61M15/0065,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Terminated,NCT01676415,CHRONIC RHINOSINUSITIS WITHOUT NASAL POLYPS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,": Northwestern Medical Faculty Foundation (NMFF) Sinus and Allergy Center, Chicago, Illinois, United States",A61M15/0065,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT03011632,SINUSITIS|ASTHMA,All,4 Years to 8 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Lodz, Poland",A61M15/0065,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Recruiting,NCT03605537,CHOANAL ATRESIA,All,up to 10 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Cincinnati Children's Hospital, Cincinnati, Ohio, United States",A61M15/0065,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61M15/0065,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21,1,DB00766,__CLAVULANIC_ACID,6878386,Recruiting,NCT03809312,CHRONIC SINUS INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Simon-Pierre Harvey-Bolduc, Québec, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,716.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.2,199.1608,87.07,5.0,2.0,2.0,18.13,44.25,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21,1,DB00766,__CLAVULANIC_ACID,6878386,Active Not Recruiting,,PNEUMONIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,716.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.2,199.1608,87.07,5.0,2.0,2.0,18.13,44.25,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21,1,DB00766,__CLAVULANIC_ACID,6878386,Completed,,ACUTE BACTERIAL SINUSITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,716.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.2,199.1608,87.07,5.0,2.0,2.0,18.13,44.25,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21,1,DB00766,__CLAVULANIC_ACID,6878386,Completed,,ACUTE OTITIS MEDIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,716.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.2,199.1608,87.07,5.0,2.0,2.0,18.13,44.25,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,1,DB00768,__OLOPATADINE,5116863,Completed,NCT01732757,"CONJUNCTIVITIS, ALLERGIC",All,"10 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Memphis, Tennessee, United States",C07D313/12,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,62.8185383683443,273.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.99,337.4122,49.77,4.0,1.0,3.0,37.44,109.55,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,1,DB00768,__OLOPATADINE,5116863,Completed,NCT01282138,ALLERGIC CONJUNCTIVITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","Contact Alcon Call Center for Trial Locations, Fort Worth, Texas, United States",C07D313/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,62.8185383683443,273.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.99,337.4122,49.77,4.0,1.0,3.0,37.44,109.55,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,1,DB00768,__OLOPATADINE,5116863,Withdrawn,NCT01076439,ALLERGIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,C07D313/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,62.8185383683443,273.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.99,337.4122,49.77,4.0,1.0,3.0,37.44,109.55,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,1,DB00768,__OLOPATADINE,5116863,Completed,NCT01007253,SEASONAL ALLERGIC RHINITIS,All,18 Years to 45 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","The University of Chicago, Chicago, Illinois, United States",C07D313/12,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,62.8185383683443,273.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.99,337.4122,49.77,4.0,1.0,3.0,37.44,109.55,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,1,DB00768,__OLOPATADINE,5116863,Completed,NCT00979615,VASOMOTOR RHINITIS,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Contact Alcon Call Center For Trial Locations, Fort Worth, Texas, United States",C07D313/12,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,62.8185383683443,273.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.99,337.4122,49.77,4.0,1.0,3.0,37.44,109.55,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,1,DB00768,__OLOPATADINE,5116863,Completed,NCT00789555,PERENNIAL ALLERGIC RHINITIS,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Contact Alcon Call Center For Trial Locations, Fort Worth, Texas, United States",C07D313/12,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,62.8185383683443,273.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.99,337.4122,49.77,4.0,1.0,3.0,37.44,109.55,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,1,DB00768,__OLOPATADINE,5116863,Recruiting,NCT03186755,"CONJUNCTIVITIS, ALLERGIC|CONJUNCTIVITIS, VERNAL",All,"6 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","CHU Sainte-Justine Hospital, Montréal, Quebec, Canada",C07D313/12,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,62.8185383683443,273.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.99,337.4122,49.77,4.0,1.0,3.0,37.44,109.55,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,1,DB00768,__OLOPATADINE,5116863,Completed,,SEASONAL ALLERGIC CONJUNCTIVITIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D313/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,62.8185383683443,273.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.99,337.4122,49.77,4.0,1.0,3.0,37.44,109.55,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,1,DB00770,__ALPROSTADIL,5886039,Unknown Status,,COMPLICATIONS,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,36.0,45.5040144561489,391.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.04,354.48699999999997,94.83,5.0,3.0,1.0,42.13,98.32,13.0,0.0,1.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,1,DB00770,__ALPROSTADIL,5886039,Unknown Status,,STROKE,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,36.0,45.5040144561489,391.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.04,354.48699999999997,94.83,5.0,3.0,1.0,42.13,98.32,13.0,0.0,1.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,1,DB00773,__ETOPOSIDE,4701327,Completed,,RETINOBLASTOMA,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
Nc1nc(=O)c2ncn(COCCO)c2[nH]1,1,DB00787,__ACYCLOVIR,RE39264,Recruiting,NCT03626376,HERPES SIMPLEX VIRUS KERATITIS,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"New York University School of Medicine, New York, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,127.082691636378,2362.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.95,225.2046,114.76,7.0,3.0,2.0,21.51,54.63,4.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1,1,DB00798,__GENTAMICIN,,Unknown status,NCT02582099,RHINOSINUSITIS,All,"7 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Faculty of Medicine Siriraj Hospital, Bangkoknoi, Bangkok, Thailand",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.6,477.5954,199.73,12.0,8.0,3.0,51.92,118.02,7.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0
CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1,1,DB00798,__GENTAMICIN,,Withdrawn,NCT02415257,VESTIBULAR SCHWANNOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Dept. OtoRhinoLaryngology Head and Neck Surgery, Skane University Hospital, Lund, Sweden",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.6,477.5954,199.73,12.0,8.0,3.0,51.92,118.02,7.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0
CCCOc1ccc(C(=O)OCCN(CC)CC)cc1N,1,DB00807,__PROPARACAINE,4022899,Not yet recruiting,NCT04283331,MYOPIA|HYPERMETROPIA|REFRACTIVE ERRORS|ASTIGMATISM,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,16.9859750713566,522.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.97,294.3892,64.79,4.0,1.0,1.0,34.0,86.04,10.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0
CCCOc1ccc(C(=O)OCCN(CC)CC)cc1N,1,DB00807,__PROPARACAINE,4022899,Recruiting,NCT04229771,EPIPHORA|DACRYOSTENOSIS|DACRYOCYSTITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","William Beaumont Hospitals, Royal Oak, Michigan, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,16.9859750713566,522.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.97,294.3892,64.79,4.0,1.0,1.0,34.0,86.04,10.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1,1,DB00809,__TROPICAMIDE,4014335,Unknown status,NCT00541177,MYOPIA,All,7 Years to 12 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Min-Sheng General Hospital, Tao-Yuan, Taiwan",A61K9/0051,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,12.1234522269451,145.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.42,284.3529,53.43,3.0,1.0,2.0,29.78,82.53,6.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1
CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1,1,DB00809,__TROPICAMIDE,4014335,Completed,NCT00877175,PRETERM INFANTS,All,1 Month to 4 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","Srinagarind Hospital, Khon Kaen, Thailand",A61K9/0051,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,12.1234522269451,145.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.42,284.3529,53.43,3.0,1.0,2.0,29.78,82.53,6.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Not yet recruiting,NCT04177342,ACHALASIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61N1/303,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT01244126,OTITIS MEDIA,All,6 Months to 6 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Texas Children's Hospital, Houston, Texas, United States",A61N1/303,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT00654511,TONSILLITIS,All,2 Years to 12 Years   (Child),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Children's National Medical Center, Washington, District of Columbia, United States",A61N1/303,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Recruiting,NCT04528173,ANESTHESIA|OPIOID USE|TONSILLITIS|SLEEP DISORDER|SURGERY,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",A61N1/303,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Not yet recruiting,NCT04292990,PAIN|NASOPHARYNGEAL CARCINOMA|HEAD AND NECK CANCER|RADIATION INDUCED ORAL MUCOSITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61N1/303,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT00654329,OTITIS,All,6 Months to 6 Years   (Child),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Children's National Medical Center, Washington, District of Columbia, United States",A61N1/303,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Unknown status,NCT02653742,"PAIN, POSTOPERATIVE|OTITIS MEDIA",All,8 Months to 7 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Albany Medical Center, Albany, New York, United States",A61N1/303,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1,1,DB00814,__MELOXICAM,6184220,Completed,NCT02229747,PHARYNGITIS,All,2 Years to 8 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,22.47274071336161,1458.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.28,351.401,99.6,5.0,2.0,3.0,34.25,88.62,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT00611195,UPPER RESPIRATORY INFECTIONS,All,25 Months to 84 Months   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University children's hospital, Basel, Switzerland",0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT01569048,CHRONIC SINUSITIS,All,"20 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Severance Hospital, Seoul, Korea, Republic of",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT01955135,RETINOPATHY,All,32 Weeks to 40 Weeks   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,,0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT02771912,SEDATION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Fondation Ophtalmique Adolphe de Rothschild, Paris, France",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT01001429,RETINAL DETACHMENT,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","UMDNJ-University Hospital, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT00786370,CATARACT,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Cooper University Hospital, Camden, New Jersey, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,1,DB00819,__ACETAZOLAMIDE,,Unknown status,NCT00485238,GLAUCOMA,All,"21 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National University Hospital, 5 Lower Kent Ridge Road, Singapore, Singapore",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0
COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,1,DB00843,__DONEPEZIL,4895841,Completed,NCT03109314,AMBLYOPIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"University of California, Berkeley, Berkeley, California, United States",C07D405/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,19.1215425368077,230.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,379.49199999999996,38.77,4.0,0.0,4.0,44.34,112.11,6.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,1,DB00844,__NALBUPHINE,4237140,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,18.5301546232982,597.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,357.4434,73.16,5.0,3.0,6.0,38.59,97.0,2.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,1,DB00844,__NALBUPHINE,4237140,Recruiting,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,18.5301546232982,597.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,357.4434,73.16,5.0,3.0,6.0,38.59,97.0,2.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0
OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,1,DB00850,__PERPHENAZINE,4175119,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,841.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.15,403.969,29.95,4.0,1.0,4.0,44.77,116.1,6.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1
CN[C@@H](C)[C@@H](O)c1ccccc1,1,DB00852,__PSEUDOEPHEDRINE,6037353,Completed,NCT03443843,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kingston General Hospital, Kingston, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,60.4201318302223,899.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.83,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN[C@@H](C)[C@@H](O)c1ccccc1,1,DB00852,__PSEUDOEPHEDRINE,6037353,Completed,NCT00377403,ACUTE RESPIRATORY INFECTIONS|ACUTE RHINOSINUSITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Washington University in St. Louis, St. Louis, Missouri, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,60.4201318302223,899.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.83,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN[C@@H](C)[C@@H](O)c1ccccc1,1,DB00852,__PSEUDOEPHEDRINE,6037353,Completed,NCT00208065,MIGRAINE|SINUSITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinvest, Inc., Springfield, Missouri, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,60.4201318302223,899.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.83,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN[C@@H](C)[C@@H](O)c1ccccc1,1,DB00852,__PSEUDOEPHEDRINE,6037353,Completed,NCT00648973,NASAL CONGESTION,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Benchmark Research - Austin, Austin, Texas, United States|Allergy and Asthma Associates, Austin, Texas, United States|Lovelace Scientific Resources, Austin, Texas, United States|Allergy/Immunology Research Center of North Texas, Dallas, Texas, United States|Kerrville Research Associates, Kerrville, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States|Benchmark Research - San Angelo, San Angelo, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Biogenics Research Institute, San Antonio, Texas, United States|Diagnostics Research Group, San Antonio, Texas, United States|Sylvana Research Associates, San Antonio, Texas, United States|Allergy Asthma Research Institute, Waco, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,60.4201318302223,899.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.83,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN[C@@H](C)[C@@H](O)c1ccccc1,1,DB00852,__PSEUDOEPHEDRINE,6037353,Completed,,ACUTE RHINOSINUSITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,60.4201318302223,899.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.83,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN[C@@H](C)[C@@H](O)c1ccccc1,1,DB00852,__PSEUDOEPHEDRINE,6037353,Completed,,ALLERGIC RHINITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,60.4201318302223,899.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.83,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN[C@@H](C)[C@@H](O)c1ccccc1,1,DB00852,__PSEUDOEPHEDRINE,6037353,Completed,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,60.4201318302223,899.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.83,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT01853696,FUCHS' DYSTROPHY|CORNEAL EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Price Vision Group, Indianapolis, Indiana, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT03123614,INTRAOCULAR PRESSURE|CORNEAL OPACITY,All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Moran Eye Center - Midvalley Location, Murray, Utah, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT00689078,ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Ophthalmic Research Associates, Andover, Massachusetts, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT01437982,"CONJUNCTIVITIS, SEASONAL ALLERGIC|CONJUNCTIVITIS, GIANT PAPILLARY|INFLAMMATION",All,"Child, Adult, Older Adult",Industry,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Bausch & Lomb Korea Ltd, Seoul, Korea, Republic of",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT01730872,CHRONIC ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Andover Eye Associates, Andover, Massachusetts, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT01244334,"CATARACTS|CORNEAL EDEMA|RETINAL STRUCTURAL CHANGE, DEPOSIT AND DEGENERATION|VISUAL ACUITY REDUCED TRANSIENTLY",All,"21 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cincinnati Eye Institute, Edgewood, Kentucky, United States|Ophthalmic Consultants of Long Island, Lynbrook, New York, United States|Carolina Eyecare, Mt Pleasant, South Carolina, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Recruiting,NCT01939691,UVEITIS|MACULAR EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Aravind Eye Hospital, Coimbatore, Tamil Nadu, India|Aravind Eye Hospital, Madurai, Tamil Nadu, India|Aravind Eye Hospital, Pondicherry, Tamil Nadu, India",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT03578276,CATARACT,All,"50 Years to 99 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Carolina Eyecare Physicians, LLC, Mount Pleasant, South Carolina, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Unknown status,NCT02557269,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medical University Sofia, University Hospital ""Alexandrovska"", Clinic of Allergy and Asthma, Sofia, Bulgaria",A61K9/0056,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Recruiting,NCT04464629,RETINAL DETACHMENT,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Midwest Eye Institute, Indianapolis, Indiana, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT00312325,REGIONAL BLOOD FLOW|OPTIC DISK,All,"19 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Clinical Pharmacology, Vienna, Austria",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Recruiting,NCT02912182,VESTIBULAR DISEASES|VESTIBULAR NEURONITIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Dept OtoRhinoLaryngology, Helsingborg, Sweden|Dept. Otorhinolaryngology, Kristianstad, Sweden|Dept. OtoRhinoLaryngology Head and Neck Surgery, Skane University Hospital, Lund, Sweden",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT00788749,NASAL POLYPS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ninewells Hospital and Medical School, Dundee, Angus, United Kingdom",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Recruiting,NCT04403516,PTERYGIUM,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"New York Eye Specialists, New York, New York, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Recruiting,NCT04351737,PTERYGIUM OF BOTH EYES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Brandon Eye Associates, Brandon, Florida, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Recruiting,NCT04316936,CATARACT SURGERY,All,"Child, Adult, Older Adult",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Silverstein Eye Centers, Kansas City, Missouri, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT00981435,GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Bascom Palmer Eye Institute, Miami, Florida, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Recruiting,NCT04200651,GLAUCOMA|CATARACT,All,"21 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The New York Eye Surgery Center, Bronx, New York, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Not yet recruiting,NCT04521140,CORNEAL EDEMA|CORNEAL DEFECT|CORNEAL TRANSPLANT|PENETRATING KERATOPLASTY|ANTERIOR CHAMBER INFLAMMATION|OCULAR PAIN,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Recruiting,NCT04168112,"KERATOCONUS, UNSTABLE|COLLAGEN CROSSLINKING|POSTOPERATIVE PAIN",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"SightMD, Babylon, New York, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Unknown status,NCT00744666,VITREORETINAL DISEASE|OCULAR HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,"Hotel Dieu Hospital, Kingston, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT03383328,POSTOPERATIVE CYSTOID MACULAR EDEMA|IRVINE-GASS SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Department of Ophthalmology, Glostrup, Capital Region, Denmark",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Not yet recruiting,NCT04426734,NON-INFECTIOUS ANTERIOR UVEITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Recruiting,NCT04549935,PATIENT PREFERENCE|PATIENT OUTCOMES|POST-OPERATIVE INFLAMMATION|GRADE OF POST-OPERATIVE CYSTOID MACULAR EDEMA|RATE OF POST-OPERATIVE CYSTOID MACULAR EDEMA,All,"22 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Briana Parker, Bozeman, Montana, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Recruiting,NCT04362241,"RETINOPATHY, DIABETIC",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ophthalmic Consultants of the Capital Region, Troy, New York, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT02028754,DRY EYE SYNDROMES|CATARACT,All,"60 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hangzhou, China",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Not yet recruiting,NCT04563299,NEOVASCULAR AGE-RELATED MACULAR DEGENERATION|DIABETIC MACULAR EDEMA|RETINAL VEIN OCCLUSION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Retina Vitreous Associates of Florida, Saint Petersburg, Florida, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,"Active, not recruiting",NCT04184999,DRY EYE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Hauser Ross Surgical Center, Sycamore, Illinois, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,1,DB00863,__RANITIDINE,5098715,Withdrawn,NCT02123498,EUSTACHIAN TUBE DYSFUNCTION|LARYNGOPHARYNGEAL REFLUX,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"11234 Anderson Street, Loma Linda, California, United States|1895 Orange Tree Lane, Suite 102, Redlands, California, United States",A61K9/2806,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,15.1132466785765,3.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.79,314.4,83.58,5.0,2.0,1.0,33.78,94.15,10.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Completed,NCT03464435,VERNAL KERATOCONJUNCTIVITIS,All,"5 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Completed,NCT01850979,SJOGREN SYNDROME|DRY EYE SYNDROME,All,40 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Sao Paulo General Hospital, Sao Paulo, SP, Brazil",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,1,DB00869,__DORZOLAMIDE,,Completed,NCT02802137,GLAUCOMA|OCULAR SURFACE DISEASE,All,"21 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.5,324.44,106.33,5.0,2.0,2.0,31.55,72.46,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,1,DB00869,__DORZOLAMIDE,,Completed,NCT03966560,"GLAUCOMA, OPEN-ANGLE",All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.5,324.44,106.33,5.0,2.0,2.0,31.55,72.46,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,1,DB00869,__DORZOLAMIDE,,Completed,NCT00811850,GLAUCOMA,All,"30 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Indianapolis, Indiana, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.5,324.44,106.33,5.0,2.0,2.0,31.55,72.46,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,1,DB00869,__DORZOLAMIDE,,Completed,NCT00822081,OPEN-ANGLE GLAUCOMA|OCULAR HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,"Barrie, Ontario, Canada",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.5,324.44,106.33,5.0,2.0,2.0,31.55,72.46,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,1,DB00869,__DORZOLAMIDE,,Unknown status,NCT00716586,RETINAL DEGENERATIONS,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Illinois Medical Center, Chicago, Illinois, United States",,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.5,324.44,106.33,5.0,2.0,2.0,31.55,72.46,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,1,DB00869,__DORZOLAMIDE,,Completed,NCT00957190,EYE DISEASE,All,"30 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.5,324.44,106.33,5.0,2.0,2.0,31.55,72.46,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,1,DB00869,__DORZOLAMIDE,,Unknown status,NCT02053298,OPEN ANGLE GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"University Hospitals Leuven, Leuven, Flemish Brabant, Belgium",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.5,324.44,106.33,5.0,2.0,2.0,31.55,72.46,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,1,DB00869,__DORZOLAMIDE,,Completed,NCT00397241,OPEN-ANGLE GLAUCOMA,All,"29 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Glaucoma Unit, A University Dept of Ophthalmology, Thessaloniki, Greece",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.5,324.44,106.33,5.0,2.0,2.0,31.55,72.46,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,1,DB00869,__DORZOLAMIDE,,Completed,NCT00273442,"OCULAR HYPERTENSION|OPEN-ANGLE GLAUCOMA|EXFOLIATION SYNDROME|GLAUCOMA, PIGMENTARY",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Little Rock Eye Clinic, Little Rock, Arkansas, United States|Omni Eye Services, Atlanta, Georgia, United States|Midwest Eye Center, Bourbonnais, Illinois, United States|Mark J. Weiss, MD, Tulsa, Oklahoma, United States|Glaucoma Consultants & Center for Eye Research, Mt. Pleasant, South Carolina, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.5,324.44,106.33,5.0,2.0,2.0,31.55,72.46,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,1,DB00869,__DORZOLAMIDE,,Completed,NCT00675207,PRIMARY OPEN ANGLE GLAUCOMA|OCULAR HYPERTENSION,All,"41 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Northwestern Ophthalmic Institute S.C., Glenview, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.5,324.44,106.33,5.0,2.0,2.0,31.55,72.46,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,1,DB00869,__DORZOLAMIDE,,Completed,NCT00545064,OCULAR HYPERTENSION|OPEN ANGLE GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.5,324.44,106.33,5.0,2.0,2.0,31.55,72.46,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,1,DB00869,__DORZOLAMIDE,,Completed,NCT00471380,GLAUCOMA|OCULAR HYPERTENSION,All,"40 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"Catania, Catania, Italy",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.5,324.44,106.33,5.0,2.0,2.0,31.55,72.46,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB14596,__LOTEPREDNOL_ETABONATE,4996335,Completed,NCT00420628,CHALAZION|HORDEOLUM,All,up to 6 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pediatric Ophthalmology of Erie, Erie, Pennsylvania, United States",C07J43/003,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,113.0,62.5885541797572,124.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.08,466.96,99.13,5.0,1.0,4.0,48.43,118.17,7.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB14596,__LOTEPREDNOL_ETABONATE,4996335,Completed,NCT01853696,FUCHS' DYSTROPHY|CORNEAL EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Price Vision Group, Indianapolis, Indiana, United States",C07J43/003,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,113.0,62.5885541797572,124.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.08,466.96,99.13,5.0,1.0,4.0,48.43,118.17,7.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB14596,__LOTEPREDNOL_ETABONATE,4996335,Withdrawn,NCT02028312,DRY EYE,All,"21 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Cincinnati Eye Institute, Edgewood, Kentucky, United States",C07J43/003,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,113.0,62.5885541797572,124.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.08,466.96,99.13,5.0,1.0,4.0,48.43,118.17,7.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB14596,__LOTEPREDNOL_ETABONATE,4996335,Completed,NCT00781300,"GLAUCOMA, OPEN-ANGLE|OCULAR HYPERTENSION",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Opthalmology, Federal University of São Paulo, São Paulo, SP, Brazil",C07J43/003,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,113.0,62.5885541797572,124.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.08,466.96,99.13,5.0,1.0,4.0,48.43,118.17,7.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB14596,__LOTEPREDNOL_ETABONATE,4996335,Completed,NCT04075227,RECURRENT PTERYGIUM OF EYE|STEROID-INDUCED GLAUCOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07J43/003,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,113.0,62.5885541797572,124.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.08,466.96,99.13,5.0,1.0,4.0,48.43,118.17,7.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB14596,__LOTEPREDNOL_ETABONATE,4996335,Completed,NCT03123614,INTRAOCULAR PRESSURE|CORNEAL OPACITY,All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Moran Eye Center - Midvalley Location, Murray, Utah, United States",C07J43/003,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,113.0,62.5885541797572,124.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.08,466.96,99.13,5.0,1.0,4.0,48.43,118.17,7.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB14596,__LOTEPREDNOL_ETABONATE,4996335,Completed,NCT00705159,CONJUNCTIVITIS,All,up to 6 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pediatric Ophthalmology of Erie, Erie, Pennsylvania, United States",C07J43/003,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,113.0,62.5885541797572,124.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.08,466.96,99.13,5.0,1.0,4.0,48.43,118.17,7.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB14596,__LOTEPREDNOL_ETABONATE,4996335,Completed,NCT01443442,ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Eye Car Center, Southern California college of Optometry, Fullerton, California, United States|Eye Care Center, Southern Caalifornia College of Optometry, Fullerton, California, United States",C07J43/003,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,113.0,62.5885541797572,124.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.08,466.96,99.13,5.0,1.0,4.0,48.43,118.17,7.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB14596,__LOTEPREDNOL_ETABONATE,4996335,Completed,NCT01437982,"CONJUNCTIVITIS, SEASONAL ALLERGIC|CONJUNCTIVITIS, GIANT PAPILLARY|INFLAMMATION",All,"Child, Adult, Older Adult",Industry,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Bausch & Lomb Korea Ltd, Seoul, Korea, Republic of",C07J43/003,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,113.0,62.5885541797572,124.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.08,466.96,99.13,5.0,1.0,4.0,48.43,118.17,7.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
COc1ccccc1OCC(O)CO,1,DB00874,__GUAIFENESIN,6372252,Completed,NCT00377403,ACUTE RESPIRATORY INFECTIONS|ACUTE RHINOSINUSITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Washington University in St. Louis, St. Louis, Missouri, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,56.0,23.589806772212896,462.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,198.2158,58.92,4.0,2.0,1.0,20.59,51.24,5.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,1,DB00878,__CHLORHEXIDINE,5538353,Completed,NCT03574246,"SORE THROAT|NAUSEA AND VOMITING, POSTOPERATIVE",All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","Ankara University Faculty of Dentistry, Ankara, Yenimahalle, Turkey",A45D34/04,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,10.940676399926,1621.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.71,505.44699999999995,167.58,10.0,10.0,2.0,54.6,181.71,9.0,1.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB00896,__RIMEXOLONE,US-20070021360-A1,Completed,NCT02816905,INTRAOCULAR PRESSURE,All,up to 13 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Cairo University Hospitals, Cairo, Egypt",1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,111.0,32.7488,15.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.64,370.533,54.37,3.0,1.0,4.0,42.91,109.07,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,1,0
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Completed,NCT00611195,UPPER RESPIRATORY INFECTIONS,All,25 Months to 84 Months   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University children's hospital, Basel, Switzerland",C07D211/58,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Completed,NCT01569048,CHRONIC SINUSITIS,All,"20 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Severance Hospital, Seoul, Korea, Republic of",C07D211/58,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Completed,NCT02484859,NASAL POLYPS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Recep Tayyip Erdogan University, Rize, Eastern Blacksea, Turkey",C07D211/58,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Completed,NCT01495377,OPIOID INDUCED SWALLOWING DISORDERS,All,18 Years to 40 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","University Hospital in Örebro, Örebro, Sweden|Örebro University Hospital, Örebro, Sweden",C07D211/58,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Completed,NCT01924234,PHARYNGEAL DYSFUNCTION|PHARYNGEAL SWALLOWING,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Örebro University Hospital, Örebro, Sweden",C07D211/58,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Terminated,NCT03401606,FAILED CONSCIOUS SEDATION DURING PROCEDURE,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",,C07D211/58,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1,1,DB00905,__BIMATOPROST,6403649,Unknown status,NCT02471105,OCULAR HYPERTENSION|GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Hommer Ophthalmology Institute, Vienna, Austria|UZ Leuven, Leuven, Vlaams Brabant, Belgium|San Paolo Hospital, Milan, Italy|Bietti Foundation, Rome, Italy|Clinical Research Centre Momorial A. de Rotschild, Geneve, Switzerland|Gloucestershire Hospitals NHS Foundation Trust, Gloucestershire, United Kingdom|Western Eye Hospital, London, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,27.170989137353892,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.41,415.5656,89.79,4.0,4.0,2.0,48.24,122.83,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1,1,DB00905,__BIMATOPROST,6403649,Completed,NCT03966560,"GLAUCOMA, OPEN-ANGLE",All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,27.170989137353892,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.41,415.5656,89.79,4.0,4.0,2.0,48.24,122.83,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1,1,DB00905,__BIMATOPROST,6403649,Completed,NCT02863705,"GLAUCOMA, OPEN-ANGLE|NORMAL TENSION GLAUCOMA",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea, Republic of|Yeungnam University Hospital, Yeungnam University College of Medicine, Daegu, Korea, Republic of|Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea, Republic of|Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea, Republic of|Seoul National University Bundang Hospital, Seoul National University College of Medicine, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea, Republic of|Kangbuk Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea, Republic of|Kim's Eye Hospital, Konyang University College of Medicine, Seoul, Korea, Republic of",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,27.170989137353892,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.41,415.5656,89.79,4.0,4.0,2.0,48.24,122.83,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1,1,DB00905,__BIMATOPROST,6403649,Completed,NCT01525173,GLAUCOMA|OCULAR HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Deerfield Beach, Florida, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,27.170989137353892,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.41,415.5656,89.79,4.0,4.0,2.0,48.24,122.83,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1,1,DB00905,__BIMATOPROST,6403649,Completed,NCT00273455,OPEN-ANGLE GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"Taustine Eye Center, Louisville, Kentucky, United States|Glaucoma Consultants & Center for Eye Research, PA, Mt. Pleasant, South Carolina, United States|Houston Eye Associates, Houston, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,27.170989137353892,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.41,415.5656,89.79,4.0,4.0,2.0,48.24,122.83,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1,1,DB00905,__BIMATOPROST,6403649,Completed,NCT01978015,"UVEITIS, ANTERIOR|CYSTOID MACULAR EDEMA",All,"18 Years to 95 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital de Clínicas, UNICAMP, Campinas, São Paulo, Brazil",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,27.170989137353892,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.41,415.5656,89.79,4.0,4.0,2.0,48.24,122.83,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1,1,DB00905,__BIMATOPROST,6403649,Completed,NCT01448837,GLAUCOMA,All,"21 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Glaucoma Unit, 1st University Department of Ophthalmology, Thessaloniki, Greece",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,27.170989137353892,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.41,415.5656,89.79,4.0,4.0,2.0,48.24,122.83,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1,1,DB00905,__BIMATOPROST,6403649,Completed,NCT00705757,GLAUCOMA|APPLICATION SITE PIGMENTATION CHANGES,All,"30 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Arlington Eye Physicians, Arlington Heights, Illinois, United States|Summa Health System, Akron, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,27.170989137353892,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.41,415.5656,89.79,4.0,4.0,2.0,48.24,122.83,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1,1,DB00905,__BIMATOPROST,6403649,Completed,NCT00539526,OPEN ANGLE GLAUCOMA|OCULAR HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"San Diego, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,27.170989137353892,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.41,415.5656,89.79,4.0,4.0,2.0,48.24,122.83,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1,1,DB00905,__BIMATOPROST,6403649,Completed,NCT01655758,OCULAR HYPERTENSION,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University Eye Clinic, Parma, Italy",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,27.170989137353892,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.41,415.5656,89.79,4.0,4.0,2.0,48.24,122.83,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1,1,DB00905,__BIMATOPROST,6403649,Completed,NCT01253902,"GLAUCOMA, OPEN-ANGLE|OCULAR HYPERTENSION",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Rogers, Arkansas, United States|Calgary, Alberta, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,27.170989137353892,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.41,415.5656,89.79,4.0,4.0,2.0,48.24,122.83,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1,1,DB00905,__BIMATOPROST,6403649,Completed,NCT01464424,GLAUCOMA|OCULAR HYPERTENSION|OPEN-ANGLE GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,27.170989137353892,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.41,415.5656,89.79,4.0,4.0,2.0,48.24,122.83,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1,1,DB00905,__BIMATOPROST,6403649,Completed,NCT02059655,GRAVES' OPHTHALMOPATHY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University Hospital of Wales, Cardiff, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,27.170989137353892,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.41,415.5656,89.79,4.0,4.0,2.0,48.24,122.83,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1,1,DB00905,__BIMATOPROST,6403649,Completed,NCT01271686,INTRAOCULAR PRESSURE|GLAUCOMA|OCULAR HYPERTENSION,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCSD Shiley Eye Center, La Jolla, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,27.170989137353892,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.41,415.5656,89.79,4.0,4.0,2.0,48.24,122.83,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1,1,DB00905,__BIMATOPROST,6403649,Completed,NCT01833741,"GLAUCOMA, PRIMARY OPEN ANGLE|OCULAR HYPERTENSION",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barrie, Ontario, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,27.170989137353892,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.41,415.5656,89.79,4.0,4.0,2.0,48.24,122.83,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1,1,DB00905,__BIMATOPROST,6403649,Completed,NCT00355446,CATARACT,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"University Hospital, Indianapolis, Indiana, United States|Veterans Affairs Medical Center, Indianapolis, Indiana, United States|Wishard Memorial Hospital, Indianapolis, Indiana, United States|IU Eye at Carmel, Indianapolis, Indiana, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,27.170989137353892,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.41,415.5656,89.79,4.0,4.0,2.0,48.24,122.83,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1
COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C,1,DB00907,__COCAINE,10149843,Completed,NCT01706952,CHRONIC SINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Other,"Department of Otolaryngology-Head and Neck Surgery. McGill University Health Center, Montreal, Quebec, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,22.078482104355306,320.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.97,303.3529,55.84,3.0,0.0,3.0,32.36,81.16,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0
CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,1,DB00912,__REPAGLINIDE,6677358,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,49.01948705312221,158.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.05,452.5857,78.87,5.0,2.0,3.0,51.49,131.83,10.0,0.0,1.0,0.0,1,1,1,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0
CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,1,DB00912,__REPAGLINIDE,6677358,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,49.01948705312221,158.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.05,452.5857,78.87,5.0,2.0,3.0,51.49,131.83,10.0,0.0,1.0,0.0,1,1,1,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0
CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12,1,DB00918,__ALMOTRIPTAN,5565447,Completed,NCT00208065,MIGRAINE|SINUSITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinvest, Inc., Springfield, Missouri, United States",C07D209/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,17.2488141440275,92.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.04,335.464,56.41,3.0,1.0,3.0,37.01,94.52,5.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0
CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12,1,DB00918,__ALMOTRIPTAN,5565447,Completed,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",C07D209/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,17.2488141440275,92.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.04,335.464,56.41,3.0,1.0,3.0,37.01,94.52,5.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0
CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1,1,DB00920,__KETOTIFEN,4232002,Completed,NCT00133627,SEASONAL ALLERGIC CONJUNCTIVITIS,All,"3 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Hospital of Shanghai Medical University, Shanghai, China",A61K9/0078,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,23.1626932791227,287.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.49,309.425,20.31,2.0,0.0,4.0,34.61,101.73,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0
CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1,1,DB00920,__KETOTIFEN,4232002,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0078,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,23.1626932791227,287.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.49,309.425,20.31,2.0,0.0,4.0,34.61,101.73,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,DB00921,__BUPRENORPHINE,5240711,Completed,,HIP ARTHROPLASTY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,11.2035154725969,326.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.53,467.6401,62.16,5.0,2.0,7.0,53.11,131.76,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CN(C)CCC=C1c2ccccc2C=Cc2ccccc21,1,DB00924,__CYCLOBENZAPRINE,7387793,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,55.0976406086367,112.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.73,275.3874,3.24,1.0,0.0,3.0,32.95,102.62,3.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
NC(N)=Nc1nc(CSCCC(N)=NS(N)(=O)=O)cs1,1,DB00927,__FAMOTIDINE,5075114,Completed,,PULMONARY ASPIRATION OF GASTRIC CONTENTS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/5047,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,19.05583276864,1184.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.2,337.445,175.83,8.0,4.0,1.0,31.66,80.46,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,1,DB00935,__OXYMETAZOLINE,6413499,Completed,NCT00487032,ALLERGIC RHINITIS|TACHYPHYLAXIS|RHINITIS MEDICAMENTOSA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Perth Royal Infirmary (Tayside NHS Trust), Perth, Perthshire, United Kingdom|Ninewells Hospital and Medical School (Tayside NHS Trust, University of Dundee), Dundee, Tayside, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,25.7582291217478,470.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.7,260.3746,44.62,3.0,2.0,2.0,30.64,79.8,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,1,DB00935,__OXYMETAZOLINE,6413499,Completed,NCT00584987,ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Chicago, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,32.0,25.7582291217478,470.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.7,260.3746,44.62,3.0,2.0,2.0,30.64,79.8,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,1,DB00935,__OXYMETAZOLINE,6413499,Completed,NCT01847131,NASAL OBSTRUCTION PRESENT FINDING,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,25.7582291217478,470.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.7,260.3746,44.62,3.0,2.0,2.0,30.64,79.8,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,1,DB00935,__OXYMETAZOLINE,6413499,"Active, not recruiting",NCT03228914,ENDOSCOPIC SINUS SURGERY|NASAL POLYPS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"The University of Texas Health Science Center at Houston, Houston, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,25.7582291217478,470.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.7,260.3746,44.62,3.0,2.0,2.0,30.64,79.8,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,1,DB00935,__OXYMETAZOLINE,6413499,Completed,NCT02559440,ADENOIDAL HYPERTROPHY,All,5 Years to 11 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,25.7582291217478,470.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.7,260.3746,44.62,3.0,2.0,2.0,30.64,79.8,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,1,DB00935,__OXYMETAZOLINE,6413499,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,32.0,25.7582291217478,470.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.7,260.3746,44.62,3.0,2.0,2.0,30.64,79.8,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,1,DB00938,__SALMETEROL,6743413,Completed,NCT01388595,ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Asthma and Allergy Research Group, University of Dundee, Dundee, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,934.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.82,415.5656,81.95,5.0,4.0,2.0,50.6,122.39,16.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0
OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,1,DB00938,__SALMETEROL,6743413,Completed,NCT00370591,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Manchester, Lancashire, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,934.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.82,415.5656,81.95,5.0,4.0,2.0,50.6,122.39,16.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Not yet recruiting,NCT04129008,CORONARY ARTERY DISEASE|GASTROESOPHAGEAL REFLUX DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Beijing Anzhen Hospital, Capital Medical University, Beijing, China",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Completed,NCT01465009,COMMON COLD|PHARYNGITIS|TONSILLITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Reading, Berkshire, United Kingdom|Manchester, Greater Manchester, United Kingdom|Chorley, Lancashire, United Kingdom|Wigan, Lancashire, United Kingdom|Liverpool, Merseyside, United Kingdom|Liverpool, Merseyside, United Kingdom|Cardiff, South Glamorgan, United Kingdom|Birmingham, West Midlands, United Kingdom",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT01469234,RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT00502775,"RHINITIS, ALLERGIC, SEASONAL",All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Albany, Georgia, United States|GSK Investigational Site, Columbus, Georgia, United States|GSK Investigational Site, Lawrenceville, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Normal, Illinois, United States|GSK Investigational Site, Evansville, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Lafayette, Indiana, United States|GSK Investigational Site, South Bend, Indiana, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Owensboro, Kentucky, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Sunset, Louisiana, United States|GSK Investigational Site, Novi, Michigan, United States|GSK Investigational Site, Ypsilanti, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Plymouth, Minnesota, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, Columbia, Missouri, United States|GSK Investigational Site, Rolla, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Warrensburg, Missouri, United States|GSK Investigational Site, Lincoln, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Papillion, Nebraska, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Sylvania, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Waco, Texas, United States|GSK Investigational Site, Greenfield, Wisconsin, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, West Allis, Wisconsin, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT01586091,PRURITUS|CHRONIC URTICARIA|ALLERGIC RHINITIS,Male,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","University of Berlin Charité, Department of Dermatology and Allergy, Berlin, Germany",A61K9/0056,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT00794768,SEASONAL ALLERGIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT02551536,ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT02175485,RHINITIS ALLERGIC,All,"20 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 392-001, Shinjuku-ku, Japan",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT00741897,"RHINITIS, ALLERGIC, PERENNIAL",All,6 Years to 11 Years   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sanofi-aventis administrative office, Makati City, Philippines",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT00637884,CAT INDUCED ALLERGIC RHINITIS,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,,A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314,1,DB00956,__HYDROCODONE,6348216,Terminated,NCT02296840,RECURRENT TONSILLITIS|OBSTRUCTIVE SLEEP APNEA|SLEEP DISORDERED BREATHING|ADVERSE REACTION TO DRUG,All,4 Years to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Children's Healthcare of Atlanta (CHOA), Atlanta, Georgia, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,34.0,56.346126203823395,1296.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.13,299.3642,38.77,4.0,0.0,5.0,32.05,82.74,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT01205984,CHRONIC RHINOSINUSITIS|CHILDREN,All,6 Years to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Gazi University Faculty of Medicine, Ankara, Turkey",A61F9/0017,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Withdrawn,NCT00037115,DEMYELINATING DISORDERS|MULTIPLE SCLEROSIS|OPTIC NEURITIS|MYELITIS|NEURITIS,All,18 Years to 50 Years   (Adult),Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MidAmerica Neuroscience Institute, Kansas City, Missouri, United States",A61F9/0017,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Recruiting,NCT04192656,SUDDEN HEARING LOSS|OBSTRUCTIVE SLEEP APNEA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Tsinhgua Changgung Hospital, Beijing, Beijing, China",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Not yet recruiting,NCT03098225,THYROID ASSOCIATED OPHTHALMOPATHY,All,"35 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,,A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Unknown status,NCT02378298,"OPHTHALMOPATHY, THYROID-ASSOCIATED",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Center for Endocrinology and Metabolism, Sahlgrenska University Hospital, Gothenburg, Sweden|MedTech West, Institute of Neuro Science and Physiology, Department for Clinical Neuro Science and Rehabilitation, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden|Department of Ophthalmology, Sahlgrenska University Hospital/Mölndal, Mölndal, Sweden|Department of Rheumatology, Sahlgrenska University Hospital/Mölndal, Mölndal, Sweden|Department of Radiology, Karolinska University Hospital, Stockholm, Sweden",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT03948191,THYROID-ASSOCIATED OPHTHALMOPATHY,All,"18 Years to 76 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, China",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Unknown status,NCT01969019,GRAVES' OPHTHALMOPATHY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Institute of Endocrine and Metabolic Diseases Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai, Shanghai, China",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT04318652,EPIPHORA DUE TO INSUFFICIENT DRAINAGE,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Amr Awara, Tanta, Gharbeyia, Egypt",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Recruiting,NCT01838174,MULTIPLE SCLEROSIS,All,18 Years to 55 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado Denver, Aurora, Colorado, United States|University of Pennsylvania Scheie Eye Institute, Philadelphia, Pennsylvania, United States",A61F9/0017,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1,1,DB00963,__BROMFENAC,8129431,Enrolling by invitation,NCT03831984,CATARACT,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Maria Camila Aguilar Sierra, Ciudad de Mexico, Mexico",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,97.6447154972381,344.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,334.165,80.39,4.0,2.0,2.0,29.93,80.26,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1
Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1,1,DB00963,__BROMFENAC,8129431,Not yet recruiting,NCT03751059,GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,97.6447154972381,344.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,334.165,80.39,4.0,2.0,2.0,29.93,80.26,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1
Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1,1,DB00963,__BROMFENAC,8129431,Completed,NCT03317847,INFLAMMATION EYE,All,"60 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Arcispedale Santa Maria Nuova IRCSS - Ophthalmology, Reggio Emilia, RE, Italy",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,97.6447154972381,344.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,334.165,80.39,4.0,2.0,2.0,29.93,80.26,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1
Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1,1,DB00963,__BROMFENAC,8129431,Completed,NCT02137161,CATARACT|PSEUDOEXFOLIATION SYNDROME,All,"60 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arcispedale Santa Maria Nuova IRCSS - Ophthalmology, Reggio Emilia, RE, Italy",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,97.6447154972381,344.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,334.165,80.39,4.0,2.0,2.0,29.93,80.26,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1
Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1,1,DB00963,__BROMFENAC,8129431,Completed,NCT00595543,ACUTE PSEUDOPHAKIC CYSTOID MACULAR EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Soll Eye Associates, Philadelphia, Pennsylvania, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,97.6447154972381,344.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,334.165,80.39,4.0,2.0,2.0,29.93,80.26,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1
Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1,1,DB00963,__BROMFENAC,8129431,Completed,NCT00520260,DRY EYE DISEASE|OCULAR COMFORT,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Florida Eye Microsurgical Institute, Boynton Beach, Florida, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,22.0,97.6447154972381,344.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,334.165,80.39,4.0,2.0,2.0,29.93,80.26,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1
Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1,1,DB00963,__BROMFENAC,8129431,Completed,NCT04022811,PTERYGIUM|PAIN,All,"45 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhongshan Opthalmic Center, Guangzhou, Guangdong, China|Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, Guangdong, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,97.6447154972381,344.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,334.165,80.39,4.0,2.0,2.0,29.93,80.26,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1
Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1,1,DB00963,__BROMFENAC,8129431,Completed,NCT03886779,TREATMENT OF OCULAR INFLAMMATION ASSOCIATED WITH CATARACT SURGERY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,22.0,97.6447154972381,344.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,334.165,80.39,4.0,2.0,2.0,29.93,80.26,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,1,DB00967,__DESLORATADINE,5178878,Completed,NCT00794846,SEASONAL ALLERGIC RHINITIS|PERENNIAL ALLERGIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.48,310.82099999999997,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,1,DB00967,__DESLORATADINE,5178878,Completed,NCT02507635,ALLERGIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.48,310.82099999999997,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,1,DB00967,__DESLORATADINE,5178878,Completed,NCT00867191,SEASONAL ALLERGIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.48,310.82099999999997,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,1,DB00967,__DESLORATADINE,5178878,Completed,NCT00805584,"RHINITIS, ALLERGIC, SEASONAL",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.48,310.82099999999997,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,1,DB00967,__DESLORATADINE,5178878,Completed,NCT00311844,"CONJUNCTIVITIS, ALLERGIC",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.48,310.82099999999997,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,1,DB00972,__AZELASTINE,5164194,Completed,NCT03004131,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Inflamax Research, Mississauga, Ontario, Canada",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,28.2223454280375,365.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.81,381.898,35.91,3.0,0.0,4.0,41.54,110.52,3.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,1,DB00972,__AZELASTINE,5164194,Completed,NCT01880840,ALLERGIC RHINITIS,All,6 Months to 5 Years   (Child),Industry|Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinical Research Center of Alabama,LLC, Birmingham, Alabama, United States|Little Rock Allergy and Asthma Clinical research Center, Little Rock, Alaska, United States|West Coast Clinical Trials, Costa Mesa, California, United States|Southern California Research, Mission Viejo, California, United States|Storms Clinical Research Institute, Colorado Springs, Colorado, United States|Sneeze, Wheeze and Itch Associates, Normal, Illinois, United States|Allergy, Asthma & Clinical Research Center, Oklahoma City, Oklahoma, United States|National Allergy, Asthna & Urticaria Centers of Charleston Pa, Charleston, Pennsylvania, United States|Texas Allergy Research Center, Dallas, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States|Paul H Ratner,MD, San Antonio, Texas, United States|Live Oak Allergy and Asthma Clinic, San Antonio, Texas, United States|Allergy and Asthma Center, Waco, Texas, United States|Pediatric Allergy,Asthma and Immunology/Allergy& Asthma care of Waco, Waco, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,28.2223454280375,365.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.81,381.898,35.91,3.0,0.0,4.0,41.54,110.52,3.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,1,DB00972,__AZELASTINE,5164194,Unknown status,NCT02238353,ALLERGIC RHINITIS|HOUSE DUST MITE ALLERGY,All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Uz Leuven Dienst Nko, Leuven, Vlaams Brabant, Belgium",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,28.2223454280375,365.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.81,381.898,35.91,3.0,0.0,4.0,41.54,110.52,3.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,1,DB00972,__AZELASTINE,5164194,Completed,NCT00979615,VASOMOTOR RHINITIS,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Contact Alcon Call Center For Trial Locations, Fort Worth, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,28.2223454280375,365.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.81,381.898,35.91,3.0,0.0,4.0,41.54,110.52,3.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,1,DB00972,__AZELASTINE,5164194,Completed,NCT00806754,"RHINITIS, ALLERGIC, PERENNIAL",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Altana/Nycomed, Encinitas, California, United States|Altana/Nycomed, Los Angeles, California, United States|Altana/Nycomed, Mission Viejo, California, United States|Altana/Nycomed, San Diego, California, United States|Altana/Nycomed, San Jose, California, United States|Altana/Nycomed, Colorado Springs, Colorado, United States|Altana/Nycomed, Denver, Colorado, United States|Altana/Nycomed, Lakewood, Colorado, United States|Altana/Nycomed, Gainesville, Georgia, United States|Altana/Nycomed, Savannah, Georgia, United States|Altana/Nycomed, Stockbridge, Georgia, United States|Altana/Nycomed, Overland Park, Kansas, United States|Altana/Nycomed, Metairie, Louisiana, United States|Altana/Nycomed, Shreveport, Louisiana, United States|Altana/Nycomed, Bethesda, Maryland, United States|Altana/Nycomed, North Dartmouth, Massachusetts, United States|Altana/Nycomed, Novi, Michigan, United States|Altana/Nycomed, Rolla, Missouri, United States|Altana/Nycomed, Papillion, Nebraska, United States|Altana/Nycomed, Skillman, New Jersey, United States|Altana/Nycomed, Raleigh, North Carolina, United States|Altana/Nycomed, Cincinnati, Ohio, United States|Altana/Nycomed, Sylvania, Ohio, United States|Altana/Nycomed, Ashland, Oregon, United States|Altana/Nycomed, Medford, Oregon, United States|Altana/Nycomed, Portland, Oregon, United States|Altana/Nycomed, Pittsburgh, Pennsylvania, United States|Altana/Nycomed, Upland, Pennsylvania, United States|Altana/Nycomed, Charleston, South Carolina, United States|Altana/Nycomed, Dallas, Texas, United States|Altana/Nycomed, San Antonio, Texas, United States|Altana/Nycomed, South Burlington, Vermont, United States|Altana/Nycomed, Newport News, Virginia, United States|Altana/Nycomed, Richmond, Virginia, United States|Altana/Nycomed, Milwaukee, Wisconsin, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,28.2223454280375,365.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.81,381.898,35.91,3.0,0.0,4.0,41.54,110.52,3.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,1,DB00972,__AZELASTINE,5164194,Terminated,NCT02953106,"ASTHMA, ALLERGIC|RHINITIS,ALLERGIC|ALLERGY",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,28.2223454280375,365.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.81,381.898,35.91,3.0,0.0,4.0,41.54,110.52,3.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0
CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,1,DB00976,__TELITHROMYCIN,5635485,Terminated,NCT00245440,MAXILLARY SINUSITIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Southeastern Researchs Associates,Inc., Taylors, South Carolina, United States",C07H17/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,25.4296802809092,13.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,812.018,171.85,11.0,1.0,5.0,90.44,214.68,11.0,1.0,0.0,0.0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,1,1,1,1,1,1,0,0,0,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,1,1,1,0,1
CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,1,DB00976,__TELITHROMYCIN,5635485,Completed,NCT00174694,SINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07H17/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,25.4296802809092,13.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,812.018,171.85,11.0,1.0,5.0,90.44,214.68,11.0,1.0,0.0,0.0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,1,1,1,1,1,1,0,0,0,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,1,1,1,0,1
CN(C)CCOC(=O)C(c1ccccc1)C1(O)CCCC1,1,DB00979,__CYCLOPENTOLATE,3962414,Recruiting,NCT03638726,CATARACT|MYDRIASIS|ADVERSE DRUG EVENT,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,"Dar El Oyoun Hospital, Cairo, Giza, Egypt",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,193.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.09,291.3853,49.77,3.0,1.0,2.0,32.51,82.81,7.0,0.0,1.0,0.0,0,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CN(C)CCOC(=O)C(c1ccccc1)C1(O)CCCC1,1,DB00979,__CYCLOPENTOLATE,3962414,Unknown status,NCT02177539,REFRACTIVE ERRORS,All,1 Year to 10 Years   (Child),Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic,"Pontificia Universidad Catolica de Chile, Departamento de Oftalmología, Santiago, Chile",A61F9/0017,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,193.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.09,291.3853,49.77,3.0,1.0,2.0,32.51,82.81,7.0,0.0,1.0,0.0,0,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1,1,DB00982,__ISOTRETINOIN,7435427,Completed,NCT01445028,PROLIFERATIVE VITREORETINOPATHY,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Wills Eye Institute, Philadelphia, Pennsylvania, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,84.76560093636421,968.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.66,300.4351,37.3,2.0,1.0,1.0,36.15,97.79,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0
CN(C)CCOC(c1ccccc1)c1ccccc1.Cn1c(=O)c2nc(Cl)[nH]c2n(C)c1=O,1,DB00985,__DIMENHYDRINATE,4007273,Completed,NCT01890538,PERIPHERAL VERTIGO,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Kocaeli University, Kocaeli, Turkey",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,14.0618903878929,603.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.44,469.97,12.47,2.0,0.0,4.0,30.02,79.93,6.0,0.0,1.0,0.0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0
CN(C)CCOC(c1ccccc1)c1ccccc1.Cn1c(=O)c2nc(Cl)[nH]c2n(C)c1=O,1,DB00985,__DIMENHYDRINATE,4007273,Completed,NCT02253524,NAUSEA|VOMITING|VERTIGO,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,14.0618903878929,603.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.44,469.97,12.47,2.0,0.0,4.0,30.02,79.93,6.0,0.0,1.0,0.0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,1,DB00990,__EXEMESTANE,4808616,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07J1/0011,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,31.7706729090946,512.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.67,296.4034,34.14,2.0,0.0,4.0,33.71,89.03,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Completed,,IGA NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,NCT02466191,PENDULAR NYSTAGMUS|OCULOPALATAL TREMOR,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospices Civils de Lyon, Lyon, France",C07C229/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Recruiting,NCT03625011,TONSILLITIS|TONSILLECTOMY,All,"3 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","Children's Healthcare of Atlanta, Atlanta, Georgia, United States",C07C229/28,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,NCT02926573,HEAD AND NECK CANCER|ACUTE PAIN|POSTOPERATIVE PAIN,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Washington University School of Medicine, Saint Louis, Missouri, United States",C07C229/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,NCT02867176,PAIN,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,,C07C229/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Unknown status,NCT02127853,HYPERALGESIA,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Seoul National University Hospital, Seoul, Korea, Republic of",C07C229/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07C229/28,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00997,__DOXORUBICIN,5013556,Active Not Recruiting,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07F9/5537,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
CN[C@@H]1CCc2[nH]c3ccc(C(N)=O)cc3c2C1,1,DB00998,__FROVATRIPTAN,5464864,Completed,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",C07D209/88,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,22.47274071336161,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.2,243.3043,70.91,2.0,3.0,3.0,27.55,71.84,2.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,1,DB00999,__HYDROCHLOROTHIAZIDE,5616599,Active Not Recruiting,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/14,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,42.0,26.1524877307542,551.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,297.7390000000001,118.36,5.0,3.0,2.0,25.35,63.11,1.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT00070707,"RHINITIS, ALLERGIC, SEASONAL|ASTHMA",All,"15 Years to 75 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Active Not Recruiting,,AIRWAY OBSTRUCTION,,,,,"FISABIO, Elche, Alicante, Spain",B65D83/54,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",B65D83/54,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB01002,__LEVOBUPIVACAINE,5708011,Completed,,ANAESTHESIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,21.059980697755602,210.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.45,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB01002,__LEVOBUPIVACAINE,5708011,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,21.059980697755602,210.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.45,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB01002,__LEVOBUPIVACAINE,5708011,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,21.059980697755602,210.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.45,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
Nc1nc2c(ncn2COC(CO)CO)c(=O)[nH]1,1,DB01004,__GANCICLOVIR,5378475,Recruiting,NCT02943057,CYTOMEGALOVIRUS INFECTION,All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Singapore National Eye Centre, Singapore, Singapore",A61K9/5073,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,46.39109632641321,1907.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.8,255.2306,134.99,7.0,4.0,2.0,24.15,61.03,5.0,0.0,1.0,0.0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0
Nc1nc2c(ncn2COC(CO)CO)c(=O)[nH]1,1,DB01004,__GANCICLOVIR,5378475,Completed,NCT00000894,CYTOMEGALOVIRUS RETINITIS|HIV INFECTIONS,All,"13 Years and older   (Child, Adult, Older Adult)",NIH,Intervention Model: Parallel Assignment|Primary Purpose: Treatment,"Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States|UCLA CARE Ctr, Los Angeles, California, United States|Univ of Miami / Bascom Palmer Eye Institute, Miami, Florida, United States|Emory Eye Clinic, Atlanta, Georgia, United States|Northwestern Univ / SOCA, Chicago, Illinois, United States|Charity Hosp / Tulane Univ Med School, New Orleans, Louisiana, United States|Johns Hopkins Hosp, Baltimore, Maryland, United States|Cornell Univ Med Ctr, New York, New York, United States|New York Hosp / Cornell Med Ctr, New York, New York, United States|Univ of North Carolina, Chapel Hill, North Carolina, United States|Julio Arroyo, West Columbia, South Carolina, United States|Univ of Texas Galveston, Galveston, Texas, United States",A61K9/5073,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,35.0,46.39109632641321,1907.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.8,255.2306,134.99,7.0,4.0,2.0,24.15,61.03,5.0,0.0,1.0,0.0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,1,DB01006,__LETROZOLE,4978672,Active Not Recruiting,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D213/57,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,27.3681184418571,752.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.86,285.3027,78.29,4.0,0.0,3.0,29.59,94.47,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB01009,__KETOPROFEN,4097522,Terminated,NCT00799838,PHARYNGOTONSILLITIS,All,4 Years to 11 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Sanofi-Aventis Administrative Office, Sao Paulo, Brazil",C07C51/09,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,24.969711903735103,4089.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.56,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB01009,__KETOPROFEN,4097522,Completed,NCT02178293,PHARYNGITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,,C07C51/09,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,24.969711903735103,4089.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.56,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB01009,__KETOPROFEN,4097522,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07C51/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,24.969711903735103,4089.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.56,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC[N+](C)(C)c1cccc(O)c1,1,DB01010,__EDROPHONIUM,4439427,Not Yet Recruiting,,ACHALASIA,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,17.281669028111402,128.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.6,166.2401,20.23,1.0,1.0,1.0,19.15,62.41,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,1,DB01012,__CINACALCET,6011068,Completed,NCT01103206,PARATHYROID HORMONE SUPPRESSION TEST WITH CINACALCET,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University hospital, Rouen, Haute Normandie, France",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,103.0,60.8801002073964,33.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.57,357.412,12.03,1.0,1.0,3.0,37.9,100.12,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,1,DB01016,__GLYBURIDE,6303146,Active Not Recruiting,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,27.105279369186203,439.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,494.004,113.6,5.0,3.0,3.0,51.75,126.98,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,1,DB01016,__GLYBURIDE,6303146,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,27.105279369186203,439.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,494.004,113.6,5.0,3.0,3.0,51.75,126.98,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0
CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1,1,DB01032,__PROBENECID,3959253,Completed,NCT00000894,CYTOMEGALOVIRUS RETINITIS|HIV INFECTIONS,All,"13 Years and older   (Child, Adult, Older Adult)",NIH,Intervention Model: Parallel Assignment|Primary Purpose: Treatment,"Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States|UCLA CARE Ctr, Los Angeles, California, United States|Univ of Miami / Bascom Palmer Eye Institute, Miami, Florida, United States|Emory Eye Clinic, Atlanta, Georgia, United States|Northwestern Univ / SOCA, Chicago, Illinois, United States|Charity Hosp / Tulane Univ Med School, New Orleans, Louisiana, United States|Johns Hopkins Hosp, Baltimore, Maryland, United States|Cornell Univ Med Ctr, New York, New York, United States|New York Hosp / Cornell Med Ctr, New York, New York, United States|Univ of North Carolina, Chapel Hill, North Carolina, United States|Julio Arroyo, West Columbia, South Carolina, United States|Univ of Texas Galveston, Galveston, Texas, United States",C07H13/08,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.0,34.760467360726,3576.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.52,285.3590000000001,74.68,4.0,1.0,1.0,29.96,73.81,6.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1,1,DB01039,__FENOFIBRATE,5145684,Not yet recruiting,NCT04140201,DIABETIC RETINOPATHY,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,B82Y5/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,19.450091377646306,499.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.86,360.83099999999996,52.6,3.0,0.0,2.0,38.15,97.13,7.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1,1,DB01039,__FENOFIBRATE,5145684,Completed,NCT01927315,DIABETES|DIABETIC RETINOPATHY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,"University Hospital of Padova, Diabetes Outpatient Clinic, Padova, Italy",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,19.450091377646306,499.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.86,360.83099999999996,52.6,3.0,0.0,2.0,38.15,97.13,7.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,1,DB01041,__THALIDOMIDE,6235756,Terminated,NCT00314665,UVEITIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Cincinnati Medical Center, Cincinnati, Ohio, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,44.9783363108072,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.42,258.2295,83.55,4.0,1.0,3.0,24.42,64.32,1.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CC12CC3CC(C)(C1)CC(N)(C3)C2,1,DB01043,__MEMANTINE,5061703,Completed,NCT02466191,PENDULAR NYSTAGMUS|OCULOPALATAL TREMOR,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospices Civils de Lyon, Lyon, France",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,18.5958643914659,484.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,179.3018,26.02,1.0,1.0,3.0,21.82,54.49,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0
COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,1,DB01044,__GATIFLOXACIN,4980470,Unknown status,NCT00347828,EYE INFECTION|INFECTION,All,"25 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Prevention,"Ophthalmic Consultants of Boston, Boston, Massachusetts, United States",C07D215/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,47.2781781966775,191.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.23,375.3941,82.11,7.0,2.0,4.0,38.29,98.82,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0
COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,1,DB01044,__GATIFLOXACIN,4980470,Completed,NCT00464438,BACTERIAL CONJUNCTIVITIS,All,up to 31 Days   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Sacramento, California, United States|Whitby, Ontario, Canada",C07D215/56,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,47.2781781966775,191.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.23,375.3941,82.11,7.0,2.0,4.0,38.29,98.82,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0
COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,1,DB01044,__GATIFLOXACIN,4980470,Completed,NCT03578276,CATARACT,All,"50 Years to 99 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Carolina Eyecare Physicians, LLC, Mount Pleasant, South Carolina, United States",C07D215/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,47.2781781966775,191.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.23,375.3941,82.11,7.0,2.0,4.0,38.29,98.82,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0
COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,1,DB01044,__GATIFLOXACIN,4980470,Completed,NCT00407017,CATARACT SURGERY,All,"Child, Adult, Older Adult",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,"The Center for Excellence in Eye Care, Miami, Florida, United States",C07D215/56,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,47.2781781966775,191.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.23,375.3941,82.11,7.0,2.0,4.0,38.29,98.82,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Unknown status,NCT01681667,PHARYNGITIS,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Albany Medical Center Emergency Department, Albany, New York, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Recruiting,NCT03783702,SINUSITIS|OPIOID USE|OPIOID ABUSE|NARCOTIC USE|OTOLARYNGOLOGIC DISEASE|POSTOPERATIVE PAIN|PAIN,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford Health Care, Stanford, California, United States|NorthShore University Health System, Evanston, Illinois, United States|Mayo Clinic, Rochester, Minnesota, United States|Albert Einstein, Bronx, New York, United States|Vanderbilt, Nashville, Tennessee, United States|University of British Columbia, Vancouver, Canada",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Terminated,NCT02296840,RECURRENT TONSILLITIS|OBSTRUCTIVE SLEEP APNEA|SLEEP DISORDERED BREATHING|ADVERSE REACTION TO DRUG,All,4 Years to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Children's Healthcare of Atlanta (CHOA), Atlanta, Georgia, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CCOP(=O)(OCC)SCC[N+](C)(C)C,1,DB01057,__ECHOTHIOPHATE,,Unknown status,NCT02544529,MYOPIA,All,9 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Danbury Eye Physicians & Surgeons, PC, Danbury, Connecticut, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.2,256.323,35.53,1.0,0.0,0.0,27.65,78.14,8.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Unknown status,NCT00545961,ACUTE RESPIRATORY INFECTION|SINUSITIS,All,6 Years to 13 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Keski-pohjanmaan keskussairaala, Kokkola, Finland|Oulu University Hospital, Oulu, Finland|Etelä-Pohjanmaan Keskussairaala, Seinäjoki, Finland",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Recruiting,NCT03809312,CHRONIC SINUS INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Simon-Pierre Harvey-Bolduc, Québec, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Terminated,NCT00493038,SINUSITIS|BACTERIAL INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","San Benedetto del Tronto, Ascoli Piceno, Italy|Esine, Brescia, Italy|Lamezia Terme, Catanzaro, Italy|Cesena, Forlì, Italy|Sestri Ponente, Genova, Italy|Monza, Monza-Brianza, Italy|Comiso, Ragusa, Italy|Bari, Italy|Benevento, Italy|Bergamo, Italy|Bologna, Italy|Bolzano, Italy|Caserta, Italy|Catania, Italy|Catania, Italy|Firenze, Italy|Foggia, Italy|Lecce, Italy|Lecco, Italy|Matera, Italy|Milano, Italy|Milano, Italy|Novara, Italy|Pavia, Italy|Perugia, Italy|Pisa, Italy|Roma, Italy|Roma, Italy|Roma, Italy|Siena, Italy|Torino, Italy|Torino, Italy|Treviso, Italy|Udine, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Completed,NCT00377403,ACUTE RESPIRATORY INFECTIONS|ACUTE RHINOSINUSITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Washington University in St. Louis, St. Louis, Missouri, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Unknown status,NCT03264911,GROUP A STREPTOCOCCAL PHARYNGITIS,All,3 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospital of Geneva (HUG), Geneva, GE, Switzerland",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Terminated,NCT03431337,"SINUSITIS, ACUTE",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Albany Medical Center Internal Medicine and Pediatrics, Cohoes, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Completed,NCT02340000,SINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Albany Medical Center Internal Medicine and Pediatrics, Latham, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Completed,NCT00147914,ACUTE BACTERIAL SINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Chicago, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Recruiting,NCT02935374,ACUTE OTITIS MEDIA,All,6 Months to 7 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Mehiläinen, private practice, Oulu, Finland",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Terminated,NCT00799838,PHARYNGOTONSILLITIS,All,4 Years to 11 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Sanofi-Aventis Administrative Office, Sao Paulo, Brazil",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(/C=C\c3scnc3C)CS[C@H]12)c1csc(N)n1,1,DB01066,__CEFDITOREN,5958915,Unknown status,NCT01553006,RHINOSINUSITIS,All,1 Year to 15 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Thammasat University, Prathumthani, Thailand",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,17.675927637117802,208.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.7,506.57800000000003,160.1,9.0,3.0,4.0,49.19,124.18,7.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1
CN(C)CCOC(c1ccccc1)c1ccccc1,1,DB01075,__DIPHENHYDRAMINE,8263647,Completed,NCT00648973,NASAL CONGESTION,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Benchmark Research - Austin, Austin, Texas, United States|Allergy and Asthma Associates, Austin, Texas, United States|Lovelace Scientific Resources, Austin, Texas, United States|Allergy/Immunology Research Center of North Texas, Dallas, Texas, United States|Kerrville Research Associates, Kerrville, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States|Benchmark Research - San Angelo, San Angelo, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Biogenics Research Institute, San Antonio, Texas, United States|Diagnostics Research Group, San Antonio, Texas, United States|Sylvana Research Associates, San Antonio, Texas, United States|Allergy Asthma Research Institute, Waco, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CN(C)CCOC(c1ccccc1)c1ccccc1,1,DB01075,__DIPHENHYDRAMINE,8263647,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CN(C)CCOC(c1ccccc1)c1ccccc1,1,DB01075,__DIPHENHYDRAMINE,8263647,Completed,,"CYSTOID MACULAR EDEMA FOLLOWING CATARACT SURGERY, BILATERAL",,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CN(C)CCOC(c1ccccc1)c1ccccc1,1,DB01075,__DIPHENHYDRAMINE,8263647,Completed,,OCULAR HYPERTENSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CN(C)CCOC(c1ccccc1)c1ccccc1,1,DB01075,__DIPHENHYDRAMINE,8263647,Completed,,DIABETIC MACULAR EDEMA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12,1,DB01079,__TEGASEROD,5510353,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D409/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,15.4417955194151,53.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.76,301.394,85.29,5.0,4.0,2.0,34.96,110.25,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C,1,DB01085,__PILOCARPINE,3947573,Completed,NCT00438048,PRIMARY SJOGREN|SECONDARY SJOGREN|XEROSTOMIA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Unidad Docente Asociada Dermatologia. Escuela de MEdicina Pontificia Universidad Catolica de Chile, Santiago, Region Metropolitana, Chile",C08L71/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,17.380233680363,24.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.15,208.2569,44.12,2.0,0.0,2.0,22.34,56.53,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1
CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C,1,DB01085,__PILOCARPINE,3947573,Completed,NCT00803803,OPEN-ANGLE GLAUCOMA,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Wills Eye Glaucoma Service, Philadelphia, Pennsylvania, United States",C08L71/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,17.380233680363,24.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.15,208.2569,44.12,2.0,0.0,2.0,22.34,56.53,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1
CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C,1,DB01085,__PILOCARPINE,3947573,Completed,NCT00762645,ANGLE-CLOSURE GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Alcon Call Center, Fort Worth, Texas, United States",C08L71/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,17.380233680363,24.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.15,208.2569,44.12,2.0,0.0,2.0,22.34,56.53,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1
CCOC(=O)c1ccc(N)cc1,1,DB01086,__BENZOCAINE,4041174,Completed,,PHARYNGITIS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,35.7789687673258,1497.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.2,165.1891,52.32,2.0,1.0,1.0,17.46,47.53,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O,1,DB01088,__ILOPROST,EP-1089970-B1,Completed,,SARCOIDOSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,57.5289020308425,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.22,360.494,77.76,4.0,3.0,2.0,42.68,105.18,9.0,0.0,1.0,0.0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Withdrawn,NCT00913562,GLAUCOMA|DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria",C07D239/42 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D239/42 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C,1,DB01129,__RABEPRAZOLE,5045552,Completed,NCT01008696,REFLUX ESOPHAGITIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D413/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,20.1728988274913,316.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.04,359.44300000000015,77.1,5.0,1.0,3.0,39.64,98.07,8.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C,1,DB01129,__RABEPRAZOLE,5045552,Completed,NCT00464308,GASTRO-OESOPHAGEAL REFLUX,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Belconnen, Australia|Bondi Junction, Australia|Brookvale, Australia|Browns Plains, Australia|Campbelltown, Australia|Campsie, Australia|Caringbah, Australia|Castle Hill, Australia|Charlestown, Australia|Dapto, Australia|Darlinghurst, Australia|Dubbo, Australia|Elizabeth, Australia|Fairfield, Australia|Hoppers Crossing, Australia|Ingleburn, Australia|Leichhardt, Australia|Maroubra, Australia|Melton, Australia|Mount Druitt, Australia|Oaklands Park, Australia|Royal Park, Australia|Sydney, Australia|Wentworthville, Australia|Wyoming, Australia",C07D413/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,20.1728988274913,316.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.04,359.44300000000015,77.1,5.0,1.0,3.0,39.64,98.07,8.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C,1,DB01129,__RABEPRAZOLE,5045552,Completed,NCT00287391,INSOMNIA|GERD,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UNC Gastroenterology and UNC Sleep Disorders Center, Chapel Hill, North Carolina, United States",C07D413/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,20.1728988274913,316.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.04,359.44300000000015,77.1,5.0,1.0,3.0,39.64,98.07,8.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C,1,DB01129,__RABEPRAZOLE,5045552,Completed,NCT00354757,GERD,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"National Taiwan Univeristy Hospital, Taipei, Taiwan",C07D413/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.1728988274913,316.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.04,359.44300000000015,77.1,5.0,1.0,3.0,39.64,98.07,8.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C,1,DB01129,__RABEPRAZOLE,5045552,Completed,NCT00304421,GASTROESOPHAGEAL REFLUX,All,"18 Years to 65 Years   (Adult, Older Adult)",U.S. Fed|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"VA Greater Los Angeles Healthcare System, Los Angeles, California, United States",C07D413/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.0,20.1728988274913,316.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.04,359.44300000000015,77.1,5.0,1.0,3.0,39.64,98.07,8.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C,1,DB01129,__RABEPRAZOLE,5045552,Unknown status,NCT02986685,REFRACTORY REFLUX ESOPHAGITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Xijing Hosipital of Digestive Disease, Xi'an, Shaanxi, China",C07D413/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.1728988274913,316.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.04,359.44300000000015,77.1,5.0,1.0,3.0,39.64,98.07,8.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C,1,DB01129,__RABEPRAZOLE,5045552,Completed,NCT00216489,GASTROESOPHAGEAL REFLUX|HEARTBURN,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D413/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,20.1728988274913,316.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.04,359.44300000000015,77.1,5.0,1.0,3.0,39.64,98.07,8.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01137,__LEVOFLOXACIN,5053407,Completed,NCT02028754,DRY EYE SYNDROMES|CATARACT,All,"60 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hangzhou, China",C07D413/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,63.377071397769896,89.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01137,__LEVOFLOXACIN,5053407,Completed,NCT04403334,CATARACT SENILE|ENDOPHTHALMITIS|ANTIBIOTIC SIDE EFFECT|SAFETY ISSUES,All,"21 Years to 100 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","Peregrine Eye and Laser Instittute, Makati City, MM, Philippines",C07D413/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,63.377071397769896,89.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01137,__LEVOFLOXACIN,5053407,Completed,NCT00645073,ACUTE BACTERIAL SINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Birmingham, Alabama, United States|Birmingham, Alabama, United States|Columbiana, Alabama, United States|Eclectic, Alabama, United States|Tuscaloosa, Alabama, United States|Mesa, Arizona, United States|Fresno, California, United States|Fresno, California, United States|Murray, Kentucky, United States|Portage, Michigan, United States|Eugene, Oregon, United States|Lake Oswego, Oregon, United States|Orangeburg, South Carolina, United States|Kingsport, Tennessee, United States|Milan, Tennessee, United States|Corsicana, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|West Jordan, Utah, United States|West Jordan, Utah, United States|Winchester, Virginia, United States|Spokane, Washington, United States|Gorzow Wielkopolski, Poland|Krakow, Poland|Krakow, Poland|Lodz, Poland|Lodz, Poland|Przybyslawice, Poland|Skierniewice, Poland|Szczecin, Poland|Szczecin, Poland|Szczecin, Poland",C07D413/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,63.377071397769896,89.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01137,__LEVOFLOXACIN,5053407,Completed,NCT00840580,CATARACT SURGERY,All,"19 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Seoul, Korea, Republic of",C07D413/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,63.377071397769896,89.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01137,__LEVOFLOXACIN,5053407,Completed,NCT00630019,CATARACT,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science,"Bucci Laser Vision & Ambulatory Surgery Center, Wilkes-Barre, Pennsylvania, United States",C07D413/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,63.377071397769896,89.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
CNCCCN1c2ccccc2CCc2ccccc21,1,DB01151,__DESIPRAMINE,3961060,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,24.5754532947288,76.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,266.3807,15.27,2.0,1.0,3.0,31.74,85.31,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,1,DB01156,__BUPROPION,5358970,Completed,NCT00666978,BLADDER CANCER|CERVICAL CANCER|ESOPHAGEAL CANCER|GASTRIC CANCER|HEAD AND NECK CANCER|KIDNEY CANCER|LEUKEMIA|LIVER CANCER|LUNG CANCER|PANCREATIC CANCER|TOBACCO USE DISORDER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, United States|Swope Health Central, Kansas City, Missouri, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,1,DB01156,__BUPROPION,5358970,Active Not Recruiting,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,1,DB01156,__BUPROPION,5358970,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,1,DB01156,__BUPROPION,5358970,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CCN(CC)CCOC(=O)c1ccc(N)cc1Cl,1,DB01161,__CHLOROPROCAINE,8969412,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,101.882995544056,725.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.72,270.755,55.56,3.0,1.0,1.0,28.74,75.1,7.0,0.0,1.0,0.0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0
CC1(C)S[C@@H]2[C@H](N=CN3CCCCCC3)C(=O)N2[C@H]1C(=O)O,1,DB01163,__AMDINOCILLIN,4127649,Recruiting,,COMPLICATIONS,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,18.201605782459602,128.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.41,325.426,73.21,5.0,1.0,3.0,34.18,84.31,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1
CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01165,__OFLOXACIN,5401741,Completed,NCT00392275,CATARACT,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,"Indiana University Hospital, Indianapolis, Indiana, United States|Richard L Rodeboush VA Medical Center, Indianapolis, Indiana, United States|Wishard Memorial Hospital, Indianapolis, Indiana, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,23.4912421199613,725.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01165,__OFLOXACIN,5401741,Not yet recruiting,NCT03655665,OTITIS MEDIA,All,6 Months to 10 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,,5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,23.4912421199613,725.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,1,DB01167,__ITRACONAZOLE,6407079,Completed,NCT00336531,NEUROBLASTOMA|BRAIN TUMOR|RETINOBLASTOMA|WILMS TUMOR|MYCOSES,All,up to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Samsung Medical Center, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1346.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.48,705.633,100.79,9.0,0.0,7.0,74.71,200.4,11.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0
CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,1,DB01175,__ESCITALOPRAM,RE34712,Recruiting,NCT03321006,HEARING LOSS|DEPRESSION,All,"60 Years to 99 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","New York State Psychiatric Institute, New York, New York, United States",C07D307/87,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,12.0,11.4992094293517,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.58,324.3919,36.26,3.0,0.0,3.0,35.3,94.02,5.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0
CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,1,DB01175,__ESCITALOPRAM,RE34712,Terminated,NCT00754793,CHRONIC SINUSITIS|FACIAL PAIN DISORDER|DEPRESSION,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Washington Medical Center, Seattle, Washington, United States",C07D307/87,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,11.4992094293517,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.58,324.3919,36.26,3.0,0.0,3.0,35.3,94.02,5.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0
O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1,1,DB01184,__DOMPERIDONE,4066772,Completed,NCT02685436,GASTROESOPHAGEAL REFLUX,All,6 Months to 2 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,,C07D235/26,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,19.5815109139818,755.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,425.911,67.92,3.0,2.0,5.0,45.61,119.37,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1
FC(F)OC(F)C(F)(F)F,1,DB01189,__DESFLURANE,5617906,Completed,NCT02379546,"STRABISMUS|ANESTHESIA, GENERAL",All,3 Years to 16 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Tuğba Karaman, Tokat, Merkez, Turkey",F16L37/47,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,22.439885829277802,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.19,168.0378,9.23,1.0,0.0,0.0,7.89,18.12,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
CCC[C@@H]1C[C@@H](C(=O)NC(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1,1,DB01190,__CLINDAMYCIN,5266329,Completed,NCT00398658,ENDOPHTHALMITIS|PROPHYLAXY OF POST TRAUMATIC ENDOPHTHALMITIS|BACTERIAL ENDOPHTHALMITIS,All,"3 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,"Ophthalmic Research Center, Tehran, Iran, Islamic Republic of",A61M31/002,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,24.1811946857225,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.76,424.983,102.26,6.0,4.0,2.0,44.65,105.72,7.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,1,1,1,0,1
CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,1,DB01194,__BRINZOLAMIDE,5240923,Completed,NCT03966560,"GLAUCOMA, OPEN-ANGLE",All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D333/34,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,22.7355797860325,148.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.65,383.50699999999995,118.8,6.0,2.0,2.0,37.93,87.2,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0
CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,1,DB01194,__BRINZOLAMIDE,5240923,Completed,NCT01471158,GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Centro Oftalmológico, Buenos Aires, Argentina",C07D333/34,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,22.7355797860325,148.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.65,383.50699999999995,118.8,6.0,2.0,2.0,37.93,87.2,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0
CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,1,DB01194,__BRINZOLAMIDE,5240923,Completed,NCT02325518,OPEN-ANGLE GLAUCOMA|OCULAR HYPERTENSION,All,"20 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)","Contact Alcon Japan Ltd. for Trial Locations, Tokyo, Japan",C07D333/34,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,22.7355797860325,148.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.65,383.50699999999995,118.8,6.0,2.0,2.0,37.93,87.2,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0
CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,1,DB01194,__BRINZOLAMIDE,5240923,Completed,NCT00675207,PRIMARY OPEN ANGLE GLAUCOMA|OCULAR HYPERTENSION,All,"41 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Northwestern Ophthalmic Institute S.C., Glenview, Illinois, United States",C07D333/34,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,22.7355797860325,148.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.65,383.50699999999995,118.8,6.0,2.0,2.0,37.93,87.2,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0
CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,1,DB01194,__BRINZOLAMIDE,5240923,Completed,NCT00471380,GLAUCOMA|OCULAR HYPERTENSION,All,"40 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"Catania, Catania, Italy",C07D333/34,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,22.7355797860325,148.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.65,383.50699999999995,118.8,6.0,2.0,2.0,37.93,87.2,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0
CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,1,DB01194,__BRINZOLAMIDE,5240923,Completed,NCT01937312,OCULAR HYPERTENSION|OPEN ANGLE GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,C07D333/34,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,22.7355797860325,148.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.65,383.50699999999995,118.8,6.0,2.0,2.0,37.93,87.2,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0
CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,1,DB01194,__BRINZOLAMIDE,5240923,Terminated,NCT00758342,INTRAOCULAR PRESSURE,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Alcon Call Center, Fort Worth, Texas, United States",C07D333/34,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,22.7355797860325,148.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.65,383.50699999999995,118.8,6.0,2.0,2.0,37.93,87.2,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0
CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,1,DB01194,__BRINZOLAMIDE,5240923,Completed,NCT01415401,GLAUCOMA|OCULAR HYPERTENSION|OPEN-ANGLE GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D333/34,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,22.7355797860325,148.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.65,383.50699999999995,118.8,6.0,2.0,2.0,37.93,87.2,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0
CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,1,DB01194,__BRINZOLAMIDE,5240923,Completed,NCT00372827,PRIMARY OPEN-ANGLE GLAUCOMA|OCULAR HYPERTENSION|PIGMENT DISPERSION GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Mainz Site, Mainz, Germany",C07D333/34,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,22.7355797860325,148.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.65,383.50699999999995,118.8,6.0,2.0,2.0,37.93,87.2,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0
CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,1,DB01194,__BRINZOLAMIDE,5240923,Completed,NCT03192826,POSTERIOR CAPSULE OPACIFICATION|OCULAR HYPERTENSION,All,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","University Hospital of Patras, Patra, Achaia, Greece",C07D333/34,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,22.7355797860325,148.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.65,383.50699999999995,118.8,6.0,2.0,2.0,37.93,87.2,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0
CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,1,DB01194,__BRINZOLAMIDE,5240923,Completed,NCT01312402,INFANTILE NYSTAGMUS SYNDROME,All,"12 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Akron Children's Hospital, Akron, Ohio, United States",C07D333/34,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,22.7355797860325,148.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.65,383.50699999999995,118.8,6.0,2.0,2.0,37.93,87.2,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0
O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,1,DB01204,__MITOXANTRONE,3977953,Completed,NCT00304291,"NEUROMYELITIS OPTICA|MYELITIS, TRANSVERSE|DEMYELINATING AUTOIMMUNE DISEASES, CNS|AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM",All,18 Years to 55 Years   (Adult),Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baird Multiple Sclerosis Center, Buffalo, New York, United States",C12C3/00,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,21.0,11.9263229224419,950.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.91,444.4809,163.18,10.0,8.0,3.0,48.49,123.53,12.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0
O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,1,DB01204,__MITOXANTRONE,3977953,Unknown status,NCT02021825,NEUROMYELITIS OPTICA|NEUROMYELITIS OPTICA SPECTRUM DISORDERS,All,18 Years to 55 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China",C12C3/00,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,11.9263229224419,950.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.91,444.4809,163.18,10.0,8.0,3.0,48.49,123.53,12.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Completed,NCT01955135,RETINOPATHY,All,32 Weeks to 40 Weeks   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,,C07D307/52,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Completed,NCT01827020,"NOSE DEFORMITIES, ACQUIRED",All,18 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Turgut Ozal Medical Center, Malatya, Turkey",C07D307/52,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Completed,NCT03054103,PHACOEMULSIFICATION|CATARACT,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",,C07D307/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Completed,NCT02072083,PREMEDICATION|OCULOCARDIAC REFLEX,All,2 Years to 11 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Erciyes university hospital, Kayseri, Turkey",C07D307/52,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Active Not Recruiting,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D307/52,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT04132570,RHINITIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Beijing Tongren Hospital, Cmu, Beijing, Beijing, China|The No.2 Hospital of Baoding, Baoding, Hebei, China|Cangzhou Center Hospital, Cangzhou, Hebei, China|The Second Hospital to Hebei Medical University, Shijiazhuang, Hebei, China|Shandong provincial hospital, Jinan, Shandong, China|The No.2 People'S Hospital Og Weifang, Weifang, Shandong, China",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT02409563,ALLERGIC RHINITIS,All,6 Years to 14 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council, Palermo, Sicily, Italy",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT02696850,RHINOSINUSITIS|CHRONIC EOSINOPHILIC RHINOSINUSITIS|ALLERGIC RHINOSINUSITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Washington University School of Medicine, Saint Louis, Missouri, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT01270256,PERENNIAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Chicago, Chicago, Illinois, United States",A61K9/008,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT00560586,OBSTRUCTIVE SLEEP APNEA,All,6 Years to 12 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kosair Children's Hospital Sleep Center, Louisville, Kentucky, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Not yet recruiting,NCT04342039,EPIGENETIC EFFECTS OF INTRANASAL STEROIDS|ENVIRONMENTAL EXPOSURE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",,A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/008,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,1,DB01224,__QUETIAPINE,4879288,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D281/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,31.639253372759104,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.93,383.50699999999995,48.3,5.0,1.0,4.0,42.78,114.09,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,1,DB01224,__QUETIAPINE,4879288,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D281/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,31.639253372759104,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.93,383.50699999999995,48.3,5.0,1.0,4.0,42.78,114.09,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,1,DB01229,__PACLITAXEL,5439686,Active Not Recruiting,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/6925,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,1,DB01233,__METOCLOPRAMIDE,6024981,Completed,NCT02253524,NAUSEA|VOMITING|VERTIGO,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.18,299.796,67.59,4.0,2.0,1.0,32.7,83.52,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,1,DB01233,__METOCLOPRAMIDE,6024981,Completed,NCT02907632,GASTROESOPHAGEAL REFLUX,All,up to 100 Days   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Nathalie Charpak, Bogotá, Cundinamarca, Colombia",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.18,299.796,67.59,4.0,2.0,1.0,32.7,83.52,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,1,DB01233,__METOCLOPRAMIDE,6024981,Completed,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.18,299.796,67.59,4.0,2.0,1.0,32.7,83.52,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,1,DB01233,__METOCLOPRAMIDE,6024981,Completed,,PREGNANCY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.18,299.796,67.59,4.0,2.0,1.0,32.7,83.52,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,1,DB01233,__METOCLOPRAMIDE,6024981,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.18,299.796,67.59,4.0,2.0,1.0,32.7,83.52,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Not yet recruiting,NCT04555694,DRY EYE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Eye Clinic, Brecksville, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT00781300,"GLAUCOMA, OPEN-ANGLE|OCULAR HYPERTENSION",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Opthalmology, Federal University of São Paulo, São Paulo, SP, Brazil",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT04075227,RECURRENT PTERYGIUM OF EYE|STEROID-INDUCED GLAUCOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Unknown status,NCT02873806,OPEN-ANGLE GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"S.V. Malayan's Ophtalmology Centre, Yerevan, Armenia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT03323047,TONSILLITIS,All,3 Years to 13 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,"Children's Hospital, London, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Not yet recruiting,NCT04479748,CATARACT,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT04403516,PTERYGIUM,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"New York Eye Specialists, New York, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT04351737,PTERYGIUM OF BOTH EYES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Brandon Eye Associates, Brandon, Florida, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT04200651,GLAUCOMA|CATARACT,All,"21 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The New York Eye Surgery Center, Bronx, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Not yet recruiting,NCT04426734,NON-INFECTIOUS ANTERIOR UVEITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT03634852,ENDOPHTHALMITIS POSTOPERATIVE,All,"38 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT02682134,SORE THROAT,All,"15 Years to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01052038,SORE THROAT|PAIN,Female,18 Years to 64 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Northwesten University, Chicago, Illinois, United States",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Unknown status,NCT01024075,CHRONIC RHINOSINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Calgary, Calgary, Alberta, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01990781,"POSTOPERATIVE SORE THROAT, COUGH, HOARSENESS",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","BP Koirala Institute of Health Sciences (BPKIHS), Dharan, Koshi, Nepal",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT03892434,BRANCH RETINAL VEIN OCCLUSION WITH MACULAR EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yeungnam university hospital, Daegu, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT03711474,DYSPHAGIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","West Virginia University Department of Orthopaedics, Morgantown, West Virginia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT02049476,"UVEITIS, INTERMEDIATE|UVEITIS, POSTERIOR",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, Maryland, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01042145,CROUP,All,1 Year to 8 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Washington University School of Medicine, St. Louis, Missouri, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT03705273,ASTHMA|CROUP,All,1 Year to 7 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01372904,CISPLATIN OTOTOXICITY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Clalit Health Services, Haifa, Israel",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT04412694,HYPOCALCEMIA|VITAMIN D DEFICIENCY|POSTOPERATIVE COMPLICATIONS|POSTOPERATIVE NAUSEA|POSTOPERATIVE PAIN|VOICE HOARSENESS|HYPOPARATHYROIDISM POSTPROCEDURAL,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","Department of General and Oncological Surgery, Medical University of Lodz, Łódź, Łódzkie, Poland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT04205916,PATIENT PREFERENCE,All,"22 Years to 100 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Ophthalmic Consultants of Long Island, Garden City, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Not yet recruiting,NCT03751059,GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Withdrawn,NCT01326585,RETINAL DETACHMENT,All,"18 Years to 79 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","St. Michael's Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT03317847,INFLAMMATION EYE,All,"60 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Arcispedale Santa Maria Nuova IRCSS - Ophthalmology, Reggio Emilia, RE, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT00805649,AGE-RELATED MACULAR DEGENERATION,All,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Abteilung für Netzhaut und Glaskörperchirurgie, Frankfurt/Main, Hessen, Germany",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Withdrawn,NCT03361709,DIABETES MELLITUS|CORNEAL ENDOTHELIAL CELL LOSS|DEXAMETHASONE ADVERSE REACTION|CORNEAL ENDOTHELIAL DECOMPENSATION,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT04465864,"GLAUCOMA, PRIMARY OPEN ANGLE|CATARACT",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Wolstan and Goldberg Eye Associates, Torrance, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT04411693,DIABETIC MACULAR EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Retina Consultants of Houston, Houston, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT02816905,INTRAOCULAR PRESSURE,All,up to 13 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Cairo University Hospitals, Cairo, Egypt",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01580020,RETINAL VEIN OCCLUSION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Bad Rothenfelde, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Bremen, Germany|Novartis Investigative Site, Chemnitz, Germany|Novartis Investigative Site, Darmstadt, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Düsseldorf, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Freiburg i. Br, Germany|Novartis Investigative Site, Glauchau, Germany|Novartis Investigative Site, Göttingen, Germany|Novartis Investigative Site, Halle, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Ingolstadt, Germany|Novartis Investigative Site, Karlsruhe, Germany|Novartis Investigative Site, Karlsruhe, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Ludwigshafen, Germany|Novartis Investigative Site, Marburg, Germany|Novartis Investigative Site, Minden, Germany|Novartis Investigative Site, Muelheim, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, München, Germany|Novartis Investigative Site, München, Germany|Novartis Investigative Site, Recklinghausen, Germany|Novartis Investigative Site, Regensburg, Germany|Novartis Investigative Site, Sulzbach, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wolfsburg, Germany|Novartis Investigative Site, Wuerzburg, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01119287,ALLERGIC CONJUNCTIVITIS,All,18 Years to 64 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","Contact Alcon Call Center For Trial Locations, Fort Worth, Texas, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01797822,KERATOCONJUNCTIVITIS SICCA|DRY EYE SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baylor College of Medicine, Alkek Eye Center, Houston, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT02137161,CATARACT|PSEUDOEXFOLIATION SYNDROME,All,"60 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arcispedale Santa Maria Nuova IRCSS - Ophthalmology, Reggio Emilia, RE, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01546402,"MACULAR EDEMA, CYSTOID|VISION DISORDERS|DIABETIC MACULAR EDEMA|CYSTOID MACULAR EDEMA FOLLOWING CATARACT SURGERY|CATARACT",All,"35 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Postgraduate Institute of Medical Education and Research, Chandigarh, India",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT04448496,DIABETIC RETINOPATHY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dong-A University Hospital, Busan, Korea, Republic of|Maryknoll Medical Center, Busan, Korea, Republic of|Gyeongsang National University Changwon Hospital, Changwon, Korea, Republic of|Yeungnam university hospital, Daegu, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Not yet recruiting,NCT04501367,VITRECTOMY|MACULAR PUCKER|RETINAL EDEMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01211327,VERNAL KERATOCONJUNCTIVITIS,All,"5 Years and older   (Child, Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Kabgayi Hospital, Gitarama/Muhanga, Rwanda",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01903720,MACULAR EDEMA|RETINAL VEIN OCCLUSION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01767545,MACULAR EDEMA CAUSED BY RETINAL VEIN OCCLUSION,All,"20 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dept. of Ophthalmology, LMU Munich, Munich, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01427751,RETINAL VEIN OCCLUSION|MACULAR EDEMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Paris, France|Munich, Germany|Tel Aviv, Israel|Milan, Italy|Madrid, Spain|London, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Unknown status,NCT02399657,DIABETES MELLITUS|MACULAR EDEMA|RETINAL EXUDATES AND DEPOSITS,All,"20 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Gyeongsang National University Hospital, Jinju, Gyeongsangnam-do, Korea, Republic of|Kosin University Gospel Hospital, Busan, Korea, Republic of|Dong-A University hospital, Busan, Korea, Republic of|Pusan national university hospital, Busan, Korea, Republic of|Inje University Haeundae Paik hospital, Busan, Korea, Republic of|Inje University Busan Paik hospital, Busan, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Active Not Recruiting,,MACULAR EDEMA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O,1,DB01235,__LEVODOPA,6858199,Completed,NCT00812760,RETINAL DISEASES,Male,19 Years to 35 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria",1,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,49.0,56.4775457401589,1144.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-2.3,197.1879,103.78,5.0,4.0,1.0,18.91,49.08,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O,1,DB01235,__LEVODOPA,6858199,Completed,NCT00432393,NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY,All,"50 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Ophthalmic research center, Tehran, Iran, Islamic Republic of",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,49.0,56.4775457401589,1144.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-2.3,197.1879,103.78,5.0,4.0,1.0,18.91,49.08,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O,1,DB01235,__LEVODOPA,6858199,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,49.0,56.4775457401589,1144.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-2.3,197.1879,103.78,5.0,4.0,1.0,18.91,49.08,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Completed,NCT01955135,RETINOPATHY,All,32 Weeks to 40 Weeks   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,,0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Terminated,NCT00665418,LARYNGOSPASM,All,25 Months to 84 Months   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,1,DB01238,__ARIPIPRAZOLE,5006528,Active Not Recruiting,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D215/227,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,1,DB01238,__ARIPIPRAZOLE,5006528,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D215/227,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,1,DB01238,__ARIPIPRAZOLE,5006528,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D215/227,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1
CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21,1,DB01242,__CLOMIPRAMINE,5008262,Terminated,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,35.8775334195774,561.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.04,314.8520000000001,6.48,2.0,0.0,3.0,35.73,95.41,4.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,1,DB01248,__DOCETAXEL,4814470,Completed,NCT00772681,HEAD AND NECK NEOPLASMS,All,"19 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sanofi-Aventis Administrative Office, Istanbul, Turkey",C07D305/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,1,DB01248,__DOCETAXEL,4814470,Unknown status,NCT03069820,"LIVER INJURY, DRUG-INDUCED",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,"The Second Afiliated Hospital of Nanchang University, Nanchang, Jiangxi, China",C07D305/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)Cn4cnnn4)[C@H]3SC2)s1,1,DB01327,__CEFAZOLIN,3937655,Unknown status,NCT02324166,VITREORETINAL SURGERY|ENDOPHTHALMITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant),,C12Q1/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,21.8484979157682,879.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.4,454.50699999999995,156.09,9.0,2.0,4.0,41.44,119.86,7.0,0.0,1.0,0.0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,1,0,1
CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,1,DB01366,__PROCATEROL,4616022,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D215/26,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,25.659664469496196,328.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.28,290.3575,81.59,4.0,4.0,2.0,31.69,84.58,5.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0
C#CCN[C@@H]1CCc2ccccc21,1,DB01367,__RASAGILINE,5387612,Terminated,NCT02068625,RETINAL DETACHMENT,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Department of Ophthalmology, Bern University Hospital, Bern, Switzerland",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,20.698576972833106,136.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.26,171.2383,12.03,1.0,1.0,2.0,20.25,54.47,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0
C#CCN[C@@H]1CCc2ccccc21,1,DB01367,__RASAGILINE,5387612,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,20.698576972833106,136.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.26,171.2383,12.03,1.0,1.0,2.0,20.25,54.47,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0
CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,1,DB01410,__CICLESONIDE,5695743,Completed,NCT00806754,"RHINITIS, ALLERGIC, PERENNIAL",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Altana/Nycomed, Encinitas, California, United States|Altana/Nycomed, Los Angeles, California, United States|Altana/Nycomed, Mission Viejo, California, United States|Altana/Nycomed, San Diego, California, United States|Altana/Nycomed, San Jose, California, United States|Altana/Nycomed, Colorado Springs, Colorado, United States|Altana/Nycomed, Denver, Colorado, United States|Altana/Nycomed, Lakewood, Colorado, United States|Altana/Nycomed, Gainesville, Georgia, United States|Altana/Nycomed, Savannah, Georgia, United States|Altana/Nycomed, Stockbridge, Georgia, United States|Altana/Nycomed, Overland Park, Kansas, United States|Altana/Nycomed, Metairie, Louisiana, United States|Altana/Nycomed, Shreveport, Louisiana, United States|Altana/Nycomed, Bethesda, Maryland, United States|Altana/Nycomed, North Dartmouth, Massachusetts, United States|Altana/Nycomed, Novi, Michigan, United States|Altana/Nycomed, Rolla, Missouri, United States|Altana/Nycomed, Papillion, Nebraska, United States|Altana/Nycomed, Skillman, New Jersey, United States|Altana/Nycomed, Raleigh, North Carolina, United States|Altana/Nycomed, Cincinnati, Ohio, United States|Altana/Nycomed, Sylvania, Ohio, United States|Altana/Nycomed, Ashland, Oregon, United States|Altana/Nycomed, Medford, Oregon, United States|Altana/Nycomed, Portland, Oregon, United States|Altana/Nycomed, Pittsburgh, Pennsylvania, United States|Altana/Nycomed, Upland, Pennsylvania, United States|Altana/Nycomed, Charleston, South Carolina, United States|Altana/Nycomed, Dallas, Texas, United States|Altana/Nycomed, San Antonio, Texas, United States|Altana/Nycomed, South Burlington, Vermont, United States|Altana/Nycomed, Newport News, Virginia, United States|Altana/Nycomed, Richmond, Virginia, United States|Altana/Nycomed, Milwaukee, Wisconsin, United States",A61K9/124,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,57.2003531900039,415.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.08,540.697,99.13,6.0,1.0,6.0,60.18,146.28,6.0,1.0,0.0,0.0,0,1,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,1,1,0,1,1,1,1,0,1
CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,1,DB01410,__CICLESONIDE,5695743,Completed,NCT01430260,ALLERGIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"handok pharmaceuticals co. LTD, Seoul, Korea, Republic of",A61K9/124,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,57.2003531900039,415.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.08,540.697,99.13,6.0,1.0,6.0,60.18,146.28,6.0,1.0,0.0,0.0,0,1,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,1,1,0,1,1,1,1,0,1
CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,1,DB01410,__CICLESONIDE,5695743,Completed,NCT01654536,PERENNIAL ALLERGIC RHINITIS,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Allergy & Asthma Associates of Southern California, Mission Viejo, California, United States|CHOC PSF AMC - Division of Allergy, Asthma and Immunology, Orange, California, United States|Allergy Associates Medical Group Inc., San Diego, California, United States|Bensch Research Associates, Stockton, California, United States|Storms Clinical Research Institute, Colorado Springs, Colorado, United States|DataQuest Medical Research LLC, Lawerenceville, Georgia, United States|Asthma & Allergy Consultants, PC, Lilburn, Georgia, United States|Gordon D Raphael, MD, Bethesda, Maryland, United States|Medical Education and Research Management Services of New England, Gardner, Massachusetts, United States|Northeast Medical Research Associates, Inc., North Dartmouth, Massachusetts, United States|Respiratory Medicine Research Institute of Michigan, PLC, Ypsilanti, Michigan, United States|Clinical Research Institute Inc., Minneappolis, Minnesota, United States|The Clinical Research Center, LLC, St. Louis, Missouri, United States|Clinical Research Group of Montanta, Bozeman, Montana, United States|Ocean Allergy & Respiratory Research Center, Brick, New Jersey, United States|Atlantic Research Center, LLC, Ocean, New Jersey, United States|Princeton Center for Clinical Research, Skillman, New Jersey, United States|Allergy and Asthma Center of NC, PA, High Point, North Carolina, United States|North Carolina Clinical Research, Raleigh, North Carolina, United States|Allergy Assocaites Research Center, Portland, Oregon, United States|Valley Clinical Research Center, Bethlehem, Pennsylvania, United States|Asthma and Allergy Research Associates, Upland, Pennsylvania, United States|National Allergy, Asthma & Uticaria Centers of Charleston, P.A., Charleston, South Carolina, United States|Isis Clinical Research, LLC, Austin, Texas, United States|Sirius Clinical Research LLC, Austin, Texas, United States|Pharmaceutical Research and Consulting Inc., Dallas, Texas, United States|Kerrville Research Associates, PA, Kerrville, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States|Biogenics Research Institute, San Antonio, Texas, United States|Sylvana Research Associates, San Antonio, Texas, United States|ASTHMA Inc. Clinical Research Center, Seattle, Washington, United States",A61K9/124,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,57.2003531900039,415.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.08,540.697,99.13,6.0,1.0,6.0,60.18,146.28,6.0,1.0,0.0,0.0,0,1,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,1,1,0,1,1,1,1,0,1
COc1cc(CC(C)N)c(OC)cc1C,1,DB01528,"__4-METHYL-2,5-DIMETHOXYAMPHETAMINE",WO-1998042331-A1,Completed,NCT02685436,GASTROESOPHAGEAL REFLUX,All,6 Months to 2 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,,5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,32.7488,13.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.02,209.2848,44.48,3.0,1.0,1.0,24.09,61.67,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2C(=O)[C@@H](N=CN3CCCCCC3)[C@H]2SC1(C)C,1,DB01605,__PIVMECILLINAM,4203972,Recruiting,,COMPLICATIONS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,25.9225035421671,142.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.23,439.569,88.51,5.0,0.0,3.0,47.7,113.03,7.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,1,1,0,1,1,1
C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O,1,DB01606,__TAZOBACTAM,6207661,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,42.0,25.1011314400706,446.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,300.291,122.46,7.0,1.0,3.0,26.22,74.82,3.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,1,1,0
CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2,1,DB01618,__MOLINDONE,4065453,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D209/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,13.831906199305902,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.09,276.374,45.33,3.0,1.0,3.0,32.0,81.06,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1
CN(C)CCC(c1ccccc1)c1ccccn1,1,DB01620,__PHENIRAMINE,4000302,Unknown status,NCT01390961,ALLERGIC CONJUNCTIVITIS,All,"18 Months and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Milton M. Hom, OD, FAAO., Azusa, California, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,20.4357379001622,367.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.85,240.3434,16.13,2.0,0.0,2.0,28.41,76.05,5.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0
CN(C)CCC(c1ccccc1)c1ccccn1,1,DB01620,__PHENIRAMINE,4000302,Unknown Status,,SEASONAL ALLERGIC CONJUNCTIVITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,20.4357379001622,367.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.85,240.3434,16.13,2.0,0.0,2.0,28.41,76.05,5.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0
O=C(O)Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1,1,DB01751,__TETRAIODOTHYROACETIC_ACID,4490221,Completed,NCT00347776,TRICHIASIS,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Johns Hopkins University, Baltimore, Maryland, United States",C07C51/377,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,19.9429146389042,24.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.99,747.8288,66.76,3.0,2.0,2.0,45.76,119.04,4.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(O)CO,1,DB01839,__PROPYLENE_GLYCOL,,Completed,,DRY EYE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.1,76.0944,40.46,2.0,2.0,0.0,8.01,18.97,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(O)CO,1,DB01839,__PROPYLENE_GLYCOL,,Completed,,MYOPIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.1,76.0944,40.46,2.0,2.0,0.0,8.01,18.97,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(O)CO,1,DB01839,__PROPYLENE_GLYCOL,,Completed,,EVAPORATIVE DRY EYE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.1,76.0944,40.46,2.0,2.0,0.0,8.01,18.97,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,DB01914,__D-GLUCOSE,,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,180.1559,118.22,6.0,5.0,0.0,16.23,37.35,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,1,DB02097,__CYTIDINE,3950325,Completed,NCT00404729,"GLAUCOMA|OPTIC NEUROPATHY, ISCHEMIC|VISUAL PATHWAYS,|OPTIC NERVE|NEURAL CONDUCTION",All,"40 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fondazione G.B. Bietti- IRCCS, Rome, Italy|Fondazione G.B. Bietti-IRCCS, Rome, Italy",C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.718988069570198,1038.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.4,54.54,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0
OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02379,__BETA-D-GLUCOSE,3964974,Unknown status,NCT01306955,BEHCET'S DISEASE,All,"10 Years to 70 Years   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Rheumatology Research Center, Tehran University of Medical Science, Tehran, Iran, Islamic Republic of",C12Q1/54,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.380562229203804,1910.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,180.1559,110.38,6.0,5.0,1.0,16.43,35.92,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CC(=O)O[C@H]1C[C@@]2(C)[C@@H](C[C@@H](O)[C@H]3[C@@]4(C)CC[C@@H](O)[C@@H](C)[C@@H]4CC[C@@]32C)/C1=C(\CCC=C(C)C)C(=O)O,1,DB02703,__FUSIDIC_ACID,4025620,Unknown status,NCT03105505,INFLAMMATION OF THE EYELIDS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barzilai Medical Center, Ashqelon, Israel",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,19.05583276864,1071.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.97,516.7092,104.06,5.0,3.0,4.0,59.76,144.12,6.0,0.0,1.0,0.0,0,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,1,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1,1,DB02709,__RESVERATROL,5747536,Completed,NCT03349619,ALLERGIC RHINITIS,All,6 Years to 16 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute of Biomedicine and Molecular Immunology (IBIM) - National Research Council of Palermo, Palermo, Italy",0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,19.05583276864,5538.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.57,228.2433,60.69,3.0,3.0,2.0,24.55,67.46,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02772,__SUCROSE,,Completed,NCT00921544,RETINOPATHY OF PREMATURITY,All,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Coombe Women and Infants University Maternity Hospital, Dublin, Ireland",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)COP(=O)(O)O)c2cc1C,1,DB03247,__FLAVIN_MONONUCLEOTIDE,3960840,Completed,NCT03245853,"KERATOCONUS|KERATOCONUS, UNSTABLE",All,"14 Years to 40 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Comprehensive EyeCare of Central Ohio, Westerville, Ohio, United States",C07H21/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,41.0686051048276,247.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.78,456.3438,201.58,11.0,6.0,3.0,42.19,107.14,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,0,0,0
Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)COP(=O)(O)O)c2cc1C,1,DB03247,__FLAVIN_MONONUCLEOTIDE,3960840,Completed,,KERATOCONUS,,,,,"FISABIO, Elche, Alicante, Spain",C07H21/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,41.0686051048276,247.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.78,456.3438,201.58,11.0,6.0,3.0,42.19,107.14,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,0,0,0
NC(CO)(CO)CO,1,DB03754,__TROMETHAMINE,,Unknown status,NCT00865540,CATARACT,All,"50 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Clínica Oftalmológica Zona Sul, Recife, Pernambuco, Brazil",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.1,121.135,86.71,4.0,4.0,0.0,12.02,28.36,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
NC(CO)(CO)CO,1,DB03754,__TROMETHAMINE,,Completed,NCT01542190,"CYSTOID MACULAR EDEMA FOLLOWING CATARACT SURGERY, BILATERAL",All,"50 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Unicamp, Campinas, Sao Paulo, Brazil|Unicamp, Campinas, Sao Paulo, Brazil",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.1,121.135,86.71,4.0,4.0,0.0,12.02,28.36,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
NC(CO)(CO)CO,1,DB03754,__TROMETHAMINE,,Completed,NCT02646072,"CYSTOID MACULAR EDEMA, POSTOPERATIVE|DIABETES MELLITUS",All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","University of Malaya, Kuala Lumpur, Wilayah Persekutuan, Malaysia",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.1,121.135,86.71,4.0,4.0,0.0,12.02,28.36,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
O=C(O)CC(O)(CC(=O)O)C(=O)O,1,DB04272,__CITRIC_ACID,8481083,Completed,NCT03578900,XEROSTOMIA|HYPOSALIVATION|QUALITY OF LIFE|SJOGREN'S SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,56.937514117333,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.3,192.1235,132.13,7.0,4.0,0.0,15.54,35.62,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,DB04465,__LACTOSE,4001198,Unknown status,NCT02557269,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medical University Sofia, University Hospital ""Alexandrovska"", Clinic of Allergy and Asthma, Sofia, Bulgaria",C13K5/00,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,21.0,12.813404792706196,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.32,68.34,4.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,DB04465,__LACTOSE,4001198,Completed,NCT02286960,DYSPHONIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"New York University School of Medicine, New York, New York, United States",C13K5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,12.813404792706196,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.32,68.34,4.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,DB04465,__LACTOSE,4001198,Completed,NCT00841230,TINNITUS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Antwerp University Hospital, Antwerp, Belgium",C13K5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,12.813404792706196,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.32,68.34,4.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,DB04465,__LACTOSE,4001198,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C13K5/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,12.813404792706196,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.32,68.34,4.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CS(=O)(=O)Nc1ccc([N+](=O)[O-])cc1Oc1ccccc1,1,DB04743,__NIMESULIDE,5283261,Completed,NCT02229747,PHARYNGITIS,All,2 Years to 8 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,6,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,16.2303127374278,128.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.56,308.31,101.22,4.0,1.0,2.0,28.87,76.31,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0
Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O,1,DB04854,__FEBUXOSTAT,5614520,Completed,,TYPE 1 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,25.7910840058317,67.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.8,316.375,83.21,5.0,1.0,2.0,33.88,93.93,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0
O=C(O)CCCN1CCC(OC(c2ccc(Cl)cc2)c2ccccn2)CC1,1,DB04890,__BEPOTASTINE,6780877,Completed,NCT01443442,ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Eye Car Center, Southern California college of Optometry, Fullerton, California, United States|Eye Care Center, Southern Caalifornia College of Optometry, Fullerton, California, United States",C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,35.3847101583194,19.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,388.88800000000003,62.66,5.0,1.0,3.0,42.18,105.1,8.0,0.0,1.0,0.0,0,1,0,1,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,1,1,1,0,1,0,1
CC1(C)C(C=C(Cl)Cl)C1C(=O)OCc1cccc(Oc2ccccc2)c1,1,DB04930,__PERMETHRIN,3944666,Completed,NCT00347763,TRACHOMA,All,12 Months to 8 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Johns Hopkins University/ Kongwa Trachoma Project, Baltimore, Maryland, United States",C07F9/4078,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,16.000328548840802,523.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.24,391.288,35.53,1.0,0.0,3.0,39.43,114.28,7.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0
CC1(C)C(C=C(Cl)Cl)C1C(=O)OCc1cccc(Oc2ccccc2)c1,1,DB04930,__PERMETHRIN,3944666,Unknown status,NCT03105505,INFLAMMATION OF THE EYELIDS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barzilai Medical Center, Ashqelon, Israel",C07F9/4078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,16.000328548840802,523.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.24,391.288,35.53,1.0,0.0,3.0,39.43,114.28,7.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0
CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2,1,DB05039,__INDACATEROL,6878721,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,58.3174192488552,28.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,392.4907,81.59,4.0,4.0,4.0,44.96,118.1,6.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,1,DB05351,__DEXLANSOPRAZOLE,6238994,Unknown status,NCT02759393,GASTROESOPHAGEAL REFLUX,All,"20 Years to 95 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,H01L28/84,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,38.5387790303702,62.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.36,67.87,4.0,1.0,3.0,34.5,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,1,DB05351,__DEXLANSOPRAZOLE,6238994,Unknown status,NCT01328652,LARYNGOPHARYNGEAL REFLUX|HYPERTROPHY OF LINGUAL TONSIL,All,18 Years to 59 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Advanced Center for Specialty Care, Chicago, Illinois, United States",H01L28/84,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,38.5387790303702,62.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.36,67.87,4.0,1.0,3.0,34.5,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,1,DB05351,__DEXLANSOPRAZOLE,6238994,Completed,,GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD),,,,,"FISABIO, Elche, Alicante, Spain",H01L28/84,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,38.5387790303702,62.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.36,67.87,4.0,1.0,3.0,34.5,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,1,DB05351,__DEXLANSOPRAZOLE,6238994,Withdrawn,,CHEST PAIN,,,,,"FISABIO, Elche, Alicante, Spain",H01L28/84,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,38.5387790303702,62.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.36,67.87,4.0,1.0,3.0,34.5,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
C=C1CC[C@H]2[C@@](C)(CC[C@@H](O)[C@@]2(C)CO)[C@@H]1C/C=C1/C(=O)OC[C@H]1O,1,DB05767,__ANDROGRAPHOLIDE,,Unknown status,NCT03134443,ACUTE TONSILLITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.57,350.455,86.99,4.0,3.0,3.0,38.27,94.93,3.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0
CC(=O)N[C@@H](CS)C(=O)O,1,DB06151,__ACETYLCYSTEINE,8148356,Completed,NCT00525551,OTOSCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Karolinska University Hospital Huddinge, Huddinge, Sweden|Karolinska University Hospital, Dept. of Otorhinolaryngology, Stockholm, Sweden|Academic Hospital, Uppsala, Sweden",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,79.3116901784431,8.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.03,163.195,66.4,3.0,3.0,0.0,15.34,37.67,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O,1,DB06203,__ALOGLIPTIN,5965584,Active Not Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,18.103041130208002,32.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.66,339.3916,93.67,5.0,1.0,3.0,35.44,104.26,3.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O,1,DB06203,__ALOGLIPTIN,5965584,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,18.103041130208002,32.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.66,339.3916,93.67,5.0,1.0,3.0,35.44,104.26,3.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)[C@H](C)[C@H]12,1,DB06211,__DORIPENEM,5317016,Completed,,PNEUMONIA,,,,,"FISABIO, Elche, Alicante, Spain",C07C307/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,21.5199490749296,64.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,420.504,162.06,8.0,5.0,3.0,42.37,99.88,6.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)[C@H](C)[C@H]12,1,DB06211,__DORIPENEM,5317016,Completed,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07C307/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,21.5199490749296,64.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,420.504,162.06,8.0,5.0,3.0,42.37,99.88,6.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0
CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1,1,DB06213,__REGADENOSON,6403567,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07H19/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,35.64754923099029,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.89,390.35400000000004,186.46,10.0,5.0,4.0,37.48,95.48,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1
CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1.O=C(O)/C=C\C(=O)O,1,DB06216,__ASENAPINE,5763476,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,19.9100597548204,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.72,401.84,12.47,1.0,0.0,4.0,30.9,81.65,2.0,0.0,1.0,0.0,0,0,1,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,1,1,1,0,0
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT00826943,ALLERGIC RHINITIS,All,"18 Years to 77 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Vanderbilt University Asthma, Sinus, and Allergy Clinic, Nashville, Tennessee, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT01586091,PRURITUS|CHRONIC URTICARIA|ALLERGIC RHINITIS,Male,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","University of Berlin Charité, Department of Dermatology and Allergy, Berlin, Germany",4,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT00894231,PERENNIAL ALLERGIC RHINITIS,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AAADRS, Coral Gables, Florida, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT00653224,SEASONAL ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Tucson, Arizona, United States|Los Angeles, California, United States|Sacramento, California, United States|San Francisco, California, United States|San Jose, California, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Gainesville, Georgia, United States|Lawrenceville, Georgia, United States|Stockbridge, Georgia, United States|Normal, Illinois, United States|Louisville, Kentucky, United States|Harvard, Massachusetts, United States|North Dartmouth, Massachusetts, United States|Novi, Michigan, United States|Minneapolis, Minnesota, United States|Berlin, New Jersey, United States|Skillman, New Jersey, United States|Verona, New Jersey, United States|Rochester, New York, United States|Asheville, North Carolina, United States|Charlotte, North Carolina, United States|Wilmington, North Carolina, United States|Cincinnati, Ohio, United States|Edmond, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|Upland, Pennsylvania, United States|Lincoln, Rhode Island, United States|Germantown, Tennessee, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|South Burlington, Vermont, United States|Arlington, Virginia, United States|Milwaukee, Wisconsin, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT00542607,"RHINITIS, ALLERGIC, SEASONAL",All,18 Years to 55 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT00521131,RHINITIS|ALLERGIC|PERENNIAL,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT00160680,"RHINITIS, ALLERGIC, PERENNIAL",,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Genova, Italy",4,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,1,DB06401,__BAZEDOXIFENE,5998402,Suspended,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,107.0,32.0992217499332,283.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.03,470.61300000000006,57.86,4.0,2.0,5.0,54.06,141.9,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1
COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1,1,DB06480,__PRUCALOPRIDE,6413988,Recruiting,NCT03676374,GERD,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UZ Leuven, Leuven, Belgium",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,8.18086613688166,98.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.09,367.87,76.82,5.0,2.0,3.0,39.08,100.67,6.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1
COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1,1,DB06480,__PRUCALOPRIDE,6413988,Recruiting,,GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD),,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,8.18086613688166,98.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.09,367.87,76.82,5.0,2.0,3.0,39.08,100.67,6.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1
Nc1ccncc1,1,DB06637,__DALFAMPRIDINE,5540938,Completed,NCT01975324,NON ARTERITIC ISCHEMIC OPTIC NEUROPATHY,All,"40 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Neuro-Ophthalmologic Associates, PC, Philadelphia, Pennsylvania, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,21.191400234091,6.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.08,94.1145,35.88,2.0,2.0,1.0,9.66,40.09,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1
N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1,1,DB06684,__VILAZODONE,5532241,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,21.0928355818394,62.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,441.5249,102.29,4.0,2.0,5.0,50.03,129.71,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1
N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1,1,DB06684,__VILAZODONE,5532241,Withdrawn,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,21.0928355818394,62.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,441.5249,102.29,4.0,2.0,5.0,50.03,129.71,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1
[N-]=[N+]=O,1,DB06690,__NITROUS_OXIDE,,Completed,NCT03365011,TINNITUS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Washington University School of Medicine, Saint Louis, Missouri, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.45,44.0128,51.21,2.0,0.0,0.0,2.55,27.67,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
[N-]=[N+]=O,1,DB06690,__NITROUS_OXIDE,,Completed,NCT00967694,GLAUCOMA|SEDATION,All,18 Years to 40 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic,"OHSU, Portland, Oregon, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.45,44.0128,51.21,2.0,0.0,0.0,2.55,27.67,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
[N-]=[N+]=O,1,DB06690,__NITROUS_OXIDE,,Completed,,GLAUCOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.45,44.0128,51.21,2.0,0.0,0.0,2.55,27.67,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1,1,DB06694,__XYLOMETAZOLINE,3933999,Unknown status,NCT02557269,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medical University Sofia, University Hospital ""Alexandrovska"", Clinic of Allergy and Asthma, Sofia, Bulgaria",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,25.1011314400706,156.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.68,244.3752,24.39,2.0,1.0,2.0,29.85,77.82,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1,1,DB06694,__XYLOMETAZOLINE,3933999,Completed,NCT00630474,OBSTRUCTIVE SLEEP APNEA SYNDROME|RHINITIS,All,"20 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pulmonary Division, University Hospital Zurich, Switzerland, Zurich, Switzerland|Pulmonary Division, University Hospital Zurich, Zurich, Switzerland",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,25.1011314400706,156.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.68,244.3752,24.39,2.0,1.0,2.0,29.85,77.82,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
CNCCc1ccccn1,1,DB06698,__BETAHISTINE,4159332,Completed,NCT00160238,MENIERE'S DISEASE,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Site 1, Marseille, France",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,19.220107189059306,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.59,136.1943,24.92,2.0,1.0,1.0,15.85,41.33,3.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CNCCc1ccccn1,1,DB06698,__BETAHISTINE,4159332,Withdrawn,,VERTIGO,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,19.220107189059306,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.59,136.1943,24.92,2.0,1.0,1.0,15.85,41.33,3.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB06699,__DEGARELIX,5925730,Suspended,,AGING,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,27.2695537896055,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1632.29,512.87,18.0,17.0,8.0,168.98,431.13,41.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,1,1,0,1,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,0,1,0,1
CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1,1,DB06700,__DESVENLAFAXINE,6673838,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,46.0,22.801289554200203,131.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.6,263.3752,43.7,3.0,2.0,2.0,30.29,78.54,4.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0
COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1,1,DB06701,__DEXMETHYLPHENIDATE,5908850,Completed,,ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,25.95535842625101,8.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.47,233.3062,38.33,2.0,1.0,2.0,26.24,66.73,4.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1,1,DB06701,__DEXMETHYLPHENIDATE,5908850,Completed,,SARCOIDOSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,25.95535842625101,8.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.47,233.3062,38.33,2.0,1.0,2.0,26.24,66.73,4.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
c1ccc2c(CC3=NCCN3)cccc2c1,1,DB06711,__NAPHAZOLINE,3933999,Unknown status,NCT01390961,ALLERGIC CONJUNCTIVITIS,All,"18 Months and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Milton M. Hom, OD, FAAO., Azusa, California, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,25.1011314400706,530.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.44,210.2744,24.39,2.0,1.0,3.0,23.77,65.52,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0
[I-].[K+],1,DB06715,__POTASSIUM_IODIDE,,Completed,NCT00946296,GRAVES DISEASE|HYPERTHYROIDISM,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"UMASS Memorial Health Care, Worcester, Massachusetts, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.2,166.0028,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C([O-])[O-].[Ca+2],1,DB06724,__CALCIUM_CARBONATE,5989588,Recruiting,NCT02370550,SJOGREN'S SYNDROME,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Peking University People's Hospital, Beijing, Beijing, China",A61K33/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,25.7582291217478,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.47,100.087,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])[O-].[Ca+2],1,DB06724,__CALCIUM_CARBONATE,5989588,Completed,NCT02031692,BENIGN PAROXYSMAL POSITIONAL VERTIGO,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Seoul National Universtiy Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of",A61K33/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,25.7582291217478,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.47,100.087,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CN1CCC(=C2c3ccccc3CCn3c(C=O)cnc32)CC1,1,DB06766,__ALCAFTADINE,5468743,Completed,NCT01732757,"CONJUNCTIVITIS, ALLERGIC",All,"10 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Memphis, Tennessee, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,23.7212263085484,9.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.09,307.3895,38.13,3.0,0.0,4.0,34.68,102.88,1.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1
CN1CCC(=C2c3ccccc3CCn3c(C=O)cnc32)CC1,1,DB06766,__ALCAFTADINE,5468743,Unknown status,NCT01808768,ALLERGIC CONJUNCTIVITIS|RHINOCONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"STARx Research Center, Edison, New Jersey, United States|STARx, Springfield, New Jersey, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,23.7212263085484,9.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.09,307.3895,38.13,3.0,0.0,4.0,34.68,102.88,1.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1
N[C@@H]1CCCCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2Cl)C1,1,DB06771,__BESIFLOXACIN,5447926,Completed,NCT01296191,CATARACT,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,"Bucci Laser Vision Institute, Wilkes-Barre, Pennsylvania, United States",C07D215/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,11.630628965687098,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.7,393.84,86.87,6.0,2.0,4.0,39.0,101.75,3.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0
N[C@@H]1CCCCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2Cl)C1,1,DB06771,__BESIFLOXACIN,5447926,Completed,NCT00924729,CATARACT SURGERY,All,"21 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","The Wilmer Eye Institute at Johns Hopkins University, Baltimore, Maryland, United States",C07D215/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,11.630628965687098,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.7,393.84,86.87,6.0,2.0,4.0,39.0,101.75,3.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,1,DB06774,__CAPSAICIN,6239180,Completed,NCT01862523,RHINITIS,All,18 Years to 60 Years   (Adult),Other,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","UZ Leuven, Leuven, Vlaams-Brabant, Belgium",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,41.4300088297501,241.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.8,305.4119,58.56,3.0,2.0,1.0,36.32,90.32,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,1,DB06774,__CAPSAICIN,6239180,Completed,NCT01223820,IDIOPATHIC RHINITIS PATIENTS|HEALTHY CONTROLS,All,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UZ Leuven, NKO-GH Kapucijnenvoer 33, Leuven, Vlaams-Brabant, Belgium",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,41.4300088297501,241.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.8,305.4119,58.56,3.0,2.0,1.0,36.32,90.32,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,1,DB06774,__CAPSAICIN,6239180,Completed,NCT02288156,NON-ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ORL, Leuven, Vlaams-Brabant, Belgium",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,41.4300088297501,241.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.8,305.4119,58.56,3.0,2.0,1.0,36.32,90.32,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,1,DB06774,__CAPSAICIN,6239180,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,41.4300088297501,241.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.8,305.4119,58.56,3.0,2.0,1.0,36.32,90.32,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1
CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB06781,__DIFLUPREDNATE,6114319,Not yet recruiting,NCT04097730,KERATITIS BACTERIAL,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kaiser Permanente Northern California, Redwood City, California, United States|Francis I. Proctor Foundaiton, San Francisco, California, United States|Aravind Eye Care System, Madurai, Tamil Nadu, India",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,17.0,27.8280868190311,812.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.28,508.5515,106.97,5.0,1.0,4.0,51.46,125.38,8.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,0,1,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1
CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB06781,__DIFLUPREDNATE,6114319,Completed,NCT01244334,"CATARACTS|CORNEAL EDEMA|RETINAL STRUCTURAL CHANGE, DEPOSIT AND DEGENERATION|VISUAL ACUITY REDUCED TRANSIENTLY",All,"21 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cincinnati Eye Institute, Edgewood, Kentucky, United States|Ophthalmic Consultants of Long Island, Lynbrook, New York, United States|Carolina Eyecare, Mt Pleasant, South Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,17.0,27.8280868190311,812.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.28,508.5515,106.97,5.0,1.0,4.0,51.46,125.38,8.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,0,1,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1
CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB06781,__DIFLUPREDNATE,6114319,Recruiting,NCT01939691,UVEITIS|MACULAR EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Aravind Eye Hospital, Coimbatore, Tamil Nadu, India|Aravind Eye Hospital, Madurai, Tamil Nadu, India|Aravind Eye Hospital, Pondicherry, Tamil Nadu, India",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,27.8280868190311,812.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.28,508.5515,106.97,5.0,1.0,4.0,51.46,125.38,8.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,0,1,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1
CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB06781,__DIFLUPREDNATE,6114319,Completed,,CATARACT,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,27.8280868190311,812.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.28,508.5515,106.97,5.0,1.0,4.0,51.46,125.38,8.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,0,1,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1
CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB06781,__DIFLUPREDNATE,6114319,Recruiting,,MACULAR EDEMA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,27.8280868190311,812.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.28,508.5515,106.97,5.0,1.0,4.0,51.46,125.38,8.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,0,1,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1
NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,1,DB06802,__NEPAFENAC,6403609,Recruiting,NCT01939691,UVEITIS|MACULAR EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Aravind Eye Hospital, Coimbatore, Tamil Nadu, India|Aravind Eye Hospital, Madurai, Tamil Nadu, India|Aravind Eye Hospital, Pondicherry, Tamil Nadu, India",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,37.0,30.949300806998,59.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.53,254.2839,86.18,3.0,2.0,2.0,26.63,74.46,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,1,DB06802,__NEPAFENAC,6403609,Completed,NCT00407017,CATARACT SURGERY,All,"Child, Adult, Older Adult",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,"The Center for Excellence in Eye Care, Miami, Florida, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,37.0,30.949300806998,59.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.53,254.2839,86.18,3.0,2.0,2.0,26.63,74.46,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,1,DB06802,__NEPAFENAC,6403609,Unknown status,NCT00865540,CATARACT,All,"50 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Clínica Oftalmológica Zona Sul, Recife, Pernambuco, Brazil",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,37.0,30.949300806998,59.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.53,254.2839,86.18,3.0,2.0,2.0,26.63,74.46,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,1,DB06802,__NEPAFENAC,6403609,Completed,NCT03886779,TREATMENT OF OCULAR INFLAMMATION ASSOCIATED WITH CATARACT SURGERY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,,7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,37.0,30.949300806998,59.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.53,254.2839,86.18,3.0,2.0,2.0,26.63,74.46,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,1,DB06802,__NEPAFENAC,6403609,Completed,NCT00818844,EPIRETINAL MEMBRANE,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Dan Miller, Cincinnati, Ohio, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,37.0,30.949300806998,59.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.53,254.2839,86.18,3.0,2.0,2.0,26.63,74.46,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,1,DB06802,__NEPAFENAC,6403609,Completed,NCT00347204,MYOPIA|HYPEROPIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,37.0,30.949300806998,59.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.53,254.2839,86.18,3.0,2.0,2.0,26.63,74.46,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,1,DB06802,__NEPAFENAC,6403609,Completed,NCT02443012,DIABETIC MACULAR EDEMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Hospital Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia|Hospital Selayang, Batu Caves, Selangor, Malaysia",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,37.0,30.949300806998,59.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.53,254.2839,86.18,3.0,2.0,2.0,26.63,74.46,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,1,DB06802,__NEPAFENAC,6403609,Completed,NCT02084576,CYSTOID MACULAR EDEMA|CATARACT,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Oftalmologico de Brasília, Brasilia, DF, Brazil",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,37.0,30.949300806998,59.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.53,254.2839,86.18,3.0,2.0,2.0,26.63,74.46,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,1,DB06802,__NEPAFENAC,6403609,Completed,NCT01395069,MACULAR EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Hotel Dieu Hospital, Kingston, Ontario, Canada",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,37.0,30.949300806998,59.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.53,254.2839,86.18,3.0,2.0,2.0,26.63,74.46,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,1,DB06802,__NEPAFENAC,6403609,Completed,NCT00494494,CYSTOID MACULAR EDEMA,All,"50 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,37.0,30.949300806998,59.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.53,254.2839,86.18,3.0,2.0,2.0,26.63,74.46,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,1,DB06802,__NEPAFENAC,6403609,Enrolling by invitation,NCT03918590,NEOVASCULAR AGE-RELATED MACULAR DEGENERATION|DIABETIC MACULAR EDEMA|RETINAL VEIN OCCLUSION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","New York Eye and Ear Infirmary, New York, New York, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,37.0,30.949300806998,59.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.53,254.2839,86.18,3.0,2.0,2.0,26.63,74.46,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,1,DB06802,__NEPAFENAC,6403609,Completed,,INTRAOCULAR PRESSURE,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,37.0,30.949300806998,59.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.53,254.2839,86.18,3.0,2.0,2.0,26.63,74.46,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,1,DB06811,__POLIDOCANOL,6942165,Withdrawn,NCT02988063,"LEG ULCER|VEINS, VARICOSE|VENOUS ULCER|REFLUX|VENOUS REFLUX|VENOUS LEG ULCER|VARICOSE VEINS|VARICOSE ULCER|VARICOSE VEINS LEG",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"OhioHealth Riverside Methodist Hospital, Columbus, Ohio, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,63.607055586357,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.15,582.8073,103.3,10.0,1.0,0.0,74.51,158.33,37.0,1.0,0.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
COc1ccc(/C=C/C(=O)Nc2ccccc2C(=O)O)cc1OC,1,DB07615,__TRANILAST,4070484,Completed,NCT00818805,ALLERGIC CONJUNCTIVITIS,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,13.1090987494609,128.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.89,327.3313,84.86,5.0,2.0,2.0,34.2,91.52,6.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0
O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,1,DB08815,__LURASIDONE,5532372,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D417/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,34.0705147949649,9.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.25,492.676,56.75,5.0,0.0,7.0,56.26,139.33,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,1
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,Recruiting,NCT03186755,"CONJUNCTIVITIS, ALLERGIC|CONJUNCTIVITIS, VERNAL",All,"6 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","CHU Sainte-Justine Hospital, Montréal, Quebec, Canada",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,Recruiting,NCT01738243,THYROID EYE DISEASE,All,"21 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Jules Stein Eye Institute, Los Angeles, California, United States|The Jules Stein Eye Institute at UCLA, Los Angeles, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,Withdrawn,NCT01838252,ECTROPION,All,"21 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Jules Stein Eye Institute, Los Angeles, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,Completed,NCT01387620,CORNEAL EDEMA|INTRAOCULAR PRESSURE,All,"50 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of São Paulo, São Paulo, Brazil",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,Active Not Recruiting,,DRY EYE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,Completed,,CATARACT,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)COc1ccccc1,1,DB08819,__TAFLUPROST,5886035,Unknown status,NCT02471105,OCULAR HYPERTENSION|GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Hommer Ophthalmology Institute, Vienna, Austria|UZ Leuven, Leuven, Vlaams Brabant, Belgium|San Paolo Hospital, Milan, Italy|Bietti Foundation, Rome, Italy|Clinical Research Centre Momorial A. de Rotschild, Geneve, Switzerland|Gloucestershire Hospitals NHS Foundation Trust, Gloucestershire, United Kingdom|Western Eye Hospital, London, United Kingdom",C07C405/0033,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,15.1132466785765,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.46,452.5313,75.99,4.0,2.0,2.0,47.77,120.59,13.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)COc1ccccc1,1,DB08819,__TAFLUPROST,5886035,Completed,NCT03612817,"GLAUCOMA, OPEN-ANGLE",All,"21 Years to 85 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"1st University Department of Ophthalmology, Thessaloníki, Makedonia, Greece",C07C405/0033,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,15.1132466785765,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.46,452.5313,75.99,4.0,2.0,2.0,47.77,120.59,13.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)COc1ccccc1,1,DB08819,__TAFLUPROST,5886035,Completed,NCT03104621,PRIMARY OPEN ANGLE GLAUCOMA,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07C405/0033,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,15.1132466785765,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.46,452.5313,75.99,4.0,2.0,2.0,47.77,120.59,13.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)COc1ccccc1,1,DB08819,__TAFLUPROST,5886035,Completed,NCT02802137,GLAUCOMA|OCULAR SURFACE DISEASE,All,"21 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,,C07C405/0033,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,15.1132466785765,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.46,452.5313,75.99,4.0,2.0,2.0,47.77,120.59,13.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)COc1ccccc1,1,DB08819,__TAFLUPROST,5886035,Completed,NCT00966940,GLAUCOMA,All,"21 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,C07C405/0033,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,15.1132466785765,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.46,452.5313,75.99,4.0,2.0,2.0,47.77,120.59,13.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)COc1ccccc1,1,DB08819,__TAFLUPROST,5886035,Completed,NCT03204487,"GLAUCOMA, OPEN-ANGLE|OCULAR HYPERTENSION",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ordination Dr. Hommer, Vienna, Austria",C07C405/0033,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,15.1132466785765,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.46,452.5313,75.99,4.0,2.0,2.0,47.77,120.59,13.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)COc1ccccc1,1,DB08819,__TAFLUPROST,5886035,Completed,NCT01369771,OCULAR HYPERTENSION|OPEN-ANGLE GLAUCOMA,All,"18 Years to 90 Years   (Adult, Older Adult)",Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"FinnMedi Oy, Clinical Trial Center, Tampere, Pirkanmaa district, Finland",C07C405/0033,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,15.1132466785765,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.46,452.5313,75.99,4.0,2.0,2.0,47.77,120.59,13.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)COc1ccccc1,1,DB08819,__TAFLUPROST,5886035,Completed,NCT01162603,PRIMARY OPEN ANGLE GLAUCOMA|OCULAR HYPERTENSION,All,"45 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Glaucoma Unit, 1st University Department of Ophthalmology, Aristotle University, AHEPA Hospital, Thessaloniki, Greece|USVD ""Centro per lo studio del glaucoma"" Spedali civili di Brescia, Brescia, Italy",C07C405/0033,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,15.1132466785765,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.46,452.5313,75.99,4.0,2.0,2.0,47.77,120.59,13.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1
CC/C=C/CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)CC)C(C)C)C(C)O)C(C)CC,1,DB08869,__TESAMORELIN,5861379,Terminated,NCT01591902,DIABETIC RETINOPATHY|HIV,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Southwest Center for HIV/AIDS, Phoenix, Arizona, United States|Spectrum Medical Group, Phoenix, Arizona, United States|5P21 Rand Schrader Clinic, Los Angeles, California, United States|University of California CARE Clinic, Los Angeles, Los Angeles, California, United States|Palmtree Clinical Research, Inc., Palm Springs, California, United States|UCSD Antiviral Research Center, San Diego, California, United States|VAMC, Infectious Disease Section 111W, San Francisco, California, United States|Capital Medical Associates, PC, Washington, District of Columbia, United States|Gary J. Richmond, M.D., PA, Fort Lauderdale, Florida, United States|Orange County Health Department, Orlando, Florida, United States|Triple O Research Institute, West Palm Beach, Florida, United States|Rowan Tree Medical , P.A., Wilton Manors, Florida, United States|Be Well Medical Center, P.C., Berkley, Michigan, United States|Southampton Clinical Research, Inc d.b.a. Central West Clinical Research, Saint Louis, Missouri, United States|Southampton Healthcare, Inc., Saint Louis, Missouri, United States|South Jersey Infectious Disease, Somers Point, New Jersey, United States|Harold Hamm Diabetes Center at the University of Oklahoma, Oklahoma City, Oklahoma, United States|Fanno Creek Clinic, LLC, Portland, Oregon, United States|Central Texas Clinical Research, Austin, Texas, United States|St. Hope Foundation, Inc., Bellaire, Texas, United States|Dallas VA Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center, Atten: HIV Research Unit, Dallas, Texas, United States|Research Access Network, Houston, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States",C07K14/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,28.8794431097147,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-35.0,5005.76,2278.76,83.0,81.0,3.0,505.02,1314.56,176.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,0
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,1,DB08895,__TOFACITINIB,7301023,Active Not Recruiting,,ULCERATIVE COLITIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,66.1697365448982,52.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.58,312.3696,88.91,5.0,1.0,3.0,32.65,87.8,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Withdrawn,NCT01076439,ALLERGIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61M15/0043,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Completed,NCT01007253,SEASONAL ALLERGIC RHINITIS,All,18 Years to 45 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","The University of Chicago, Chicago, Illinois, United States",A61M15/0043,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Completed,NCT00682643,"RHINITIS, ALLERGIC, PERENNIAL",All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Oxford, Alabama, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Mission Viejo, California, United States|GSK Investigational Site, Rolling Hills Estates, California, United States|GSK Investigational Site, Roseville, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Jose, California, United States|GSK Investigational Site, Stockton, California, United States|GSK Investigational Site, Vista, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Colorado Springs, Colorado, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Englewood, Colorado, United States|GSK Investigational Site, Wheat Ridge, Colorado, United States|GSK Investigational Site, Tallahassee, Florida, United States|GSK Investigational Site, Conyers, Georgia, United States|GSK Investigational Site, Gainesville, Georgia, United States|GSK Investigational Site, Lawrenceville, Georgia, United States|GSK Investigational Site, Stockbridge, Georgia, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, South Bend, Indiana, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, North Dartmouth, Massachusetts, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Bozeman, Montana, United States|GSK Investigational Site, Bellevue, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Ocean, New Jersey, United States|GSK Investigational Site, Skillman, New Jersey, United States|GSK Investigational Site, Asheville, North Carolina, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Sylvania, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Summerville, South Carolina, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, Kerrville, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Waco, Texas, United States|GSK Investigational Site, South Burlington, Vermont, United States|GSK Investigational Site, Spokane, Washington, United States|GSK Investigational Site, Greenfield, Wisconsin, United States",A61M15/0043,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Completed,NCT00502775,"RHINITIS, ALLERGIC, SEASONAL",All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Albany, Georgia, United States|GSK Investigational Site, Columbus, Georgia, United States|GSK Investigational Site, Lawrenceville, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Normal, Illinois, United States|GSK Investigational Site, Evansville, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Lafayette, Indiana, United States|GSK Investigational Site, South Bend, Indiana, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Owensboro, Kentucky, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Sunset, Louisiana, United States|GSK Investigational Site, Novi, Michigan, United States|GSK Investigational Site, Ypsilanti, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Plymouth, Minnesota, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, Columbia, Missouri, United States|GSK Investigational Site, Rolla, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Warrensburg, Missouri, United States|GSK Investigational Site, Lincoln, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Papillion, Nebraska, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Sylvania, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Waco, Texas, United States|GSK Investigational Site, Greenfield, Wisconsin, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, West Allis, Wisconsin, United States",A61M15/0043,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Terminated,NCT01013701,PATIENTS WITH NASAL POLYPS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,A61M15/0043,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Completed,NCT00891436,ALLERGIC CONJUNCTIVITIS TO TREE POLLEN OR GRASS POLLEN,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Rush University Medical Center, Chicago, Illinois, United States",A61M15/0043,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Active Not Recruiting,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61M15/0043,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,1,DB08907,__CANAGLIFLOZIN,6723340,Active Not Recruiting,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2031,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,1,DB08907,__CANAGLIFLOZIN,6723340,Active Not Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2031,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N,1,DB08931,__RIOCIGUAT,6743798,Unknown Status,,SARCOIDOSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D471/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,37.68455204418978,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.27,422.4157,138.07,8.0,2.0,4.0,41.9,135.25,5.0,0.0,1.0,0.0,1,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0
CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC,1,DB09009,__ARTICAINE,5858410,Completed,,PERIODONTITIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/10,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,57.0,18.792993695969106,356.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.93,284.374,67.43,3.0,2.0,1.0,30.54,76.78,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC,1,DB09009,__ARTICAINE,5858410,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/10,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,57.0,18.792993695969106,356.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.93,284.374,67.43,3.0,2.0,1.0,30.54,76.78,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07C255/13,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07C255/13,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Terminated,NCT02985242,"DIABETES MELLITUS, TYPE II",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hannover Medical School, University Eye Hospital and CRC Core Facility Hannover, Hanover, Lower Saxony, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Recruiting,NCT04215445,DIABETIC RETINOPATHY|CHRONIC KIDNEY DISEASES|DIABETES MELLITUS,All,"35 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UKM Medical Centre, Kuala Lumpur, Wilayah Persekutuan, Malaysia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
COC1=C(OC)C(=O)C(CCCCCCCCCCCCO)=C(C)C1=O,1,DB09081,__IDEBENONE,4436753,"Active, not recruiting",NCT02774005,LEBER'S HEREDITARY OPTIC NEUROPATHY (LHON),All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Retinal Consultants of Arizona, Phoenix, Arizona, United States|Palo Alto Medical Foundation, Palo Alto, California, United States|Stanford Byers Eye Institute, Stanford, California, United States|University of Colorado Health Eye Center, Aurora, Colorado, United States|Emory University Hospital, Atlanta, Georgia, United States|Bethesda Neurology, LLC, Bethesda, Maryland, United States|Washington University, Saint Louis, Missouri, United States|New York Eye and Ear Infirmary, New York, New York, United States|University of Virginia, Charlottesville, Virginia, United States|AKH - Medizinische Universitaet Wien, Wien, Austria|CHU Saint-Pierre, Brussels, Belgium|Cliniques Universitaire Saint-Luc, Brussels, Belgium|UZ Leuven - Campus Sint-Rafaël, Leuven, Belgium|C. H. U. Sart Tilman, Liège, Belgium|UMHAT ""Alexandrovska"" EAD, Sofia, Bulgaria|Friedrich-Baur-Institut, Muenchen, Germany|Università di Bologna-Clinica Neurologica-Dipartimento di Scienze Neurologiche, Bologna, Italy|SPZOZ Spital Uniwersytecki w Krakowie, Oddzial Kliniczny Okulistyki i Onkologii Okulistycznej, Krakow, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego, Poznań, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 2 PUM w Szczecinie, Szczecin, Poland|Samodzielny Publiczny Kliniczny Szpital Okulistyczny, Warszawa, Poland|Uniwersytecki Szpital Kliniczny, Wrocław, Poland|Centro Hospitalar de São João, EPE, Porto, Portugal|Institut Catala de Retina, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|University Hospital of Wales, Cardiff, United Kingdom|Moorfields Eye Hospital, London, United Kingdom|Manchester Royal Eye Hospital, Manchester, United Kingdom|Queen's Hospital, Romford, United Kingdom",C07C50/28,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,38.834472987124904,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.5,366.49800000000016,72.83,5.0,1.0,1.0,43.87,105.72,14.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12,1,DB09084,__BENZYDAMINE,4211782,Completed,NCT03574246,"SORE THROAT|NAUSEA AND VOMITING, POSTOPERATIVE",All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","Ankara University Faculty of Dentistry, Ankara, Yenimahalle, Turkey",3,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,38.0,32.8877389679459,285.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,309.413,30.29,3.0,0.0,3.0,35.62,105.56,7.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0
CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12,1,DB09084,__BENZYDAMINE,4211782,Completed,NCT03074968,INTUBATION COMPLICATION,All,"6 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","SNUH, Seoul, Jongro Gu, Korea, Republic of",3,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,38.0,32.8877389679459,285.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,309.413,30.29,3.0,0.0,3.0,35.62,105.56,7.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0
CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(c1ccccc1)N(C)C,1,DB09089,__TRIMEBUTINE,5693337,Unknown status,NCT02986685,REFRACTORY REFLUX ESOPHAGITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Xijing Hosipital of Digestive Disease, Xi'an, Shaanxi, China",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,28.780878457463107,189.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.94,387.476,57.23,5.0,0.0,2.0,42.43,108.94,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0
[Mg+2].[OH-].[OH-],1,DB09104,__MAGNESIUM_HYDROXIDE,5989588,Completed,,GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD),,,,,"FISABIO, Elche, Alicante, Spain",A61K33/10,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,25.0,25.7582291217478,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.57,58.32,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C([O-])CN1CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)[O-])CC1.[Gd+3],1,DB09132,__GADOTERIC_ACID,,Recruiting,NCT02529475,MENIERE'S DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"GrenobleUniversityHospital, Grenoble, France|Hôpital Lariboisière, Paris, France|Hôpital Charles Nicolle, Rouen, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.23,558.65,170.65,12.0,1.0,1.0,38.15,128.93,8.0,1.0,0.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
[Cl-].[Na+],1,DB09153,__SODIUM_CHLORIDE,6248726,Not yet recruiting,NCT04213508,OTORHINOLARYNGOLOGIC DISEASES|RHINOSINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","Imam abdulrahman bin faisal university, Dammam, Eastern Province, Saudi Arabia",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,104.609950923016,13.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.06,58.44300000000001,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
[Cl-].[Na+],1,DB09153,__SODIUM_CHLORIDE,6248726,Withdrawn,NCT00366613,CATARACT SURGERY,All,"4 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Storm Eye Institute, Medical University of South Carolina, Charleston, South Carolina, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,104.609950923016,13.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.06,58.44300000000001,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
COc1ccc(Oc2cc(N(C)CCOc3ccc(CC4SC(=O)NC4=O)cc3)ncn2)cc1,1,DB09198,__LOBEGLITAZONE,,Active Not Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,480.54,102.88,7.0,1.0,4.0,49.64,129.63,10.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
NC(=O)CN1CCCC1=O,1,DB09210,__PIRACETAM,4115579,Completed,NCT01890538,PERIPHERAL VERTIGO,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Kocaeli University, Kocaeli, Turkey",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,11.006386168093801,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.6,142.1558,63.4,2.0,1.0,1.0,13.96,35.06,2.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
NC(=O)CN1CCCC1=O,1,DB09210,__PIRACETAM,4115579,Completed,,"VERTIGO, PERIPHERAL",,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,11.006386168093801,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.6,142.1558,63.4,2.0,1.0,1.0,13.96,35.06,2.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB09214,__DEXKETOPROFEN,4097522,Completed,NCT03768882,SORE THROAT,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pamukkale University, Denizli, Turkey",C07C51/09,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,24.969711903735103,126.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.88,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB09214,__DEXKETOPROFEN,4097522,Active Not Recruiting,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",C07C51/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,24.969711903735103,126.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.88,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
O=[Si]([O-])O[Si]([O-])([O-])O[Si](=O)[O-].[Mg+2].[Mg+2],1,DB09281,__MAGNESIUM_TRISILICATE,,Completed,,GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD),,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.7,260.857,144.84,6.0,0.0,0.0,11.91,11.36,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0
Cn1cc(C(=O)[C@@H]2CCc3[nH]cnc3C2)c2ccccc21,1,DB09290,__RAMOSETRON,6235745,Completed,,PONV,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,19.220107189059306,160.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.22,279.343,50.68,2.0,1.0,4.0,31.2,82.14,2.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,1
CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O,1,DB09292,__SACUBITRIL,7468390,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,71.2950984619807,9.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.9,411.49800000000016,92.7,4.0,2.0,2.0,44.48,114.06,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1
O=S(=O)([O-])[O-].[Zn+2],1,DB09322,__ZINC_SULFATE,,Not yet recruiting,NCT04050488,"EARLY-ONSET SEPSES, NEONATAL|PERIVENTRICULAR HAEMORRHAGE NEONATAL|BRONCHOPULMONARY DYSPLASIA|RETINOPATHY OF PREMATURITY|ENTEROCOLITIS, NECROTIZING|SMALL FOR GESTATIONAL AGE INFANT",All,up to 3 Days   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,161.472,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,1,DB09374,__INDOCYANINE_GREEN_ACID_FORM,6915154,Completed,NCT03969108,THYROID CANCER|THYROID GOITER|GRAVES DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University Health Network, Toronto, Ontario, Canada",A61B5/0261,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,58.7773876260292,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.26,753.99,114.99,7.0,2.0,6.0,87.2,231.13,14.0,1.0,0.0,0.0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1,0,1,1,1,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,0,1
O=P([O-])(O)O.[K+],1,DB09413,__MONOPOTASSIUM_PHOSPHATE,10632150,Recruiting,,POSTOPERATIVE COMPLICATIONS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0019,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,12.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.0,136.0855,80.59,4.0,2.0,0.0,5.53,13.53,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=P([O-])(O)O.[Na+],1,DB09449,"__SODIUM_PHOSPHATE,_MONOBASIC",7084130,Completed,,DRY EYE,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0048,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,55.6561736380623,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.0,119.977,80.59,4.0,2.0,0.0,5.53,13.53,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C(O)[C@H](O)[C@@H](O)C(=O)O,1,DB09459,__L-TARTARIC_ACID,,Not yet recruiting,NCT04007276,"GLAUCOMA|GLAUCOMA, OPEN-ANGLE|GLAUCOMA; DRUGS|DROOPY EYELID|PTOSIS|GLAUCOMA, PRIMARY OPEN ANGLE",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,150.0868,115.06,6.0,4.0,0.0,11.33,26.21,3.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C(O)[C@H](O)[C@@H](O)C(=O)O,1,DB09459,__L-TARTARIC_ACID,,Completed,NCT03966560,"GLAUCOMA, OPEN-ANGLE",All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,150.0868,115.06,6.0,4.0,0.0,11.33,26.21,3.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C(O)[C@H](O)[C@@H](O)C(=O)O,1,DB09459,__L-TARTARIC_ACID,,Recruiting,NCT03782701,EYELID DROOP,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bascom Palmer Eye Institute, Miami, Florida, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,150.0868,115.06,6.0,4.0,0.0,11.33,26.21,3.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C(O)[C@H](O)[C@@H](O)C(=O)O,1,DB09459,__L-TARTARIC_ACID,,Completed,NCT00811850,GLAUCOMA,All,"30 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Indianapolis, Indiana, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,150.0868,115.06,6.0,4.0,0.0,11.33,26.21,3.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C(O)[C@H](O)[C@@H](O)C(=O)O,1,DB09459,__L-TARTARIC_ACID,,"Active, not recruiting",NCT03323164,GLAUCOMA; DRUGS|NORMAL TENSION GLAUCOMA|PRIMARY OPEN-ANGLE GLAUCOMA,All,"18 Years to 90 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,"Glaucoma Research Center - Wills Eye Hospital, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,150.0868,115.06,6.0,4.0,0.0,11.33,26.21,3.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C(O)[C@H](O)[C@@H](O)C(=O)O,1,DB09459,__L-TARTARIC_ACID,,Completed,NCT02863705,"GLAUCOMA, OPEN-ANGLE|NORMAL TENSION GLAUCOMA",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea, Republic of|Yeungnam University Hospital, Yeungnam University College of Medicine, Daegu, Korea, Republic of|Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea, Republic of|Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea, Republic of|Seoul National University Bundang Hospital, Seoul National University College of Medicine, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea, Republic of|Kangbuk Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea, Republic of|Kim's Eye Hospital, Konyang University College of Medicine, Seoul, Korea, Republic of",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,150.0868,115.06,6.0,4.0,0.0,11.33,26.21,3.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C(O)[C@H](O)[C@@H](O)C(=O)O,1,DB09459,__L-TARTARIC_ACID,,Completed,NCT02003534,"GLAUCOMA, OPEN-ANGLE|OCULAR HYPERTENSION",All,"Child, Adult, Older Adult",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai, China",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,150.0868,115.06,6.0,4.0,0.0,11.33,26.21,3.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C(O)[C@H](O)[C@@H](O)C(=O)O,1,DB09459,__L-TARTARIC_ACID,,Completed,NCT01525173,GLAUCOMA|OCULAR HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Deerfield Beach, Florida, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,150.0868,115.06,6.0,4.0,0.0,11.33,26.21,3.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C(O)[C@H](O)[C@@H](O)C(=O)O,1,DB09459,__L-TARTARIC_ACID,,Completed,NCT00822081,OPEN-ANGLE GLAUCOMA|OCULAR HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,"Barrie, Ontario, Canada",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,150.0868,115.06,6.0,4.0,0.0,11.33,26.21,3.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
OCC(O)CO,1,DB09462,__GLYCERIN,9034300,Completed,NCT00987727,DRY EYE SYNDROMES|KERATOCONJUNCTIVITIS SICCA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Paris, France",A61K49/226,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,55.0976406086367,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,92.0938,60.69,3.0,3.0,0.0,8.93,20.52,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
OCC(O)CO,1,DB09462,__GLYCERIN,9034300,Completed,NCT00761202,DRY EYE,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"London, United Kingdom",A61K49/226,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,55.0976406086367,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,92.0938,60.69,3.0,3.0,0.0,8.93,20.52,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Ca+2].[Ca+2].[Ca+2],1,DB11093,__CALCIUM_CITRATE,,Active Not Recruiting,,SARCOIDOSIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.13,498.43199999999996,140.62,7.0,1.0,0.0,14.23,68.14,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Mg+2].[Mg+2].[Mg+2],1,DB11110,__MAGNESIUM_CITRATE,,Recruiting,,ULCERATIVE COLITIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.08,451.11300000000006,140.62,7.0,1.0,0.0,14.25,68.14,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
O=C([O-])c1ccccn1.O=C([O-])c1ccccn1.O=C([O-])c1ccccn1.[Cr+3],1,DB11255,__CHROMIUM_PICOLINATE,,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.9,418.3005,53.02,3.0,0.0,3.0,10.94,41.62,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].[Ca+2].[Ca+2].[Ca+2],1,DB11348,__CALCIUM_PHOSPHATE,,Not Yet Recruiting,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,310.177,86.25,4.0,0.0,0.0,4.93,11.29,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
O=C(CCCN1CCN(c2ccccn2)CC1)c1ccc(F)cc1,1,DB11376,__AZAPERONE,4508715,Completed,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,35.64754923099029,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.73,327.403,36.44,4.0,0.0,3.0,36.19,94.27,6.0,0.0,1.0,0.0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1
CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21,1,DB11591,__BILASTINE,EP-0818454-A1,Completed,NCT02513290,ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07D335/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,82.3671943982422,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.02,463.62199999999996,67.59,5.0,1.0,4.0,54.96,135.58,10.0,0.0,1.0,0.0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,1,0,1
CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21,1,DB11591,__BILASTINE,EP-0818454-A1,Unknown status,NCT02557269,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medical University Sofia, University Hospital ""Alexandrovska"", Clinic of Allergy and Asthma, Sofia, Bulgaria",C07D335/02,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,82.3671943982422,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.02,463.62199999999996,67.59,5.0,1.0,4.0,54.96,135.58,10.0,0.0,1.0,0.0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,1,0,1
CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21,1,DB11591,__BILASTINE,EP-0818454-A1,Completed,NCT02576041,ALLERGIC RHINITIS|URTICARIA,All,21 Years to 55 Years   (Adult),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy",C07D335/02,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,82.3671943982422,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.02,463.62199999999996,67.59,5.0,1.0,4.0,54.96,135.58,10.0,0.0,1.0,0.0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,1,0,1
CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21,1,DB11591,__BILASTINE,EP-0818454-A1,Completed,NCT02761252,SEASONAL ALLERGIC RHINOCONJUNCTIVITIS|ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cakovec, Croatia|Rijeka, Croatia|Zagreb, Croatia|Brno, Czechia|Ostrava Hrabuvka, Czechia|Teplice, Czechia|Dreieich, Germany|Heidelberg, Germany|Catania, Italy|Florence, Italy|Modena, Italy|Pavia, Italy|Verona, Italy|Riga, Latvia|Bialystok, Poland|Bielsko-Biala, Poland|Gdansk, Poland|Katowice, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Nowy Duninow, Poland|Poznan, Poland|Rzeszow, Poland|Tarnow, Poland|Wroclaw, Poland|Brasov, Romania|Bucharest, Romania|Cluj Napoca, Romania|Ploieşti, Romania|Bardejov, Slovakia|Levice, Slovakia",C07D335/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,82.3671943982422,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.02,463.62199999999996,67.59,5.0,1.0,4.0,54.96,135.58,10.0,0.0,1.0,0.0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,1,0,1
CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3c(c2Cl)CCN(C(=O)c2ccc4ccoc4c2)C3)C(=O)O)c1,1,DB11611,__LIFITEGRAST,7314938,Recruiting,NCT04413253,DRY EYE,All,"Child, Adult, Older Adult",Other|Industry,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Eye Surgeons of Indiana, Indianapolis, Indiana, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,62.0,37.848826464609104,15.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.96,615.48,133.99,6.0,2.0,5.0,59.49,154.48,7.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,1,0,1,1,1,1,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,0
CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3c(c2Cl)CCN(C(=O)c2ccc4ccoc4c2)C3)C(=O)O)c1,1,DB11611,__LIFITEGRAST,7314938,Withdrawn,NCT03431272,CONTACT LENS DRY EYE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,62.0,37.848826464609104,15.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.96,615.48,133.99,6.0,2.0,5.0,59.49,154.48,7.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,1,0,1,1,1,1,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,0
CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3c(c2Cl)CCN(C(=O)c2ccc4ccoc4c2)C3)C(=O)O)c1,1,DB11611,__LIFITEGRAST,7314938,Withdrawn,NCT03408015,OCULAR DISCOMFORT|OCULAR INFLAMMATION|DRY EYE|CONTACT LENS COMPLICATION|KERATOCONJUNCTIVITIS SICCA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,62.0,37.848826464609104,15.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.96,615.48,133.99,6.0,2.0,5.0,59.49,154.48,7.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,1,0,1,1,1,1,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,0
CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3c(c2Cl)CCN(C(=O)c2ccc4ccoc4c2)C3)C(=O)O)c1,1,DB11611,__LIFITEGRAST,7314938,Completed,NCT03686878,CONTACT LENS|CONTACT LENS DISCOMFORT|CONTACT LENS DRYNESS,All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Eye & Vision, Richardson, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,62.0,37.848826464609104,15.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.96,615.48,133.99,6.0,2.0,5.0,59.49,154.48,7.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,1,0,1,1,1,1,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,0
CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3c(c2Cl)CCN(C(=O)c2ccc4ccoc4c2)C3)C(=O)O)c1,1,DB11611,__LIFITEGRAST,7314938,Not yet recruiting,NCT03952481,DRY EYE|DRY EYE SYNDROMES|DRY EYES CHRONIC,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Weill Cornell Ophthalmology, New York, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,62.0,37.848826464609104,15.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.96,615.48,133.99,6.0,2.0,5.0,59.49,154.48,7.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,1,0,1,1,1,1,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,0
O=C(NC(Cc1cc(=O)[nH]c2ccccc12)C(=O)O)c1ccc(Cl)cc1,1,DB11656,__REBAMIPIDE,5476858,Completed,NCT02755753,GASTROESOPHAGEAL REFLUX,All,"20 Years to 70 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Yang Shiming, Chongqing, Chongqing, China|Soonchunhyang University Bucheon Hospital, Bucheon, Korea, Republic of|Kyungpook National University Medical Center, Daegu, Korea, Republic of|Konyang University Hospital, Daejeon, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,23.425532351793603,66.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.32,370.79,95.5,4.0,3.0,3.0,36.82,98.5,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
O=C(NC(Cc1cc(=O)[nH]c2ccccc12)C(=O)O)c1ccc(Cl)cc1,1,DB11656,__REBAMIPIDE,5476858,Completed,NCT03608761,DRY EYE SYNDROMES|SJÖGREN SYNDROME,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Hospital Nacional Profesor A. Posadas, El Palomar, Buenos Aires, Argentina",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,23.425532351793603,66.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.32,370.79,95.5,4.0,3.0,3.0,36.82,98.5,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
O=C(CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1)OCCCCO[N+](=O)[O-],1,DB11660,__LATANOPROSTENE_BUNOD,6211233,Not yet recruiting,NCT04140279,OCULAR HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Bausch Site 001, Rochester, Minnesota, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,16.8217006509373,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.94,507.624,139.36,7.0,3.0,2.0,56.95,136.66,19.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,1,1
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,1,DB11672,__CURCUMIN,4138212,Completed,,PERIODONTITIS,,,,,"FISABIO, Elche, Alicante, Spain",C09B61/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,17.905911825704802,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.62,368.3799,93.06,6.0,2.0,2.0,38.12,103.81,8.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,1,DB11672,__CURCUMIN,4138212,Not Yet Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C09B61/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,17.905911825704802,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.62,368.3799,93.06,6.0,2.0,2.0,38.12,103.81,8.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1
CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1,1,DB11675,__MOSAPRIDE,4870074,Completed,NCT00729339,GASTROESOPHAGEAL REFLUX,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Lotung Poh-Ai Hospital, Lotung Town, Ilan County, Taiwan",C07D413/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,29.109427298301807,83.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.14,421.9,76.82,5.0,2.0,3.0,43.79,112.34,7.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1
CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1,1,DB11675,__MOSAPRIDE,4870074,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D413/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,29.109427298301807,83.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.14,421.9,76.82,5.0,2.0,3.0,43.79,112.34,7.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1
NCCC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)O,1,DB11695,__CARNOSINE,4529602,Recruiting,,GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD),,,,,"FISABIO, Elche, Alicante, Spain",C07C309/58,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,13.0433889812932,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,226.2325,121.1,5.0,4.0,1.0,22.37,55.56,6.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1
OC[C@H]1O[C@@H](c2ccc(F)c(Cc3cc4ccccc4s3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB11698,__IPRAGLIFLOZIN,EP-2009010-A1,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61P3/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,32.7488,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.49,404.45,90.15,5.0,4.0,4.0,40.7,102.41,4.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1
CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)c1c[nH]c3ccccc13)C2,1,DB11699,__TROPISETRON,5032578,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,9.92217499332635,632.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.14,284.3529,45.33,2.0,1.0,4.0,31.35,81.5,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0
CNCc1cc(-c2ccccc2F)n(S(=O)(=O)c2cccnc2)c1,1,DB11739,__VONOPRAZAN,US-20070060623-A1,Recruiting,NCT04028466,GERD|GASTRO ESOPHAGEAL REFLUX,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","St. Luke's Medical Center, Quezon City, National Capital Region, Philippines",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,30.1279287049015,26.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.78,345.39,63.99,4.0,1.0,3.0,34.23,90.16,4.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1
CNCc1cc(-c2ccccc2F)n(S(=O)(=O)c2cccnc2)c1,1,DB11739,__VONOPRAZAN,US-20070060623-A1,Completed,NCT03116841,REFLUX ESOPHAGITIS,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tokatsu Tsujinaka Hospital, Abiko, Chiba, Japan|Amada Clinic, Koriyama, Fukushima, Japan|Aoyama Clinic, Kobe, Hyogo, Japan|Kashiwara Municipal Hospital, Kashiwara, Osaka, Japan|Saino Clinic, Tokorozawa, Saitama, Japan|Masuyama Clinic, Otawara, Tochigi, Japan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,30.1279287049015,26.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.78,345.39,63.99,4.0,1.0,3.0,34.23,90.16,4.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1
CNC(=N)NCCC[C@H](N)C(=O)O,1,DB11815,__TILARGININE,EP-0765668-A1,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K36/88,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,59.0,31.080720343333503,21.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.5,188.2275,111.23,6.0,5.0,0.0,20.01,58.7,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1
CS(=O)(=O)n1cc2c(n1)CN([C@H]1CO[C@H](c3cc(F)ccc3F)[C@@H](N)C1)C2,1,DB11992,__OMARIGLIPTIN,WO-2013003249-A1,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,32.7488,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.63,398.43,90.45,6.0,1.0,4.0,39.42,95.14,2.0,0.0,1.0,0.0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0
CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1=C(C)C(=O)c2ccccc2C1=O,1,DB12148,__MENATETRENONE,5044091,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A23L3/44,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,34.0,16.591716462350302,43.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.24,444.659,34.14,2.0,0.0,2.0,54.92,145.51,11.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
C[N+](C)(C)CCOP(=O)([O-])OP(=O)(O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O,1,DB12153,__CITICOLINE,4203893,Completed,NCT03046693,NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY,All,"20 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Departemen Mata Fakultas Kedokteran Universitas Indonesia- RSCM Kirana, Jakarta, DKI Jakarta, Indonesia",G01N33/531,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,20.6657220887492,173.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,488.324,213.5,10.0,4.0,2.0,42.54,113.58,10.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0
C[N+](C)(C)CCOP(=O)([O-])OP(=O)(O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O,1,DB12153,__CITICOLINE,4203893,Completed,,GLAUCOMA,,,,,"FISABIO, Elche, Alicante, Spain",G01N33/531,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,20.6657220887492,173.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,488.324,213.5,10.0,4.0,2.0,42.54,113.58,10.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0
CC1=NN(c2ccccc2)C(=O)C1,1,DB12243,__EDARAVONE,6933310,Completed,,STROKE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,57.2989178422554,88.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.53,174.203,32.67,2.0,0.0,2.0,18.61,49.49,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0
CC(C)(C)NCC(O)c1ccccc1Cl,1,DB12248,__TULOBUTEROL,4018818,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07C49/86,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,23.4912421199613,364.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,227.73,32.26,2.0,2.0,1.0,24.53,63.88,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
N[C@@H](CC(=O)N1CCc2c(nc(C(F)(F)F)nc2C(F)(F)F)C1)CN1CC(F)(F)CCC1=O,1,DB12412,__GEMIGLIPTIN,WO-2006104356-A1,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,32.7488,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.02,489.37,92.42,5.0,1.0,3.0,39.04,97.25,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0
O=[O+][O-],1,DB12510,__OZONE,,Recruiting,,OCULAR INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.21,47.997,74.27,3.0,0.0,0.0,2.31,4.24,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0
O=[O+][O-],1,DB12510,__OZONE,,Unknown Status,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.21,47.997,74.27,3.0,0.0,0.0,2.31,4.24,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0
CCC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1,1,DB12545,__INDOBUFEN,4010274,Not yet recruiting,NCT04129008,CORONARY ARTERY DISEASE|GASTROESOPHAGEAL REFLUX DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Beijing Anzhen Hospital, Capital Medical University, Beijing, China",C07D209/46,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,16.4931518100987,152.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.04,295.33799999999997,57.61,3.0,1.0,3.0,32.14,83.75,4.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](C[C@H](F)C4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB12553,__FLUOCINOLONE,,Completed,NCT00543296,UVEITIS,All,"Child, Adult, Older Adult",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duke University Eye Center, Durham, North Carolina, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.9,412.43,115.06,6.0,4.0,4.0,40.14,99.21,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,1,1,0,1
O=C(CS(=O)Cc1ccco1)NC/C=C\COc1cc(CN2CCCCC2)ccn1,1,DB12770,__LAFUTIDINE,WO-2002098352-A2,Completed,,PULMONARY ASPIRATION OF GASTRIC CONTENTS,,,,,"FISABIO, Elche, Alicante, Spain",A61K45/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,50.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,431.55,84.67,5.0,1.0,3.0,46.25,120.24,11.0,0.0,1.0,0.0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1
NC(CO)C(=O)NNCc1ccc(O)c(O)c1O,1,DB12783,__BENSERAZIDE,4241082,Completed,,RETINAL DISEASES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,28.090925891702,519.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-2.3,257.246,148.07,7.0,7.0,1.0,24.49,73.23,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1
O=C(Nc1ccccc1-c1ccc(Cl)cc1)c1cccnc1Cl,1,DB12792,__BOSCALID,6235684,Completed,,DRY EYE,,,,,"FISABIO, Elche, Alicante, Spain",A01N37/50,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,14.751842953654,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.91,343.207,41.99,2.0,1.0,3.0,33.9,95.24,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC1=CCC(O)(C(C)C)CC1,1,DB12816,__TERPINEN-4-OL,4570022,Completed,NCT04441528,SEBORRHEIC BLEPHARITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Istanbul University-Cerrahpasa, Istanbul, Turkey",C07C29/103,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,9.13365777531366,397.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,154.253,20.23,1.0,1.0,1.0,18.7,48.31,1.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0
CCOC(=O)c1c(N)sc2c1CCN(Cc1ccccc1)C2,1,DB13001,__TINORIDINE,5518738,Completed,NCT01224756,PAIN|INFLAMMATION,All,18 Years to 60 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Semarang, Central Java, Indonesia|Jakarta, DKI Jakarta, Indonesia|Surabaya, East Java, Indonesia|Bandung, West Java, Indonesia",A61K9/1617,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,15.3432308671635,157.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.2,316.42,55.56,3.0,1.0,3.0,34.64,90.05,5.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1
CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1,1,DB13139,__LEVOSALBUTAMOL,5836299,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C09K3/30,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,44.61693258588471,642.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.87,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12,1,DB13165,__RIPASUDIL,US-20060142270-A1,Recruiting,NCT03249337,FUCHS' ENDOTHELIAL DYSTROPHY,All,"18 Years to 91 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"NorthShore University HealthSystem, Glenview, Illinois, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,32.7488,5.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.72,323.39,62.3,4.0,1.0,3.0,31.25,82.56,1.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1
[Fe+3].[OH-].[OH-].[OH-],1,DB13423,__FERRIC_HYDROXIDE,,Recruiting,NCT03748043,IRON-DEFICIENCY,All,3 Years to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"South Valley University, Qinā, Egypt",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.77,106.866,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1
CC(C(=O)O)c1ccc2c(c1)Cc1cccnc1O2,1,DB13514,__PRANOPROFEN,3931205,Completed,NCT03355638,MACULAR EDEMA,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,29.635105443643603,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.54,255.2686,59.42,3.0,1.0,3.0,26.86,70.02,2.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,1,1,1,1,0,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1
COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C,1,DB13762,__DEXRABEPRAZOLE,WO-2004052882-A1,Completed,NCT02689999,GASTROESOPHAGEAL REFLUX DISEASE,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ege University Gastroenterology Department, Izmir, Bornova, Turkey|Ankara University Gastroenterology Department, Ankara, Turkey|On Dokuz Mayıs University Gastroenterology Department, Samsun, Turkey",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,32.7488,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.04,359.44300000000015,77.1,5.0,1.0,3.0,39.48,98.07,8.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
[Bi+3].[O-]c1c([O-])c(Br)c(Br)c(Br)c1Br.[OH-],1,DB13818,__BIBROCATHOL,,Completed,NCT01357538,BLEPHARITIS|SIGNS AND SYMPTOMS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kharkov District Clinical Hospital, Kharkov, Ukraine",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.37,649.6669999999998,46.12,2.0,0.0,1.0,23.03,81.61,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT03443843,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kingston General Hospital, Kingston, Ontario, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00487032,ALLERGIC RHINITIS|TACHYPHYLAXIS|RHINITIS MEDICAMENTOSA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Perth Royal Infirmary (Tayside NHS Trust), Perth, Perthshire, United Kingdom|Ninewells Hospital and Medical School (Tayside NHS Trust, University of Dundee), Dundee, Tayside, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT03004131,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Inflamax Research, Mississauga, Ontario, Canada",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00788749,NASAL POLYPS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ninewells Hospital and Medical School, Dundee, Angus, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Unknown status,NCT02402465,ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","The University of Chicago Medicine, Chicago, Illinois, United States",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Unknown status,NCT02238353,ALLERGIC RHINITIS|HOUSE DUST MITE ALLERGY,All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Uz Leuven Dienst Nko, Leuven, Vlaams Brabant, Belgium",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT01439815,ALLERGIC RHINITIS|ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Ora, Inc., Andover, Massachusetts, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00848965,"RHINITIS, ALLERGIC, PERENNIAL|ALLERGIC RHINITIS",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Vienna, Austria",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00682643,"RHINITIS, ALLERGIC, PERENNIAL",All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Oxford, Alabama, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Mission Viejo, California, United States|GSK Investigational Site, Rolling Hills Estates, California, United States|GSK Investigational Site, Roseville, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Jose, California, United States|GSK Investigational Site, Stockton, California, United States|GSK Investigational Site, Vista, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Colorado Springs, Colorado, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Englewood, Colorado, United States|GSK Investigational Site, Wheat Ridge, Colorado, United States|GSK Investigational Site, Tallahassee, Florida, United States|GSK Investigational Site, Conyers, Georgia, United States|GSK Investigational Site, Gainesville, Georgia, United States|GSK Investigational Site, Lawrenceville, Georgia, United States|GSK Investigational Site, Stockbridge, Georgia, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, South Bend, Indiana, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, North Dartmouth, Massachusetts, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Bozeman, Montana, United States|GSK Investigational Site, Bellevue, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Ocean, New Jersey, United States|GSK Investigational Site, Skillman, New Jersey, United States|GSK Investigational Site, Asheville, North Carolina, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Sylvania, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Summerville, South Carolina, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, Kerrville, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Waco, Texas, United States|GSK Investigational Site, South Burlington, Vermont, United States|GSK Investigational Site, Spokane, Washington, United States|GSK Investigational Site, Greenfield, Wisconsin, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00502775,"RHINITIS, ALLERGIC, SEASONAL",All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Albany, Georgia, United States|GSK Investigational Site, Columbus, Georgia, United States|GSK Investigational Site, Lawrenceville, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Normal, Illinois, United States|GSK Investigational Site, Evansville, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Lafayette, Indiana, United States|GSK Investigational Site, South Bend, Indiana, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Owensboro, Kentucky, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Sunset, Louisiana, United States|GSK Investigational Site, Novi, Michigan, United States|GSK Investigational Site, Ypsilanti, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Plymouth, Minnesota, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, Columbia, Missouri, United States|GSK Investigational Site, Rolla, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Warrensburg, Missouri, United States|GSK Investigational Site, Lincoln, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Papillion, Nebraska, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Sylvania, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Waco, Texas, United States|GSK Investigational Site, Greenfield, Wisconsin, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, West Allis, Wisconsin, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00903227,ASTHMA|ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Asthma and Allergy Research Group, Ninewells Hospital and University of Dundee, Dundee, Angus, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00296530,ASTHMA,All,"15 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"GSK Investigational Site, Ozark, Alabama, United States|GSK Investigational Site, Tempe, Arizona, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Fountain Valley, California, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Palmdale, California, United States|GSK Investigational Site, Riverside, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Jose, California, United States|GSK Investigational Site, Stockton, California, United States|GSK Investigational Site, Vista, California, United States|GSK Investigational Site, Colorado Springs, Colorado, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Wheat Ridge, Colorado, United States|GSK Investigational Site, Coral Gables, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Sarasota, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Lawrenceville, Georgia, United States|GSK Investigational Site, Lilburn, Georgia, United States|GSK Investigational Site, Marietta, Georgia, United States|GSK Investigational Site, Kenilworth, Illinois, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Covington, Louisiana, United States|GSK Investigational Site, Lafayette, Louisiana, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, Chevy Chase, Maryland, United States|GSK Investigational Site, North Andover, Massachusetts, United States|GSK Investigational Site, Ypsilanti, Michigan, United States|GSK Investigational Site, Rolla, Missouri, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Ocean, New Jersey, United States|GSK Investigational Site, Skillman, New Jersey, United States|GSK Investigational Site, Ithaca, New York, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, North Olmsted, Ohio, United States|GSK Investigational Site, Sylvania, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Lake Oswego, Oregon, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Collegeville, Pennsylvania, United States|GSK Investigational Site, Gibsonia, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, East Providence, Rhode Island, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Greer, South Carolina, United States|GSK Investigational Site, Chattanooga, Tennessee, United States|GSK Investigational Site, Germantown, Tennessee, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Corsicana, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Killeen, Texas, United States|GSK Investigational Site, Plano, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Waco, Texas, United States|GSK Investigational Site, Murray, Utah, United States|GSK Investigational Site, West Jordan, Utah, United States|GSK Investigational Site, South Burlington, Vermont, United States|GSK Investigational Site, Charlottesville, Virginia, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Unknown status,NCT00235053,"ASTHMA|CANDIDIASIS, ORAL|VOICE DISORDERS",All,18 Years to 55 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Allergy & Asthma Medical Group & Research Center, San Diego, California, United States",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Terminated,NCT01013701,PATIENTS WITH NASAL POLYPS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00891436,ALLERGIC CONJUNCTIVITIS TO TREE POLLEN OR GRASS POLLEN,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Rush University Medical Center, Chicago, Illinois, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT02338362,"OCULAR HYPERTENSION|GLAUCOMA, OPEN-ANGLE",All,"18 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00655109,"CONJUNCTIVITIS, ALLERGIC",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ophthalmic Research Associates, Inc, North Andover, Massachusetts, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O,1,DB13873,__FENOFIBRIC_ACID,7259186,Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,37.68455204418978,168.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.97,318.75,63.6,4.0,1.0,2.0,32.42,83.19,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C,1,DB13928,__SEMAGLUTIDE,6899699,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/31593,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,40.9043306844083,25.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-17.0,4113.641,1646.18,67.0,57.0,6.0,427.73,1047.99,149.0,1.0,0.0,0.0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1
Cc1ccc(C(=O)OCc2ccc([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1,1,DB13931,__NETARSUDIL,8450344,Completed,NCT03808688,"GLAUCOMA, OPEN-ANGLE|OCULAR HYPERTENSION",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Atlantis Eyecare, Huntington Beach, California, United States|Harvard Eye Associates, Laguna Hills, California, United States|North Bay Eye Associates, Inc, Petaluma, California, United States|Shettle Eye Research Inc, Largo, Florida, United States|Center For Sight, Sarasota, Florida, United States|Coastal Research Associates, LLC, Roswell, Georgia, United States|Wheaton Eye Clinic, Ltd, Wheaton, Illinois, United States|Stiles Eyecare Excellence and Glaucoma Institute, PA, Overland Park, Kansas, United States|Gaddie Eye Centers, LLC, Louisville, Kentucky, United States|Glaucoma Consultants, Baltimore, Maryland, United States|Tekwani Vision Center, Saint Louis, Missouri, United States|Mark J. Weiss, M.D., Inc., Tulsa, Oklahoma, United States|Scott & Christie and Associates, PC, Cranberry Township, Pennsylvania, United States|Valley Eye Professionals, LLC, Huntingdon Valley, Pennsylvania, United States|Carolina Cataract & Laser Center, Ladson, South Carolina, United States|Total Eye Care, PA, Memphis, Tennessee, United States|VRF Eye Specialty Group, Memphis, Tennessee, United States|Advancing Vision Research, Nashville, Tennessee, United States|Keystone Research, Austin, Texas, United States|Cataract & Glaucoma Center, El Paso, Texas, United States|Houston Eye Associates, Houston, Texas, United States|The Eye Centers of Racine and Kenosha, Racine, Wisconsin, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,37.0,58.0874350602681,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.77,453.542,94.31,4.0,2.0,4.0,51.09,134.66,8.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1
Cc1ccc(C(=O)OCc2ccc([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1,1,DB13931,__NETARSUDIL,8450344,Completed,,OCULAR HYPERTENSION,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,37.0,58.0874350602681,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.77,453.542,94.31,4.0,2.0,4.0,51.09,134.66,8.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1
CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21,1,DB14185,__ARIPIPRAZOLE_LAUROXIL,8431576,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,34.2019343313004,10.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.91,660.72,62.32,5.0,0.0,4.0,76.95,183.74,20.0,1.0,0.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,1,0,0,1,1,0,1,0,1,0,1,0,0,0,1,1,1
O=P([O-])([O-])O.[Na+].[Na+],1,DB14502,"__SODIUM_PHOSPHATE,_DIBASIC",7687075,Completed,NCT01730872,CHRONIC ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Andover Eye Associates, Andover, Massachusetts, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,48.0,64.3955728043697,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,141.9588,83.42,4.0,1.0,0.0,5.24,12.41,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=P([O-])([O-])O.[Na+].[Na+],1,DB14502,"__SODIUM_PHOSPHATE,_DIBASIC",7687075,Completed,NCT01534195,ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Andover Eye Associates, Andover, Massachusetts, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,48.0,64.3955728043697,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,141.9588,83.42,4.0,1.0,0.0,5.24,12.41,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=P([O-])([O-])O.[Na+].[Na+],1,DB14502,"__SODIUM_PHOSPHATE,_DIBASIC",7687075,Withdrawn,NCT01326585,RETINAL DETACHMENT,All,"18 Years to 79 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","St. Michael's Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,48.0,64.3955728043697,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,141.9588,83.42,4.0,1.0,0.0,5.24,12.41,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT01853696,FUCHS' DYSTROPHY|CORNEAL EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Price Vision Group, Indianapolis, Indiana, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT03123614,INTRAOCULAR PRESSURE|CORNEAL OPACITY,All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Moran Eye Center - Midvalley Location, Murray, Utah, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT00689078,ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Ophthalmic Research Associates, Andover, Massachusetts, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT01437982,"CONJUNCTIVITIS, SEASONAL ALLERGIC|CONJUNCTIVITIS, GIANT PAPILLARY|INFLAMMATION",All,"Child, Adult, Older Adult",Industry,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Bausch & Lomb Korea Ltd, Seoul, Korea, Republic of",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT01244334,"CATARACTS|CORNEAL EDEMA|RETINAL STRUCTURAL CHANGE, DEPOSIT AND DEGENERATION|VISUAL ACUITY REDUCED TRANSIENTLY",All,"21 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cincinnati Eye Institute, Edgewood, Kentucky, United States|Ophthalmic Consultants of Long Island, Lynbrook, New York, United States|Carolina Eyecare, Mt Pleasant, South Carolina, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Recruiting,NCT01939691,UVEITIS|MACULAR EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Aravind Eye Hospital, Coimbatore, Tamil Nadu, India|Aravind Eye Hospital, Madurai, Tamil Nadu, India|Aravind Eye Hospital, Pondicherry, Tamil Nadu, India",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT03578276,CATARACT,All,"50 Years to 99 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Carolina Eyecare Physicians, LLC, Mount Pleasant, South Carolina, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Recruiting,NCT04464629,RETINAL DETACHMENT,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Midwest Eye Institute, Indianapolis, Indiana, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Recruiting,NCT04403516,PTERYGIUM,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"New York Eye Specialists, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Recruiting,NCT04351737,PTERYGIUM OF BOTH EYES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Brandon Eye Associates, Brandon, Florida, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Recruiting,NCT04316936,CATARACT SURGERY,All,"Child, Adult, Older Adult",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Silverstein Eye Centers, Kansas City, Missouri, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Recruiting,NCT04200651,GLAUCOMA|CATARACT,All,"21 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The New York Eye Surgery Center, Bronx, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Not yet recruiting,NCT04521140,CORNEAL EDEMA|CORNEAL DEFECT|CORNEAL TRANSPLANT|PENETRATING KERATOPLASTY|ANTERIOR CHAMBER INFLAMMATION|OCULAR PAIN,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Recruiting,NCT04168112,"KERATOCONUS, UNSTABLE|COLLAGEN CROSSLINKING|POSTOPERATIVE PAIN",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"SightMD, Babylon, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Not yet recruiting,NCT04426734,NON-INFECTIOUS ANTERIOR UVEITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Recruiting,NCT04362241,"RETINOPATHY, DIABETIC",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ophthalmic Consultants of the Capital Region, Troy, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Not yet recruiting,NCT04563299,NEOVASCULAR AGE-RELATED MACULAR DEGENERATION|DIABETIC MACULAR EDEMA|RETINAL VEIN OCCLUSION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Retina Vitreous Associates of Florida, Saint Petersburg, Florida, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,"Active, not recruiting",NCT04184999,DRY EYE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Hauser Ross Surgical Center, Sycamore, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Not yet recruiting,NCT04501367,VITRECTOMY|MACULAR PUCKER|RETINAL EDEMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Unknown status,NCT00677664,DIABETIC RETINOPATHY,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Federal University of Sao Paulo, Sao Paulo, SP, Brazil",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Unknown status,NCT02557269,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medical University Sofia, University Hospital ""Alexandrovska"", Clinic of Allergy and Asthma, Sofia, Bulgaria",G06M1/163,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,NCT00817050,ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,G06M1/163,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,NCT02559440,ADENOIDAL HYPERTROPHY,All,5 Years to 11 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,G06M1/163,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,NCT03705793,CHRONIC RHINOSINUSITIS (DIAGNOSIS)|ALLERGIC RHINOSINUSITIS|CHRONIC EOSINOPHILIC RHINOSINUSITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Washington University School of Medicine, Saint Louis, Missouri, United States|Washington University, Saint Louis, Missouri, United States",G06M1/163,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,NCT00834119,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,G06M1/163,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Terminated,NCT00491374,PERENNIAL ALLERGIC RHINITIS,All,18 Years to 45 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,G06M1/163,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Unknown status,NCT02110654,SINUSITIS|NASAL POLYPS|ASTHMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"the first affiliated hospital, Sun Yat-sen University, Guangzhou, Guangdong, China",G06M1/163,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,NCT01118312,ASTHMA|RHINITIS|SINUSITIS,All,"6 Years and older   (Child, Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Arizona, Tucson, Arizona, United States|University of California, San Diego, San Diego, California, United States|National Jewish Health, Denver, Colorado, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Univeristy of Miami School of Medicine, Miami, Florida, United States|University of South Florida College of Medicine, Tampa, Florida, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States|University of Missouri, Kansas City School of Medicine, Kansas City, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|North Shore-Long Island Jewish Health System, New Hyde Park, New York, United States|New York University School of Medicine, New York, New York, United States|New York Medical College, Valhalla, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Davis Heart and Lung Research Institute, Columbus, Ohio, United States|Baylor College of Medicine, Houston, Texas, United States|Vermont Lung Center at the University of Vermont, Burlington, Vermont, United States|Univeristy of Virginia, Charlottesville, Virginia, United States",G06M1/163,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,NCT00359216,PERENNIAL ALLERGIC RHINITIS|OBSTRUCTIVE SLEEP APNEA|SLEEP DISORDER,All,18 Years to 60 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,G06M1/163,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Terminated,NCT00553891,NASAL OBSTRUCTION|ADENOIDS HYPERTROPHY|ADENOIDECTOMY,All,2 Years to 11 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,G06M1/163,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,NCT01098071,ADENOIDS,All,2 Years to 11 Years   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,G06M1/163,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Terminated,NCT01616160,NASAL POLYPS,All,"21 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Massachusetts General Hospital, Boston, Massachusetts, United States",G06M1/163,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,,"RHINITIS, ALLERGIC, SEASONAL",,,,,"FISABIO, Elche, Alicante, Spain",G06M1/163,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",G06M1/163,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
O=C([O-])[O-],1,DB14531,__CARBONATE_ION,,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.53,60.0089,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC1CCCC1,1,DB14541,__HYDROCORTISONE_CYPIONATE,4304765,Completed,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0051,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,13.799051315222002,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.53,486.649,100.9,5.0,2.0,5.0,54.76,132.33,7.0,0.0,1.0,0.0,0,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)OCCl,1,DB00873,__LOTEPREDNOL,6106819,Completed,NCT00420628,CHALAZION|HORDEOLUM,All,up to 6 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pediatric Ophthalmology of Erie, Erie, Pennsylvania, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,32.5591901271073,113.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.2,394.889,83.83,4.0,2.0,4.0,41.29,102.65,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)OCCl,1,DB00873,__LOTEPREDNOL,6106819,Completed,NCT01853696,FUCHS' DYSTROPHY|CORNEAL EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Price Vision Group, Indianapolis, Indiana, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,32.5591901271073,113.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.2,394.889,83.83,4.0,2.0,4.0,41.29,102.65,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)OCCl,1,DB00873,__LOTEPREDNOL,6106819,Withdrawn,NCT02028312,DRY EYE,All,"21 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Cincinnati Eye Institute, Edgewood, Kentucky, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,32.5591901271073,113.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.2,394.889,83.83,4.0,2.0,4.0,41.29,102.65,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)OCCl,1,DB00873,__LOTEPREDNOL,6106819,Completed,NCT00781300,"GLAUCOMA, OPEN-ANGLE|OCULAR HYPERTENSION",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Opthalmology, Federal University of São Paulo, São Paulo, SP, Brazil",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,32.5591901271073,113.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.2,394.889,83.83,4.0,2.0,4.0,41.29,102.65,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)OCCl,1,DB00873,__LOTEPREDNOL,6106819,Completed,NCT04075227,RECURRENT PTERYGIUM OF EYE|STEROID-INDUCED GLAUCOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,32.5591901271073,113.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.2,394.889,83.83,4.0,2.0,4.0,41.29,102.65,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)OCCl,1,DB00873,__LOTEPREDNOL,6106819,Completed,NCT03123614,INTRAOCULAR PRESSURE|CORNEAL OPACITY,All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Moran Eye Center - Midvalley Location, Murray, Utah, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,32.5591901271073,113.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.2,394.889,83.83,4.0,2.0,4.0,41.29,102.65,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)OCCl,1,DB00873,__LOTEPREDNOL,6106819,Unknown status,NCT02974387,MUST BE PRK CANDIDATE,All,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,32.5591901271073,113.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.2,394.889,83.83,4.0,2.0,4.0,41.29,102.65,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)OCCl,1,DB00873,__LOTEPREDNOL,6106819,Completed,NCT00705159,CONJUNCTIVITIS,All,up to 6 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pediatric Ophthalmology of Erie, Erie, Pennsylvania, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,32.5591901271073,113.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.2,394.889,83.83,4.0,2.0,4.0,41.29,102.65,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)OCCl,1,DB00873,__LOTEPREDNOL,6106819,Completed,NCT01456780,MEIBOMIAN GLAND DYSFUNCTION|POSTERIOR BLEPHARITIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Massachusetts Eye & Ear Infirmary, Boston, Massachusetts, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,32.5591901271073,113.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.2,394.889,83.83,4.0,2.0,4.0,41.29,102.65,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)OCCl,1,DB00873,__LOTEPREDNOL,6106819,Completed,NCT01443442,ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Eye Car Center, Southern California college of Optometry, Fullerton, California, United States|Eye Care Center, Southern Caalifornia College of Optometry, Fullerton, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,32.5591901271073,113.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.2,394.889,83.83,4.0,2.0,4.0,41.29,102.65,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)OCCl,1,DB00873,__LOTEPREDNOL,6106819,Completed,NCT01437982,"CONJUNCTIVITIS, SEASONAL ALLERGIC|CONJUNCTIVITIS, GIANT PAPILLARY|INFLAMMATION",All,"Child, Adult, Older Adult",Industry,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Bausch & Lomb Korea Ltd, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,32.5591901271073,113.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.2,394.889,83.83,4.0,2.0,4.0,41.29,102.65,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)COP(=O)(O)O,1,DB14631,__PREDNISOLONE_PHOSPHATE,6024981,Terminated,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,3.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.92,440.42900000000003,141.36,7.0,4.0,4.0,43.42,109.37,4.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)COC(=O)CCC(=O)O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB14644,__METHYLPREDNISOLONE_HEMISUCCINATE,WO-2003082251-A2,Recruiting,NCT04192656,SUDDEN HEARING LOSS|OBSTRUCTIVE SLEEP APNEA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Tsinhgua Changgung Hospital, Beijing, Beijing, China",A61K9/0007,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,32.7488,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.43,474.55,138.2,7.0,3.0,4.0,49.87,123.09,7.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)COC(=O)CCC(=O)O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB14644,__METHYLPREDNISOLONE_HEMISUCCINATE,WO-2003082251-A2,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0007,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,32.7488,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.43,474.55,138.2,7.0,3.0,4.0,49.87,123.09,7.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)COC(=O)CCC(=O)O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB14644,__METHYLPREDNISOLONE_HEMISUCCINATE,WO-2003082251-A2,Completed,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0007,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,32.7488,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.43,474.55,138.2,7.0,3.0,4.0,49.87,123.09,7.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@@]21C,1,DB14646,__PREDNISONE_ACETATE,4478818,Not yet recruiting,NCT04501367,VITRECTOMY|MACULAR PUCKER|RETINAL EDEMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/0051,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,9.593626152487731,32.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.25,400.471,97.74,5.0,1.0,4.0,42.51,106.72,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@@]21C,1,DB14646,__PREDNISONE_ACETATE,4478818,Not Yet Recruiting,,EVAPORATIVE DRY EYE,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0051,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,9.593626152487731,32.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.25,400.471,97.74,5.0,1.0,4.0,42.51,106.72,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@@]21C,1,DB14646,__PREDNISONE_ACETATE,4478818,Not Yet Recruiting,,MACULAR PUCKER,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0051,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,9.593626152487731,32.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.25,400.471,97.74,5.0,1.0,4.0,42.51,106.72,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OC(C)OC(=O)C(C)c1ccc(-c2ccccc2)c(F)c1,1,DB14938,__FLURBIPROFEN_AXETIL,4766148,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D307/33,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,38.5387790303702,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.36,330.355,52.6,2.0,0.0,2.0,34.15,87.16,7.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)OC(C)OC(=O)C(C)c1ccc(-c2ccccc2)c(F)c1,1,DB14938,__FLURBIPROFEN_AXETIL,4766148,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D307/33,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,38.5387790303702,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.36,330.355,52.6,2.0,0.0,2.0,34.15,87.16,7.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB15566,__PREDNISOLONE_ACETATE,5881926,Completed,NCT01853696,FUCHS' DYSTROPHY|CORNEAL EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Price Vision Group, Indianapolis, Indiana, United States",A61K9/0095,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,41.0,66.49828538573679,109.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.17,402.4807,100.9,5.0,2.0,4.0,42.93,107.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB15566,__PREDNISOLONE_ACETATE,5881926,Completed,NCT03123614,INTRAOCULAR PRESSURE|CORNEAL OPACITY,All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Moran Eye Center - Midvalley Location, Murray, Utah, United States",A61K9/0095,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,41.0,66.49828538573679,109.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.17,402.4807,100.9,5.0,2.0,4.0,42.93,107.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB15566,__PREDNISOLONE_ACETATE,5881926,Completed,NCT00689078,ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Ophthalmic Research Associates, Andover, Massachusetts, United States",A61K9/0095,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,41.0,66.49828538573679,109.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.17,402.4807,100.9,5.0,2.0,4.0,42.93,107.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB15566,__PREDNISOLONE_ACETATE,5881926,Completed,NCT01437982,"CONJUNCTIVITIS, SEASONAL ALLERGIC|CONJUNCTIVITIS, GIANT PAPILLARY|INFLAMMATION",All,"Child, Adult, Older Adult",Industry,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Bausch & Lomb Korea Ltd, Seoul, Korea, Republic of",A61K9/0095,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,41.0,66.49828538573679,109.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.17,402.4807,100.9,5.0,2.0,4.0,42.93,107.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB15566,__PREDNISOLONE_ACETATE,5881926,Completed,NCT01244334,"CATARACTS|CORNEAL EDEMA|RETINAL STRUCTURAL CHANGE, DEPOSIT AND DEGENERATION|VISUAL ACUITY REDUCED TRANSIENTLY",All,"21 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cincinnati Eye Institute, Edgewood, Kentucky, United States|Ophthalmic Consultants of Long Island, Lynbrook, New York, United States|Carolina Eyecare, Mt Pleasant, South Carolina, United States",A61K9/0095,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,41.0,66.49828538573679,109.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.17,402.4807,100.9,5.0,2.0,4.0,42.93,107.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB15566,__PREDNISOLONE_ACETATE,5881926,Recruiting,NCT01939691,UVEITIS|MACULAR EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Aravind Eye Hospital, Coimbatore, Tamil Nadu, India|Aravind Eye Hospital, Madurai, Tamil Nadu, India|Aravind Eye Hospital, Pondicherry, Tamil Nadu, India",A61K9/0095,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,41.0,66.49828538573679,109.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.17,402.4807,100.9,5.0,2.0,4.0,42.93,107.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB15566,__PREDNISOLONE_ACETATE,5881926,Completed,NCT03578276,CATARACT,All,"50 Years to 99 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Carolina Eyecare Physicians, LLC, Mount Pleasant, South Carolina, United States",A61K9/0095,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,41.0,66.49828538573679,109.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.17,402.4807,100.9,5.0,2.0,4.0,42.93,107.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB15566,__PREDNISOLONE_ACETATE,5881926,Recruiting,NCT04464629,RETINAL DETACHMENT,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Midwest Eye Institute, Indianapolis, Indiana, United States",A61K9/0095,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,41.0,66.49828538573679,109.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.17,402.4807,100.9,5.0,2.0,4.0,42.93,107.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB15566,__PREDNISOLONE_ACETATE,5881926,Recruiting,NCT04403516,PTERYGIUM,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"New York Eye Specialists, New York, New York, United States",A61K9/0095,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,41.0,66.49828538573679,109.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.17,402.4807,100.9,5.0,2.0,4.0,42.93,107.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB15566,__PREDNISOLONE_ACETATE,5881926,Recruiting,NCT04351737,PTERYGIUM OF BOTH EYES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Brandon Eye Associates, Brandon, Florida, United States",A61K9/0095,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,41.0,66.49828538573679,109.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.17,402.4807,100.9,5.0,2.0,4.0,42.93,107.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB15566,__PREDNISOLONE_ACETATE,5881926,Recruiting,NCT04316936,CATARACT SURGERY,All,"Child, Adult, Older Adult",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Silverstein Eye Centers, Kansas City, Missouri, United States",A61K9/0095,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,41.0,66.49828538573679,109.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.17,402.4807,100.9,5.0,2.0,4.0,42.93,107.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB15566,__PREDNISOLONE_ACETATE,5881926,Recruiting,NCT04200651,GLAUCOMA|CATARACT,All,"21 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The New York Eye Surgery Center, Bronx, New York, United States",A61K9/0095,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,41.0,66.49828538573679,109.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.17,402.4807,100.9,5.0,2.0,4.0,42.93,107.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB15566,__PREDNISOLONE_ACETATE,5881926,Not yet recruiting,NCT04521140,CORNEAL EDEMA|CORNEAL DEFECT|CORNEAL TRANSPLANT|PENETRATING KERATOPLASTY|ANTERIOR CHAMBER INFLAMMATION|OCULAR PAIN,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/0095,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,41.0,66.49828538573679,109.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.17,402.4807,100.9,5.0,2.0,4.0,42.93,107.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB15566,__PREDNISOLONE_ACETATE,5881926,Recruiting,NCT04168112,"KERATOCONUS, UNSTABLE|COLLAGEN CROSSLINKING|POSTOPERATIVE PAIN",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"SightMD, Babylon, New York, United States",A61K9/0095,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,41.0,66.49828538573679,109.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.17,402.4807,100.9,5.0,2.0,4.0,42.93,107.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB15566,__PREDNISOLONE_ACETATE,5881926,Not yet recruiting,NCT04426734,NON-INFECTIOUS ANTERIOR UVEITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/0095,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,41.0,66.49828538573679,109.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.17,402.4807,100.9,5.0,2.0,4.0,42.93,107.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB15566,__PREDNISOLONE_ACETATE,5881926,Recruiting,NCT04362241,"RETINOPATHY, DIABETIC",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ophthalmic Consultants of the Capital Region, Troy, New York, United States",A61K9/0095,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,41.0,66.49828538573679,109.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.17,402.4807,100.9,5.0,2.0,4.0,42.93,107.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB15566,__PREDNISOLONE_ACETATE,5881926,Not yet recruiting,NCT04563299,NEOVASCULAR AGE-RELATED MACULAR DEGENERATION|DIABETIC MACULAR EDEMA|RETINAL VEIN OCCLUSION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Retina Vitreous Associates of Florida, Saint Petersburg, Florida, United States",A61K9/0095,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,41.0,66.49828538573679,109.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.17,402.4807,100.9,5.0,2.0,4.0,42.93,107.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB15566,__PREDNISOLONE_ACETATE,5881926,"Active, not recruiting",NCT04184999,DRY EYE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Hauser Ross Surgical Center, Sycamore, Illinois, United States",A61K9/0095,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,41.0,66.49828538573679,109.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.17,402.4807,100.9,5.0,2.0,4.0,42.93,107.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB15566,__PREDNISOLONE_ACETATE,5881926,Completed,,CORNEAL EDEMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0095,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,41.0,66.49828538573679,109.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.17,402.4807,100.9,5.0,2.0,4.0,42.93,107.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O,1,,_DEXTRAN,4201772,Completed,NCT01732757,"CONJUNCTIVITIS, ALLERGIC",All,"10 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Memphis, Tennessee, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,26.0,25.298260744573803,78.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O,1,,_DEXTRAN,4201772,Completed,NCT01282138,ALLERGIC CONJUNCTIVITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","Contact Alcon Call Center for Trial Locations, Fort Worth, Texas, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,26.0,25.298260744573803,78.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O,1,,_DEXTRAN,4201772,Completed,NCT01978015,"UVEITIS, ANTERIOR|CYSTOID MACULAR EDEMA",All,"18 Years to 95 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital de Clínicas, UNICAMP, Campinas, São Paulo, Brazil",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,25.298260744573803,78.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0
CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1.[Cl-],1,,_BENZALKONIUM_CHLORIDE,3992432,Completed,NCT03104621,PRIMARY OPEN ANGLE GLAUCOMA,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07C17/208,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,20.928561161420106,23.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0
CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1.[Cl-],1,,_BENZALKONIUM_CHLORIDE,3992432,Completed,NCT03323528,PHARYNGITIS,All,"18 Years to 99 Years   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","doc-HNO for the DoriPha investigators, Röthenbach an der Pegnitz, Germany",C07C17/208,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,24.0,20.928561161420106,23.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0
CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1,1,,_BENZALKONIUM,EP-0842248-B1,Completed,NCT03104621,PRIMARY OPEN ANGLE GLAUCOMA,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07D335/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,81.61153206431341,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0
CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1,1,,_BENZALKONIUM,EP-0842248-B1,Completed,NCT03323528,PHARYNGITIS,All,"18 Years to 99 Years   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","doc-HNO for the DoriPha investigators, Röthenbach an der Pegnitz, Germany",C07D335/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,13.0,81.61153206431341,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Completed,NCT03464435,VERNAL KERATOCONJUNCTIVITIS,All,"5 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Completed,NCT01850979,SJOGREN SYNDROME|DRY EYE SYNDROME,All,40 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Sao Paulo General Hospital, Sao Paulo, SP, Brazil",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)[O-])c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21.[Na+],1,,_INDOCYANINE_GREEN,3959455,Completed,NCT03969108,THYROID CANCER|THYROID GOITER|GRAVES DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University Health Network, Toronto, Ontario, Canada",A61K51/0485,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,10.809256863590601,2060.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1,0,1,1,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,1,0,1
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)O,1,,_LOTEPREDNOL,US-20050020551-A1,Completed,NCT00420628,CHALAZION|HORDEOLUM,All,up to 6 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pediatric Ophthalmology of Erie, Erie, Pennsylvania, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,48.0,50.5308117209799,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)O,1,,_LOTEPREDNOL,US-20050020551-A1,Completed,NCT01853696,FUCHS' DYSTROPHY|CORNEAL EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Price Vision Group, Indianapolis, Indiana, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,48.0,50.5308117209799,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)O,1,,_LOTEPREDNOL,US-20050020551-A1,Withdrawn,NCT02028312,DRY EYE,All,"21 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Cincinnati Eye Institute, Edgewood, Kentucky, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,48.0,50.5308117209799,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)O,1,,_LOTEPREDNOL,US-20050020551-A1,Completed,NCT00781300,"GLAUCOMA, OPEN-ANGLE|OCULAR HYPERTENSION",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Opthalmology, Federal University of São Paulo, São Paulo, SP, Brazil",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,48.0,50.5308117209799,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)O,1,,_LOTEPREDNOL,US-20050020551-A1,Completed,NCT04075227,RECURRENT PTERYGIUM OF EYE|STEROID-INDUCED GLAUCOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,48.0,50.5308117209799,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)O,1,,_LOTEPREDNOL,US-20050020551-A1,Completed,NCT03123614,INTRAOCULAR PRESSURE|CORNEAL OPACITY,All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Moran Eye Center - Midvalley Location, Murray, Utah, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,48.0,50.5308117209799,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)O,1,,_LOTEPREDNOL,US-20050020551-A1,Unknown status,NCT02974387,MUST BE PRK CANDIDATE,All,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,48.0,50.5308117209799,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)O,1,,_LOTEPREDNOL,US-20050020551-A1,Completed,NCT00705159,CONJUNCTIVITIS,All,up to 6 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pediatric Ophthalmology of Erie, Erie, Pennsylvania, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,48.0,50.5308117209799,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)O,1,,_LOTEPREDNOL,US-20050020551-A1,Completed,NCT01456780,MEIBOMIAN GLAND DYSFUNCTION|POSTERIOR BLEPHARITIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Massachusetts Eye & Ear Infirmary, Boston, Massachusetts, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,48.0,50.5308117209799,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)O,1,,_LOTEPREDNOL,US-20050020551-A1,Completed,NCT01443442,ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Eye Car Center, Southern California college of Optometry, Fullerton, California, United States|Eye Care Center, Southern Caalifornia College of Optometry, Fullerton, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,48.0,50.5308117209799,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)O,1,,_LOTEPREDNOL,US-20050020551-A1,Completed,NCT01437982,"CONJUNCTIVITIS, SEASONAL ALLERGIC|CONJUNCTIVITIS, GIANT PAPILLARY|INFLAMMATION",All,"Child, Adult, Older Adult",Industry,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Bausch & Lomb Korea Ltd, Seoul, Korea, Republic of",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,48.0,50.5308117209799,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1,1,,_BEPOTASTINE,EP-0949260-A1,Completed,NCT01443442,ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Eye Car Center, Southern California college of Optometry, Fullerton, California, United States|Eye Care Center, Southern Caalifornia College of Optometry, Fullerton, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,52.8635084909341,67.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,1,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,1,1,1,0,1,0,1
Cc1ccc(C(=O)OCC2=CCC([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)C=C2)c(C)c1,1,,_NETARSUDIL,,Completed,NCT03808688,"GLAUCOMA, OPEN-ANGLE|OCULAR HYPERTENSION",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Atlantis Eyecare, Huntington Beach, California, United States|Harvard Eye Associates, Laguna Hills, California, United States|North Bay Eye Associates, Inc, Petaluma, California, United States|Shettle Eye Research Inc, Largo, Florida, United States|Center For Sight, Sarasota, Florida, United States|Coastal Research Associates, LLC, Roswell, Georgia, United States|Wheaton Eye Clinic, Ltd, Wheaton, Illinois, United States|Stiles Eyecare Excellence and Glaucoma Institute, PA, Overland Park, Kansas, United States|Gaddie Eye Centers, LLC, Louisville, Kentucky, United States|Glaucoma Consultants, Baltimore, Maryland, United States|Tekwani Vision Center, Saint Louis, Missouri, United States|Mark J. Weiss, M.D., Inc., Tulsa, Oklahoma, United States|Scott & Christie and Associates, PC, Cranberry Township, Pennsylvania, United States|Valley Eye Professionals, LLC, Huntingdon Valley, Pennsylvania, United States|Carolina Cataract & Laser Center, Ladson, South Carolina, United States|Total Eye Care, PA, Memphis, Tennessee, United States|VRF Eye Specialty Group, Memphis, Tennessee, United States|Advancing Vision Research, Nashville, Tennessee, United States|Keystone Research, Austin, Texas, United States|Cataract & Glaucoma Center, El Paso, Texas, United States|Houston Eye Associates, Houston, Texas, United States|The Eye Centers of Racine and Kenosha, Racine, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,1,1,0,1,1,0,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1
COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314.O.O=P(O)(O)O,1,,_CODEINE_PHOSPHATE,,Completed,NCT03784105,ESOPHAGEAL MOTILITY DISORDERS,All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","Jan Tack, Leuven, Belgium|UZ Leuven, Leuven, Belgium",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN[C@@H](C)[C@@H](O)c1ccccc1.CN[C@@H](C)[C@@H](O)c1ccccc1.O=S(=O)(O)O,1,,_PSEUDOEPHEDRINE_SULFATE,4601894,Completed,NCT03443843,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kingston General Hospital, Kingston, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,15.770344360253803,99.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])c1cc(O)ccc1O.O=S(=O)([O-])c1cc(O)ccc1O.[Ca+2],1,,_CALCIUM_DOBESILATE,4511557,Not yet recruiting,NCT04283162,DIABETIC RETINOPATHY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, Southeast University, Nanjing, Jiangsu, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,31.869237561346196,68.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0
Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O,1,,_BRIMONIDINE_TARTRATE,WO-1995003798-A2,Not yet recruiting,NCT04007276,"GLAUCOMA|GLAUCOMA, OPEN-ANGLE|GLAUCOMA; DRUGS|DROOPY EYELID|PTOSIS|GLAUCOMA, PRIMARY OPEN ANGLE",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,32.7488,19.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O,1,,_BRIMONIDINE_TARTRATE,WO-1995003798-A2,Completed,NCT03966560,"GLAUCOMA, OPEN-ANGLE",All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,32.7488,19.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O,1,,_BRIMONIDINE_TARTRATE,WO-1995003798-A2,Recruiting,NCT03782701,EYELID DROOP,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bascom Palmer Eye Institute, Miami, Florida, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,32.7488,19.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O,1,,_BRIMONIDINE_TARTRATE,WO-1995003798-A2,Completed,NCT00811850,GLAUCOMA,All,"30 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Indianapolis, Indiana, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,32.7488,19.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O,1,,_BRIMONIDINE_TARTRATE,WO-1995003798-A2,"Active, not recruiting",NCT03323164,GLAUCOMA; DRUGS|NORMAL TENSION GLAUCOMA|PRIMARY OPEN-ANGLE GLAUCOMA,All,"18 Years to 90 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,"Glaucoma Research Center - Wills Eye Hospital, Philadelphia, Pennsylvania, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,32.7488,19.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O,1,,_BRIMONIDINE_TARTRATE,WO-1995003798-A2,Completed,NCT02863705,"GLAUCOMA, OPEN-ANGLE|NORMAL TENSION GLAUCOMA",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea, Republic of|Yeungnam University Hospital, Yeungnam University College of Medicine, Daegu, Korea, Republic of|Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea, Republic of|Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea, Republic of|Seoul National University Bundang Hospital, Seoul National University College of Medicine, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea, Republic of|Kangbuk Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea, Republic of|Kim's Eye Hospital, Konyang University College of Medicine, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,32.7488,19.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O,1,,_BRIMONIDINE_TARTRATE,WO-1995003798-A2,Completed,NCT02003534,"GLAUCOMA, OPEN-ANGLE|OCULAR HYPERTENSION",All,"Child, Adult, Older Adult",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,32.7488,19.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O,1,,_BRIMONIDINE_TARTRATE,WO-1995003798-A2,Completed,NCT01525173,GLAUCOMA|OCULAR HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Deerfield Beach, Florida, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,32.7488,19.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O,1,,_BRIMONIDINE_TARTRATE,WO-1995003798-A2,Completed,NCT00822081,OPEN-ANGLE GLAUCOMA|OCULAR HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,"Barrie, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,32.7488,19.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21.Cl,1,,_DORZOLAMIDE_HYDROCHLORIDE,5620970,Completed,NCT03966560,"GLAUCOMA, OPEN-ANGLE",All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,22.3413211770262,84.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21.Cl,1,,_DORZOLAMIDE_HYDROCHLORIDE,5620970,Completed,NCT00811850,GLAUCOMA,All,"30 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Indianapolis, Indiana, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,22.3413211770262,84.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21.Cl,1,,_DORZOLAMIDE_HYDROCHLORIDE,5620970,Completed,NCT02325518,OPEN-ANGLE GLAUCOMA|OCULAR HYPERTENSION,All,"20 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)","Contact Alcon Japan Ltd. for Trial Locations, Tokyo, Japan",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,22.3413211770262,84.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21.Cl,1,,_DORZOLAMIDE_HYDROCHLORIDE,5620970,Completed,NCT00545064,OCULAR HYPERTENSION|OPEN ANGLE GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,22.3413211770262,84.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1.O=C(O)/C=C\C(=O)O,1,,_TIMOLOL_MALEATE,4281654,Completed,NCT03966560,"GLAUCOMA, OPEN-ANGLE",All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/0051,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,15.901763896589198,234.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,1,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1.O=C(O)/C=C\C(=O)O,1,,_TIMOLOL_MALEATE,4281654,Completed,NCT00811850,GLAUCOMA,All,"30 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Indianapolis, Indiana, United States",A61K9/0051,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,15.901763896589198,234.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,1,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1.O=C(O)/C=C\C(=O)O,1,,_TIMOLOL_MALEATE,4281654,"Active, not recruiting",NCT03323164,GLAUCOMA; DRUGS|NORMAL TENSION GLAUCOMA|PRIMARY OPEN-ANGLE GLAUCOMA,All,"18 Years to 90 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,"Glaucoma Research Center - Wills Eye Hospital, Philadelphia, Pennsylvania, United States",A61K9/0051,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,23.0,15.901763896589198,234.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,1,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1.O=C(O)/C=C\C(=O)O,1,,_TIMOLOL_MALEATE,4281654,Completed,NCT01170884,GLAUCOMA|OCULAR HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Dallas, Texas, United States",A61K9/0051,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,15.901763896589198,234.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,1,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1.O=C(O)/C=C\C(=O)O,1,,_TIMOLOL_MALEATE,4281654,Completed,NCT00822081,OPEN-ANGLE GLAUCOMA|OCULAR HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,"Barrie, Ontario, Canada",A61K9/0051,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,23.0,15.901763896589198,234.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,1,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1.O=C(O)/C=C\C(=O)O,1,,_TIMOLOL_MALEATE,4281654,Completed,NCT00273442,"OCULAR HYPERTENSION|OPEN-ANGLE GLAUCOMA|EXFOLIATION SYNDROME|GLAUCOMA, PIGMENTARY",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Little Rock Eye Clinic, Little Rock, Arkansas, United States|Omni Eye Services, Atlanta, Georgia, United States|Midwest Eye Center, Bourbonnais, Illinois, United States|Mark J. Weiss, MD, Tulsa, Oklahoma, United States|Glaucoma Consultants & Center for Eye Research, Mt. Pleasant, South Carolina, United States",A61K9/0051,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,15.901763896589198,234.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,1,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1.O=C(O)/C=C\C(=O)O,1,,_TIMOLOL_MALEATE,4281654,Completed,NCT00545064,OCULAR HYPERTENSION|OPEN ANGLE GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/0051,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,15.901763896589198,234.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,1,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1.O=C(O)/C=C\C(=O)O,1,,_TIMOLOL_MALEATE,4281654,Completed,NCT01978015,"UVEITIS, ANTERIOR|CYSTOID MACULAR EDEMA",All,"18 Years to 95 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital de Clínicas, UNICAMP, Campinas, São Paulo, Brazil",A61K9/0051,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,15.901763896589198,234.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,1,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1.O=C(O)/C=C\C(=O)O,1,,_TIMOLOL_MALEATE,4281654,Completed,NCT00330577,PRIMARY OPEN ANGLE GLAUCOMA|OCULAR HYPERTENSION,All,"29 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"Glaucoma Unit, A University Dept of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece",A61K9/0051,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,15.901763896589198,234.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,1,1,0,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1.O=C(O)/C=C\C(=O)O,1,,_TIMOLOL_MALEATE,4281654,Completed,NCT00804648,"GLAUCOMA, OPEN ANGLE|OCULAR HYPERTENSION",All,"21 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Bourbonnais, Illinois, United States|Charlotte, North Carolina, United States",A61K9/0051,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,15.901763896589198,234.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,1,1,0,1
COc1ccc2[n-]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.COc1ccc2[n-]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.[Mg+2],1,,_ESOMEPRAZOLE_MAGNESIUM,EP-0101136-A2,Completed,NCT00637845,HEARTBURN|GASTROESOPHAGEAL REFLUX DISEASE,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07D335/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,48.0,32.7488,16.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
COc1ccc2[n-]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.COc1ccc2[n-]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.[Mg+2],1,,_ESOMEPRAZOLE_MAGNESIUM,EP-0101136-A2,Completed,NCT00206180,EROSIVE ESOPHAGITIS|REFLUX ESOPHAGITIS|GASTROESOPHAGEAL REFLUX DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,"Research Site, Alabaster, Alabama, United States|Research Site, Anaheim, California, United States|Research Site, Dinuba, California, United States|Research Site, Fresno, California, United States|Research Site, Orange, California, United States|Research Site, San Diego, California, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Zephyr Hills, Florida, United States|Research Site, Decatur, Georgia, United States|Research Site, Rome, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Oakbrook Terrace, Illinois, United States|Research Site, Urbana, Illinois, United States|Research Site, Louisville, Kentucky, United States|Research Site, Covington, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Chevy Chase, Maryland, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Troy, Michigan, United States|Research Site, Egg Harbor Township, New Jersey, United States|Research Site, Passaic, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, New York, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Jacksonville, North Carolina, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, N Providence, Rhode Island, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Bellevue, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Milwaukee, Wisconsin, United States",C07D335/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,48.0,32.7488,16.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,1,,_LANSOPRAZOLE,,Completed,NCT00637845,HEARTBURN|GASTROESOPHAGEAL REFLUX DISEASE,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,1,,_LANSOPRAZOLE,,Unknown status,NCT02278081,RHINITIS|NASAL OBSTRUCTION|GERD,All,"7 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,1,,_LANSOPRAZOLE,,Terminated,NCT00369265,LARYNGOPHARYNGEAL REFLUX,All,"18 Years to 89 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Henry Ford Hospital, Department of Otolaryngology, Detroit, Michigan, United States|American Institute for Voice and Ear Research, Philadelphia, Pennsylvania, United States|Cornell University, Van Lawrence Voice Center, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,1,,_LANSOPRAZOLE,,Terminated,NCT01404832,GASTROESOPHAGEAL REFLUX DISEASE|EOSINOPHILIC ESOPHAGITIS,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Dallas VA Medical Center, Dallas, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,1,,_LANSOPRAZOLE,,Completed,NCT02958046,GASTROESOPHAGEAL REFLUX,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department Of Gastroenterology, Faculty Of Medicine, Ege University, Izmir, Turkey, İzmir, Turkey",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,1,,_LANSOPRAZOLE,,Completed,NCT01008696,REFLUX ESOPHAGITIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,1,,_LANSOPRAZOLE,,Unknown status,NCT00237068,ASTHMA,All,4 Years to 11 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Emory Children's Center, Atlanta, Georgia, United States|Children's Center for Digestive Healthcare, Atlanta, Georgia, United States|Georgia Pediatric Pulmonology Associates/ CHOA, Atlanta, Georgia, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,1,,_LANSOPRAZOLE,,Completed,NCT01082029,OTITIS MEDIA WITH EFFUSION,All,1 Year to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Mcmaster University Medical Centre 3V1 Clinic, Hamilton, Ontario, Canada",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,1,,_LANSOPRAZOLE,,Terminated,NCT00637416,DYSPHONIA,All,"3 Years to 18 Years   (Child, Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Kansas Medical Center, Kansas City, Kansas, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_ESOMEPRAZOLE,,Completed,NCT00637845,HEARTBURN|GASTROESOPHAGEAL REFLUX DISEASE,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_ESOMEPRAZOLE,,Completed,NCT00206180,EROSIVE ESOPHAGITIS|REFLUX ESOPHAGITIS|GASTROESOPHAGEAL REFLUX DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,"Research Site, Alabaster, Alabama, United States|Research Site, Anaheim, California, United States|Research Site, Dinuba, California, United States|Research Site, Fresno, California, United States|Research Site, Orange, California, United States|Research Site, San Diego, California, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Zephyr Hills, Florida, United States|Research Site, Decatur, Georgia, United States|Research Site, Rome, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Oakbrook Terrace, Illinois, United States|Research Site, Urbana, Illinois, United States|Research Site, Louisville, Kentucky, United States|Research Site, Covington, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Chevy Chase, Maryland, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Troy, Michigan, United States|Research Site, Egg Harbor Township, New Jersey, United States|Research Site, Passaic, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, New York, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Jacksonville, North Carolina, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, N Providence, Rhode Island, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Bellevue, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Milwaukee, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_ESOMEPRAZOLE,,Completed,NCT00410592,GASTROESOPHAGEAL REFLUX,All,"18 Years to 69 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Anaheim, California, United States|Research Site, Orange, California, United States|Research Site, San Diego, California, United States|Research Site, Miami, Florida, United States|Research Site, Chicago, Illinois, United States|Research SIte, Chapel Hill, North Carolina, United States|Research Site, Houston, Texas, United States|Research Site, San Juan, Puerto Rico",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_ESOMEPRAZOLE,,Withdrawn,NCT02530879,LARYNGOPHARYNGEAL REFLUX,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Temple Otolaryngology, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_ESOMEPRAZOLE,,Completed,NCT00628667,CHRONIC POSTERIOR LARYNGITIS (CPL),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_ESOMEPRAZOLE,,Unknown status,NCT02277886,GASTROESOPHAGEAL REFLUX DISEASE|HEARTBURN|SLEEP DISTURBANCE,All,"20 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chang Gung Memorial Hospital, Taipei, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_ESOMEPRAZOLE,,Completed,NCT00628342,GASTROESOPHAGEAL REFLUX DISEASE,All,"18 Years to 85 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_ESOMEPRAZOLE,,Completed,NCT00635414,GERD,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_ESOMEPRAZOLE,,Completed,NCT00384592,GASTRO-OESOPHAGEAL REFLUX DISEASE,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Allerton, United Kingdom|Research Site, Ashford, United Kingdom|Research Site, Atherstone, United Kingdom|Research Site, Ayrshire, United Kingdom|Research Site, Bath, United Kingdom|Research Site, Blackpool, United Kingdom|Research SIte, Bolton, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Fowey, United Kingdom|Research SIte, Glasgow, United Kingdom|Research Site, Hamilton, United Kingdom|Research Site, Motherwell, United Kingdom|Research Site, Stevenage, United Kingdom|Research Site, Warminster, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_ESOMEPRAZOLE,,Completed,NCT01349413,DYSPEPSIA|GASTROESOPHAGEAL REFLUX,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","Prince of Wales Hospital, Hong Kong, Hong Kong",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_ESOMEPRAZOLE,,Completed,NCT00472550,GASTROESOPHAGEAL REFLUX|HEARTBURN,Male,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"Dep. Medicine II, University Hospital Mannheim, Mannheim, Germany",,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_ESOMEPRAZOLE,,Completed,NCT00228527,GASTROESOPHAGEAL REFLUX DISEASE (GERD)|EROSIVE ESOPHAGITIS|NON-EROSIVE ESOPHAGITIS,All,1 Year to 11 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Research Site, Mobile, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Wilmington, Delaware, United States|Research Site, Orlando, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Park Ridge, Illinois, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Troy, Michigan, United States|Research Site, Jackson, Mississippi, United States|Research Site, St. Louis, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Morristown, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, Buffalo, New York, United States|Research Site, West Islip, New York, United States|Research Site, Columbus, Ohio, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Burlington, Vermont, United States|Research Site, Norfolk, Virginia, United States|Research Site, Brussels (Jette), Belgium|Research Site, Brussels (Laeken), Belgium|Research Site, Brussels (Woluwé-St-Lambert), Belgium|Research Site, Brussels, Belgium|Research Site, Leuven, Belgium|Research Site, Lille, France|Research Site, Paris, France|Research Site, Tours, France|Research Site, Genova, GE, Italy|Research Site, Parma, PR, Italy|Research Site, Roma, RM, Italy|Research Site, Napoli, Italy",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_ESOMEPRAZOLE,,Completed,NCT01397084,GASTROESOPHAGEAL REFLUX DISEASE|GERD|REFLUX ESOPHAGITIS,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_ESOMEPRAZOLE,,Completed,NCT01119768,NON EROSIVE REFLUX DISEASE|CHRONIC GASTRITIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Guangzhou, Guangdong, China|Research Site, Wuhan, Hubei, China|Research Site, Nanjing, Jiangsu, China|Research Site, Jinan, Shandong, China|Research Site, Xian, Shanxi, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Beijin, China|Research Site, Shanghai, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_ESOMEPRAZOLE,,Completed,NCT00464308,GASTRO-OESOPHAGEAL REFLUX,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Belconnen, Australia|Bondi Junction, Australia|Brookvale, Australia|Browns Plains, Australia|Campbelltown, Australia|Campsie, Australia|Caringbah, Australia|Castle Hill, Australia|Charlestown, Australia|Dapto, Australia|Darlinghurst, Australia|Dubbo, Australia|Elizabeth, Australia|Fairfield, Australia|Hoppers Crossing, Australia|Ingleburn, Australia|Leichhardt, Australia|Maroubra, Australia|Melton, Australia|Mount Druitt, Australia|Oaklands Park, Australia|Royal Park, Australia|Sydney, Australia|Wentworthville, Australia|Wyoming, Australia",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC.O,1,,_CISAPRIDE,6224905,Terminated,NCT01281553,GASTROESOPHAGEAL REFLUX,All,1 Month to 18 Months   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,A61K9/2072,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,28.9122979937986,9.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Completed,NCT01825408,SINUSITIS,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Otolaryngology-Head and Neck Surgery clinics at UNC Hospitals, Chapel Hill, North Carolina, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,"Active, not recruiting",NCT04167085,EPISTAXIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","100 UCLA Medical Plaza, Los Angeles, California, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Recruiting,NCT03162497,DRY EYE SYNDROMES|MEIBOMIAN GLAND DYSFUNCTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Gerhard Garhofer, Vienna, Austria",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Completed,NCT00803452,BLEPHARITIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kentucky Lions Eye Center, Louisville, Kentucky, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+],1,,_PREDNISOLONE_SODIUM_PHOSPHATE,4304765,Completed,NCT01730872,CHRONIC ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Andover Eye Associates, Andover, Massachusetts, United States",A61K9/0051,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,13.799051315222002,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+],1,,_PREDNISOLONE_SODIUM_PHOSPHATE,4304765,Completed,NCT01534195,ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Andover Eye Associates, Andover, Massachusetts, United States",A61K9/0051,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,13.799051315222002,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0
CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONATE,,Completed,NCT04441528,SEBORRHEIC BLEPHARITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Istanbul University-Cerrahpasa, Istanbul, Turkey",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONATE,,Enrolling by invitation,NCT03831984,CATARACT,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Maria Camila Aguilar Sierra, Ciudad de Mexico, Mexico",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONATE,,Completed,NCT02117687,DRY EYE SYNDROMES|KERATOCONJUNCTIVITIS SICCA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Paris, France|London, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONATE,,Unknown status,NCT02595606,DRY EYE SYNDROMES|DIABETES MELLITUS,All,"17 Years to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Clinical Research Center, Guangzhou, Guangdong, China",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONATE,,Completed,NCT00938704,DRY EYE,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Ulm, Germany",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,1,0,1,0,0
CC1(O)CCC(C(C)(C)O)CC1,1,,_TERPIN,4738966,Completed,NCT04441528,SEBORRHEIC BLEPHARITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Istanbul University-Cerrahpasa, Istanbul, Turkey",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,20.961416045504,56.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0
Cn1c(=O)c2nc[nH]c2n(C)c1=O,1,,_THEOPHYLLINE,3935196,Completed,NCT00157937,ASTHMA|ALLERGIC RHINITIS,All,18 Years to 60 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,21.191400234091,1897.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)[O-])CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1.[Na+],1,,_MONTELUKAST_SODIUM,6221880,Completed,NCT00157937,ASTHMA|ALLERGIC RHINITIS,All,18 Years to 60 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,18.5958643914659,27.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)[O-])CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1.[Na+],1,,_MONTELUKAST_SODIUM,6221880,Completed,NCT00545844,ASTHMA,All,"15 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,18.5958643914659,27.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)[O-])CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1.[Na+],1,,_MONTELUKAST_SODIUM,6221880,Completed,NCT00380705,ASTHMA|RHINITIS ALLERGIC,All,"6 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,18.5958643914659,27.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)O,1,,_RIP,,Recruiting,NCT03249337,FUCHS' ENDOTHELIAL DYSTROPHY,All,"18 Years to 91 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"NorthShore University HealthSystem, Glenview, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,1,1,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,1,0,0
CNC(C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](C(C)N)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O,1,,_GENTAMICIN,,Unknown status,NCT02582099,RHINOSINUSITIS,All,"7 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Faculty of Medicine Siriraj Hospital, Bangkoknoi, Bangkok, Thailand",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1
CNC(C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](C(C)N)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O,1,,_GENTAMICIN,,Withdrawn,NCT02415257,VESTIBULAR SCHWANNOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Dept. OtoRhinoLaryngology Head and Neck Surgery, Skane University Hospital, Lund, Sweden",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1
CCOP(=O)(OCC)SCC[N+](C)(C)C.[I-],1,,_ECHOTHIOPHATE_IODIDE,3962414,Unknown status,NCT02544529,MYOPIA,All,9 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Danbury Eye Physicians & Surgeons, PC, Danbury, Connecticut, United States",A61F9/0017,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,171.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_OMEPRAZOLE,,Withdrawn,NCT02123498,EUSTACHIAN TUBE DYSFUNCTION|LARYNGOPHARYNGEAL REFLUX,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"11234 Anderson Street, Loma Linda, California, United States|1895 Orange Tree Lane, Suite 102, Redlands, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_OMEPRAZOLE,,Withdrawn,NCT02530879,LARYNGOPHARYNGEAL REFLUX,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Temple Otolaryngology, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_OMEPRAZOLE,,Completed,NCT03086070,LARYNGOPHARYNGEAL REFLUX|CHRONIC RHINOSINUSITIS (DIAGNOSIS),All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_OMEPRAZOLE,,Recruiting,NCT04028466,GERD|GASTRO ESOPHAGEAL REFLUX,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","St. Luke's Medical Center, Quezon City, National Capital Region, Philippines",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_OMEPRAZOLE,,Completed,NCT02685436,GASTROESOPHAGEAL REFLUX,All,6 Months to 2 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,,,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_OMEPRAZOLE,,Completed,NCT02505945,GERD GASTROESOPHAGEAL REFLUX DISEASE,All,"21 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of South Alabama, Mobile, Alabama, United States|Bapist Health, Heber Springs, Arkansas, United States|University of Southern California, Los Angeles, California, United States|UCSD, San Diego, California, United States|SurgOne Foregut Institute, Englewood, Colorado, United States|Albany Surgical PC, Albany, Georgia, United States|Esophageal Institute of Atlanta, PC., Atlanta, Georgia, United States|St. Elizabeth Healthcare, Edgewood, Kentucky, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Cuyuna Regional Medical Center, Crosby, Minnesota, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Adirondack Surgical Group, LLC, Saranac Lake, New York, United States|University Hospitals Cleveland Medical Center - Geauga, Cleveland, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|The Oregon Clinic, Portland, Oregon, United States|Albert Einstein Healthcare Network, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Scott and White Memorial Hospital, Round Rock, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Gundersen Lutheran, La Crosse, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_OMEPRAZOLE,,Unknown status,NCT02140073,GERD,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Gastroenterology and Nutrition Department. Byelorussian Medical Academy Postgraduate Education, Minsk, Belarus|Mother and Child National Reaserch Centre, Minsk, Belarus",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_OMEPRAZOLE,,Terminated,NCT01777854,LARYNGOPHARYNGEAL REFLUX|THROAT PAIN,All,7 Years to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Genesys Regional Medical Center, Grand Blanc, Michigan, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_OMEPRAZOLE,,Completed,NCT00492622,GASTROPARESIS|GASTROESOPHAGEAL REFLUX DISEASE,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Digestive Health Center, University of Louisville Hospital, Louisville, Kentucky, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3[nH]2)c1OC,1,,_PANTOPRAZOLE,,Withdrawn,NCT02123498,EUSTACHIAN TUBE DYSFUNCTION|LARYNGOPHARYNGEAL REFLUX,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"11234 Anderson Street, Loma Linda, California, United States|1895 Orange Tree Lane, Suite 102, Redlands, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0
COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3[nH]2)c1OC,1,,_PANTOPRAZOLE,,Completed,NCT00410592,GASTROESOPHAGEAL REFLUX,All,"18 Years to 69 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Anaheim, California, United States|Research Site, Orange, California, United States|Research Site, San Diego, California, United States|Research Site, Miami, Florida, United States|Research Site, Chicago, Illinois, United States|Research SIte, Chapel Hill, North Carolina, United States|Research Site, Houston, Texas, United States|Research Site, San Juan, Puerto Rico",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0
COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3[nH]2)c1OC,1,,_PANTOPRAZOLE,,Unknown status,NCT02213887,PSYCHOTIC DISORDERS|GASTROESOPHAGEAL REFLUX,All,"19 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"UBC Hospital - Detwiller Pavilion, Vancouver, British Columbia, Canada",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0
COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3[nH]2)c1OC,1,,_PANTOPRAZOLE,,Completed,NCT00307944,ACID REFLUX DISEASE|OBSTRUCTIVE SLEEP APNEA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"University Ear, Nose and Throat Specialists, Cincinnati, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0
COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3[nH]2)c1OC,1,,_PANTOPRAZOLE,,Terminated,NCT00449813,GASTROESOPHAGEAL REFLUX DISEASE|NON-EROSIVE REFLUX DISEASE,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Altana Pharma/Nycomed, BT Oss, Netherlands|Altana Pharma/Nycomed, Den Helder, Netherlands|Altana Pharma/Nycomed, EH Geldrop, Netherlands|Altana Pharma/Nycomed, Basel, Switzerland|Altana Pharma/Nycomed, Basel, Switzerland|Altana Pharma/Nycomed, Biel/Bienne, Switzerland|Altana Pharma/Nycomed, Bülach, Switzerland|Altana Pharma/Nycomed, Locarno, TI., Switzerland|Altana Pharma/Nycomed, Luzern, Switzerland|Altana Pharma/Nycomed, Luzern, Switzerland|Altana Pharma/Nycomed, Reinach BL, Switzerland|Altana Pharma/Nycomed, Sion, Switzerland|Altana Pharma/Nycomed, Thun, Switzerland|Altana Pharma/Nycomed, Winterthur, Switzerland|Altana Pharma/Nycomed, Zürich, Switzerland",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0
COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3[nH]2)c1OC,1,,_PANTOPRAZOLE,,Completed,NCT00261339,GASTROESOPHAGEAL REFLUX|GERD|GORD,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Altana Pharma/Nycomed, Antrim, United Kingdom|Altana Pharma/Nycomed, Ashford, United Kingdom|Altana Pharma/Nycomed, Aston Clinton, Aylesbury, United Kingdom|Altana Pharma/Nycomed, Atherstone, Warwick, United Kingdom|Altana Pharma/Nycomed, Bangor, Northern Ireland, United Kingdom|Altana Pharma/Nycomed, Barry, Vale of Glamorgan, Cardiff, United Kingdom|Altana Pharma/Nycomed, Barry, United Kingdom|Altana Pharma/Nycomed, Bath, United Kingdom|Altana Pharma/Nycomed, Bath, United Kingdom|Altana Pharma/Nycomed, Belfast, United Kingdom|Altana Pharma/Nycomed, Belfast, United Kingdom|Altana Pharma/Nycomed, Bexhill-on-Sea, Easr Sussex, United Kingdom|Altana Pharma/Nycomed, Blackpool, United Kingdom|Altana Pharma/Nycomed, Bradford on Avon, Wiltshire, United Kingdom|Altana Pharma/Nycomed, Cardiff (Wales), United Kingdom|Altana Pharma/Nycomed, Chesterfield, United Kingdom|Altana Pharma/Nycomed, Chesterfield, United Kingdom|Altana Pharma/Nycomed, Chippenham, Wiltshire, United Kingdom|Altana Pharma/Nycomed, Chippenham, United Kingdom|Altana Pharma/Nycomed, Cookstown, United Kingdom|Altana Pharma/Nycomed, Crawley, West Sussex, United Kingdom|Altana Pharma/Nycomed, Crawley, United Kingdom|Altana Pharma/Nycomed, Downpatrick, Northern Ireland, United Kingdom|Altana Pharma/Nycomed, Dronfield, United Kingdom|Altana Pharma/Nycomed, Ely, United Kingdom|Altana Pharma/Nycomed, Glasgow, United Kingdom|Altana Pharma/Nycomed, Hull, United Kingdom|Altana Pharma/Nycomed, Kent, United Kingdom|Altana Pharma/Nycomed, Keresely End, Coventry, United Kingdom|Altana Pharma/Nycomed, Leigh Lancs, United Kingdom|Altana Pharma/Nycomed, Leigh on Sea, Essex, United Kingdom|Altana Pharma/Nycomed, Lisburn, United Kingdom|Altana Pharma/Nycomed, Middlesex, United Kingdom|Altana Pharma/Nycomed, New Street, Ledbury, United Kingdom|Altana Pharma/Nycomed, Sheffield, United Kingdom|Altana Pharma/Nycomed, Sheffield, United Kingdom|Altana Pharma/Nycomed, Slough, Berks, United Kingdom|Altana Pharma/Nycomed, Somerset, United Kingdom|Altana Pharma/Nycomed, Southdown, Bath, United Kingdom|Altana Pharma/Nycomed, St George's Way, Sunderland, United Kingdom|Altana Pharma/Nycomed, Sunbury on Thames, Middlesex, United Kingdom|Altana Pharma/Nycomed, Trowbridge, Wilts, United Kingdom|Altana Pharma/Nycomed, Trowbridge, United Kingdom|Altana Pharma/Nycomed, Warminster Wiltshire, United Kingdom|Altana Pharma/Nycomed, Watford, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0
CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2.O=S(=O)(O)O,1,,_ATROPINE_SULFATE,3965255,Completed,NCT03158142,MYOPIA,All,18 Years to 40 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"State University of New York College of Optometry, New York, New York, United States",A61K9/282,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,25.725374237664,283.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,0,0
CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2.O=S(=O)(O)O,1,,_ATROPINE_SULFATE,3965255,Recruiting,NCT03638726,CATARACT|MYDRIASIS|ADVERSE DRUG EVENT,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,"Dar El Oyoun Hospital, Cairo, Giza, Egypt",A61K9/282,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,25.725374237664,283.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,0,0
Br.COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3.O,1,,_DEXTROMETHORPHAN_HYDROBROMIDE,4316888,Completed,NCT00377403,ACUTE RESPIRATORY INFECTIONS|ACUTE RHINOSINUSITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Washington University in St. Louis, St. Louis, Missouri, United States",8,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,10.0,22.3084662929423,267.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0
COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC.Cl,1,,_PRAZOSIN_HYDROCHLORIDE,4092315,Completed,NCT00487032,ALLERGIC RHINITIS|TACHYPHYLAXIS|RHINITIS MEDICAMENTOSA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Perth Royal Infirmary (Tayside NHS Trust), Perth, Perthshire, United Kingdom|Ninewells Hospital and Medical School (Tayside NHS Trust, University of Dundee), Dundee, Tayside, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,26.9410049487669,287.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1.Cl,1,,_AZELASTINE_HYDROCHLORIDE,5811547,Completed,NCT03004131,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Inflamax Research, Mississauga, Ontario, Canada",A61K9/14,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,39.4587157847183,107.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1.Cl,1,,_AZELASTINE_HYDROCHLORIDE,5811547,Completed,NCT01880840,ALLERGIC RHINITIS,All,6 Months to 5 Years   (Child),Industry|Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinical Research Center of Alabama,LLC, Birmingham, Alabama, United States|Little Rock Allergy and Asthma Clinical research Center, Little Rock, Alaska, United States|West Coast Clinical Trials, Costa Mesa, California, United States|Southern California Research, Mission Viejo, California, United States|Storms Clinical Research Institute, Colorado Springs, Colorado, United States|Sneeze, Wheeze and Itch Associates, Normal, Illinois, United States|Allergy, Asthma & Clinical Research Center, Oklahoma City, Oklahoma, United States|National Allergy, Asthna & Urticaria Centers of Charleston Pa, Charleston, Pennsylvania, United States|Texas Allergy Research Center, Dallas, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States|Paul H Ratner,MD, San Antonio, Texas, United States|Live Oak Allergy and Asthma Clinic, San Antonio, Texas, United States|Allergy and Asthma Center, Waco, Texas, United States|Pediatric Allergy,Asthma and Immunology/Allergy& Asthma care of Waco, Waco, Texas, United States",A61K9/14,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,39.4587157847183,107.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,,_BECLOMETHASONE,4041055,Unknown status,NCT02687100,"ANESTHESIA, ENDOTRACHEAL",All,"18 Months to 90 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,C07J1/0048,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,2076.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,,_BECLOMETHASONE,4041055,Completed,NCT02646904,ALLERGIC RHINITIS,All,6 Years to 16 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council, Palermo, Sicily, Italy|Institute of Biomedicine and Molecular Immunology, IBIM, Palermo, Italy",C07J1/0048,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,2076.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,1,,_ANGIOTENSIN,,Terminated,NCT02358642,PNEUMONIA|NEUROLOGICAL DYSPHAGIA,All,"60 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Prince of Wales Hospital, Hong Kong, Hong Kong",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,1,0,0,1,1,1,1,1,1
Nc1nc(O)c2ncn(COCCO)c2n1,1,,_ACYCLOVIR,,Recruiting,NCT03626376,HERPES SIMPLEX VIRUS KERATITIS,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"New York University School of Medicine, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,Completed,NCT01267136,TONSILLITIS|PAIN,All,4 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States",C07C213/10,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,Completed,NCT02484859,NASAL POLYPS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Recep Tayyip Erdogan University, Rize, Eastern Blacksea, Turkey",C07C213/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S@@+]([O-])c1nc2ccccc2[nH]1,1,,_DEXLANSOPRAZOLE,,Unknown status,NCT02759393,GASTROESOPHAGEAL REFLUX,All,"20 Years to 95 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S@@+]([O-])c1nc2ccccc2[nH]1,1,,_DEXLANSOPRAZOLE,,Unknown status,NCT01328652,LARYNGOPHARYNGEAL REFLUX|HYPERTROPHY OF LINGUAL TONSIL,All,18 Years to 59 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Advanced Center for Specialty Care, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C,1,,_RABEPRAZOLE,,Completed,NCT01008696,REFLUX ESOPHAGITIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0
COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C,1,,_RABEPRAZOLE,,Completed,NCT00464308,GASTRO-OESOPHAGEAL REFLUX,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Belconnen, Australia|Bondi Junction, Australia|Brookvale, Australia|Browns Plains, Australia|Campbelltown, Australia|Campsie, Australia|Caringbah, Australia|Castle Hill, Australia|Charlestown, Australia|Dapto, Australia|Darlinghurst, Australia|Dubbo, Australia|Elizabeth, Australia|Fairfield, Australia|Hoppers Crossing, Australia|Ingleburn, Australia|Leichhardt, Australia|Maroubra, Australia|Melton, Australia|Mount Druitt, Australia|Oaklands Park, Australia|Royal Park, Australia|Sydney, Australia|Wentworthville, Australia|Wyoming, Australia",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0
COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C,1,,_RABEPRAZOLE,,Completed,NCT00287391,INSOMNIA|GERD,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UNC Gastroenterology and UNC Sleep Disorders Center, Chapel Hill, North Carolina, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0
COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C,1,,_RABEPRAZOLE,,Completed,NCT00354757,GERD,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"National Taiwan Univeristy Hospital, Taipei, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0
COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C,1,,_RABEPRAZOLE,,Completed,NCT00304421,GASTROESOPHAGEAL REFLUX,All,"18 Years to 65 Years   (Adult, Older Adult)",U.S. Fed|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"VA Greater Los Angeles Healthcare System, Los Angeles, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0
COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C,1,,_RABEPRAZOLE,,Unknown status,NCT02986685,REFRACTORY REFLUX ESOPHAGITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Xijing Hosipital of Digestive Disease, Xi'an, Shaanxi, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0
COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C,1,,_RABEPRAZOLE,,Completed,NCT00216489,GASTROESOPHAGEAL REFLUX|HEARTBURN,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12.Cl,1,,_MOXIFLOXACIN_HYDROCHLORIDE,6548079,Completed,NCT00758199,CATARACT,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Altos Eye Physicians, Los Altos, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,14.2590196923961,67.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12.Cl,1,,_MOXIFLOXACIN_HYDROCHLORIDE,6548079,Completed,NCT03634852,ENDOPHTHALMITIS POSTOPERATIVE,All,"38 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,14.2590196923961,67.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,,_KETOROLAC_TROMETHAMINE,5091182,Unknown status,NCT00865540,CATARACT,All,"50 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Clínica Oftalmológica Zona Sul, Recife, Pernambuco, Brazil",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,19.1215425368077,386.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0
NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,,_KETOROLAC_TROMETHAMINE,5091182,Completed,NCT01542190,"CYSTOID MACULAR EDEMA FOLLOWING CATARACT SURGERY, BILATERAL",All,"50 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Unicamp, Campinas, Sao Paulo, Brazil|Unicamp, Campinas, Sao Paulo, Brazil",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,19.1215425368077,386.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0
NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,,_KETOROLAC_TROMETHAMINE,5091182,Completed,NCT02646072,"CYSTOID MACULAR EDEMA, POSTOPERATIVE|DIABETES MELLITUS",All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","University of Malaya, Kuala Lumpur, Wilayah Persekutuan, Malaysia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,19.1215425368077,386.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21.Cl,1,,_OLOPATADINE_HYDROCHLORIDE,WO-2001054687-A1,Completed,NCT01282138,ALLERGIC CONJUNCTIVITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","Contact Alcon Call Center for Trial Locations, Fort Worth, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,32.7488,57.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21.Cl,1,,_OLOPATADINE_HYDROCHLORIDE,WO-2001054687-A1,Completed,NCT00789555,PERENNIAL ALLERGIC RHINITIS,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Contact Alcon Call Center For Trial Locations, Fort Worth, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,32.7488,57.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21.Cl,1,,_OLOPATADINE_HYDROCHLORIDE,WO-2001054687-A1,Recruiting,NCT03186755,"CONJUNCTIVITIS, ALLERGIC|CONJUNCTIVITIS, VERNAL",All,"6 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","CHU Sainte-Justine Hospital, Montréal, Quebec, Canada",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,32.7488,57.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1.O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,,_CHLORHEXIDINE_GLUCONATE,4199567,Completed,NCT03574246,"SORE THROAT|NAUSEA AND VOMITING, POSTOPERATIVE",All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","Ankara University Faculty of Dentistry, Ankara, Yenimahalle, Turkey",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,15.6389248239183,476.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0
CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl,1,,_BENZYDAMINE_HYDROCHLORIDE,4749794,Completed,NCT03574246,"SORE THROAT|NAUSEA AND VOMITING, POSTOPERATIVE",All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","Ankara University Faculty of Dentistry, Ankara, Yenimahalle, Turkey",C07D231/56,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,22.3084662929423,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0
CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl,1,,_BENZYDAMINE_HYDROCHLORIDE,4749794,Completed,NCT03074968,INTUBATION COMPLICATION,All,"6 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","SNUH, Seoul, Jongro Gu, Korea, Republic of",C07D231/56,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,22.3084662929423,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Completed,NCT03634852,ENDOPHTHALMITIS POSTOPERATIVE,All,"38 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,A61L2/0023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Completed,NCT01154153,"RHINITIS, ALLERGIC, SEASONAL",All,2 Years to 12 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Investigational Site Number 840003, Cypress, California, United States|Investigational Site Number 840006, Stockbridge, Georgia, United States|Investigational Site Number 840007, North Dartmouth, Massachusetts, United States|Investigational Site Number 840010, Plymouth, Minnesota, United States|Investigational Site Number 840001, Omaha, Nebraska, United States|Investigational Site Number 840008, Raleigh, North Carolina, United States|Investigational Site Number 840002, Spartanburg, South Carolina, United States|Investigational Site Number 840005, San Antonio, Texas, United States",A61L2/0023,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Unknown status,NCT02379000,EXUDATIVE RETINAL DETACHMENT|UVEAL MELANOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Charité Universitätsmedizin Berlin, Berlin, Germany",A61L2/0023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Completed,NCT02877485,NASAL OBSTRUCTION,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Stanford Hospital and Clinics, Stanford, California, United States",A61L2/0023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Unknown status,NCT02917564,GLAUCOMA|CHOROIDAL EFFUSIONS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",A61L2/0023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Not yet recruiting,NCT04075136,EXUDATIVE AGE RELATED MACULAR DEGENERATION,All,"50 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,A61L2/0023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,"Active, not recruiting",NCT02806752,WET MACULAR DEGENERATION,All,"50 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Beijing Aier Intech Eye Hospital, Beijing, Beijing, China|Guangzhou Aier Eye Hospital, Guanzhou, Guangdong, China|Shenzhen Aier Eye Hospital, Shenzhen, Guangdong, China|Shenzhen Eye Hospital, Shenzhen, Guangdong, China|Harbin Aier Eye Hospital, Harbin, Heilongjiang, China|Wuhan General Hospital of PLA, Wuhan, Hubei, China|The Eye Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China",A61L2/0023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Withdrawn,NCT02598869,UVEITIS|CYSTOID MACULAR EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,A61L2/0023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])O.[Na+],1,,_DEXAMETHASONE_SODIUM_PHOSPHATE,,Withdrawn,NCT01326585,RETINAL DETACHMENT,All,"18 Years to 79 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","St. Michael's Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C(/C=C\c3scnc3C)CS[C@H]12)c1csc(N)n1,1,,_CEFDITOREN_PIVOXIL,5994340,Unknown status,NCT01553006,RHINOSINUSITIS,All,1 Year to 15 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Thammasat University, Prathumthani, Thailand",C07D409/12,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,27.0395696010185,136.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,1,0,1,0,1,1,0,1,1,0,1,1,0,1,0,1,1,0,0,1,1,0,0,0,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,0,1
CN(C)CCOC(c1ccccc1)c1ccccc1.Cn1c(=O)c2[nH]c(Cl)nc2n(C)c1=O,1,,_DIMENHYDRINATE,4007273,Completed,NCT01890538,PERIPHERAL VERTIGO,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Kocaeli University, Kocaeli, Turkey",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,14.0618903878929,603.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0
CN(C)CCOC(c1ccccc1)c1ccccc1.Cn1c(=O)c2[nH]c(Cl)nc2n(C)c1=O,1,,_DIMENHYDRINATE,4007273,Completed,NCT02253524,NAUSEA|VOMITING|VERTIGO,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,14.0618903878929,603.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0
O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+],1,,_DICLOFENAC_SODIUM,4234601,Unknown status,NCT03458923,DIABETIC MACULAR EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cairo University, Cairo, Egypt",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,23.0312737427873,504.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
Cl.Cl.O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,,_CETIRIZINE_HYDROCHLORIDE,5993833,Recruiting,NCT03340740,ALLERGIC RHINITIS|ASTHMA,All,"6 Years to 20 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Jacobi Medical Center, Bronx, New York, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,29.3394114868888,77.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCCOc1ccc(C(=O)OCCN(CC)CC)cc1N.Cl,1,,_PROPARACAINE_HYDROCHLORIDE,4474751,Recruiting,NCT04229771,EPIPHORA|DACRYOSTENOSIS|DACRYOCYSTITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","William Beaumont Hospitals, Royal Oak, Michigan, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,54.0,16.591716462350302,63.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0
CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,1,,_IVERMECTIN,4389397,Not yet recruiting,NCT03570814,TRACHOMA|LYMPHATIC FILARIASES,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,3,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.961416045504,1324.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,1,0,1
CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,1,,_IVERMECTIN,4389397,Withdrawn,NCT01903057,TRACHOMA|LYMPHATIC FILARIASIS,All,"5 Years to 65 Years   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","National Institute of Health, Ministry of Health, Maputo, Mozambique",3,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.961416045504,1324.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,1,0,1
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,1,,_ACARBOSE,,Unknown status,NCT01175486,DIABETES,All,"30 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Taipei Veterans General Hospital, Taiwan, Taipei, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1.Cl,1,,_BUPROPION_HYDROCHLORIDE,RE33994,Completed,NCT00666978,BLADDER CANCER|CERVICAL CANCER|ESOPHAGEAL CANCER|GASTRIC CANCER|HEAD AND NECK CANCER|KIDNEY CANCER|LEUKEMIA|LIVER CANCER|LUNG CANCER|PANCREATIC CANCER|TOBACCO USE DISORDER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, United States|Swope Health Central, Kansas City, Missouri, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,35.3190003901517,98.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC.Cl,1,,_ALFUZOSIN_HYDROCHLORIDE,5545738,Completed,NCT03144596,BENIGN PROSTATIC HYPERPLASIA|PUPIL ANOMALY|CHOROID DISEASE,Male,"45 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D405/12,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.5486560298979,153.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1.Cl,1,,_TAMSULOSIN_HYDROCHLORIDE,6294711,Completed,NCT03144596,BENIGN PROSTATIC HYPERPLASIA|PUPIL ANOMALY|CHOROID DISEASE,Male,"45 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C12N15/8286,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,25.9225035421671,332.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0
COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O,1,,_IDEBENONE,4271083,"Active, not recruiting",NCT02774005,LEBER'S HEREDITARY OPTIC NEUROPATHY (LHON),All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Retinal Consultants of Arizona, Phoenix, Arizona, United States|Palo Alto Medical Foundation, Palo Alto, California, United States|Stanford Byers Eye Institute, Stanford, California, United States|University of Colorado Health Eye Center, Aurora, Colorado, United States|Emory University Hospital, Atlanta, Georgia, United States|Bethesda Neurology, LLC, Bethesda, Maryland, United States|Washington University, Saint Louis, Missouri, United States|New York Eye and Ear Infirmary, New York, New York, United States|University of Virginia, Charlottesville, Virginia, United States|AKH - Medizinische Universitaet Wien, Wien, Austria|CHU Saint-Pierre, Brussels, Belgium|Cliniques Universitaire Saint-Luc, Brussels, Belgium|UZ Leuven - Campus Sint-Rafaël, Leuven, Belgium|C. H. U. Sart Tilman, Liège, Belgium|UMHAT ""Alexandrovska"" EAD, Sofia, Bulgaria|Friedrich-Baur-Institut, Muenchen, Germany|Università di Bologna-Clinica Neurologica-Dipartimento di Scienze Neurologiche, Bologna, Italy|SPZOZ Spital Uniwersytecki w Krakowie, Oddzial Kliniczny Okulistyki i Onkologii Okulistycznej, Krakow, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego, Poznań, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 2 PUM w Szczecinie, Szczecin, Poland|Samodzielny Publiczny Kliniczny Szpital Okulistyczny, Warszawa, Poland|Uniwersytecki Szpital Kliniczny, Wrocław, Poland|Centro Hospitalar de São João, EPE, Porto, Portugal|Institut Catala de Retina, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|University Hospital of Wales, Cardiff, United Kingdom|Moorfields Eye Hospital, London, United Kingdom|Manchester Royal Eye Hospital, Manchester, United Kingdom|Queen's Hospital, Romford, United Kingdom",C07C39/11,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,30.5550421979917,352.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCNC(=O)c1cccnc1)C(=O)N[C@H](CCCCNC(=O)c1cccnc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](C)C(N)=O,1,,_ANTIDE,,Completed,NCT00251732,GASTROESOPHAGEAL REFLUX,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|U.S. Fed|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Southern Arizona VA Health Care System, Tucson, Arizona, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,0,0,1,1,1,1,1,1,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1
COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[n-]2)c1C.[Na+],1,,_RABEPRAZOLE_SODIUM,WO-2001097753-A2,Completed,NCT00216489,GASTROESOPHAGEAL REFLUX|HEARTBURN,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,32.7488,35.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0
CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1,1,,_CLINDAMYCIN,3957983,Completed,NCT00398658,ENDOPHTHALMITIS|PROPHYLAXY OF POST TRAUMATIC ENDOPHTHALMITIS|BACTERIAL ENDOPHTHALMITIS,All,"3 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,"Ophthalmic Research Center, Tehran, Iran, Islamic Republic of",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.226164808312195,1162.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,1,1,1,0,1
CN(C)CCC(c1ccccc1)c1ccccn1.O=C(O)/C=C\C(=O)O,1,,_PHENIRAMINE_MALEATE,4631284,Unknown status,NCT01390961,ALLERGIC CONJUNCTIVITIS,All,"18 Months and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Milton M. Hom, OD, FAAO., Azusa, California, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,17.2488141440275,86.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0
Nc1nc(O)c2ncn(COC(CO)CO)c2n1,1,,_GANCICLOVIR,,Recruiting,NCT02943057,CYTOMEGALOVIRUS INFECTION,All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Singapore National Eye Centre, Singapore, Singapore",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
Nc1nc(O)c2ncn(COC(CO)CO)c2n1,1,,_GANCICLOVIR,,Completed,NCT00000894,CYTOMEGALOVIRUS RETINITIS|HIV INFECTIONS,All,"13 Years and older   (Child, Adult, Older Adult)",NIH,Intervention Model: Parallel Assignment|Primary Purpose: Treatment,"Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States|UCLA CARE Ctr, Los Angeles, California, United States|Univ of Miami / Bascom Palmer Eye Institute, Miami, Florida, United States|Emory Eye Clinic, Atlanta, Georgia, United States|Northwestern Univ / SOCA, Chicago, Illinois, United States|Charity Hosp / Tulane Univ Med School, New Orleans, Louisiana, United States|Johns Hopkins Hosp, Baltimore, Maryland, United States|Cornell Univ Med Ctr, New York, New York, United States|New York Hosp / Cornell Med Ctr, New York, New York, United States|Univ of North Carolina, Chapel Hill, North Carolina, United States|Julio Arroyo, West Columbia, South Carolina, United States|Univ of Texas Galveston, Galveston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
COCCCOc1ccnc(C[S@@+]([O-])c2nc3ccccc3[nH]2)c1C,1,,_DEXRABEPRAZOLE,WO-2004052882-A1,Completed,NCT02689999,GASTROESOPHAGEAL REFLUX DISEASE,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ege University Gastroenterology Department, Izmir, Bornova, Turkey|Ankara University Gastroenterology Department, Ankara, Turkey|On Dokuz Mayıs University Gastroenterology Department, Samsun, Turkey",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,32.7488,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0
C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)O)c(CCC(=O)OC)c4C)C1(C)C3=CC=C(C(=O)OC)C1C(=O)OC.C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)OC)c(CCC(=O)O)c4C)C1(C)C3=CC=C(C(=O)OC)C1C(=O)OC,1,,_VERTEPORFIN,,Not yet recruiting,NCT04075136,EXUDATIVE AGE RELATED MACULAR DEGENERATION,All,"50 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0
C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)O)c(CCC(=O)OC)c4C)C1(C)C3=CC=C(C(=O)OC)C1C(=O)OC.C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)OC)c(CCC(=O)O)c4C)C1(C)C3=CC=C(C(=O)OC)C1C(=O)OC,1,,_VERTEPORFIN,,Completed,NCT00135837,AGE-RELATED MACULAR DEGENERATION,All,"50 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis, Basel, Switzerland",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0
C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)O)c(CCC(=O)OC)c4C)C1(C)C3=CC=C(C(=O)OC)C1C(=O)OC.C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)OC)c(CCC(=O)O)c4C)C1(C)C3=CC=C(C(=O)OC)C1C(=O)OC,1,,_VERTEPORFIN,,Completed,NCT00331435,AGE RELATED MACULAR DEGENERATION,All,"50 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Nagoya City University Hospital, Aichi, Japan|Nagoya University, Aichi, Japan|Kyushu University, Fukuoka, Japan|Fukushima Medical University School of Medicine, Fukushima, Japan|Gunma University, Gunma, Japan|Kagawa University, Kagawa, Japan|Kyoto University, Kyoto, Japan|Osaka University, Osaka, Japan|Kansai Medical University Takii Hospital, Osaka, Japan|Kansai Medical University Hirakata Hospital, Osaka, Japan|Sapporo City general hospital, Sapporo, Japan|Shiga University of Medical Science, Shiga, Japan|Surugadai Nihon University Hospital, Tokyo, Japan|Kyorin University, Tokyo, Japan|Toho University, Tokyo, Japan|Tokyo University Ohashi Medical Center, Tokyo, Japan|Yamanashi University, Yamanashi, Japan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0
C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)O)c(CCC(=O)OC)c4C)C1(C)C3=CC=C(C(=O)OC)C1C(=O)OC.C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)OC)c(CCC(=O)O)c4C)C1(C)C3=CC=C(C(=O)OC)C1C(=O)OC,1,,_VERTEPORFIN,,Completed,NCT01846273,AGE-RELATED MACULAR DEGENERATION|POLYPOIDAL CHOROIDAL VASCULOPATHY,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Hongkong, Hong Kong|Novartis Investigative Site, Nagoya-city, Aichi, Japan|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Fukuoka city, Fukuoka, Japan|Novartis Investigative Site, Fukushima-city, Fukushima, Japan|Novartis Investigative Site, Maebashi city, Gunma, Japan|Novartis Investigative Site, Amagasaki city, Hyogo, Japan|Novartis Investigative Site, Kobe-city, Hyogo, Japan|Novartis Investigative Site, Kobe-shi, Hyogo, Japan|Novartis Investigative Site, Inashiki-gun, Ibaraki, Japan|Novartis Investigative Site, Kita-gun, Kagawa, Japan|Novartis Investigative Site, Sakyo-ku, Kyoto, Japan|Novartis Investigative Site, Tsu-city, Mie, Japan|Novartis Investigative Site, Okayama-city, Okayama, Japan|Novartis Investigative Site, Hirakata-city, Osaka, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Ohtsu-city, Shiga, Japan|Novartis Investigative Site, Bunkyo ku, Tokyo, Japan|Novartis Investigative Site, Chiyoda-ku, Tokyo, Japan|Novartis Investigative Site, Mitaka-city, Tokyo, Japan|Novartis Investigative Site, Shinjuku ku, Tokyo, Japan|Novartis Investigative Site, Chiba, Japan|Novartis Investigative Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Seocho-gu, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Petaling Jaya, Selangor Darul Ehsan, Malaysia|Novartis Investigative Site, Batu Caves, Selangor, Malaysia|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Taipei, Taiwan, ROC, Taiwan|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Kaohsiung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan|Novartis Investigative Site, Songkla, Hat Yai, Thailand|Novartis Investigative Site, Bangkok, Thailand",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0
C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)O)c(CCC(=O)OC)c4C)C1(C)C3=CC=C(C(=O)OC)C1C(=O)OC.C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)OC)c(CCC(=O)O)c4C)C1(C)C3=CC=C(C(=O)OC)C1C(=O)OC,1,,_VERTEPORFIN,,Completed,NCT00473642,AGE-RELATED MACULOPATHY|CHOROIDAL NEOVASCULARIZATION,All,"50 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Eagle Mountain Vision, Tulsa, Oklahoma, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0
N#[N+][O-],1,,_NITROUS_OXIDE,,Completed,NCT03365011,TINNITUS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Washington University School of Medicine, Saint Louis, Missouri, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
N#[N+][O-],1,,_NITROUS_OXIDE,,Completed,NCT00967694,GLAUCOMA|SEDATION,All,18 Years to 40 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic,"OHSU, Portland, Oregon, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Cl.Cl.O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,,_LEVOCETIRIZINE_DIHYDROCHLORIDE,WO-2003059328-A1,Completed,NCT00653224,SEASONAL ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Tucson, Arizona, United States|Los Angeles, California, United States|Sacramento, California, United States|San Francisco, California, United States|San Jose, California, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Gainesville, Georgia, United States|Lawrenceville, Georgia, United States|Stockbridge, Georgia, United States|Normal, Illinois, United States|Louisville, Kentucky, United States|Harvard, Massachusetts, United States|North Dartmouth, Massachusetts, United States|Novi, Michigan, United States|Minneapolis, Minnesota, United States|Berlin, New Jersey, United States|Skillman, New Jersey, United States|Verona, New Jersey, United States|Rochester, New York, United States|Asheville, North Carolina, United States|Charlotte, North Carolina, United States|Wilmington, North Carolina, United States|Cincinnati, Ohio, United States|Edmond, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|Upland, Pennsylvania, United States|Lincoln, Rhode Island, United States|Germantown, Tennessee, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|South Burlington, Vermont, United States|Arlington, Virginia, United States|Milwaukee, Wisconsin, United States",A61K9/0095,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
Cl.Cl.O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,,_LEVOCETIRIZINE_DIHYDROCHLORIDE,WO-2003059328-A1,Completed,NCT00542607,"RHINITIS, ALLERGIC, SEASONAL",All,18 Years to 55 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,,A61K9/0095,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
Cl.Cl.O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,,_LEVOCETIRIZINE_DIHYDROCHLORIDE,WO-2003059328-A1,Completed,NCT00521131,RHINITIS|ALLERGIC|PERENNIAL,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,A61K9/0095,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
C[N+](C)(C)CCOP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O,1,,_CITICOLINE,,Completed,NCT03046693,NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY,All,"20 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Departemen Mata Fakultas Kedokteran Universitas Indonesia- RSCM Kirana, Jakarta, DKI Jakarta, Indonesia",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0
NC(CS)C(=O)O,1,,_CYSTEINE,,Not yet recruiting,NCT04226456,"OTOTOXIC HEARING LOSS|OTOTOXIC HEARING LOSS, BILATERAL|OTOTOXICITY|TINNITUS",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(=O)N[C@H]1[C@H](O[C@@H]2[C@@H](C(=O)O)O[C@@H](O[C@H]3[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]3NC(C)=O)[C@H](O)[C@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONIC_ACID,,Recruiting,NCT03186755,"CONJUNCTIVITIS, ALLERGIC|CONJUNCTIVITIS, VERNAL",All,"6 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","CHU Sainte-Justine Hospital, Montréal, Quebec, Canada",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@H]1[C@H](O[C@@H]2[C@@H](C(=O)O)O[C@@H](O[C@H]3[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]3NC(C)=O)[C@H](O)[C@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONIC_ACID,,Recruiting,NCT01738243,THYROID EYE DISEASE,All,"21 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Jules Stein Eye Institute, Los Angeles, California, United States|The Jules Stein Eye Institute at UCLA, Los Angeles, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@H]1[C@H](O[C@@H]2[C@@H](C(=O)O)O[C@@H](O[C@H]3[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]3NC(C)=O)[C@H](O)[C@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONIC_ACID,,Withdrawn,NCT01838252,ECTROPION,All,"21 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Jules Stein Eye Institute, Los Angeles, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@H]1[C@H](O[C@@H]2[C@@H](C(=O)O)O[C@@H](O[C@H]3[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]3NC(C)=O)[C@H](O)[C@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONIC_ACID,,Completed,NCT01387620,CORNEAL EDEMA|INTRAOCULAR PRESSURE,All,"50 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of São Paulo, São Paulo, Brazil",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1,1,,_BACITRACIN,,Withdrawn,NCT00671541,CHRONIC SINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Lahey Clinic, Inc, Burlington, Massachusetts, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,0,1,1,1,1,0,0,1,1,0,1,1,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1
O=C([O-])P(=O)([O-])[O-].[Na+].[Na+].[Na+],1,,_FOSCARNET_SODIUM,,Completed,NCT00002125,CYTOMEGALOVIRUS RETINITIS|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Industry,Primary Purpose: Treatment,"Dr Ralph Hansen, Beverly Hills, California, United States|Dr Milan Fiala, Los Angeles, California, United States|Dr G Michael Wool, Los Angeles, California, United States|AIDS Community Research Consortium, Redwood City, California, United States|Ingenix Kern McNeill Decatur, Atlanta, Georgia, United States|Dr John Karedes, Indianapolis, Indiana, United States|Dr Paul Benson, Berkley, Michigan, United States|Dr Ronald Nahass, Somerville, New Jersey, United States|Dr Ronald J Grossman, New York, New York, United States|Community Health Network, Rochester, New York, United States|Austin Infectious Disease Consultants, Austin, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1,1,,_RETINAL,3953524,Unknown status,NCT02149615,OPTIC DISC SWELLING,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital Zurich, Zurich, ZH, Switzerland",C07C33/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,25.561099817244703,248.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1,1,,_RETINAL,3953524,Completed,NCT00802269,PROLIFERATIVE DIABETIC RETINOPATHY,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Asociacion para Evitar la Ceguera en Mexico, Mexico City, DF, Mexico",C07C33/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,25.561099817244703,248.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1,1,,_RETINAL,3953524,Completed,NCT01710839,"CENTRAL RETINAL, HEMI RETINAL & BRACH RETINAL VEIN OCCLUSIONS",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Retina Consultants of Houston/The Medical Center, Houston, Texas, United States|Retina Consultants of Houston, Katy, Texas, United States|Retina Consultants of Houston, The Woodlands, Texas, United States",C07C33/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,25.561099817244703,248.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,1,,_DOCETAXEL,,Completed,NCT00772681,HEAD AND NECK NEOPLASMS,All,"19 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sanofi-Aventis Administrative Office, Istanbul, Turkey",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,1,,_DOCETAXEL,,Unknown status,NCT03069820,"LIVER INJURY, DRUG-INDUCED",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,"The Second Afiliated Hospital of Nanchang University, Nanchang, Jiangxi, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,0,DB00104,__OCTREOTIDE,5538739,Terminated,NCT00248157,DIABETIC RETINOPATHY,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K38/31,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,66.1368816608144,16.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.42,1019.25,332.22,12.0,13.0,5.0,107.65,269.77,17.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,0,DB00104,__OCTREOTIDE,5538739,Terminated,NCT00170742,PROLIFERATIVE DIABETIC RETINOPATHY,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis, Basel, Switzerland",A61K38/31,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,66.1368816608144,16.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.42,1019.25,332.22,12.0,13.0,5.0,107.65,269.77,17.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0
Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,0,DB00163,__VITAMIN_E,3932634,Terminated,NCT02758990,"OBESITY|RHINITIS|RHINITIS, ALLERGIC|RESPIRATORY SOUNDS|DYSPNEA|HEADACHE|MIGRAINE DISORDERS|ARTHRITIS|ARTHRALGIA|ANXIETY|SLEEP INITIATION AND MAINTENANCE DISORDERS|SLEEP DEPRIVATION",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Verifomics, LLC, Dallas, Texas, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,13.1090987494609,9855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.84,430.7061,29.46,2.0,1.0,2.0,55.29,135.37,12.0,1.0,0.0,0.0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0
O=C(O)CCCC[C@@H]1CCSS1,0,DB00166,__LIPOIC_ACID,4100150,Terminated,NCT01880372,MODERATE NON-PROLIFERATIVE DIABETIC RETINOPATHY,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ferris State University, Big Rapids, Michigan, United States|Retina Specialists of Michigan, Grand Rapids, Michigan, United States",C07K14/565,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,19.022977884556106,2457.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.75,206.326,37.3,2.0,1.0,1.0,21.74,54.37,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,0,DB00175,__PRAVASTATIN,5622985,Terminated,NCT00467831,HERMANSKY-PUDLAK SYNDROME (HPS)|PULMONARY FIBROSIS|OCULOCUTANEOUS ALBINISM|PLATELET STORAGE POOL DEFICIENCY|METABOLIC DISEASE,All,"18 Years to 70 Years   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,24.1154849175547,325.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.23,424.5277,124.29,6.0,4.0,2.0,46.56,113.6,11.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0
Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,0,DB00220,__NELFINAVIR,5484926,Terminated,NCT02080416,NON-HODGKIN LYMPHOMA|HODGKIN LYMPHOMA|KAPOSI SARCOMA|GASTRIC CANCER|NASOPHARYNGEAL CANCER|EBV|CASTLEMAN DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",C07C323/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,23.425532351793603,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.61,567.7819999999998,101.9,5.0,4.0,4.0,63.8,162.67,10.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,1,1,0,0
CC(C)C[C@H](CN)CC(=O)O,0,DB00230,__PREGABALIN,6197819,Terminated,NCT02924675,EARACHE,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CHRU, Hôpital Claude Huriez, Lille, France",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,0,DB00230,__PREGABALIN,6197819,Withdrawn,NCT03603626,POST-OPERATIVE ANALGESIA|CSOM - CHRONIC SUPPURATIVE OTITIS MEDIA,All,18 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Dhulikhel Hospital, Dhulikhel, Kavre, Nepal",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
Nc1ccc(O)c(C(=O)O)c1,0,DB00244,__MESALAZINE,5541170,Withdrawn,NCT00514982,HERMANSKI-PUDLAK SYNDROME|COLITIS|CYTOKINES|LYMPHOCYTES|DRUG EVALUATION,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",A61K9/2846,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,16.690281114601902,1899.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.75,153.1354,83.55,4.0,3.0,1.0,14.26,40.0,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1c[nH]cn1,0,DB00290,__BLEOMYCIN,,Withdrawn,NCT00198328,HEAD NECK CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Inovio Biomedical Corporation, San Diego, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.41,1415.5520000000001,627.07,28.0,20.0,6.0,139.19,343.83,36.0,1.0,0.0,0.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
CCCC(CCC)C(=O)O,0,DB00313,__VALPROIC_ACID,6419953,Withdrawn,NCT00181220,NASOPHARYNGEAL CARCINOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkin Singapore International Medical Center, Singapore, Singapore",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,42.9084786135238,1051.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.54,144.2114,37.3,2.0,1.0,0.0,17.0,40.25,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,0,DB00317,__GEFITINIB,5457105,Terminated,NCT00033449,STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado, Denver, Colorado, United States",C07D239/94,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,29.0,14.2590196923961,1102.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.02,446.902,68.74,7.0,1.0,4.0,46.11,117.51,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1
CN(C)CCC=C1c2ccccc2CCc2ccccc21,0,DB00321,__AMITRIPTYLINE,3965255,Terminated,NCT02434523,LARYNGEAL DISEASES|CHRONIC LARYNGEAL NEUROPATHY,All,18 Years to 64 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Boston Medical Center, Boston, Massachusetts, United States",A61K9/282,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,25.725374237664,663.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.1,277.4033,3.24,1.0,0.0,3.0,33.74,101.51,3.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,0,DB00335,__ATENOLOL,4256108,Withdrawn,NCT03578354,VESTIBULAR MIGRAINE|MIGRAINE DISORDERS|VESTIBULAR DISEASES,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,66.0,21.8813527998521,533.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.57,266.3361,84.58,4.0,3.0,1.0,29.98,73.51,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
O.O=S(=O)(OC[C@H]1O[C@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O)O[Al](O)O.O[Al](O)O,0,DB00364,__SUCRALFATE,,Withdrawn,NCT02039869,GASTROESOPHAGEAL REFLUX DISEASE|NON EROSIVE REFLUX DISEASE|DYSPEPSIA,All,"18 Years to 79 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,"Ochsner Medical Center, Kenner, Louisiana, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Virginia Commonwealth University, Richmond, Virginia, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.74,1558.67,772.17,35.0,16.0,2.0,107.19,180.03,37.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2,0,DB00377,__PALONOSETRON,5202333,Terminated,NCT00895245,NAUSEA AND VOMITING|STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",C07D471/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,50.0,22.7355797860325,147.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.72,296.414,23.55,2.0,0.0,5.0,33.9,88.52,1.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,DB00441,__GEMCITABINE,4808614,Terminated,NCT02789189,RECURRENT AND METASTATIC NASOPHARYNGEAL CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D317/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12,0,DB00468,__QUININE,3960559,Terminated,NCT02630472,RHINITIS|SINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Pennsylvania, Philadelphia, Pennsylvania, United States",H01L23/291,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,31.507833836423696,2213.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.82,324.4168,45.59,4.0,1.0,4.0,35.96,94.69,4.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,0,DB00480,__LENALIDOMIDE,5635517,Terminated,NCT00482911,INTRAOCULAR MELANOMA|MALIGNANT CONJUNCTIVAL NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,0,DB00530,__ERLOTINIB,5747498,Terminated,NCT00573989,HEAD AND NECK CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UNC Linberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States",C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,32.0,23.228403047290502,847.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.13,393.4357,74.73,7.0,1.0,3.0,43.48,107.79,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,0,DB00530,__ERLOTINIB,5747498,Terminated,NCT01192815,STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE III VERRUCOUS CARCINOMA OF THE LARYNX|STAGE III VERRUCOUS CARCINOMA OF THE ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV VERRUCOUS CARCINOMA OF THE LARYNX|STAGE IV VERRUCOUS CARCINOMA OF THE ORAL CAVITY,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,32.0,23.228403047290502,847.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.13,393.4357,74.73,7.0,1.0,3.0,43.48,107.79,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,0,DB00530,__ERLOTINIB,5747498,Withdrawn,NCT01332279,RECURRENT METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY|RECURRENT SALIVARY GLAND CANCER|RECURRENT SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|RECURRENT SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|RECURRENT VERRUCOUS CARCINOMA OF THE LARYNX|RECURRENT VERRUCOUS CARCINOMA OF THE ORAL CAVITY|SALIVARY GLAND SQUAMOUS CELL CARCINOMA|TONGUE CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,23.228403047290502,847.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.13,393.4357,74.73,7.0,1.0,3.0,43.48,107.79,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Terminated,NCT00482911,INTRAOCULAR MELANOMA|MALIGNANT CONJUNCTIVAL NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Terminated,NCT00006054,IMMUNOLOGIC DEFICIENCY SYNDROMES|CHEDIAK-HIGASHI SYNDROME|COMMON VARIABLE IMMUNODEFICIENCY|GRAFT VERSUS HOST DISEASE|X-LINKED LYMPHOPROLIFERATIVE SYNDROME|FAMILIAL ERYTHROPHAGOCYTIC LYMPHOHISTIOCYTOSIS|HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS|X-LINKED AGAMMAGLOBULINEMIA|WISKOTT-ALDRICH SYNDROME|CHRONIC GRANULOMATOUS DISEASE|X-LINKED HYPER IGM SYNDROME|SEVERE COMBINED IMMUNODEFICIENCY|LEUKOCYTE ADHESION DEFICIENCY SYNDROME|VIRUS-ASSOCIATED HEMOPHAGOCYTIC SYNDROME,All,"up to 35 Years   (Child, Adult)",Other,Primary Purpose: Treatment,"Fairview University Medical Center, Minneapolis, Minnesota, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Terminated,NCT00499733,CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Brady Urological Institute at Johns Hopkins Hospital, Baltimore, Maryland, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Withdrawn,NCT03829566,NEUROMYELITIS OPTICA|DEVIC'S DISEASE|NMO SPECTRUM DISORDER,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Withdrawn,NCT00003273,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|NEUROBLASTOMA|RETINOBLASTOMA|SARCOMA,All,up to 10 Years   (Child),Other,Primary Purpose: Treatment,"Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Maine Children's Cancer Program, Scarborough, Maine, United States|Spectrum Health and DeVos Children's Hospital, Grand Rapids, Michigan, United States|Children's Hospital of Omaha, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Albert Einstein Clinical Cancer Center, Bronx, New York, United States|Winthrop University Hospital, Mineola, New York, United States|NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Beth Israel Hospital North, New York, New York, United States|State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States|State University of New York - Upstate Medical University, Syracuse, New York, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States|Children's Hospital, Buenos Aires, Argentina|British Columbia Children's Hospital, Vancouver, British Columbia, Canada",7,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,0,DB00549,__ZAFIRLUKAST,4859692,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D249/18,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,40.214378118647204,840.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.84,575.675,115.73,6.0,2.0,5.0,62.0,158.58,8.0,1.0,0.0,0.0,1,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,0,1,0,1
OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,0,DB00581,__LACTULOSE,4057655,Withdrawn,NCT00732108,MIGRAINE|HEADACHE|DIZZINESS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of California, San Francisco, San Francisco, California, United States",C13K13/005,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,16.0988932010924,393.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.3,342.2965,189.53,11.0,8.0,2.0,31.49,68.77,5.0,1.0,0.0,0.0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0
CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,0,DB00601,__LINEZOLID,5688792,Terminated,NCT00359632,OPTIC NERVE DISEASES,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"St. Bernards Research Center, Jonesboro, Arkansas, United States|Triple O Research Institute, PA, West Palm Beach, Florida, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Henry Ford Health System, Detroit, Michigan, United States|University of Minnesota, Department of Medicine/Division of Infectious Diseases, Minneapolis, Minnesota, United States|Drexel University College of Medicine, Partnership Comprehensive Care Practice, Philadelphia, Pennsylvania, United States|Associates in Infectious Disease and Tropical Medicine, Pittsburgh, Pennsylvania, United States|Azienda Ospedaliera Universitaria di San Martino, Genova, Italy|Ospedale San Martino, Clinica Malattie Infettive, Genova, Italy|Università di Genova, Genova, Italy|Clinica Malattie Infettive, Azienda Ospedaliero Universitaria Santa Maria della Misericordia, Udine, Italy|Infektionskliniken 1-73, Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden",C07D413/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,20.468592784246,159.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.61,337.3461,71.11,5.0,1.0,3.0,34.06,84.47,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0
CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc(S(C)=O)cc1,0,DB00605,__SULINDAC,4207340,Withdrawn,NCT01245816,FAMILIAL ADENOMATOUS POLYPOSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,17.7416374052855,1478.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.96,356.411,54.37,3.0,1.0,3.0,37.2,99.56,4.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc(S(C)=O)cc1,0,DB00605,__SULINDAC,4207340,Withdrawn,,FAMILIAL ADENOMATOUS POLYPOSIS (FAP),,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,17.7416374052855,1478.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.96,356.411,54.37,3.0,1.0,3.0,37.2,99.56,4.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(Cl)c4[C@@H](O)[C@H]3C[C@@H]12,0,DB00618,__DEMECLOCYCLINE,3966922,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A23K20/174,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,59.237356003203296,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.4,464.853,181.62,9.0,6.0,4.0,43.8,114.35,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,0,DB00642,__PEMETREXED,5344932,Terminated,NCT00573989,HEAD AND NECK CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UNC Linberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,0,DB00650,__LEUCOVORIN,4148999,Withdrawn,NCT00003273,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|NEUROBLASTOMA|RETINOBLASTOMA|SARCOMA,All,up to 10 Years   (Child),Other,Primary Purpose: Treatment,"Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Maine Children's Cancer Program, Scarborough, Maine, United States|Spectrum Health and DeVos Children's Hospital, Grand Rapids, Michigan, United States|Children's Hospital of Omaha, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Albert Einstein Clinical Cancer Center, Bronx, New York, United States|Winthrop University Hospital, Mineola, New York, United States|NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Beth Israel Hospital North, New York, New York, United States|State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States|State University of New York - Upstate Medical University, Syracuse, New York, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States|Children's Hospital, Buenos Aires, Argentina|British Columbia Children's Hospital, Vancouver, British Columbia, Canada",C07D487/14,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.46,473.44599999999997,215.55,11.0,7.0,3.0,46.33,126.66,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1
CNC1(C)C2CCC(C2)C1(C)C,0,DB00657,__MECAMYLAMINE,4168308,Terminated,NCT00414206,MACULAR DEGENERATION,All,"50 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Hospital de Olhos de Araraquara, Araraquara, Brazil|Centro Brasileiro de Ciências Visuais, Belo Horizonte, Brazil|Instituto da Visão, Belo Horizonte, Brazil|Centro Brasileiro de Cirurgia dos Olhos, Goiânia, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil|Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil|Clínica de Olhos Dr. Suel Abujamra, São Paulo, Brazil|Hospital das Clínicas Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil|Hospital de Olhos de São Paulo, São Paulo, Brazil|Hospital São Paulo - Setor de Pesquisa Clínica, São Paulo, Brazil|University Hospital Brno, Department of Ophthalmology, Brno, Czech Republic|Eye Clinic University Hospital, Hradec Kralove, Czech Republic|Ophthalmology Nemocnice Litomysl, Litomyšl, Czech Republic|University Hospital Olomouc, Department of Ophthalmology, Olomouc, Czech Republic|Faculty Hospital Kralovske Vinohrady, Dept. of Ophthalmology, Prague, Czech Republic|Cornea Lexum Praha, Praha, Czech Republic|Cif Biotec, CP, Mexico|Hospital Conde de Valenciana, CP, Mexico|Fundación Hospital ""Nuestra Sra de la Luz"" I.A.P., Delegación Cuauhtémoc, Mexico|Asociación Para Evitar la Ceguera, Mexico City, Mexico|Hospital General de México, Mexico City, Mexico|Hospital San José Tec de Monterrey, Monterrey, Mexico|Klinika Chorób Oczu, Gdansk, Poland|Oddział Okulistyczny Okręgowy Szpital Kolejowy, Katowice, Poland|Klinika Okulistyczna, Lodz, Poland|Oddział Okulistyki, Samodzielny Publiczny Szpital Kliniczny Nr 1 Przemienienia Pańskiego AM w Poznaniu, Poznań, Poland|Katedra i Klinika Okulistyki, Samodzielny Publiczny Kliniczny Szpital Okulistyczny, Warsaw, Poland|Katedra i Klinika Okulistyki, Akademia Medyczna we Wrocławiu, Wrocław, Poland|Republican Ophthalmologic Hospital of MH of Republic of Tatarstan, Kazan, Russian Federation|IRTC ""Eye Microsurgery"" n. a. S.N. Fyodorov, Moscow, Russian Federation|Moscow Scientific Research Institute of Eye Diseases, Moscow, Russian Federation|CJSC ""Inter Yuna"", Rostov-on Don, Russian Federation|City Consultative Diagnostic Centre # 1 (St. Petersburg), St. Petersburg, Russian Federation|IRTC ""Eye Microsurgery"" n. a. S.N. Fyodorov, St. Petersburg, Russian Federation|Military Medical Academy n.a. S.M.Kirov of Ministry of Defence, St. Petersburg, Russian Federation|St. Petersburg State Medical University n. a. Pavlov, St. Petersburg, Russian Federation|Kyiv City Centre of Eye Vascular and Endocrine Diseases of Organ of Vision, Kyiv, Ukraine|Kyiv City Ophthalmologic Hospital ""Eye Microsurgery Centre"", Kyiv, Ukraine|Kyiv City Ophthalmologic Hospital, Kyiv, Ukraine|V.P. Filatov Institute of Eye Diseases and Tissue Pathology of AMS of Ukraine, Odessa, Ukraine|Zaporizhzhya Center of Vision Rehabilitation, Odessa, Ukraine|S.I. Georgiyevsky Crimean State Medical University, Simferopol, Ukraine",A61K9/1075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,21.8156430316844,265.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.13,167.2911,12.03,1.0,1.0,2.0,20.74,51.83,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,0,DB00678,__LOSARTAN,5210079,Terminated,NCT00467831,HERMANSKY-PUDLAK SYNDROME (HPS)|PULMONARY FIBROSIS|OCULOCUTANEOUS ALBINISM|PLATELET STORAGE POOL DEFICIENCY|METABOLIC DISEASE,All,"18 Years to 70 Years   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(=O)O)[C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2,0,DB00681,__AMPHOTERICIN_B,6406713,Withdrawn,NCT04018417,FUCHS' ENDOTHELIAL DYSTROPHY,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Price Vision Group, Indianapolis, Indiana, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,85.6855376907123,1454.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.66,924.079,319.61,17.0,12.0,3.0,99.45,244.67,3.0,1.0,0.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,0,DB00687,__FLUDROCORTISONE,4041055,Terminated,NCT01186185,"HEARING LOSS, SENSORINEURAL",All,"18 Years to 89 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oregon Health & Science University, Portland, Oregon, United States",C07J1/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,626.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.35,380.4504,94.83,5.0,3.0,4.0,39.53,96.93,2.0,0.0,1.0,0.0,1,0,1,0,1,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,1,0,0
Nc1nc2ccc(OC(F)(F)F)cc2s1,0,DB00740,__RILUZOLE,5527814,Terminated,NCT00211224,MULTIPLE SYSTEM ATROPHY|PROGRESSIVE SUPRANUCLEAR PALSY,All,"30 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Institute of Psychiatry, King's College London, London, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,19.9100597548204,188.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.83,234.19799999999998,48.14,3.0,1.0,2.0,18.59,44.37,2.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0
CC(c1cc2ccccc2s1)N(O)C(N)=O,0,DB00744,__ZILEUTON,4873259,Terminated,NCT00467831,HERMANSKY-PUDLAK SYNDROME (HPS)|PULMONARY FIBROSIS|OCULOCUTANEOUS ALBINISM|PLATELET STORAGE POOL DEFICIENCY|METABOLIC DISEASE,All,"18 Years to 70 Years   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",C07D307/81,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,25.0,20.961416045504,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.01,236.29,66.56,2.0,2.0,2.0,24.14,61.96,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,0
NC(=O)CS(=O)C(c1ccccc1)c1ccccc1,0,DB00745,__MODAFINIL,RE37516,Terminated,NCT00591019,TINNITUS,All,"20 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Masking: Single (Participant)|Primary Purpose: Treatment,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",A61K9/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,33.5119817655393,214.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.75,273.35,60.16,2.0,1.0,2.0,28.71,77.39,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,0,DB00806,__PENTOXIFYLLINE,4189469,Terminated,NCT01893450,GRAVES OPHTHALMOPATHY,All,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,45.471159572065105,704.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.08,278.307,75.51,4.0,0.0,2.0,29.27,73.52,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0
CN(C)CCC(c1ccc(Br)cc1)c1ccccn1,0,DB00835,__BROMPHENIRAMINE,4000302,Withdrawn,NCT01177852,INFLAMMATION|COUGH|RHINITIS,All,2 Years to 12 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,20.4357379001622,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.63,319.2390000000001,16.13,2.0,0.0,2.0,32.08,83.67,5.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Terminated,NCT01857752,RETINOBLASTOMA,All,"up to 21 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Unidad Nacional de Oncologia Pediatrica, Guatemala, Guatemala",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Withdrawn,NCT00003273,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|NEUROBLASTOMA|RETINOBLASTOMA|SARCOMA,All,up to 10 Years   (Child),Other,Primary Purpose: Treatment,"Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Maine Children's Cancer Program, Scarborough, Maine, United States|Spectrum Health and DeVos Children's Hospital, Grand Rapids, Michigan, United States|Children's Hospital of Omaha, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Albert Einstein Clinical Cancer Center, Bronx, New York, United States|Winthrop University Hospital, Mineola, New York, United States|NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Beth Israel Hospital North, New York, New York, United States|State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States|State University of New York - Upstate Medical University, Syracuse, New York, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States|Children's Hospital, Buenos Aires, Argentina|British Columbia Children's Hospital, Vancouver, British Columbia, Canada",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Withdrawn,NCT02976441,ASTROCYTOMA|BRAINSTEM GLIOMA|EPENDYMOMA|MIXED GLIOMA|OLIGODENDROGLIOMA|OPTIC NERVE GLIOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Withdrawn,NCT01260103,OPTIC NERVE GLIOMA,All,"6 Months to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,0,DB00904,__ONDANSETRON,5344658,Withdrawn,NCT02460055,DYSPHAGIA|RESPIRATORY COMPLICATIONS,All,5 Years to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,,C07D403/06,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,19.5486560298979,384.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.56,293.363,39.82,2.0,0.0,4.0,33.16,86.78,2.0,0.0,1.0,0.0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0
NS(=O)(=O)Cc1noc2ccccc12,0,DB00909,__ZONISAMIDE,4172896,Withdrawn,NCT02049073,NOISE-INDUCED HEARING LOSS,All,18 Years to 30 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Washington University School of Medicine, Saint Louis, Missouri, United States",C07D261/20,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,16.8217006509373,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.67,212.226,86.19,3.0,1.0,2.0,19.48,50.3,2.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0
CS(=O)(=O)OCCCCOS(C)(=O)=O,0,DB01008,__BUSULFAN,5430057,Terminated,NCT00623077,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|KIDNEY CANCER|LIVER CANCER|RETINOBLASTOMA|SARCOMA,All,"up to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States",2,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,21.0928355818394,3071.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.9,246.30200000000002,86.74,4.0,0.0,0.0,23.64,49.57,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
CS(=O)(=O)OCCCCOS(C)(=O)=O,0,DB01008,__BUSULFAN,5430057,Terminated,NCT00006054,IMMUNOLOGIC DEFICIENCY SYNDROMES|CHEDIAK-HIGASHI SYNDROME|COMMON VARIABLE IMMUNODEFICIENCY|GRAFT VERSUS HOST DISEASE|X-LINKED LYMPHOPROLIFERATIVE SYNDROME|FAMILIAL ERYTHROPHAGOCYTIC LYMPHOHISTIOCYTOSIS|HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS|X-LINKED AGAMMAGLOBULINEMIA|WISKOTT-ALDRICH SYNDROME|CHRONIC GRANULOMATOUS DISEASE|X-LINKED HYPER IGM SYNDROME|SEVERE COMBINED IMMUNODEFICIENCY|LEUKOCYTE ADHESION DEFICIENCY SYNDROME|VIRUS-ASSOCIATED HEMOPHAGOCYTIC SYNDROME,All,"up to 35 Years   (Child, Adult)",Other,Primary Purpose: Treatment,"Fairview University Medical Center, Minneapolis, Minnesota, United States",2,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,21.0928355818394,3071.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.9,246.30200000000002,86.74,4.0,0.0,0.0,23.64,49.57,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
CS(=O)(=O)OCCCCOS(C)(=O)=O,0,DB01008,__BUSULFAN,5430057,Terminated,NCT00003926,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|CHILDHOOD GERM CELL TUMOR|CHORDOMA|KIDNEY CANCER|LIVER CANCER|NEUROBLASTOMA|OVARIAN CANCER|RETINOBLASTOMA|SARCOMA,All,"1 Year to 45 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"University of Minnesota Cancer Center, Minneapolis, Minnesota, United States",2,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,21.0928355818394,3071.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.9,246.30200000000002,86.74,4.0,0.0,0.0,23.64,49.57,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,0,DB01017,__MINOCYCLINE,5908838,Terminated,NCT01219673,HEAD AND NECK CANCER,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","UT MD Anderson Cancer Center, Houston, Texas, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,18.0,15.3432308671635,351.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.03,457.4764,164.63,9.0,5.0,4.0,45.9,122.54,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,0,DB01017,__MINOCYCLINE,5908838,Terminated,NCT01073813,MULTIPLE SCLEROSIS|OPTIC NEURITIS,All,18 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,6,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,15.3432308671635,351.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.03,457.4764,164.63,9.0,5.0,4.0,45.9,122.54,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT01466855,RETINOBLASTOMA,All,up to 15 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",C07D491/22,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,0,DB01042,__MELPHALAN,8410077,Terminated,NCT00623077,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|KIDNEY CANCER|LIVER CANCER|RETINOBLASTOMA|SARCOMA,All,"up to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,76.0,40.8714758003244,5796.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.22,305.2,66.56,4.0,2.0,1.0,31.38,78.23,8.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,0,DB01042,__MELPHALAN,8410077,Terminated,NCT02116959,ADVANCED INTRA-OCULAR RETINOBLASTOMA|RETINOBLASTOMA,All,"3 Months to 18 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, San Francisco, San Francisco, California, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,76.0,40.8714758003244,5796.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.22,305.2,66.56,4.0,2.0,1.0,31.38,78.23,8.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,0,DB01042,__MELPHALAN,8410077,Terminated,NCT00003926,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|CHILDHOOD GERM CELL TUMOR|CHORDOMA|KIDNEY CANCER|LIVER CANCER|NEUROBLASTOMA|OVARIAN CANCER|RETINOBLASTOMA|SARCOMA,All,"1 Year to 45 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"University of Minnesota Cancer Center, Minneapolis, Minnesota, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,76.0,40.8714758003244,5796.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.22,305.2,66.56,4.0,2.0,1.0,31.38,78.23,8.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,0,DB01042,__MELPHALAN,8410077,Terminated,NCT01558960,RETINOBLASTOMA,All,"up to 20 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hadassah-Hebrew University Medical Center, Jerusalem, Israel",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,76.0,40.8714758003244,5796.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.22,305.2,66.56,4.0,2.0,1.0,31.38,78.23,8.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,0,DB01065,__MELATONIN,4309415,Terminated,NCT00911053,INSOMNIA|BLINDNESS|DAYTIME SLEEPINESS,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Oregon Health and Science University, Portland, Oregon, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,37.0,32.854884083862,1835.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.42,232.2783,54.12,2.0,2.0,2.0,25.65,66.28,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,0,DB01065,__MELATONIN,4309415,Terminated,NCT00795236,SLEEP DISORDER|BLINDNESS,All,"5 Years to 20 Years   (Child, Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oregon Health and Science University, Portland, Oregon, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,37.0,32.854884083862,1835.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.42,232.2783,54.12,2.0,2.0,2.0,25.65,66.28,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,0,DB01065,__MELATONIN,4309415,Terminated,NCT00688935,BLINDNESS,All,"1 Year to 20 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,"Sleep and Mood Disorders Lab, Oregon Health & Science University, Portland, Oregon, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,37.0,32.854884083862,1835.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.42,232.2783,54.12,2.0,2.0,2.0,25.65,66.28,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,0,DB01065,__MELATONIN,4309415,Withdrawn,NCT00915616,GASTROESOPHAGEAL REFLUX,All,42 Years to 56 Years   (Adult),Other,Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,37.0,32.854884083862,1835.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.42,232.2783,54.12,2.0,2.0,2.0,25.65,66.28,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,0,DB01076,__ATORVASTATIN,4681893,Suspended,NCT02022293,NASOPHARYNGEAL CARCINOMA|RADIATION THERAPY COMPLICATION,All,"40 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Dongguan People's Hospital, Dongguan, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China|Zengcheng People's Hospital, Zengcheng, Guangdong, China|The Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Terminated,NCT01267240,PARANASAL SINUS SQUAMOUS CELL CARCINOMA|RECURRENT HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA|RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA|RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA|RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA|STAGE IVA HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA|STAGE IVA LARYNGEAL SQUAMOUS CELL CARCINOMA|STAGE IVA ORAL CAVITY SQUAMOUS CELL CARCINOMA|STAGE IVA OROPHARYNGEAL SQUAMOUS CELL CARCINOMA|STAGE IVB HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA|STAGE IVB LARYNGEAL SQUAMOUS CELL CARCINOMA|STAGE IVB ORAL CAVITY SQUAMOUS CELL CARCINOMA|STAGE IVB OROPHARYNGEAL SQUAMOUS CELL CARCINOMA|STAGE IVC HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA|STAGE IVC LARYNGEAL SQUAMOUS CELL CARCINOMA|STAGE IVC ORAL CAVITY SQUAMOUS CELL CARCINOMA|STAGE IVC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA,All,"19 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tower Cancer Research Foundation, Beverly Hills, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Contra Costa Regional Medical Center, Martinez, California, United States|Veterans Administration Hospital - Martinez, Martinez, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|City of Hope South Pasadena, South Pasadena, California, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|London Health Sciences Centre-Corporate, London, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada",C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Withdrawn,NCT02915172,ADVANCED CANCER|MALIGNANT NEOPLASM OF BREAST|MALIGNANT NEOPLASMS OF BONE AND ARTICULAR CARTILAGE|MALIGNANT NEOPLASMS OF DIGESTIVE ORGANS|MALIGNANT NEOPLASMS OF EYE BRAIN AND OTHER PARTS OF CENTRAL NERVOUS SYSTEM|MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS|MALIGNANT NEOPLASMS OF ILL-DEFINED SECONDARY AND UNSPECIFIED SITES|MALIGNANT NEOPLASMS OF INDEPENDENT (PRIMARY) MULTIPLE SITES|MALIGNANT NEOPLASMS OF LIP ORAL CAVITY AND PHARYNX|MALIGNANT NEOPLASMS OF MALE GENITAL ORGANS|MALIGNANT NEOPLASMS OF MESOTHELIAL AND SOFT TISSUE|MALIGNANT NEOPLASMS OF RESPIRATORY AND INTRATHORACIC ORGANS|MALIGNANT NEOPLASMS OF THYROID AND OTHER ENDOCRINE GLANDS|MALIGNANT NEOPLASMS OF URINARY TRACT,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Withdrawn,NCT00095641,RECURRENT SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|RECURRENT SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|RECURRENT SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,,C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1,0,DB01114,__CHLORPHENIRAMINE,6383471,Terminated,NCT02722083,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Germantown, Tennessee, United States",A61K47/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,114.0,37.0274543625125,1611.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.74,274.788,16.13,2.0,0.0,2.0,30.82,80.85,5.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0
Nc1ccc2cc3ccc(N)cc3nc2c1,0,DB01123,__PROFLAVINE,4189423,Terminated,NCT01456143,SQUAMOUS CELL CARCINOMA|NEOPLASIA|HEAD AND NECK CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",C07D209/48,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,18.661574159633602,291.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1,209.2465,64.93,3.0,2.0,3.0,23.17,65.46,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0
O=P(O)(O)C(Sc1ccc(Cl)cc1)P(=O)(O)O,0,DB01133,__TILUDRONIC_ACID,4876248,Terminated,NCT01617057,OTOSCLEROSIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Beaujon Hospital, Paris, France",C07F9/6541,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,19.5815109139818,1090.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.62,318.608,115.06,6.0,4.0,1.0,25.37,65.11,4.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
NCCCNCCSP(=O)(O)O,0,DB01143,__AMIFOSTINE,5424471,Terminated,NCT00003926,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|CHILDHOOD GERM CELL TUMOR|CHORDOMA|KIDNEY CANCER|LIVER CANCER|NEUROBLASTOMA|OVARIAN CANCER|RETINOBLASTOMA|SARCOMA,All,"1 Year to 45 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"University of Minnesota Cancer Center, Minneapolis, Minnesota, United States",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,22.47274071336161,3.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.4,214.22299999999998,95.58,5.0,4.0,0.0,21.01,51.28,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0
NCCCNCCSP(=O)(O)O,0,DB01143,__AMIFOSTINE,5424471,Terminated,NCT00025298,DRUG/AGENT TOXICITY BY TISSUE/ORGAN|HEAD AND NECK CANCER|ORAL COMPLICATIONS|RADIATION TOXICITY,All,"15 Years to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Primary Purpose: Treatment,"Institut Jules Bordet, Brussels, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|U.Z. Gasthuisberg, Leuven, Belgium|CRLCC Nantes - Atlantique, Nantes-Saint Herblain, France|Centre Antoine Lacassagne, Nice, France|Ospedale Santa Croce, Cuneo, Italy|Istituto Nazionale per la Ricerca sul Cancro, Genoa (Genova), Italy|Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano (Milan), Italy|Istituto Nazionale per lo Studio e la Cura dei Tumori, Naples, Italy|Hospital General de Jerez, Jerez, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Istanbul University-Institute of Oncology, Istanbul, Turkey|Beatson Oncology Centre, Glasgow, Scotland, United Kingdom",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,22.47274071336161,3.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.4,214.22299999999998,95.58,5.0,4.0,0.0,21.01,51.28,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0
NCCCNCCSP(=O)(O)O,0,DB01143,__AMIFOSTINE,5424471,Terminated,NCT00503776,DYSPHAGIA|HEAD AND NECK CANCER|MUCOSITIS|XEROSTOMIA,All,"21 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,33.0,22.47274071336161,3.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.4,214.22299999999998,95.58,5.0,4.0,0.0,21.01,51.28,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0
O=P1(NCCCl)OCCCN1CCCl,0,DB01181,__IFOSFAMIDE,5252341,Terminated,NCT00623077,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|KIDNEY CANCER|LIVER CANCER|RETINOBLASTOMA|SARCOMA,All,"up to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,13.831906199305902,2428.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.57,261.086,41.57,2.0,1.0,1.0,23.94,58.48,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0
O=P1(NCCCl)OCCCN1CCCl,0,DB01181,__IFOSFAMIDE,5252341,Terminated,NCT00484601,REFRACTORY NASOPHARYNGEAL CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins Singapore International Medical Center, Singapore, Singapore",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,13.831906199305902,2428.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.57,261.086,41.57,2.0,1.0,1.0,23.94,58.48,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0
O=P1(NCCCl)OCCCN1CCCl,0,DB01181,__IFOSFAMIDE,5252341,Terminated,NCT02137096,RECURRENT NASOPHARYNX CARCINOMA,All,"2 Years to 30 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UF Health Shands Hospital, Gainesville, Florida, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,13.831906199305902,2428.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.57,261.086,41.57,2.0,1.0,1.0,23.94,58.48,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0
CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,0,DB01200,__BROMOCRIPTINE,5468755,Terminated,NCT01893450,GRAVES OPHTHALMOPATHY,All,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,23.8855007289677,1010.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.2,654.595,118.21,6.0,3.0,7.0,66.44,165.51,5.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,1
CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,0,DB01200,__BROMOCRIPTINE,5468755,Withdrawn,NCT03384524,DIABETIC MACULAR EDEMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,23.8855007289677,1010.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.2,654.595,118.21,6.0,3.0,7.0,66.44,165.51,5.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,1
CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,0,DB01216,__FINASTERIDE,6046183,Terminated,NCT01585441,RETINAL DISEASE,All,"18 Years and older   (Adult, Older Adult)",NIH|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,25.4296802809092,1662.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.53,372.5441,58.2,2.0,2.0,4.0,43.93,108.2,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,1,0,0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,0,DB01268,__SUNITINIB,6573293,Terminated,NCT00482911,INTRAOCULAR MELANOMA|MALIGNANT CONJUNCTIVAL NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States",C07D403/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,0,DB01268,__SUNITINIB,6573293,Terminated,NCT00906360,METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY SQUAMOUS CELL CARCINOMA|RECURRENT METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY|RECURRENT SALIVARY GLAND CANCER|RECURRENT SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|RECURRENT SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|RECURRENT VERRUCOUS CARCINOMA OF THE LARYNX|RECURRENT VERRUCOUS CARCINOMA OF THE ORAL CAVITY|SALIVARY GLAND SQUAMOUS CELL CARCINOMA|STAGE III SALIVARY GLAND CANCER|STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|STAGE III VERRUCOUS CARCINOMA OF THE LARYNX|STAGE III VERRUCOUS CARCINOMA OF THE ORAL CAVITY|STAGE IV SALIVARY GLAND CANCER|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|STAGE IV VERRUCOUS CARCINOMA OF THE LARYNX|STAGE IV VERRUCOUS CARCINOMA OF THE ORAL CAVITY|TONGUE CANCER|UNTREATED METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Evanston CCOP-NorthShore University HealthSystem, Evanston, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Fort Wayne Medical Oncology and Hematology Inc - State Boulevard, Fort Wayne, Indiana, United States|University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States|University of Michigan University Hospital, Ann Arbor, Michigan, United States|Saint John's Mercy Medical Center, Saint Louis, Missouri, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States",C07D403/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,0,DB01268,__SUNITINIB,6573293,Terminated,NCT00673816,VON HIPPEL-LINDAU SYNDROME,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",C07D403/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0
O=C([O-])O.[Na+],0,DB01390,__SODIUM_BICARBONATE,5840737,Terminated,NCT01066741,OROPHARYNX CANCER|HYPOPHARYNX CANCER,All,"18 Years to 85 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,"Centre Léon Bérard, Lyon, France",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,28.32091008028911,11.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.06,84.0066,60.36,3.0,1.0,0.0,3.86,20.34,0.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0,DB01590,__EVEROLIMUS,5665772,Terminated,NCT01313390,HEAD AND NECK CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCL Cancer Institute, London, England, United Kingdom",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,29.109427298301807,997.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.01,958.24,204.66,13.0,3.0,4.0,106.61,261.71,9.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0,DB01590,__EVEROLIMUS,5665772,Terminated,NCT00857259,CHOROIDAL NEO-VASCULAR AGE-ONSET MACULAR DEGENERATION|AGE-RELATED MACULAR DEGENERATION,All,"50 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Retina-Vitreous Associates Medical Group, Beverley Hills, California, United States|Retinal Consultants Medical Group, Inc., Sacramento, California, United States|Porter Adventist Hospital, Diagnostic Eye Laboratory, Denver, Colorado, United States|Discover Vision Center, Independence, Missouri, United States|Novartis Investigative Site, Bristol, United Kingdom|Novartis Investigative Site, Frimley, United Kingdom|Novartis Investigative Site, Liverpool, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Oxford, United Kingdom|Novartis Investigative site, Portsmouth, United Kingdom|Novartis Investigative Site, Southampton, United Kingdom|Novartis Investigator Site, Wolverhampton, United Kingdom",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,29.109427298301807,997.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.01,958.24,204.66,13.0,3.0,4.0,106.61,261.71,9.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0,DB01590,__EVEROLIMUS,5665772,Withdrawn,NCT01332279,RECURRENT METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY|RECURRENT SALIVARY GLAND CANCER|RECURRENT SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|RECURRENT SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|RECURRENT VERRUCOUS CARCINOMA OF THE LARYNX|RECURRENT VERRUCOUS CARCINOMA OF THE ORAL CAVITY|SALIVARY GLAND SQUAMOUS CELL CARCINOMA|TONGUE CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,29.109427298301807,997.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.01,958.24,204.66,13.0,3.0,4.0,106.61,261.71,9.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(=O)O)c3ccsc3)C(=O)N2[C@H]1C(=O)O,0,DB01607,__TICARCILLIN,4127649,Withdrawn,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,18.201605782459602,934.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.99,384.42699999999996,124.01,6.0,3.0,3.0,36.14,87.93,5.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)nc(N)[nH]c21,0,DB01610,__VALGANCICLOVIR,6083953,Terminated,NCT02606266,CONGENITAL CYTOMEGALOVIRUS (CMV),All,6 Months to 12 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Robert Debré Hospital, Paris, France",C07D473/00,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,40.017248814144004,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.81,354.3617,167.08,9.0,4.0,2.0,34.88,86.6,9.0,0.0,1.0,0.0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)nc(N)[nH]c21,0,DB01610,__VALGANCICLOVIR,6083953,Terminated,NCT01655212,CONGENITAL CYTOMEGALOVIRUS INFECTION|SENSORINEURAL HEARING LOSS,All,up to 12 Weeks   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Department Medical Microbiology, Leiden University Medical Center, Leiden, Zuid Holland, Netherlands",C07D473/00,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,40.017248814144004,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.81,354.3617,167.08,9.0,4.0,2.0,34.88,86.6,9.0,0.0,1.0,0.0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0
CCCCCON=O,0,DB01612,__AMYL_NITRITE,,Withdrawn,NCT02428959,DYSPHAGIA|ACHALASIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Johns Hopkins Hospital, Baltimore, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.98,117.1463,38.66,2.0,0.0,0.0,12.84,31.68,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
CCCCCON=O,0,DB01612,__AMYL_NITRITE,,Withdrawn,,ACHALASIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.98,117.1463,38.66,2.0,0.0,0.0,12.84,31.68,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Suspended,NCT01587352,OCULAR MELANOMA WITH EXTRAOCULAR EXTENSION|RECURRENT UVEAL MELANOMA|STAGE IV UVEAL MELANOMA AJCC V7,All,"18 Years and older   (Adult, Older Adult)",NIH|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT01267240,PARANASAL SINUS SQUAMOUS CELL CARCINOMA|RECURRENT HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA|RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA|RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA|RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA|STAGE IVA HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA|STAGE IVA LARYNGEAL SQUAMOUS CELL CARCINOMA|STAGE IVA ORAL CAVITY SQUAMOUS CELL CARCINOMA|STAGE IVA OROPHARYNGEAL SQUAMOUS CELL CARCINOMA|STAGE IVB HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA|STAGE IVB LARYNGEAL SQUAMOUS CELL CARCINOMA|STAGE IVB ORAL CAVITY SQUAMOUS CELL CARCINOMA|STAGE IVB OROPHARYNGEAL SQUAMOUS CELL CARCINOMA|STAGE IVC HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA|STAGE IVC LARYNGEAL SQUAMOUS CELL CARCINOMA|STAGE IVC ORAL CAVITY SQUAMOUS CELL CARCINOMA|STAGE IVC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA,All,"19 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tower Cancer Research Foundation, Beverly Hills, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Contra Costa Regional Medical Center, Martinez, California, United States|Veterans Administration Hospital - Martinez, Martinez, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|City of Hope South Pasadena, South Pasadena, California, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|London Health Sciences Centre-Corporate, London, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT01249443,"HIV INFECTION|RECURRENT ANAL CANCER|RECURRENT BREAST CANCER|RECURRENT ESOPHAGEAL CANCER|RECURRENT GASTRIC CANCER|RECURRENT METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY|RECURRENT NON-SMALL CELL LUNG CANCER|RECURRENT OVARIAN EPITHELIAL CANCER|RECURRENT SALIVARY GLAND CANCER|RECURRENT SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|RECURRENT SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|RECURRENT VERRUCOUS CARCINOMA OF THE LARYNX|RECURRENT VERRUCOUS CARCINOMA OF THE ORAL CAVITY|SALIVARY GLAND SQUAMOUS CELL CARCINOMA|STAGE IV ANAL CANCER|STAGE IV BREAST CANCER|STAGE IV ESOPHAGEAL CANCER|STAGE IV GASTRIC CANCER|STAGE IV NON-SMALL CELL LUNG CANCER|STAGE IV OVARIAN EPITHELIAL CANCER|STAGE IV SALIVARY GLAND CANCER|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|STAGE IV VERRUCOUS CARCINOMA OF THE LARYNX|STAGE IV VERRUCOUS CARCINOMA OF THE ORAL CAVITY|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UC San Diego Moores Cancer Center, La Jolla, California, United States|UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, United States|Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Boston Medical Center, Boston, Massachusetts, United States|Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States|Montefiore Medical Center, Bronx, New York, United States|Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States|Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Withdrawn,NCT03022565,UVEAL MELANOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
NC(=O)c1cccnc1,0,DB02701,__NICOTINAMIDE,3931207,Terminated,NCT02758990,"OBESITY|RHINITIS|RHINITIS, ALLERGIC|RESPIRATORY SOUNDS|DYSPNEA|HEADACHE|MIGRAINE DISORDERS|ARTHRITIS|ARTHRALGIA|ANXIETY|SLEEP INITIATION AND MAINTENANCE DISORDERS|SLEEP DEPRIVATION",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Verifomics, LLC, Dallas, Texas, United States",C07D207/44,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,24.7397277151481,6368.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,122.1246,55.98,2.0,1.0,1.0,11.71,32.98,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
CSCC[C@@H](N)C(=O)O,0,DB02893,__D-METHIONINE,,Terminated,NCT02903355,NOISE-INDUCED HEARING LOSS,All,21 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Moncrief Army Community Hospital, Fort Jackson, South Carolina, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,149.211,63.32,3.0,2.0,0.0,15.46,37.59,4.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1
OC[C@H]1O[C@H](O)[C@H](F)[C@@H](O)[C@@H]1O,0,DB04282,__2-DEOXY-2-FLUORO-Α-D-GLUCOSE,,Terminated,NCT01283178,SALIVARY GLAND SQUAMOUS CELL CARCINOMA|STAGE II SALIVARY GLAND CANCER|STAGE II SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE II SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE II SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE II VERRUCOUS CARCINOMA OF THE ORAL CAVITY|STAGE III SALIVARY GLAND CANCER|STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE III VERRUCOUS CARCINOMA OF THE ORAL CAVITY|STAGE IV SALIVARY GLAND CANCER|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV VERRUCOUS CARCINOMA OF THE ORAL CAVITY,All,"19 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Virginia Commonwealth University, Richmond, Virginia, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,182.1469,90.15,5.0,4.0,1.0,15.44,34.23,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
S=P(N1CC1)(N1CC1)N1CC1,0,DB04572,__THIOTEPA,4766149,Terminated,NCT00623077,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|KIDNEY CANCER|LIVER CANCER|RETINOBLASTOMA|SARCOMA,All,"up to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,27.532392862276396,109.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.17,189.218,9.03,3.0,0.0,3.0,18.23,50.72,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
S=P(N1CC1)(N1CC1)N1CC1,0,DB04572,__THIOTEPA,4766149,Terminated,NCT00003926,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|CHILDHOOD GERM CELL TUMOR|CHORDOMA|KIDNEY CANCER|LIVER CANCER|NEUROBLASTOMA|OVARIAN CANCER|RETINOBLASTOMA|SARCOMA,All,"1 Year to 45 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"University of Minnesota Cancer Center, Minneapolis, Minnesota, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,27.532392862276396,109.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.17,189.218,9.03,3.0,0.0,3.0,18.23,50.72,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
S=P(N1CC1)(N1CC1)N1CC1,0,DB04572,__THIOTEPA,4766149,Withdrawn,NCT00003273,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|NEUROBLASTOMA|RETINOBLASTOMA|SARCOMA,All,up to 10 Years   (Child),Other,Primary Purpose: Treatment,"Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Maine Children's Cancer Program, Scarborough, Maine, United States|Spectrum Health and DeVos Children's Hospital, Grand Rapids, Michigan, United States|Children's Hospital of Omaha, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Albert Einstein Clinical Cancer Center, Bronx, New York, United States|Winthrop University Hospital, Mineola, New York, United States|NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Beth Israel Hospital North, New York, New York, United States|State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States|State University of New York - Upstate Medical University, Syracuse, New York, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States|Children's Hospital, Buenos Aires, Argentina|British Columbia Children's Hospital, Vancouver, British Columbia, Canada",7,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,27.532392862276396,109.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.17,189.218,9.03,3.0,0.0,3.0,18.23,50.72,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,0,DB04849,__CEDIRANIB,WO-2001074360-A1,Withdrawn,NCT04184518,UVEAL MELANOMA|METASTATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Instituto Catalá d'Oncología L'Hospitalet, L'Hospitalet De Llobregat, Barcelona, Spain|H. U. Virgen de la Victoria, Málaga, Spain|Clínica Universidad de Navarra, Pamplona, Spain|H.U. Virgen Macarena, Sevilla, Spain|Hospital General Universitario de Valencia, Valencia, Spain",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,32.7488,26.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.77,450.5053,72.5,5.0,1.0,5.0,48.77,125.16,8.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,0,DB04868,__NILOTINIB,7169791,Terminated,NCT01201538,GROWING VESTIBULAR SCHWANNOMAS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Toronto Western Hospital, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,42.9084786135238,336.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,529.5158,97.62,6.0,2.0,5.0,52.35,152.85,7.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1
CC1(C)CC(C)(C)CC(C)(N)C1,0,DB04926,__NERAMEXANE,6034134,Terminated,NCT00799942,"NYSTAGMUS, CONGENITAL|NYSTAGMUS, ACQUIRED|MULTIPLE SCLEROSIS",All,"18 Years to 81 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Leicester, Leicester Royal Infirmary, Ophthalmology Group, Leicester, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,18.333025318795,37.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.74,169.30700000000004,26.02,1.0,1.0,1.0,21.66,53.62,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0
CC1(C)CC(C)(C)CC(C)(N)C1,0,DB04926,__NERAMEXANE,6034134,Terminated,NCT00827008,SUBJECTIVE TINNITUS,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Paradigm Clinical Research, Tucson, Arizona, United States|Providence Clinical Research, Burbank, California, United States|Central California Clinical Research, Fresno, California, United States|UC Davis Health System Department of Otolaryngology, Sacramento, California, United States|Colorado Otolaryngology Associates, Colorado Springs, Colorado, United States|New West Physicians, Golden, Colorado, United States|Visions Clinical Research, Boynton Beach, Florida, United States|Clinical Research of West Florida, Tampa, Florida, United States|Deerpath Physicians Group, Gurnee, Illinois, United States|Knight Center for Integrated Health,, Peoria, Illinois, United States|University of Kansas Department of Otolaryngology Head & Neck Surgery, Kansas City, Kansas, United States|Heartland Research Associates, LLC., Wichita, Kansas, United States|Heartland Research Associates, LLC., Wichita, Kansas, United States|Commonwealth Ear, Nose & Throat, Louisville, Kentucky, United States|Glacier Ear, Nose, and Throat, Head and Neck Surgery, P.C., Kalispell, Montana, United States|Immedicenter, Bloomfield, New Jersey, United States|David L. Bortniker, M.D, FACS, Somerville, New Jersey, United States|Montefiore Medical Center Attn: Anxiety and Depression Center, Bronx, New York, United States|Erie County Medical Center, Department of Rehabilitation Medicine, Buffalo, New York, United States|Cary Medical Research, Cary, North Carolina, United States|Wake Research Associates, LLC, Raleigh, North Carolina, United States|Wilmington Medical Research, Wilmington, North Carolina, United States|Piedmont Medical Research, Winston-Salem, North Carolina, United States|Medical University of South Carolina - Department of Otolaryngology, Department of Otolaryngology - Head & Neck Surgery, Charleston, South Carolina, United States|Future Search Trials of Neurology, Austin, Texas, United States|FutureSearch Trials of Dallas, Dallas, Texas, United States|R/D Clinical Research, Inc., Lake Jackson, Texas, United States|South Texas Research Alliance LLC, Laredo, Texas, United States|Research Across America, Plano, Texas, United States|Advanced Clinical Research, West Jordon, Utah, United States|Health Research of Hampton Roads, Inc., Newport News, Virginia, United States|Krankenhaus der Elisabethinen, Graz, Austria|Bezirkskrankenhaus Kufstein Dr. Christof Pauli (PI: Prim. Dr. Peter Ostertag, Kufstein, Austria|Clin Pharm International GmbH, Zentrum Wien, Vienna, Austria|University Hospital Brussels, Brussels, Belgium|Clinique Universitaire Saint-luc, Bruxelles, Belgium|AZ Sint Lucas, ENT department, Gent, Belgium|University Hospital Leuven, ENT Department, Leuven, Belgium|Consultório Dr. Marcelo Rates, Belo Horizonte/Mimaf Gerais, Brazil|Osmar Clayton Person, Santo André/SP, Brazil|Instituto Ganz Sanchez, São Paulo/SP, Brazil|Clínica OTOSUL, Valenca/RJ, Brazil|Medico, Chodov, Prague, Czech Republic|prof. MUDr. Ivo Šlapák, Brno, Czech Republic|Teaching University Hospital, ORL klinika, Brno, Czech Republic|ORL oddělení, Karlovarská krajská nemocncie a.s., Karlovy Vary, Czech Republic|Oblastní nemocnice Kladno a.s., Nemocnice Středočeského kraje, Kladno, Czech Republic|Pro-audio,s.r.o.-private ENT clinic, Mladá Boleslav, Czech Republic|ORL oddělení, Všeobecná Fakultní Nemocnice v Praze, Praha, Czech Republic|ORL oddělení , Karlovarská krajská nemocnice a. s., Sokolov, Czech Republic|Dr. Ebbo, Issy les moulineaux, France|Dr. Sarfati, La seyne sur Mer, France|Centre Hospitalier de Bretagne Sud Service ORL-B9, Lorient, France|Dr. Bonfils, Paris, France|Dr. Ohresser, Paris, France|Hopital Nord, Saint-etienne, France|Dr. Fraysse, Toulouse cedex, France|Service ORL CHU Bretonneau, Tours, France|Hopital Paul BROUSSE Polyclinique, Villejuif, France|Dr. Kühne, Elisabeth, Halle, Saale, Germany|Dr. med. Norbert Pasch, Aachen, Germany|Charité, Universitätsmedizin Berlin-Tinnituszentrum, Berlin, Germany|Klin. Forschung Berlin Buch GmbH, Berlin, Germany|Dr. med. Frank Reintjes, Braunschweig, Germany|DM Helena Sigal, Chemnitz, Germany|Dr. Klaus Peter Jayme, Darmstadt, Germany|Dr. Christian Dörr, Dresden, Germany|HNO-Praxis im Gesundheitszentrum, Duisburg, Germany|Dr. Gieselmann, Werner, Heiligenhaus, Germany|Dr. Wolfgang Lotte, Iserlohn, Germany|Dr. Dr. med. Hans-Detlev Stahl, Leipzig, Germany|HNO Praxis, Lichtenfels, Germany|Dr. Dannesberger, Lorsch, Germany|ClinPharm International, Magdeburg, Germany|HNO Gemeinschaftpraxis, Meppen, Germany|Martin Canis, MD, Munich, Germany|Dr. Susanne Wiedemann, Nuernberg, Germany|Dr. med. Ulrike Walter, Nürnberg, Germany|Dr. Norbert Staab, Schlüchtern, Germany|Dr. Hannelore Neumaier, Wiesbaden, Germany|Unidad Médica de Especialidades del Noroeste (UMEN), Centro Culiacán Sinaloa, Mexico|Hospital General de Chihuahua. ""Dr. Salvador Anchondo"", Chihuahua C.P. 31000, Mexico|Hospital Christus Muguerza del Parque, Chihuahua CP 3100, Mexico|Internal Medicine Clin Trials (IMED), Col Obispado, Monterrey , N.L. C.P. 64060, Mexico|Hospital Civil de Guadalajara, Col. El Retiro CP 44280 Cuadalajara Jalis, Mexico|Grupo Médico Terranova, CP 44630 Guadalajara Jalisco, Mexico|Clinical Research Instutute S.C., Edo. de México CP 54055, Mexico|Instituto Biomédico de Investigación A.C., Fracc. Bosques del Prado Norte Aguascalientes, Mexico|Unidad de Investigación Clínica Cardiometábolica de Occidente S.C. (UNICAMO), Jalisco, 44150, Mexico|Monterrey International Research Center (MIRC), Nuevo León CP 64000, Mexico|Hospital Universitario Dr. José Eleuterio González. Edificio Elizondo Barragán, Servicio de Otorrinolaringología, Nuevo León CP 64400, Mexico|Hospital Central ""Dr. Ignacio Morones Prieto"" Servicio de Otorrinolaringología, San Luis Potosí, SLP, México, 78240, Mexico|Andromed Zoetermeer, Zoetermeer, EK, Netherlands|Andromed Oost, Velp, ES, Netherlands|Rijnland Ziekenhuis, ENT department, Leiderdorp, GA, Netherlands|Andromed Rotterdam, Rotterdam, HC, Netherlands|Adromed Nijmegen, Nijmegen, HL, Netherlands|Andromed Leiden, Leiderdorp, RA, Netherlands|Andromed Breda, Breda, VL, Netherlands|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Poland|Niepubliczny Zaklad Opieki Zdrowotnej Prywatne Centrum Medyczne PROMEDIS, Gdansk, Poland|Szpital Miejski im. J.Brudzinskiego, Gdynia, Poland|Samodzielny Publiczny Szpital Kliniczny im. Andrzeja Mieleckiego Slaskiego Uniwersytetu Medycznego w Katowicach, Katowice, Poland|NZOZ Specjalistyczne Centrum Medyczne Nowomed, Krakow, Poland|Niepubliczny Zaklad Opieki Zdrowotnej PROMED, Krakow, Poland|Specjalistyczny Gabinet Otolaryngologiczny, Krakow, Poland|Szpital Specjalistyczny im. Stefana Zeromskiego, SP ZOZ w Krakowie, Oddzial Otolaryngologii, Krakow, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi, Lodz, Poland|Wojewodzki Szpital Specjalistyczny im. Stefana Kardynała Wyszynskiego Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Lublin, Poland|Wojewodzki Szpital Specjalistyczny w Olsztynie, Olsztyn, Poland|Instytut Fizjologii i Patologii Sluchu, Warszawa, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 we Wroclawiu, Wroclaw, Poland|Hospital Militar Regional nº 1 Serviço de Otorrinolaringologia, Porto, Portugal|Louis Leipoldt Mediclinic, Bellville, South Africa|Lakeview Hospital, Benoni, South Africa|1007 Louis Pasteur Building, Pretoria, South Africa|GCT Eastmed Clinical Trial centre, Pretoria, South Africa|Constantiaberg Medi Clinic,, Western Cape, South Africa|Prince Alfred House, Wynberg, South Africa|Hospital Sagunto, Sagunto, Valencia, Spain|Fundación Hospital de Alcorcón, Otorhinolaryngology, Alcorcon - Madrid, Spain|Hospital Clínico Barcelona, Dept. Of ORL, Barcelona, Spain|Hospital Puerta del Hierro, Madrid- Servicio de ORL, Madrid, Spain|Hospital Universitario Príncipe de Asturias, Madrid, Spain|Clínica Universitaria de Navarra, Dept. ORL, Pamplona, Navarra, Spain|Hospital Universitario de Salamanca- Hospital Virgen de la Vega, Salamanca, Spain|Oldfield Surgery, Bath, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|Avondale Surgery, Research Office, Chesterfield, United Kingdom|Burbage Surgery, Leicestershire, United Kingdom|The university Hospitals of Leicester, Leicester Royal Infirmary, Leicester, United Kingdom|The Freeman Hospital, Newcastle upon Tyne, United Kingdom|Wansford and Kings Cliffe Practice, Petereborough, United Kingdom|Frome Medical Practice, Somerset, United Kingdom|Sherbourne Medical Centre, Warwickshire, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,18.333025318795,37.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.74,169.30700000000004,26.02,1.0,1.0,1.0,21.66,53.62,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0
Nc1ccn([C@H]2C[C@H](O)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)O2)c(=O)n1,0,DB04983,__DENUFOSOL,,Terminated,NCT00083967,RETINAL DETACHMENT,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Retina Center, P.C., Tucson, Arizona, United States|Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States|Retina Vitreous Associates Medical Group, Los Angeles, California, United States|Retina Consultants San Diego, Poway, California, United States|Danbury Eye Physicians & Surgeons, P.C., Danbury, Connecticut, United States|Retina Group of Florida, Ft. Lauderdale, Florida, United States|Central Florida Retina, Orlando, Florida, United States|The University of Chicago, Chicago, Illinois, United States|Illinois Retina Associates, S.C., Joliet, Illinois, United States|Midwest Eye Institute, Indianapolis, Indiana, United States|University of Kentucky, The Kentucky Clinic, Lexington, Kentucky, United States|Maine Vitreoretinal Consultants, Bangor, Maine, United States|National Retina Institute, Chevy Chase, Maryland, United States|New England Eye Center, Boston, Massachusetts, United States|Kresge Eye Institute/Hutzel Hospital, Detroit, Michigan, United States|Retina Associates, Kansas City, Missouri, United States|Retina Associates of NJ, Millburn, New Jersey, United States|Retina Associates of NJ, Teaneck, New Jersey, United States|Retina Associates of NJ, Wayne, New Jersey, United States|NY Eye and Ear Infirmary, New York, New York, United States|Carolina Eye Associates, Southern Pines, North Carolina, United States|Retina Associates of Cleveland, Beachwood, Ohio, United States|Retina Assocites of Cleveland, Inc., Cleveland, Ohio, United States|Cleveland Clinical Foundation, Cleveland, Ohio, United States|Retina Associates of Cleveland, Lakewood, Ohio, United States|Retina Associates of Cleveland, Lorain, Ohio, United States|Retina Associates of Cleveland, Middleburg Heights, Ohio, United States|Scheie Eye Institute, Philadelphia, Pennsylvania, United States|Austin Retina, Austin, Texas, United States|Vitreoretinal Consultants, Houston, Texas, United States|Wagner Mandell Retina Center, Norfolk, Virginia, United States|Wagner Mandell Retina Center, Virginia Beach, Virginia, United States|Medical College of Wisconsin/The Eye Institute, Milwaukee, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.19,773.323,382.6,18.0,9.0,4.0,60.36,145.31,14.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,1,0,0,0
Nc1ccn([C@H]2C[C@H](O)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)O2)c(=O)n1,0,DB04983,__DENUFOSOL,,Terminated,NCT00114062,CYSTOID MACULAR EDEMA|UVEITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.19,773.323,382.6,18.0,9.0,4.0,60.36,145.31,14.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,1,0,0,0
Nc1ccn([C@H]2C[C@H](O)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)O2)c(=O)n1,0,DB04983,__DENUFOSOL,,Withdrawn,NCT00135655,"MACULAR EDEMA, CYSTOID",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.19,773.323,382.6,18.0,9.0,4.0,60.36,145.31,14.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,1,0,0,0
Nc1ccn([C@H]2C[C@H](O)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)O2)c(=O)n1,0,DB04983,__DENUFOSOL,,Terminated,,CYSTOID MACULAR EDEMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.19,773.323,382.6,18.0,9.0,4.0,60.36,145.31,14.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,1,0,0,0
O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1,0,DB05016,__ATALUREN,US-20040204461-A1,Withdrawn,NCT04117880,ANIRIDIA,All,"2 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,38.0,21.7499332635167,46.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.96,284.242,76.22,4.0,1.0,3.0,27.66,94.66,3.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0
O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1,0,DB05239,__COBIMETINIB,7803839,Withdrawn,,MELANOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D401/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,68.0,47.7710014579354,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.35,531.318,64.6,4.0,3.0,4.0,44.75,115.85,4.0,1.0,0.0,0.0,1,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@@]21C,0,DB05288,__ANECORTAVE_ACETATE,4041055,Terminated,NCT00211471,SEVERE DIABETIC RETINOPATHY|CENTRAL RETINAL VEIN OCCLUSION|CHRONIC INFLAMMATION|INFECTIOUS DISEASES,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Manhattan Eye, Ear & Throat Hospital, New York, New York, United States",C07J1/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,92.0,20.7314318569169,111.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.33,386.4813,80.67,4.0,1.0,4.0,42.64,105.81,4.0,0.0,1.0,0.0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@@]21C,0,DB05288,__ANECORTAVE_ACETATE,4041055,Terminated,NCT00788541,OPEN-ANGLE GLAUCOMA|OCULAR HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","Contact Alcon Call Center For Trial Locations, Fort Worth, Texas, United States",C07J1/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,92.0,20.7314318569169,111.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.33,386.4813,80.67,4.0,1.0,4.0,42.64,105.81,4.0,0.0,1.0,0.0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@@]21C,0,DB05288,__ANECORTAVE_ACETATE,4041055,Terminated,NCT00065728,MACULAR DEGENERATION,All,"50 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Belgium,France,Germany,Hungary,Italy,Netherlands,Poland,Spain,Sweden,UK, Central Contact Ft. Worth, Texas, United States",C07J1/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,92.0,20.7314318569169,111.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.33,386.4813,80.67,4.0,1.0,4.0,42.64,105.81,4.0,0.0,1.0,0.0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@@]21C,0,DB05288,__ANECORTAVE_ACETATE,4041055,Terminated,NCT00211367,EYE INJURIES,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Manhattan Eye, Ear & Throat Hospital, New York, New York, United States",C07J1/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,92.0,20.7314318569169,111.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.33,386.4813,80.67,4.0,1.0,4.0,42.64,105.81,4.0,0.0,1.0,0.0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@@]21C,0,DB05288,__ANECORTAVE_ACETATE,4041055,Terminated,NCT00211406,DIABETIC RETINOPATHY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Manhattan Eye, Ear & Throat Hospital, New York, New York, United States",C07J1/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,92.0,20.7314318569169,111.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.33,386.4813,80.67,4.0,1.0,4.0,42.64,105.81,4.0,0.0,1.0,0.0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@@]21C,0,DB05288,__ANECORTAVE_ACETATE,4041055,Withdrawn,NCT00705770,OPEN-ANGLE GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",,C07J1/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,92.0,20.7314318569169,111.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.33,386.4813,80.67,4.0,1.0,4.0,42.64,105.81,4.0,0.0,1.0,0.0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@@]21C,0,DB05288,__ANECORTAVE_ACETATE,4041055,Withdrawn,NCT00211354,RETINAL VEIN OCCLUSION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Manhattan Eye, Ear & Throat Hospital, New York, New York, United States",C07J1/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,92.0,20.7314318569169,111.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.33,386.4813,80.67,4.0,1.0,4.0,42.64,105.81,4.0,0.0,1.0,0.0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@@]21C,0,DB05288,__ANECORTAVE_ACETATE,4041055,Terminated,,AMD,,,,,"FISABIO, Elche, Alicante, Spain",C07J1/0048,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,111.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.33,386.4813,80.67,4.0,1.0,4.0,42.64,105.81,4.0,0.0,1.0,0.0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@@]21C,0,DB05288,__ANECORTAVE_ACETATE,4041055,Terminated,,DRY AMD,,,,,"FISABIO, Elche, Alicante, Spain",C07J1/0048,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,111.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.33,386.4813,80.67,4.0,1.0,4.0,42.64,105.81,4.0,0.0,1.0,0.0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,1,0,1
COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,0,DB05294,__VANDETANIB,RE42353,Terminated,NCT00720083,HEAD AND NECK CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States|USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States|Radiological Associates of Sacramento Medical Group, Incorporated, Sacramento, California, United States|CCOP - Christiana Care Health Services, Newark, Delaware, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Winship Cancer Institute of Emory University, Altanta, Georgia, United States|Ingalls Cancer Care Center at Ingalls Memorial Hospital, Harvey, Illinois, United States|Cancer Institute at St. John's Hospital, Springfield, Illinois, United States|Saint John's Cancer Center at Saint John's Medical Center, Anderson, Indiana, United States|Methodist Cancer Center at Methodist Hospital, Indianapolis, Indiana, United States|Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, United States|James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky, United States|Charach Cancer Center at Huron Valley - Sinai Hospital, Commerce, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Regional Cancer Center at Singing River Hospital, Pascagoula, Mississippi, United States|Truman Medical Center - Hospital Hill, Kansas City, Missouri, United States|CCOP - Kansas City, Kansas City, Missouri, United States|David C. Pratt Cancer Center at St. John's Mercy, Saint Louis, Missouri, United States|Saint Elizabeth Cancer Institute at Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Renown Institute for Cancer at Renown Regional Medical Center, Reno, Nevada, United States|Memorial Sloan-Kettering Cancer Center - Basking Ridge, Basking Ridge, New Jersey, United States|Radiation Oncology Associates, PA, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan-Kettering Cancer Center, Commack, New York, United States|Highland Hospital of Rochester, Rochester, New York, United States|James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States|Memorial Sloan-Kettering Cancer Center - Rockville Centre, Rockville Centre, New York, United States|Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow, New York, United States|Leo W. Jenkins Cancer Center at ECU Medical School, Greenville, North Carolina, United States|Summa Center for Cancer Care at Akron City Hospital, Akron, Ohio, United States|Barberton Citizens Hospital, Barberton, Ohio, United States|Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Lake/University Ireland Cancer Center, Mentor, Ohio, United States|North Coast Cancer Care, Incorporated, Sandusky, Ohio, United States|Flower Hospital Cancer Center, Sylvania, Ohio, United States|Oklahoma University Cancer Institute, Oklahoma City, Oklahoma, United States|Geisinger Cancer Institute at Geisinger Health, Danville, Pennsylvania, United States|Fox Chase Cancer Center Buckingham, Furlong, Pennsylvania, United States|Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States|McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center, Reading, Pennsylvania, United States|York Cancer Center at Apple Hill Medical Center, York, Pennsylvania, United States|Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Sentara Cancer Institute at Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States|Schiffler Cancer Center at Wheeling Hospital, Wheeling, West Virginia, United States|Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Gundersen Lutheran Center for Cancer and Blood, La Crosse, Wisconsin, United States|Bay Area Cancer Care Center at Bay Area Medical Center, Marinette, Wisconsin, United States|Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States|Veterans Affairs Medical Center - Milwaukee, Milwaukee, Wisconsin, United States|Regional Cancer Center at Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|Waukesha Memorial Hospital Regional Cancer Center, Waukesha, Wisconsin, United States",C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,18.0,163.518758085381,548.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.01,475.35400000000004,59.51,6.0,1.0,4.0,47.1,118.63,6.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0
COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,0,DB05294,__VANDETANIB,RE42353,Withdrawn,NCT00937417,"BREAST CANCER|HEAD AND NECK CANCER|LUNG CANCER|PROSTATE CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,18.0,163.518758085381,548.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.01,475.35400000000004,59.51,6.0,1.0,4.0,47.1,118.63,6.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0
CCOc1ccc(-c2nc(-c3cccc(C(=O)O)n3)cs2)cc1OCC,0,DB05298,__TETOMILAST,5643932,Terminated,,ULCERATIVE COLITIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D417/14,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,25.4296802809092,35.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.38,370.42199999999997,81.54,6.0,1.0,3.0,39.86,107.91,7.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0
NCCc1c[nH]cn1,0,DB05381,__HISTAMINE,,Terminated,NCT01777464,HOUSE DUST MITE ALLERGY,All,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,"uz leuven ORL, Leuven, Vlaams Brabant, Belgium",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,111.1451,54.7,2.0,2.0,1.0,12.08,31.66,2.0,0.0,1.0,0.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0
NCCc1c[nH]cn1,0,DB05381,__HISTAMINE,,Terminated,NCT00387738,"RHINITIS, ALLERGIC, SEASONAL",All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Center Of Research Excellence, Oxford, Alabama, United States|Atlanta Allergy & Asthma Clinic, Stockbridge, Georgia, United States|Clinical Research of Atlanta, Stockbridge, Georgia, United States|Sneeze, Wheeze, and Itch Associates, Normal, Illinois, United States|Research Center of Indiana, Indianapolis, Indiana, United States|Asthma and Allergy Research Center, Minneapolis, Minnesota, United States|Clinical Research Institute, Plymouth, Minnesota, United States|Clinical Research of the Ozarks, Columbia, Missouri, United States|Clinical Research of The Ozarks, Rolla, Missouri, United States|Clinical Research Center, Saint Louis, Missouri, United States|Clinical Research of the Ozarks, Warrensburg, Missouri, United States|Midwest Allergy & Asthma Clinic, Omaha, Nebraska, United States|Creighton University, Omaha, Nebraska, United States|Asthma & Allergy Center, Papillion, Nebraska, United States|Princeton Center for Clinical Research, Skillman, New Jersey, United States|Allergy & Asthma Center, High Point, North Carolina, United States|Allergy & Respiratory Center, Canton, Ohio, United States|Bernstein Clinical Research Center, Cincinnati, Ohio, United States|Allergy, Asthma and Clinical Research Center, Oklahoma City, Oklahoma, United States|Asthma & Allergy Research Associates, Upland, Pennsylvania, United States|AARA Research Center, Dallas, Texas, United States|Pharmaceutical Research & Consulting, Dallas, Texas, United States|Kerrville Allergy and Asthma Associates, Kerrville, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States|Sylvana Research, San Antonio, Texas, United States|Asthma, Allergy & Sinus Center, Greenfield, Wisconsin, United States|University of Wisconsin Madison Medical School, Madison, Wisconsin, United States|Advanced Healthcare, Milwaukee, Wisconsin, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,111.1451,54.7,2.0,2.0,1.0,12.08,31.66,2.0,0.0,1.0,0.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0
CC(=O)[O-].CC(=O)[O-].CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[n-]2)C(CCCO)=C4C)C(C)=C3CCCO.[Gd+3],0,DB05428,__MOTEXAFIN_GADOLINIUM,,Terminated,NCT00080028,HEAD AND NECK CANCER|OROPHARYNX CANCER|LARYNX CANCER|HYPOPHARYNX CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duke University Medical Center, Durham, North Carolina, United States|University of Texas, San Antonio Health Science Center, San Antonio, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.95,1148.4,178.75,15.0,2.0,5.0,103.73,243.08,28.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1
CS(=O)(=O)O.O=c1[nH]c2c(c3ccccc13)Cc1cc(S(=O)(=O)NCCCN3CCOCC3)ccc1-2,0,DB05549,__INO-1001,,Terminated,,MELANOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.22,535.63,87.74,5.0,2.0,5.0,47.65,121.05,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1
CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21,0,DB05575,__MOTESANIB,US-20030125339-A1,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,62.0,48.9209224008706,24.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.59,373.4509,78.94,5.0,3.0,4.0,40.66,114.77,5.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1
CC1(C)CC(OC(=O)C2CC2)CC(C)(C)N1O,0,DB05650,__OT-551,,Terminated,NCT00333060,EPIRETINAL MEMBRANE|MACULAR HOLE,All,"50 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,"Peoria, Arizona, United States|Beverly Hills, California, United States|Sacramento, California, United States|Denver, Colorado, United States|Miami, Florida, United States|Tallahassee, Florida, United States|Chicago, Illinois, United States|Joliet, Illinois, United States|Baltimore, Maryland, United States|Cherry Hill, New Jersey, United States|Forrest Hills, New Jersey, United States|New York, New York, United States|Cleveland, Ohio, United States|Bala Cynwyd, Pennsylvania, United States|West Chester, Pennsylvania, United States|Abilene, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,241.331,49.77,3.0,1.0,2.0,26.92,64.85,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0
CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,0,DB05676,__APREMILAST,6020358,Terminated,NCT00889421,UVEITIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oregon Health & Science University, Portland, Oregon, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,15.0803917944927,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.86,460.5,119.08,7.0,1.0,3.0,46.71,119.1,8.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0
CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl,0,DB05943,__RESATORVID,US-20110184034-A1,Terminated,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,32.7488,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.45,361.81,72.47,3.0,1.0,2.0,33.37,85.5,5.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,1
CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,0,DB06195,__SELICICLIB,US-20020049218-A1,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61P17/00 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,32.7488,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.11,354.4493,87.89,6.0,3.0,3.0,40.43,106.14,8.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,1,1,1,1,0,0,1,1,1,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1
NC(=O)c1cn(Cc2c(F)cccc2F)nn1,0,DB06201,__RUFINAMIDE,6740669,Withdrawn,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D249/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,68.5352881989363,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.95,238.1935,73.8,3.0,1.0,2.0,20.42,67.07,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0
NCCCC(N)(C(=O)O)C(F)F,0,DB06243,__EFLORNITHINE,4330559,Terminated,NCT00033371,COLORECTAL CANCER|FAMILIAL ADENOMATOUS POLYPOSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M D Anderson Cancer Center, Houston, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,15.408940635331302,178.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-2.0,182.171,89.34,4.0,3.0,0.0,15.8,37.73,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0
NCCCC(N)(C(=O)O)C(F)F,0,DB06243,__EFLORNITHINE,4330559,Withdrawn,NCT01245816,FAMILIAL ADENOMATOUS POLYPOSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,15.408940635331302,178.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-2.0,182.171,89.34,4.0,3.0,0.0,15.8,37.73,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0
CCOc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)cn1,0,DB06346,__FIBOFLAPON,US-20070105866-A1,Terminated,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,56.4775457401589,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.63,637.84,86.47,6.0,1.0,5.0,73.86,186.32,13.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,0,1,0,1,1,0,1,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1
NC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1,0,DB06413,__ARMODAFINIL,4927855,Terminated,NCT01219673,HEAD AND NECK CANCER,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","UT MD Anderson Cancer Center, Houston, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,39.754409741473104,527.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.75,273.35,60.16,2.0,1.0,2.0,28.2,77.39,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0
CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CC[C@H](NCCCNCCCCN)C[C@@H]1C[C@H]3O)OS(=O)(=O)O,0,DB06461,__SQUALAMINE,5607691,Terminated,NCT00139282,"""WET"" AGE-RELATED MACULAR DEGENERATION",All,"50 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States|Eldorado Retina Associates, Louisville, Colorado, United States|Florida Eye Microsurgical Institute, Boynton Beach, Florida, United States|National Ophthalmic Research Institute, Fort Myers, Florida, United States|University of Florida, Jacksonville, Florida, United States|Magruder Eye Institute, Orlando, Florida, United States|East Florida Eye Institute, Stuart, Florida, United States|Retina Associates of Florida, Tampa, Florida, United States|Center for Retina and Macular Disease, Winter Haven, Florida, United States|Midwest Eye Institute, Indianapolis, Indiana, United States|Retina Associates, PA, Shawnee Mission, Kansas, United States|Cumberland Valley Retina Consultants, PC, Hagerstown, Maryland, United States|Delaware Valley Retina Associates, Lawrenceville, New Jersey, United States|Retina Associates of New Jersey, Teaneck, New Jersey, United States|MaculaCare, New York, New York, United States|Charlotte Eye, Ear, Nose & Throat Associates, Charlotte, North Carolina, United States|Horizon Eye Care, Charlotte, North Carolina, United States|The Ohio State University, Havener Eye Institute, Columbus, Ohio, United States|Penn State Ophthalmology, Hershey, Pennsylvania, United States|Retina Vitreous Consultants, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Genaera Corporation, Plymouth Meeting, Pennsylvania, United States|Carolina Retina Center, Columbia, South Carolina, United States|Black Hills Regional Eye Institute, Rapid City, South Dakota, United States|Southeastern Retina Associates, Kingsport, Tennessee, United States|Retina Research Center, Austin, Texas, United States|Garcia & Associates, MD, PA, Houston, Texas, United States|John Moran Eye Center, Salt Lake City, Utah, United States|Virginia Retina Center, Leesburg, Virginia, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,21.3556746545103,338.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.48,627.97,133.91,7.0,5.0,4.0,77.15,174.42,16.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,0,0,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,0
CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CC[C@H](NCCCNCCCCN)C[C@@H]1C[C@H]3O)OS(=O)(=O)O,0,DB06461,__SQUALAMINE,5607691,Withdrawn,NCT02511613,AGE-RELATED MACULAR DEGENERATION,All,"50 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Investigational Site, Beverly Hills, California, United States|Investigational Site, Hagerstown, Maryland, United States|Investigational Site, New York, New York, United States|Investigational Site, Houston, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,21.3556746545103,338.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.48,627.97,133.91,7.0,5.0,4.0,77.15,174.42,16.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,0,0,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,0
CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CC[C@H](NCCCNCCCCN)C[C@@H]1C[C@H]3O)OS(=O)(=O)O,0,DB06461,__SQUALAMINE,5607691,Withdrawn,NCT02349516,DIABETIC RETINOPATHY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NJ Retina, New Brunswick, New Jersey, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,21.3556746545103,338.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.48,627.97,133.91,7.0,5.0,4.0,77.15,174.42,16.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,0,0,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,0
COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)cc1,0,DB06510,__MURAGLITAZAR,EP-1607103-A1,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,29.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.04,516.55,111.33,6.0,1.0,4.0,54.85,149.03,12.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0
CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(=O)O,0,DB06536,__TESAGLITAZAR,6258850,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07C309/65,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,23.688371424464503,77.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.18,408.465,99.13,6.0,1.0,2.0,42.56,103.52,11.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C,0,DB06573,__REBIMASTAT,WO-2003048119-A2,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.75,499.67,127.92,5.0,4.0,1.0,54.52,131.54,11.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,0,DB06589,__PAZOPANIB,7105530,Terminated,NCT01362348,MACULAR DEGENERATION,All,"50 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Winter Haven, Florida, United States|GSK Investigational Site, Decatur, Georgia, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Grand Rapids, Michigan, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Paris cedex 10, France|GSK Investigational Site, Paris cedex 12, France|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Bonn, Nordrhein-Westfalen, Germany|GSK Investigational Site, Muenster, Nordrhein-Westfalen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany",C07D231/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,56.773239696913606,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.59,437.51800000000003,119.03,7.0,2.0,4.0,45.41,132.18,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,1,1,1,1,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0
CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(=O)O)C[C@H]1NC(=N)N,0,DB06614,__PERAMIVIR,6562861,Terminated,NCT00958776,COUGH|SORE THROAT|NASAL CONGESTION|HEADACHE|FEVER|SEASONAL INFLUENZA,All,"12 Years and older   (Child, Adult, Older Adult)",Industry|U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","La Mesa, California, United States|Long Beach, California, United States|Modesto, California, United States|Oceanside, California, United States|Pulmonary Consultants PC Physicians Medical Group, Inc., Orange, California, United States|Orange, California, United States|UC Davis Medical Center, Sacramento, California, United States|Sharp Chula Vista Medical Center, San Diego, California, United States|San Diego, California, United States|Denver, Colorado, United States|Drogue Medical, LLC, Wheat Ridge, Colorado, United States|Washington Hospital Center CAR, Washington, District of Columbia, United States|Washington, District of Columbia, United States|Ft. Lauderdale, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|West Palm Beach, Florida, United States|Florida Hospital, Winter Park, Florida, United States|Columbus, Georgia, United States|DeKalb Medical Center, Decatur, Georgia, United States|Savannah, Georgia, United States|Honolulu, Hawaii, United States|Medical Arts Associates, Ltd., Moline, Illinois, United States|Springfield, Illinois, United States|South Bend, Indiana, United States|Kentucky Lung Clinic, Hazard, Kentucky, United States|Natchitoches, Louisiana, United States|New Orleans, Louisiana, United States|Annapolis, Maryland, United States|Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Wayne State University - Hutzel Hospital, Detroit, Michigan, United States|Wayne State University, Department of Emergency Medicine, Detroit, Michigan, United States|Detroit, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|William Beaumont Hospital, Troy, Michigan, United States|Washington University School of Medicine, St. Louis, Missouri, United States|St. Louis, Missouri, United States|Las Vegas, Nevada, United States|New Brunswick, New Jersey, United States|Bronx, New York, United States|Manhasset, New York, United States|New York, New York, United States|University of North Carolina at Chapel Hill AIDS Clinical Trials Unit, Chapel Hill, North Carolina, United States|Remington-Davis, Inc., Columbus, Ohio, United States|Dayton, Ohio, United States|Kettering, Ohio, United States|Regional Infection Diseases Infusion Center Inc., Lima, Ohio, United States|ID Clinical Research, LTD, Toledo, Ohio, United States|Medical College Of Ohio, Toledo, Ohio, United States|Toledo, Ohio, United States|Allentown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|East Providence, Rhode Island, United States|Charleston, South Carolina, United States|Sioux Falls, South Dakota, United States|San Antonio, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Carilion Infectious Disease, Roanoke, Virginia, United States|VA Medical Center - Salem, Salem, Virginia, United States|Hospital del Torax Dr. Antonio A. Cetrangolo, Buenos Aires, Argentina|Buenos Aires, Argentina|Caba, Argentina|Cordoba, Argentina|Mendoza, Argentina|Merlo, Argentina|Rosario, Argentina|Santa Fe, Argentina|Vicente Lopez, Argentina|Bruxelles, Belgium|Liege, Belgium|Mons, Belgium|Sarajevo, Bosnia and Herzegovina|Tuzla, Bosnia and Herzegovina|Belo Horizonte, MG, Brazil|Curitiba, PR, Brazil|Passo Fundo, RS, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil|Porto Alegre, RS, Brazil|Campinas, SP, Brazil|Santo Andre, SP, Brazil|Santos, SP, Brazil|Sao Paulo, SP, Brazil|Plovdiv, Bulgaria|DDPPDI - Ruse, Ruse, Bulgaria|Fifth MHAT-Sofia, AD, Sofia, Bulgaria|MHAT - Tokuda Hospital Sofia, AD, Sofia, Bulgaria|Military Medical Academy - MHAT, Sofia, Bulgaria|Sofia, Bulgaria|MHAT - Tokuda Hospital Sofia, AD, Stara Zagora, Bulgaria|MHAT 'Dr. St. Cherkezov', AD, Veliko Tarnovo, Bulgaria|Kelowna, British Columbia, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|Kingston, Ontario, Canada|Toronto, Ontario, Canada|Chicoutimi, Quebec, Canada|Sherbrooke, Quebec, Canada|Quebec, Canada|Hospital Clinico Regional Dr. Guillermo Grant Benavente, Concepcion, Chile|Hosp. de Urgencia Asistencia Publica Dr. Alejandro del Rio, Santiago, Chile|Santiago, Chile|Temuco, Chile|Fakultni nemocnice Brno, Brno, Czech Republic|Hradec Kralove, Czech Republic|Praha, Czech Republic|Tabor, Czech Republic|Krajska zdravotni, a.s. - Masarykova nemocnice v Ustinad La, Usti nad Labem, Czech Republic|Berlin, Germany|Erlangen, Germany|Goettingen, Germany|Koeln, Germany|Mainz, Germany|Universitaetsklinikum Regensburg, Regensburg, Germany|Debrecen, Hungary|Fehergyarmat, Hungary|Fejer Megyei Szent Gyorgy Korhaz, Szekesfehervar, Hungary|Principal SMO Dr. Bugyi Istvan Korhaz Szentes, Szentes, Hungary|Zalaegerszeg, Hungary|Hyderabad, Andhra Pradesh, India|Secunderabad, Andhra Pradesh, India|Ahmedabad, Gujarat, India|Karamsad, Gujarat, India|Surat, Gujarat, India|Vadodara, Gujarat, India|Faridabad, Haryana, India|Srinagar, Jammu & Kashmir, India|Bangalore, Karnataka, India|Mangalore, Karnataka, India|Ernakulam, Kerala, India|Thrissur, Kerala, India|Trivandrum, Kerala, India|Cherthala, Maharashtra, India|Mumbai, Maharashtra, India|Nagpur, Maharashtra, India|Nashik, Maharashtra, India|Pune, Maharashtra, India|Mohali, Punjab, India|Bikaner, Rajasthan, India|Fortis Escort Hospital, Jaipur, Rajasthan, India|Apollo First Med Hospitals, Chennai, Tamil Nadu, India|Life Line Multispecialty Hospital, Chennai, Tamil Nadu, India|Chennai, Tamil Nadu, India|Coimbatore, Tamil Nadu, India|Lucknow, Uttar Pradesh, India|Kolkata, West Bengal, India|Delhi, India|Afula, Israel|Haifa, Israel|Holon, Israel|Jerusalem, Israel|Kfar Saba, Israel|Ramat Gan, Israel|Tel Aviv, Israel|Liepaja, Latvia|Rezekne, Latvia|Valmiera, Latvia|Ventspils, Latvia|Beirut, Lebanon|Arequipa, Peru|Cuzco, Peru|Lima, Peru|Bydgoszcz, Poland|Lancut, Poland|Lodz, Poland|Mielec, Poland|Poznan, Poland|Pulawy, Poland|Engels, Russian Federation|Niznhy Novgorod, Russian Federation|Novosibirsk, Russian Federation|St. Petersburg, Russian Federation|Tomsk, Russian Federation|Belgrade, Serbia|Kragujevac, Serbia|Nis, Serbia|Novi Sad, Serbia|Trnava, Slovakia|Middelburg, Mpumalanga, South Africa|Bloemfontein, South Africa|Dundee, South Africa|Durban, South Africa|Krugersdorp, South Africa|Limpopo, South Africa|Port Elizabeth, South Africa|Pretoria, South Africa|Somerset West, South Africa|Worcester, South Africa|Chernivci, Ukraine|Donetsk, Ukraine|Kharkiv, Ukraine|Kyiv, Ukraine|Odesa, Ukraine|Poltava, Ukraine|Sumy, Ukraine|Vinnytsya, Ukraine|Leicester, United Kingdom",C07D339/08,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,41.0,35.5818394628226,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.27,328.4072,148.53,7.0,6.0,1.0,34.85,94.46,7.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0
CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1,0,DB06626,__AXITINIB,6534524,Terminated,NCT01533948,EXTRAOCULAR EXTENSION MELANOMA|METASTATIC INTRAOCULAR MELANOMA|RECURRENT INTRAOCULAR MELANOMA|RECURRENT MELANOMA|STAGE IIIA INTRAOCULAR MELANOMA|STAGE IIIA MELANOMA|STAGE IIIB INTRAOCULAR MELANOMA|STAGE IIIB MELANOMA|STAGE IIIC INTRAOCULAR MELANOMA|STAGE IIIC MELANOMA|STAGE IV INTRAOCULAR MELANOMA|STAGE IV MELANOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",C07D401/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,14.0,16.7231359986858,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.17,386.47,70.67,3.0,2.0,4.0,42.58,115.14,5.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,0
CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1,0,DB06641,__PERIFOSINE,EP-1135193-B1,Terminated,NCT00062387,HEAD AND NECK CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago Cancer Research Center, Chicago, Illinois, United States|Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States|Evanston Northwestern Health Care - Evanston Hospital, Evanston, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|LaGrange Memorial Hospital, LaGrange, Illinois, United States|Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, United States|Oncology/Hematology Associates of Central Illinois, P.C., Peoria, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Fort Wayne Medical Oncology and Hematology, Incorporated, Fort Wayne, Indiana, United States|CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States|Oncology Care Associates, P.L.L.C., Saint Joseph, Michigan, United States|Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,34.7933222448099,15.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.82,461.668,58.59,2.0,0.0,1.0,58.14,142.15,20.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0
C[C@@H](O[C@H]1OCCN(Cc2nc(=O)n(P(=O)(O)O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,0,DB06717,__FOSAPREPITANT,5691336,Terminated,NCT00895245,NAUSEA AND VOMITING|STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",C07D413/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,25.0,26.5796012238444,22.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.89,614.4066,123.93,9.0,3.0,4.0,49.92,138.63,9.0,0.0,1.0,0.0,0,1,1,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,0,1,0,1
CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O,0,DB06791,__LANREOTIDE,5595760,Terminated,NCT00288522,THYROID-ASSOCIATED OPHTHALMOPATHY,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Hospital General d'Alacant, Alicante, Spain",A61M5/284,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,22.505595597445502,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.87,1096.33,355.08,12.0,13.0,6.0,114.68,292.92,17.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,0,1,0,1,0,0
NCCNCCNCCN,0,DB06824,__TRIETHYLENETETRAMINE,3931122,Terminated,NCT01213888,DIABETIC RETINOPATHY,All,"19 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Care Provider)","Eye Care Centre - Vancouver Coastal Health, Vancouver, British Columbia, Canada",C02F1/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,23.3926774677098,4248.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,146.2339,76.1,4.0,4.0,0.0,18.04,43.32,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
NCCNCCNCCN,0,DB06824,__TRIETHYLENETETRAMINE,3931122,Withdrawn,NCT01295073,MACULAR EDEMA FOLLOWING CATARACT SURGERY,All,"19 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Univeristy of British Columbia/Vancouver Coastal Health Authority - Eye Care Center, Vancouver, British Columbia, Canada",C02F1/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,23.3926774677098,4248.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,146.2339,76.1,4.0,4.0,0.0,18.04,43.32,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
Oc1ccc([C@@H]2Oc3ccc(O)cc3[C@@H]3CCC[C@@H]32)cc1,0,DB07933,__ERTEBEREL,,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.85,282.3337,49.69,3.0,2.0,4.0,30.27,80.5,1.0,0.0,1.0,0.0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1
CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1,0,DB07941,__PH-797804,US-20040058964-A1,Withdrawn,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D213/64,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,70.0,40.3786525390665,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,477.29900000000004,58.64,3.0,1.0,3.0,43.79,116.85,4.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0
Cn1cc(-c2ccncc2)c(-c2ccc(OCc3ccc4ccccc4n3)cc2)n1,0,DB08387,__MARDEPODECT,WO-2005120514-A1,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,32.7488,128.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.01,392.4525,52.83,4.0,0.0,5.0,43.9,127.18,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1
CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1,0,DB08828,__VISMODEGIB,7888364,Suspended,NCT02523014,INTRACRANIAL MENINGIOMA|RECURRENT MENINGIOMA|NF2 GENE MUTATION,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Arizona Oncology Services Foundation, Scottsdale, Arizona, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|PCR Oncology, Arroyo Grande, California, United States|Sutter Auburn Faith Hospital, Auburn, California, United States|Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States|Eden Hospital Medical Center, Castro Valley, California, United States|Sutter Davis Hospital, Davis, California, United States|Kaiser Permanente-Fremont, Fremont, California, United States|Palo Alto Medical Foundation-Fremont, Fremont, California, United States|Kaiser Permanente-Fresno, Fresno, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Memorial Medical Center, Modesto, California, United States|Kaiser Permanente-Modesto, Modesto, California, United States|Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States|Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States|USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States|Sutter Cancer Research Consortium, Novato, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|Palo Alto Medical Foundation Health Care, Palo Alto, California, United States|Keck Medical Center of USC Pasadena, Pasadena, California, United States|Kaiser Permanente-Redwood City, Redwood City, California, United States|Kaiser Permanente-Richmond, Richmond, California, United States|Kaiser Permanente-Roseville, Roseville, California, United States|Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States|Sutter Roseville Medical Center, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente-South Sacramento, Sacramento, California, United States|Kaiser Permanente - Sacramento, Sacramento, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Kaiser Permanente San Leandro, San Leandro, California, United States|Kaiser Permanente-San Rafael, San Rafael, California, United States|Kaiser San Rafael-Gallinas, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Kaiser Permanente-Stockton, Stockton, California, United States|Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, United States|Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|Grand Valley Oncology, Grand Junction, Colorado, United States|Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Rocky Mountain Cancer Centers-Parker, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers-Thornton, Thornton, Colorado, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Mount Sinai Comprehensive Cancer Center at Aventura, Aventura, Florida, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Cancer Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Cancer Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Radiation Oncology of Northern Illinois, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, United States|Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States|Memorial Regional Cancer Center Day Road, Mishawaka, Indiana, United States|Reid Health, Richmond, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Mary Greeley Medical Center, Ames, Iowa, United States|McFarland Clinic PC - Ames, Ames, Iowa, United States|McFarland Clinic PC-Boone, Boone, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|McFarland Clinic PC-Trinity Cancer Center, Fort Dodge, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|McFarland Clinic PC-Jefferson, Jefferson, Iowa, United States|McFarland Clinic PC-Marshalltown, Marshalltown, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Kansas Institute of Medicine Cancer and Blood Center, Lenexa, Kansas, United States|Minimally Invasive Surgery Hospital, Lenexa, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas-Manhattan, Manhattan, Kansas, United States|Cancer Center of Kansas - McPherson, McPherson, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Ascension Via Christi Hospitals Wichita, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Oncology Hematology Care Inc-Crestview, Crestview Hills, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|Caro Cancer Center, Caro, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, United States|Beaumont Hospital - Dearborn, Dearborn, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, United States|Genesee Hematology Oncology PC, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Academic Hematology Oncology Specialists, Grosse Pointe Woods, Michigan, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, United States|Saint Mary's Oncology/Hematology Associates of Marlette, Marlette, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Hospital Niles, Niles, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Hope Cancer Center, Pontiac, Michigan, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Great Lakes Cancer Management Specialists-Rochester Hills, Rochester Hills, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Advanced Breast Care Center PLLC, Warren, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, United States|Macomb Hematology Oncology PC, Warren, Michigan, United States|Michigan Breast Specialists-Warren, Warren, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Essentia Health Saint Joseph's Medical Center, Brainerd, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Lake Region Healthcare Corporation-Cancer Care, Fergus Falls, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Essentia Health Hibbing Clinic, Hibbing, Minnesota, United States|Fairview Clinics and Surgery Center Maple Grove, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Essentia Health Virginia Clinic, Virginia, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri, United States|Central Care Cancer Center - Bolivar, Bolivar, Missouri, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Cox Cancer Center Branson, Branson, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital Joplin, Joplin, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Liberty Radiation Oncology Center, Liberty, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Mercy Hospital Washington, Washington, Missouri, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|Nebraska Medicine-Bellevue, Bellevue, Nebraska, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|Heartland Hematology and Oncology, Kearney, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Nebraska Medicine-Village Pointe, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Hematology and Oncology Consultants PC, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Carson Tahoe Regional Medical Center, Carson City, Nevada, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson, Nevada, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States|OptumCare Cancer Care at Seven Hills, Henderson, Nevada, United States|21st Century Oncology-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States|Desert West Surgery, Las Vegas, Nevada, United States|OptumCare Cancer Care at Oakey, Las Vegas, Nevada, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Shadow, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, United States|21st Century Oncology, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, United States|Cancer Therapy and Integrative Medicine, Las Vegas, Nevada, United States|21st Century Oncology-Vegas Tenaya, Las Vegas, Nevada, United States|Ann M Wierman MD LTD, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, United States|OptumCare Cancer Care at MountainView, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada, United States|21st Century Oncology-Fort Apache, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|OptumCare Cancer Care at Fort Apache, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|University Cancer Center, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada-Pahrump, Pahrump, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Saint Mary's Regional Medical Center, Reno, Nevada, United States|Radiation Oncology Associates, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, United States|Montefiore Medical Center-Weiler Hospital, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Glens Falls Hospital, Glens Falls, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Northwell Health/Center for Advanced Medicine, Lake Success, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|Lenox Hill Hospital, New York, New York, United States|Mount Sinai Hospital, New York, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|NYP/Weill Cornell Medical Center, New York, New York, United States|AdventHealth Infusion Center Asheville, Asheville, North Carolina, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|AdventHealth Hendersonville, Hendersonville, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Essentia Health Cancer Center-South University Clinic, Fargo, North Dakota, United States|Indu and Raj Soin Medical Center, Beavercreek, Ohio, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Dayton Physicians LLC-Miami Valley South, Centerville, Ohio, United States|Miami Valley Hospital South, Centerville, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Oncology Hematology Care Inc-Eden Park, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Mercy West, Cincinnati, Ohio, United States|University of Cincinnati/Barrett Cancer Center, Cincinnati, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Anderson, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Blue Ash, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Dayton Physician LLC-Miami Valley Hospital North, Dayton, Ohio, United States|Miami Valley Hospital North, Dayton, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Delaware Radiation Oncology, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Oncology Hematology Care Inc-Healthplex, Fairfield, Ohio, United States|Armes Family Cancer Center, Findlay, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Orion Cancer Care, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Dayton Physicians LLC-Atrium, Franklin, Ohio, United States|Dayton Physicians LLC-Wayne, Greenville, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|First Dayton Cancer Care, Kettering, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|OhioHealth Mansfield Hospital, Mansfield, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|OhioHealth Marion General Hospital, Marion, Ohio, United States|Dayton Physicians LLC-Signal Point, Middletown, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|Dayton Physicians LLC-Wilson, Sidney, Ohio, United States|Springfield Regional Cancer Center, Springfield, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|Dayton Physicians LLC-Upper Valley, Troy, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|University Pointe, West Chester, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Cancer Institute Clackamas Clinic, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|UPMC-Heritage Valley Health System Beaver, Beaver, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|UPMC Cancer Centers - Arnold Palmer Pavilion, Greensburg, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazleton, Hazleton, Pennsylvania, United States|UPMC-Johnstown/John P. Murtha Regional Cancer Center, Johnstown, Pennsylvania, United States|Geisinger Medical Oncology-Lewisburg, Lewisburg, Pennsylvania, United States|Lewistown Hospital, Lewistown, Pennsylvania, United States|UPMC Cancer Center at UPMC McKeesport, McKeesport, Pennsylvania, United States|UPMC-Coraopolis/Heritage Valley Radiation Oncology, Moon, Pennsylvania, United States|UPMC-Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Saint Margaret, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|UPMC-Shadyside Hospital, Pittsburgh, Pennsylvania, United States|UPMC Jefferson Regional Radiation Oncology, Pittsburgh, Pennsylvania, United States|UPMC-Passavant Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Saint Clair Hospital Cancer Center, Pittsburgh, Pennsylvania, United States|Geisinger Cancer Services-Pottsville, Pottsville, Pennsylvania, United States|Community Medical Center, Scranton, Pennsylvania, United States|Geisinger Medical Oncology-Selinsgrove, Selinsgrove, Pennsylvania, United States|UPMC Cancer Center at UPMC Northwest, Seneca, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|UPMC Uniontown Hospital Radiation Oncology, Uniontown, Pennsylvania, United States|UPMC Washington Hospital Radiation Oncology, Washington, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States|Gibbs Cancer Center-Gaffney, Gaffney, South Carolina, United States|Greenville Health System Cancer Institute-Andrews, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Butternut, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Faris, Greenville, South Carolina, United States|Prisma Health Greenville Memorial Hospital, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Eastside, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Greer, Greer, South Carolina, United States|Gibbs Cancer Center-Pelham, Greer, South Carolina, United States|Prisma Health Cancer Institute - Seneca, Seneca, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Prisma Health Cancer Institute - Spartanburg, Spartanburg, South Carolina, United States|MGC Hematology Oncology-Union, Union, South Carolina, United States|Memorial Hospital, Chattanooga, Tennessee, United States|Vanderbilt-Ingram Cancer Center Cool Springs, Franklin, Tennessee, United States|Pulmonary Medicine Center of Chattanooga-Hixson, Hixson, Tennessee, United States|Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Memorial GYN Plus, Ooltewah, Tennessee, United States|Dell Seton Medical Center at The University of Texas, Austin, Texas, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|Parkland Memorial Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Memorial Hermann Texas Medical Center, Houston, Texas, United States|Farmington Health Center, Farmington, Utah, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|South Jordan Health Center, South Jordan, Utah, United States|Central Vermont Medical Center/National Life Cancer Treatment, Berlin, Vermont, United States|University of Vermont Medical Center, Burlington, Vermont, United States|University of Vermont and State Agricultural College, Burlington, Vermont, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Inova Schar Cancer Institute, Fairfax, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|Cancer Care Center at Island Hospital, Anacortes, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Peninsula Cancer Center, Poulsbo, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Kaiser Permanente Washington, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|Olympic Medical Cancer Care Center, Sequim, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|MultiCare Deaconess Cancer and Blood Specialty Center - Valley, Spokane Valley, Washington, United States|MultiCare Deaconess Cancer and Blood Specialty Center - Downtown, Spokane, Washington, United States|MultiCare Deaconess Cancer and Blood Specialty Center - North, Spokane, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|United Hospital Center, Bridgeport, West Virginia, United States|WVUH-Berkely Medical Center, Martinsburg, West Virginia, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|Camden Clark Medical Center, Parkersburg, West Virginia, United States|Duluth Clinic Ashland, Ashland, Wisconsin, United States|Aurora Cancer Care-Southern Lakes VLCC, Burlington, Wisconsin, United States|Marshfield Clinic-Chippewa Center, Chippewa Falls, Wisconsin, United States|Marshfield Clinic Cancer Center at Sacred Heart, Eau Claire, Wisconsin, United States|Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin, United States|Aurora Health Center-Fond du Lac, Fond Du Lac, Wisconsin, United States|Aurora Health Care Germantown Health Center, Germantown, Wisconsin, United States|Aurora Cancer Care-Grafton, Grafton, Wisconsin, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|Aurora Cancer Care-Kenosha South, Kenosha, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Aurora Bay Area Medical Group-Marinette, Marinette, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States|Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aurora Sinai Medical Center, Milwaukee, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|ProHealth D N Greenwald Center, Mukwonago, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin, United States|Aurora Cancer Care-Racine, Racine, Wisconsin, United States|Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, United States|Vince Lombardi Cancer Clinic-Sheboygan, Sheboygan, Wisconsin, United States|Ascension Saint Michael's Hospital, Stevens Point, Wisconsin, United States|Marshfield Clinic Stevens Point Center, Stevens Point, Wisconsin, United States|Aurora Medical Center in Summit, Summit, Wisconsin, United States|Vince Lombardi Cancer Clinic-Two Rivers, Two Rivers, Wisconsin, United States|Aurora Cancer Care-Waukesha, Waukesha, Wisconsin, United States|ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States|Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States|Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States|Aurora West Allis Medical Center, West Allis, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Big Horn Basin Cancer Center, Cody, Wyoming, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States",C07D417/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,55.0,65.4469290950532,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.22,421.29699999999997,76.13,4.0,1.0,3.0,39.49,107.81,4.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,0,1,1,0,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0
CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,0,DB08868,__FINGOLIMOD,5604229,Terminated,NCT01757691,ACUTE DEMYLELINATING OPTIC NEURITIS,All,18 Years to 50 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novartis Investigative Site, St. Petersburg, Florida, United States|Novartis Investigative Site, Majadahonda, Madrid, Spain",C07C217/52,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,52.0,32.0992217499332,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,307.4708,66.48,3.0,3.0,1.0,38.81,93.28,12.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,0,DB08896,__REGORAFENIB,7351834,Terminated,NCT02222207,MACULAR DEGENERATION,All,"50 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Tucson, Arizona, United States|Arcadia, California, United States|Beverly Hills, California, United States|Campbell, California, United States|Costa Mesa, California, United States|Laguna Hills, California, United States|Mountain View, California, United States|Santa Ana, California, United States|Golden, Colorado, United States|Boynton Beach, Florida, United States|Fort Myers, Florida, United States|Miami, Florida, United States|Plantation, Florida, United States|Sarasota, Florida, United States|Stuart, Florida, United States|Winter Haven, Florida, United States|Decatur, Georgia, United States|New Albany, Indiana, United States|Leawood, Kansas, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|Eunice, Louisiana, United States|Boston, Massachusetts, United States|Grand Rapids, Michigan, United States|Florissant, Missouri, United States|Teaneck, New Jersey, United States|Asheville, North Carolina, United States|West Mifflin, Pennsylvania, United States|Greenville, South Carolina, United States|Rapid City, South Dakota, United States|Austin, Texas, United States|Houston, Texas, United States|McAllen, Texas, United States|San Antonio, Texas, United States|Temple, Texas, United States|The Woodlands, Texas, United States|Charlottesville, Virginia, United States|Strathfield, New South Wales, Australia|Sydney, New South Wales, Australia|Westmead, New South Wales, Australia|Nedlands, Western Australia, Australia|Parramatta, Australia|Wien, Austria|Wien, Austria|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Halifax, Nova Scotia, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Sherbrooke, Quebec, Canada|Osorno, Los Lagos, Chile|Metropolitana, Santiago, Chile|Vitacura, Santiago, Chile|Santiago, Chile|Bogota, Distrito Capital de Bogotá, Colombia|Hradec Kralove, Czech Republic|Praha 2, Czech Republic|Praha 4, Czech Republic|Praha 7, Czech Republic|Paris, Cedex 12, France|Boredaux, France|Lyon, France|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|München, Bayern, Germany|Bonn, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Hamburg, Germany|Hong Kong, Hong Kong|Kowloon, Hong Kong|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Pecs, Hungary|Afula, Israel|Beer Sheva, Israel|Haifa, Israel|Haifa, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Rehovot, Israel|Tel Aviv, Israel|Zerifin, Israel|Udine, Friuli-Venezia Giulia, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Firenze, Toscana, Italy|Padova, Veneto, Italy|Ancona, Italy|Bologna, Italy|Milano, Italy|Sassari, Italy|Inba-gun, Chiba, Japan|Miyako-gun, Fukuoka, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Himeji, Hyogo, Japan|Yamato, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Iga, Mie, Japan|Chofu, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Ota-ku, Tokyo, Japan|Taito-ku, Tokyo, Japan|Fukuoka, Japan|Kumamoto, Japan|Nagasaki, Japan|Nara, Japan|Osaka, Japan|Osaka, Japan|Seongnam-si, Gyeonggido, Korea, Republic of|Busan, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Bratislava, Slovakia|Ruzomberok, Slovakia|Trencin, Slovakia|Zilina, Slovakia|Zilina, Slovakia|L'Hospitalet de Llobregat, Barcelona, Spain|San Cugat del Vallès, Barcelona, Spain|Barakaldo, Vizcaya, Spain|Albacete, Spain|Barcelona, Spain|Sevilla, Spain|Sevilla, Spain|Valencia, Spain|Valencia, Spain|Valladolid, Spain|Bern, Switzerland|Lausanne, Switzerland|Zürich, Switzerland",C07D209/46,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,41.0,98.630362019754,40.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.53,482.815,92.35,3.0,3.0,3.0,41.23,114.73,6.0,0.0,1.0,0.0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,1,0,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,0,DB08936,__CHLORCYCLIZINE,4000302,Withdrawn,,SEASONAL ALLERGIC RHINITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,20.4357379001622,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.16,300.82599999999996,6.48,2.0,0.0,3.0,33.89,89.74,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,0,DB09078,__LENVATINIB,7253286,Withdrawn,NCT02915172,ADVANCED CANCER|MALIGNANT NEOPLASM OF BREAST|MALIGNANT NEOPLASMS OF BONE AND ARTICULAR CARTILAGE|MALIGNANT NEOPLASMS OF DIGESTIVE ORGANS|MALIGNANT NEOPLASMS OF EYE BRAIN AND OTHER PARTS OF CENTRAL NERVOUS SYSTEM|MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS|MALIGNANT NEOPLASMS OF ILL-DEFINED SECONDARY AND UNSPECIFIED SITES|MALIGNANT NEOPLASMS OF INDEPENDENT (PRIMARY) MULTIPLE SITES|MALIGNANT NEOPLASMS OF LIP ORAL CAVITY AND PHARYNX|MALIGNANT NEOPLASMS OF MALE GENITAL ORGANS|MALIGNANT NEOPLASMS OF MESOTHELIAL AND SOFT TISSUE|MALIGNANT NEOPLASMS OF RESPIRATORY AND INTRATHORACIC ORGANS|MALIGNANT NEOPLASMS OF THYROID AND OTHER ENDOCRINE GLANDS|MALIGNANT NEOPLASMS OF URINARY TRACT,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,51.6478777798312,65.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.03,426.86,115.57,4.0,3.0,4.0,42.29,112.21,6.0,0.0,1.0,0.0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0
O=S(=O)(O)CCS,0,DB09110,__COENZYME_M,,Terminated,NCT00623077,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|KIDNEY CANCER|LIVER CANCER|RETINOBLASTOMA|SARCOMA,All,"up to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,142.197,54.37,3.0,2.0,0.0,12.54,29.13,2.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=S(=O)(O)CCS,0,DB09110,__COENZYME_M,,Withdrawn,NCT03829566,NEUROMYELITIS OPTICA|DEVIC'S DISEASE|NMO SPECTRUM DISORDER,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,142.197,54.37,3.0,2.0,0.0,12.54,29.13,2.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O,0,DB09265,__LIXISENATIDE,7918833,Terminated,NCT02231658,DIABETES,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"St. Josef-Hospital, Universitätsklinik, Bochum, Germany|Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany",A61M5/3157,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,56.806094580997495,39.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-33.0,4858.56,2060.16,78.0,70.0,8.0,505.8,1221.37,169.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1
C[Se]CC[C@H](N)C(=O)O,0,DB11142,__SELENOMETHIONINE,,Terminated,NCT01682031,CHEMOTHERAPEUTIC AGENT TOXICITY|MUCOSITIS|RADIATION TOXICITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|XEROSTOMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Supportive Care,"Roswell Park Cancer Institute, Buffalo, New York, United States|Waikato Hospital, Hamilton, New Zealand",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.5,196.11,63.32,3.0,2.0,0.0,14.64,42.91,4.0,0.0,1.0,0.0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
OC[C@H](O)[C@@H](O)[C@H](O)CO,0,DB11195,__XYLITOL,,Withdrawn,NCT02950311,OTITIS MEDIA WITH EFFUSION,All,6 Months to 3 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.5,152.1458,101.15,5.0,5.0,0.0,14.42,32.44,4.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1,0,DB11658,__QAV-680,EP-1761529-B1,Terminated,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K45/06 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,71.9521961436579,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.73,358.41,89.26,5.0,1.0,3.0,36.7,94.91,5.0,0.0,1.0,0.0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0
Cc1cc(O[C@@H](CCC(F)(F)F)c2ccc(C(=O)NCCC(=O)O)cc2)cc(C)c1-c1ccc(C(C)(C)C)cc1,0,DB11704,__ADOMEGLIVANT,,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.28,555.638,75.63,4.0,2.0,3.0,59.13,150.1,12.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0
CCC[C@@H](Nc1c(Cc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1,0,DB11711,__NAVARIXIN,,Withdrawn,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.43,410.47,99.85,5.0,2.0,3.0,43.63,114.86,8.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0
O=C(CN[C@@H]1CCNC1)N1CCC[C@H]1B(O)O,0,DB11723,__DUTOGLIPTIN,,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.1,241.1,84.83,5.0,4.0,2.0,25.94,58.91,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0
O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO,0,DB11735,__GALACTOSE,3933788,Terminated,NCT00427986,DIABETIC MACULAR OEDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Ophthalmology, Glostrup Hospital, University of Copenhagen, Nordre Ringvej 57,, Glostrup, Denmark",C12P21/005,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,30.817881270662603,12963.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,180.1559,118.22,6.0,5.0,0.0,16.13,37.35,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0
CC(=O)NCCOC(=O)[C@H](Oc1cccc(C(F)(F)F)c1)c1ccc(Cl)cc1,0,DB11811,__ARHALOFENATE,US-20120232302-A1,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61P3/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,69.0,32.7488,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.98,415.79,64.63,3.0,1.0,2.0,38.21,95.9,9.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,1,0,0,1,1,1,0
C=Cc1c(C)c2cc3nc(c(CC(=O)N[C@@H](CC(=O)O)C(=O)O)c4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CC)c(C)c4C(=O)O)[C@@H](CCC(=O)O)[C@@H]3C,0,DB11812,__TALAPORFIN,,Terminated,NCT00102115,MACULAR DEGENERATION|CHOROIDAL NEOVASCULARIZATION,All,"50 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Texas Retina, Dallas, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.23,711.7719999999997,235.66,11.0,7.0,5.0,76.96,189.23,12.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,1,1,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0
C=Cc1c(C)c2cc3nc(c(CC(=O)N[C@@H](CC(=O)O)C(=O)O)c4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CC)c(C)c4C(=O)O)[C@@H](CCC(=O)O)[C@@H]3C,0,DB11812,__TALAPORFIN,,Terminated,,MACULAR DEGENERATION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.23,711.7719999999997,235.66,11.0,7.0,5.0,76.96,189.23,12.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,1,1,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0
COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1,0,DB11973,__TESEVATINIB,US-20080166359-A1,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,65.0,44.058399556459,12.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.51,491.39,59.51,6.0,1.0,5.0,51.0,127.76,6.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0
CN1C[C@H]2[C@@H](C1)[C@@H]2CN(Cc1ccc(F)c(Cl)c1)C(=O)c1cn(C)cn1,0,DB11993,__PF-03463275,,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.08,376.86,41.37,3.0,0.0,4.0,38.83,100.25,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,1,0
Cc1ccc2c(NC[C@](O)(CC(C)(C)c3cc(F)cc4c3OCC4)C(F)(F)F)cccc2n1,0,DB12041,__MAPRACORAT,WO-2009007137-A2,Terminated,NCT01298752,INFLAMMATION|PAIN|CATARACT,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Bausch & Lomb Incorporated, Rochester, New York, United States",A61K9/0014,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,38.0,32.7488,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.99,462.48900000000003,54.38,4.0,2.0,4.0,45.38,119.05,7.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1
COc1ccc(CC2OC(=O)NC2=O)cc1C(=O)NCc1ccc(C(F)(F)F)cc1,0,DB12055,__MK-0767,,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,422.36,93.73,4.0,2.0,3.0,38.43,99.23,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,1,1
COc1ccc(CC2OC(=O)NC2=O)cc1C(=O)NCc1ccc(C(F)(F)F)cc1,0,DB12055,__MK-0767,,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,422.36,93.73,4.0,2.0,3.0,38.43,99.23,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,1,1
CC(C)(C)c1cc(NC(=O)NCc2ccccc2Sc2ccc3nnc(-c4ccccc4SCCO)n3c2)n(-c2ccc(O)c(Cl)c2)n1,0,DB12138,__PF-03715455,7511057,Terminated,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D471/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,43.66414094745271,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.95,700.273,129.6,6.0,4.0,6.0,72.53,208.94,11.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,0,1
c1cnc2c(c1)C[C@@]1(CN3CCC1CC3)O2,0,DB12145,__AZD-0328,US-20030166935-A1,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D335/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,11.7620485020226,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.51,216.28400000000002,25.36,3.0,0.0,4.0,23.72,61.85,0.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
O=C(O)c1c(O)c(Cc2ccc(Cl)cc2)nc2c3c(ccc12)CCCC3,0,DB12211,__PSI-697,US-20050101569-A1,Terminated,NCT00367692,SCLERITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double,,C07D221/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,81.0,49.2166163576254,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.06,367.83,70.42,4.0,2.0,4.0,38.62,100.82,3.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0
O=C(N[C@@H]1CC[C@@H](c2cccc(F)c2F)CN(CC(F)(F)F)C1=O)N1CCC(n2c(=O)[nH]c3ncccc32)CC1,0,DB12228,__TELCAGEPANT,EP-2007764-B1,Terminated,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",C07D335/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,28.68231380521161,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.44,566.523,97.88,4.0,2.0,5.0,52.43,134.6,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,1,1,1,1,1,0
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(OCCOC4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0,DB12236,__BEXAGLIFLOZIN,WO-2009026537-A1,Withdrawn,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61P3/00 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,32.7488,19.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.33,464.94,108.61,7.0,4.0,4.0,49.38,118.44,9.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1
CC/C(=C(/c1ccc(/C=C/C(=O)O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl,0,DB12253,__GDC-0810,WO-2012037411-A2,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,52.0,32.7488,11.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.36,446.91,65.98,3.0,2.0,4.0,46.2,135.99,6.0,0.0,1.0,0.0,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1
OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,0,DB12310,__TREHALOSE,4010078,Withdrawn,NCT04226924,OCULOPHARYNGEAL MUSCULAR DYSTROPHY,All,"50 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ecogene-21, Chicoutimi, Quebec, Canada|Montreal Neurological Institute and Hospital, Montréal, Quebec, Canada|CHU de Québec-Université Laval- Hôpital Enfant-Jésus, Québec, Quebec, Canada",C12M41/46,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,12.222016879196598,9047.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.2,68.34,4.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
C[C@@H](O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,0,DB12406,__LISOFYLLINE,5281731,Terminated,,TYPE 1 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07F7/1804,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,14.1604550401445,245.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.78,280.328,78.67,4.0,1.0,2.0,30.03,74.65,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0
Cc1oc(-c2ccccc2)nc1COc1ccc(CO/N=C(\CCC(=O)O)c2ccccc2)cc1,0,DB12511,__IMIGLITAZAR,6251926,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,19.3515267253947,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.16,470.525,94.15,6.0,1.0,4.0,52.47,141.78,11.0,1.0,0.0,0.0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,1,0
CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC,0,DB12518,__RACLOPRIDE,6150353,Withdrawn,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,14.4890038809831,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.19,347.24,61.8,4.0,2.0,2.0,35.02,88.07,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0
O=N[O-],0,DB12529,__NITRITE,,Withdrawn,NCT02428959,DYSPHAGIA|ACHALASIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Johns Hopkins Hospital, Baltimore, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.17,46.0055,52.49,3.0,0.0,0.0,2.44,7.6,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(=O)N(C)c1cccc(-c2ccnc3c(C(=O)c4cccs4)cnn23)c1,0,DB12590,__INDIPLON,US-20030004346-A1,Terminated,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,48.9537772849545,44.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.01,376.43,67.57,4.0,0.0,4.0,39.66,114.23,4.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,1,1,1
NC(=O)C1(NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](Cc2csc3ccccc23)NC(=O)C2CCNCC2)CCNCC1,0,DB12678,__RELAMORELIN,,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.82,790.98,199.34,7.0,8.0,7.0,84.58,218.07,15.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,0,1,0,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,1,1,0,1,1,0,0,0,1,1,1,1,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0
c1ccc2c(c1)-c1nc-2nc2[nH]c(nc3nc([nH]c4nc(n1)-c1ccccc1-4)-c1ccccc1-3)c1ccccc21,0,DB12983,__PHTHALOCYANINE,3931097,Terminated,NCT00023790,BREAST CANCER|HEAD AND NECK CANCER|LYMPHOMA|METASTATIC CANCER|NON-MELANOMATOUS SKIN CANCER|SARCOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",C08F255/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,13.0762438653771,6019.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.79,514.552,108.92,6.0,2.0,9.0,57.9,155.73,0.0,1.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0
c1ccc2c(c1)-c1nc-2nc2[nH]c(nc3nc([nH]c4nc(n1)-c1ccccc1-4)-c1ccccc1-3)c1ccccc21,0,DB12983,__PHTHALOCYANINE,3931097,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C08F255/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,13.0762438653771,6019.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.79,514.552,108.92,6.0,2.0,9.0,57.9,155.73,0.0,1.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0
O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1,0,DB13061,__MLN8054,US-20050256102-A1,Terminated,,ADVANCED MALIGNANCIES,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,62.0,50.9907800981539,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.2,476.86199999999997,87.47,6.0,2.0,5.0,46.81,124.5,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,0,0,1,0,1
OCC(O)CN1CCN(c2ccccc2)CC1,0,DB13785,__DROPROPIZINE,4699911,Withdrawn,NCT01177852,INFLAMMATION|COUGH|RHINITIS,All,2 Years to 12 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07C309/00,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,13.0433889812932,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.63,236.315,46.94,4.0,2.0,2.0,26.77,68.79,4.0,0.0,1.0,0.0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1
O=C([O-])[O-].[K+].[K+],0,DB13977,__POTASSIUM_CARBONATE,,Withdrawn,,GASTRO-OESOPHAGEAL REFLUX,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.49,138.2055,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
C[C@]12CC[C@@H]3c4ccc(OC(=O)N(CCCl)CCCl)cc4CC[C@H]3[C@@H]1CC[C@@H]2OP(=O)(O)O,0,DB14674,__ESTRAMUSTINE_PHOSPHATE,,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.23,520.38,96.3,4.0,2.0,4.0,53.82,127.09,8.0,0.0,1.0,0.0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,1,1,1,1,1,0
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H]2CCCN2C(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCCN)NC(=O)[C@H](CCN)NC1=O,0,DB14777,__MUREPAVADIN,,Terminated,,PNEUMONIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.8,1553.8370000000002,617.98,22.0,22.0,7.0,161.06,403.1,21.0,1.0,0.0,0.0,0,1,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0
O=[N+]([O-])c1nccn1CC(O)C[18F],0,DB14830,__FLUOROMISONIDAZOLE_F-18,,Withdrawn,,MELANOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.46,188.149,81.19,4.0,1.0,1.0,15.65,40.27,4.0,0.0,1.0,0.0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
COc1cc2c(cc1OCCC[18F])CCN1C[C@@H](CC(C)C)[C@H](O)C[C@H]21,0,DB14945,__FLORBENAZINE_F-18,,Terminated,,TYPE 1 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.2,364.49199999999996,41.93,4.0,1.0,3.0,42.07,101.86,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0
CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2C[C@@H]3C[C@H]2CN3c2cc(C(F)(F)F)ncn2)(C(C)C)C1,0,DB14955,__PF-04634817,US-20110144129-A1,Terminated,NCT01994291,"MACULAR EDEMA, DIABETIC",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Retina Research Institute, LLC, Phoenix, Arizona, United States|Retinal Consultants of Arizona, Phoenix, Arizona, United States|Sunny View Medical Center, Phoenix, Arizona, United States|Premier Research Group Limited, Phoenix, Arizona, United States|Retina Centers, P.C., Tucson, Arizona, United States|Retina Institute of California, Arcadia, California, United States|Retina Vitreous Associates Medical Group, Beverly Hills, California, United States|Retinal Diagnostic Center, Campbell, California, United States|Retina Associates of Orange County, Laguna Hills, California, United States|Southern California Desert Retina Consultants, Palm Desert, California, United States|American Institute of Research (Administrative Only), Whittier, California, United States|New England Retina Associates, New London, Connecticut, United States|Bascom Palmer Eye Institute, Miami, Florida, United States|Fort Lauderdale Eye Institute, Plantation, Florida, United States|Center for Retina and Macular Disease, Winter Haven, Florida, United States|Southeast Retina Center, PC, Augusta, Georgia, United States|Midwest Eye Institute, Indianapolis, Indiana, United States|Tufts Medical Center, Boston, Massachusetts, United States|TLC Eyecare & Laser Center, Jackson, Michigan, United States|Wm Beaumont Medical Office Building, Royal Oak, Michigan, United States|Charlotte Eye Ear Nose and Throat Associates PA, Charlotte, North Carolina, United States|Retina Associates of Cleveland, Inc., Cleveland, Ohio, United States|Retina Associates of Cleveland, Youngstown, Ohio, United States|Dean McGee Eye Institute, Oklahoma City, Oklahoma, United States|University of Oklahoma -OU Physicians, Oklahoma City, Oklahoma, United States|Retina Vitreous Consultants, Pittsburgh, Pennsylvania, United States|Associates in Ophthalmology Ltd, West Mifflin, Pennsylvania, United States|Black Hills Regional Eye Institute, Rapid City, South Dakota, United States|Brain B.Berger,MD,PA, Austin, Texas, United States|Retina Research Center, Austin, Texas, United States|Retina Consultants of Houston, PA, Houston, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States|Rocky Mountain Retina Consultants, Salt Lake City, Utah, United States|MC Comac Medical, Sofia, Bulgaria|Fakultní nemocnice Hradec Králové, Ocni klinika, Hradec Kralove, Czech Republic|Fakultní nemocnice Hradec Králové, Nemocnicni lekarna, Hradec Kralove, Czech Republic|Fakultni nemocnice Ostrava, lekarna, Ostrava - Poruba, Czech Republic|Fakultni nemocnice Ostrava, Ocni klinika, Ostrava - Poruba, Czech Republic|Fakultni nemocnice Kralovske Vinohrady, Oftalmologicka klinika, Praha 10, Czech Republic|Fakultni nemocnice Kralovske Vinohrady, Ustavni lekarna, Praha 10, Czech Republic|Universitätsklinikum Regensburg, Regensburg, Bavaria, Germany|Charite - Universitaetsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany|Universitaetsmedizin Goettingen, Goettingen, Germany|Universitatsmedizin Mainz, Mainz, Germany|Augenärzte am St. Franziskus-Hospital, Muenster, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Knappschaftsklinikum GmbH, Sulzbach, Saar, Germany|Universitatsklinikum Tubingen, Tubingen, Germany|Semmelweis Egyetem, Szemészeti Klinika, Budapest, Hungary|Bajcsy-Zsilinszky Korhaz, Szemeszet, Budapest, Hungary|Budapest Retina Associates Kft., Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Szemklinika, Debrecen, Hungary|Ganglion Orvosi Kozpont, Pecs, Hungary|Csolnoky Ferenc Korhaz, Szemeszeti Osztaly, Veszprem, Hungary|Hadassah Medical Organization, Hadassah Medical Center, Ein Karem, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel|Kaplan Medical Center, Rehovot, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Spitalul Clinic Republican, Chisinau, Moldova, Republic of|Uniwersytecki Szpital Kliniczny Im. Jana Mikulicza Radeckiego We Wrocławiu, Klinika Okulistyki, Wroclaw, Poland|Med Life SA, Sectia Oftalmologie, Bucuresti, Romania|Institutul National de Diabet, Nutritie si Boli Metabolice ""N.C.Paulescu"", Bucuresti, Romania",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,28.5508942688761,4.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.22,511.59,79.82,7.0,1.0,5.0,51.84,128.3,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,1,1,1,0,1,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,0,1,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,0,0,0,1,0,1,0,1,1,0,1,0,1
CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2C[C@@H]3C[C@H]2CN3c2cc(C(F)(F)F)ncn2)(C(C)C)C1,0,DB14955,__PF-04634817,US-20110144129-A1,Terminated,,DIABETIC MACULAR EDEMA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,28.5508942688761,4.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.22,511.59,79.82,7.0,1.0,5.0,51.84,128.3,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,1,1,1,0,1,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,0,1,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,0,0,0,1,0,1,0,1,1,0,1,0,1
CCC[C@H](c1ccc(C(=O)NCCC(=O)O)cc1)[C@H](c1ccc(Cl)cc1)c1c[nH]c2c(F)cc(C)cc12,0,DB14957,__MK-3577,EP-2079688-B1,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,57.923160639848795,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.27,521.03,82.19,3.0,3.0,4.0,55.92,144.7,10.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CN(Cc1ccc(/C=C/C(=O)NO)cc1)CC12CC3CC(CC(C3)C1)C2,0,DB14979,__MARTINOSTAT,,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.17,354.494,52.57,3.0,2.0,4.0,40.91,105.37,6.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C(c1ccc2nonc2c1)N1CCCCC1,0,DB15012,__FARAMPATOR,6110935,Terminated,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,42.4813651204336,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.87,231.255,59.23,3.0,0.0,3.0,23.67,63.15,1.0,0.0,1.0,0.0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1
O=C(c1ccc2nonc2c1)N1CCCCC1,0,DB15012,__FARAMPATOR,6110935,Withdrawn,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,42.4813651204336,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.87,231.255,59.23,3.0,0.0,3.0,23.67,63.15,1.0,0.0,1.0,0.0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1
CCCCCCCC/C(=C\CCCCCCCC(=O)O)[N+](=O)[O-],0,DB15026,__CXA-10,WO-2009129495-A1,Withdrawn,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,32.7488,14.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.26,327.465,80.44,4.0,1.0,0.0,39.06,92.77,16.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0
CN1C(=O)c2c(nn(Cc3ccc(-c4cccc(F)n4)cc3)c2Nc2ccccc2)N2C1=N[C@@H]1CCC[C@@H]12,0,DB15039,__ITI-214,US-20120238589-A1,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,27.2695537896055,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.04,507.57300000000004,78.65,6.0,1.0,7.0,54.23,154.78,5.0,1.0,0.0,0.0,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0
CCc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc2c(c1)OCCO2,0,DB15048,__LICOGLIFLOZIN,WO-2011048112-A1,Withdrawn,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,87.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.96,416.47,108.61,7.0,4.0,4.0,44.51,109.51,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1
CN1N=C2CCN(C(=O)[C@@H](COCc3ccccc3)NC(=O)C(C)(C)N)C[C@@]2(Cc2ccccc2)C1=O,0,DB15205,__CAPROMORELIN,6107306,Terminated,,AGING,,,,,"FISABIO, Elche, Alicante, Spain",C07K5/0202,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,87.0,17.7416374052855,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.59,505.619,117.33,6.0,2.0,4.0,54.59,140.17,9.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,0,1,0,1
CC[C@@H](Oc1cccc(CN(CCCOc2ccc(OC)cc2)c2nc3ccccc3o2)c1)C(=O)O,0,DB15212,__PEMAFIBRATE,,Terminated,NCT03345901,DIABETIC RETINOPATHY|DIABETIC MACULAR EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Arizona Retina and Vitreous Consultants, Phoenix, Arizona, United States|Retinal Diagnostic Center, Campbell, California, United States|Macula & Retina Institute, Glendale, California, United States|Atlantis Eye Care, Huntington Beach, California, United States|Loma Linda University Health Care, Department of Ophthalmology, Loma Linda, California, United States|South Coast Retina Center, Long Beach, California, United States|Northern California Retina Vitreous Associates, Mountain View, California, United States|Retinal Consultants of Southern California Medical Group, Inc., Westlake Village, California, United States|National Ophthalmic Research Institute, Fort Myers, Florida, United States|University of Florida College of Med., Department of Ophthalmology, Jacksonville Health Science Cent, Jacksonville, Florida, United States|Florida Retina Consultants, Lakeland, Florida, United States|Retina Macula Specialists of Miami, Miami, Florida, United States|Florida Retina Institute, Orlando, Florida, United States|Southeast Eye Institute, P.A. dba Eye Associates of Pinellas, Pinellas Park, Florida, United States|Sarasota Retina Institute, Sarasota, Florida, United States|Emory Eye Center, Atlanta, Georgia, United States|Emory Eye Center, Atlanta, Georgia, United States|Southeast Retina Center, P.C., Augusta, Georgia, United States|Thomas Eye Group, Sandy Springs, Georgia, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|University of Illinois at Chicago Medical Center, Chicago, Illinois, United States|NorthShore University HealthSystem, Glenview, Illinois, United States|Illinois Retina Associates, S.C., Oak Park, Illinois, United States|John-Kenyon American Eye Institute, New Albany, Indiana, United States|Wolfe Eye Clinic, West Des Moines, Iowa, United States|Mid-America Retina Consultants, P.A., Overland Park, Kansas, United States|Retina Associates, P.A., Shawnee Mission, Kansas, United States|Retina and Vitreous Associates of Kentucky, Lexington, Kentucky, United States|Eye Associates of Northeast Louisiana dba Haik Humble Eye Center, West Monroe, Louisiana, United States|Eye Associates of Northeast Louisiana dba Haik Humble Eye Center, West Monroe, Louisiana, United States|Elman Retina Group, P.A., Baltimore, Maryland, United States|Wilmer Eye Institute at Johns Hopkins, Baltimore, Maryland, United States|Valley Eye Physicians and Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Dept of Ophthalmology and Eye Care Services, Detroit, Michigan, United States|Henry Ford Health System, Dept of Ophthalmology and Eye Care Services, Detroit, Michigan, United States|Vitreo-Retinal Associates, Grand Rapids, Michigan, United States|Retina Center, PA, Minneapolis, Minnesota, United States|Retina Center, PA, Minneapolis, Minnesota, United States|The Retina Institute, Saint Louis, Missouri, United States|Eye Associates of New Mexico, Albuquerque, New Mexico, United States|Eye Associates of New Mexico, Albuquerque, New Mexico, United States|MaculaCare, New York, New York, United States|Retina Associates of Western New York, Rochester, New York, United States|Retina-Vitreous Surgeons of Central New York, PC, Syracuse, New York, United States|Western Carolina Clinical Research, LLC, Asheville, North Carolina, United States|Kittner Eye Center, Chapel Hill, North Carolina, United States|Kittner Eye Center, Chapel Hill, North Carolina, United States|Charlotte Eye, Ear, Nose and Throat Assoc., PA, Charlotte, North Carolina, United States|Retina Vitreous Center, Edmond, Oklahoma, United States|Dean A. McGee Eye Institute, Oklahoma City, Oklahoma, United States|Retina Vitreous Consultants, Monroeville, Pennsylvania, United States|Southeastern Retina Associates, Chattanooga, Tennessee, United States|Southeastern Retina Associates, P.C., Knoxville, Tennessee, United States|Retina Research Center, Austin, Texas, United States|Robert E. Torti, MD, PA dba Retina Specialists, DeSoto, Texas, United States|Valley Retina Institute, DeSoto, Texas, United States|Retina Center of Texas, Grapevine, Texas, United States|Baylor Eye Physicians and Surgeons, Houston, Texas, United States|Baylor Eye Physicians and Surgeons, Houston, Texas, United States|Retina Consultants of Houston, PA, Houston, Texas, United States|Valley Retina Institute, McAllen, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States|Retinal Consultants of San Antonio, San Antonio, Texas, United States|Retina Institute of Virginia, Richmond, Virginia, United States|University of Wisconsin-Madison, Dept of Ophthalmology/Retina Service, Madison, Wisconsin, United States|UBC/VCHA Eye Care Centre, Vancouver, British Columbia, Canada|University Health Network - Toronto Western Hospital, Toronto, Canada",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,5.22,490.556,94.26,7.0,1.0,4.0,53.86,134.68,13.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CC[C@@H](Oc1cccc(CN(CCCOc2ccc(OC)cc2)c2nc3ccccc3o2)c1)C(=O)O,0,DB15212,__PEMAFIBRATE,,Terminated,,DIABETIC MACULAR EDEMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,5.22,490.556,94.26,7.0,1.0,4.0,53.86,134.68,13.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H]1CCCN1C(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](NC(=O)[C@H]1CCCN1C(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CO)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](N)CC(=O)O)C(C)C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(=N)N)C(=O)N1CCC[C@@H]1C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)NCC(N)=O)[C@H](C)O)[C@H](C)O,0,DB15231,__BRIMAPITIDE,,Terminated,,"HEARING LOSS, IDIOPATHIC SUDDEN SENSORINEURAL",,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-28.0,3822.514,1794.88,71.0,64.0,7.0,407.86,1061.81,126.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,1,1,0,1,1,1
CC[C@@H](Oc1cccc(-n2c(C)c(C(=O)c3ccc(OC)cc3)c3ccc(OC(F)(F)F)cc32)c1)C(=O)O,0,DB15242,__MK-0533,US-20050277685-A1,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D209/10,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,39.0,42.2842358159305,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.4,527.496,86.99,6.0,1.0,4.0,51.64,138.96,10.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(C)(C)c1ccc(S(=O)(=O)Nc2ccc(Cl)cc2C(=O)c2cc[n+]([O-])cc2)cc1,0,DB15250,__VERCIRNON,US-20130059893-A1,Withdrawn,,ULCERATIVE COLITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,37.848826464609104,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.15,444.93,90.18,4.0,1.0,3.0,45.01,118.09,5.0,0.0,1.0,0.0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0
C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1,0,DB15266,__TAK-580,,Terminated,,MELANOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.15,506.29,135.78,7.0,3.0,3.0,43.95,114.04,6.0,0.0,1.0,0.0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1
Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O,0,DB15291,__BMS-986142,US-20140378475-A1,Terminated,NCT02843659,SJÖGREN'S SYNDROME,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","St Joseph Heritage Healthcare, Fullerton, California, United States|Local Institution, Palo Alto, California, United States|Local Institution, Sarasota, Florida, United States|North Georgia Rheumatology Group, Lawrenceville, Georgia, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Local Institution, Tupelo, Mississippi, United States|Arthritis And Osteoporosis Associates, Pa, Freehold, New Jersey, United States|New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, United States|Local Institution, Mineola, New York, United States|Pmg Research Of Wilmington Llc, Wilmington, North Carolina, United States|Paramount Medical Research & Consulting, Llc, Middleburg Heights, Ohio, United States|Altoona Center For Clinical Research, Duncansville, Pennsylvania, United States|Local Institution, Philadelphia, Pennsylvania, United States|Local Institution, Wexford, Pennsylvania, United States|Acme Research, Llc, Orangeburg, South Carolina, United States|West Tennessee Research Institute, Jackson, Tennessee, United States|Tekton Research Inc, Austin, Texas, United States|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Santiago De Chile, Metropolitana, Chile|Local Institution, Bogota, Cundinamarca, Colombia|Local Institution, Bogota, Colombia|Local Institution, Cali, Colombia|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Local Institution, Mexico City, Distrito Fededral, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Veracruz, Mexico|Local Institution, Cercado De Lima, Lima, Peru|Local Institution, Lima, Peru|Instituto De Ginecologia Y Reproduccion Inv. Clinical Sac, Lima, Peru|Klinika Reumatologii i Chorob Wewnetrznych, Wroclaw, Poland|Local Institution, San Juan, Puerto Rico|Local Institution, Moscow, Russian Federation|Local Institution, Stellenbosch, Western CAPE, South Africa",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,22.505595597445502,2.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.71,572.613,119.73,4.0,3.0,6.0,59.43,155.31,2.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,1,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,1,1,1,1,1,0,0
C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)[nH]n2)c2cccn2n1,0,DB15399,__BMS-754807,8492328,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C12Q1/6886,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,62.2600053389186,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.81,461.4948,116.13,7.0,3.0,6.0,48.1,139.75,6.0,0.0,1.0,0.0,1,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,1
CCCCCc1cccc(CC(=O)O)c1,0,DB15447,__SETOGEPRAM,WO-2010127448-A1,Terminated,,ALSTRÖM SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,32.7488,128.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.84,206.285,37.3,2.0,1.0,1.0,24.07,60.81,6.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0
Cc1cn([C@H]2C[C@H](O)[C@@H](COP(=O)(O)O[C@H]3C[C@H](n4cc(C)c(=O)[nH]c4=O)O[C@@H]3COP(=O)(O)O[C@@H]3[C@@H](COP(=O)(O)O[C@@H]4[C@@H](COP(=O)(O)O[C@@H]5[C@@H](COP(=O)(O)O[C@@H]6[C@@H](COP(=O)(O)O[C@@H]7[C@@H](COP(=O)(O)O[C@@H]8[C@@H](COP(=O)(O)O[C@@H]9[C@@H](COP(=O)(O)O[C@@H]%10[C@@H](COP(=O)(O)O[C@@H]%11[C@@H](COP(=O)(O)O[C@@H]%12[C@@H](COP(=O)(O)O[C@@H]%13[C@@H](COP(=O)(O)O[C@@H]%14[C@@H](COP(=O)(O)O[C@@H]%15[C@@H](COP(=O)(O)O[C@@H]%16[C@@H](COP(=O)(O)O[C@@H]%17[C@@H](COP(=O)(O)O[C@@H]%18[C@@H](COP(=O)(O)O[C@@H]%19[C@@H](COP(=O)(O)O[C@@H]%20[C@@H](COP(=O)(O)O[C@@H]%21[C@@H](CO)O[C@@H](n%22cnc%23c(N)ncnc%23%22)[C@@H]%21O)O[C@@H](n%21ccc(N)nc%21=O)[C@@H]%20O)O[C@@H](n%20ccc(N)nc%20=O)[C@@H]%19O)O[C@@H](n%19ccc(=O)[nH]c%19=O)[C@@H]%18O)O[C@@H](n%18ccc(N)nc%18=O)[C@@H]%17O)O[C@@H](n%17cnc%18c(N)ncnc%18%17)[C@@H]%16O)O[C@@H](n%16ccc(N)nc%16=O)[C@@H]%15O)O[C@@H](n%15ccc(N)nc%15=O)[C@@H]%14O)O[C@@H](n%14cnc%15c(N)ncnc%15%14)[C@@H]%13O)O[C@@H](n%13cnc%14c(N)ncnc%14%13)[C@@H]%12O)O[C@@H](n%12cnc%13c(=O)[nH]c(N)nc%13%12)[C@@H]%11O)O[C@@H](n%11cnc%12c(=O)[nH]c(N)nc%12%11)[C@@H]%10O)O[C@@H](n%10ccc(N)nc%10=O)[C@@H]9O)O[C@@H](n9ccc(N)nc9=O)[C@@H]8O)O[C@@H](n8cnc9c(N)ncnc98)[C@@H]7O)O[C@@H](n7cnc8c(=O)[nH]c(N)nc87)[C@@H]6O)O[C@@H](n6ccc(N)nc6=O)[C@@H]5O)O[C@@H](n5cnc6c(N)ncnc65)[C@@H]4O)O[C@@H](n4ccc(N)nc4=O)[C@@H]3O)O2)c(=O)[nH]c1=O,0,,_BEVASIRANIB,,Terminated,NCT00499590,MACULAR DEGENERATION,All,"50 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Retinal Consultants of Arizona (site 209), Phoenix, Arizona, United States|Associated Retina Consultants (site 286), Phoenix, Arizona, United States|Retina Centers PC (site 215), Tucson, Arizona, United States|Eye Medical Center (site 287), Fresno, California, United States|Northern California Retina Vitreous Associates (site 320), Mountain View, California, United States|Retina Institute of California (site 207), Pasadena, California, United States|Retina Consultants San Diego (site 232), Poway, California, United States|Retinal Consultants Medical Group (site 289), Sacramento, California, United States|Orange County Retina Medical Group (site 252), Santa Ana, California, United States|Miramar Eye Specialists Medical Group (site 245), Ventura, California, United States|The Eye Care Group, PC (site 315), Waterbury, Connecticut, United States|Florida Eye Clinic (site 257), Altamonte Springs, Florida, United States|Florida Eye Microsurgical Institute, Inc. (site 217), Boynton Beach, Florida, United States|Retina Health Center (site 247), Fort Myers, Florida, United States|National Ophthalmic Research Institute at Retina Consultants of SW Florida (site 270), Fort Myers, Florida, United States|Magruder Eye Institute (site 264), Orlando, Florida, United States|Southern Vitreoretinal Associates, PL (site 309), Tallahassee, Florida, United States|University of South Florida Eye Institute (site 311), Tampa, Florida, United States|Center for Retina and Macular Disease (site 293), Winter Haven, Florida, United States|Southeast Retina Center (site 268), Augusta, Georgia, United States|Midwest Eye Institute (site 253), Indianapolis, Indiana, United States|Retina Associates, PA (site 295), Shawnee Mission, Kansas, United States|Vitreo-Retinal Consultants & Surgeons, P.A. (site 274), Wichita, Kansas, United States|Eye Centers of Louisville (site 251), Louisville, Kentucky, United States|Retina Specialists (site 231), Towson, Maryland, United States|Retina Associates St. Louis (site 300), Florissant, Missouri, United States|Eye Foundation of Kansas City Truman Medical Center (site 272), Kansas City, Missouri, United States|Retinal Consultants of Nevada (site 273), Las Vegas, Nevada, United States|Eyesight Ophthalmic Services, PA (site 290), Portsmouth, New Hampshire, United States|Delaware Valley Retina Associates (site 261), Lawrenceville, New Jersey, United States|Retina-Vitreous Consultants (site 216), Livingston, New Jersey, United States|Retina Associates of New Jersey (site 298), Teaneck, New Jersey, United States|Capital Region Retina (site 316), Albany, New York, United States|New York Eye & Ear Infirmary (site 272), New York, New York, United States|Vitreous-Retina-Macula Consultants of New York (site 239), New York, New York, United States|Carolina Eye Associates (site 308), Southern Pines, North Carolina, United States|Retina Associates of Cleveland (site 228), Beachwood, Ohio, United States|Cincinnati Eye Institute (site 285), Cincinnati, Ohio, United States|Retina Associates of Cleveland, Inc. (site 219), Lakewood, Ohio, United States|Retina-Vitreous Associates (site 266), Toledo, Ohio, United States|Retina and Vitreous Center of Southern Oregon (site 271), Ashland, Oregon, United States|Ophthalmology Associates of PA (site 297), Bala Cynwyd, Pennsylvania, United States|Palmetto Retina Center (site 275), West Columbia, South Carolina, United States|Black Hills Regional Eye Institute (site 202), Rapid City, South Dakota, United States|Southeastern Retina Associates, PC (Site 250), Knoxville, Tennessee, United States|Retina Research Institute of Texas, L.L.C. (site 269), Abilene, Texas, United States|Austin Retina Associates (site 304), Austin, Texas, United States|Retina Research Center (site 204), Austin, Texas, United States|University of Texas Medical Branch- Galveston (site 301, Galveston, Texas, United States|Houston Eye Associates (site 321), Houston, Texas, United States|Valley Retina Institue, PA (site 258), McAllen, Texas, United States|Eye Care Associates of East Texas (site 282), Tyler, Texas, United States|Rocky Mountain Retina Consultants (site 256), Salt Lake City, Utah, United States|University of Utah, John A. Moran Eye Center (site 205), Salt Lake City, Utah, United States|University of Virginia- Ophthalmology Dept. (site 254), Charlottesville, Virginia, United States|Calgary Retina Consultants (site 318), Calgary, Alberta, Canada|Ivey Eye Institute (site 314), London, Ontario, Canada|Canadian Centre for Advanced Eye Therapeutics (site 291), Mississauga, Ontario, Canada|Sunnybrook Health Sciences Centre (site 305), Toronto, Ontario, Canada|Eye Centre Pasqua Hospital (site 299), Regina, Saskatchewan, Canada",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,1,1,0,1,1,1,1,0,1,0
Cc1cn([C@H]2C[C@H](O)[C@@H](COP(=O)(O)O[C@H]3C[C@H](n4cc(C)c(=O)[nH]c4=O)O[C@@H]3COP(=O)(O)O[C@@H]3[C@@H](COP(=O)(O)O[C@@H]4[C@@H](COP(=O)(O)O[C@@H]5[C@@H](COP(=O)(O)O[C@@H]6[C@@H](COP(=O)(O)O[C@@H]7[C@@H](COP(=O)(O)O[C@@H]8[C@@H](COP(=O)(O)O[C@@H]9[C@@H](COP(=O)(O)O[C@@H]%10[C@@H](COP(=O)(O)O[C@@H]%11[C@@H](COP(=O)(O)O[C@@H]%12[C@@H](COP(=O)(O)O[C@@H]%13[C@@H](COP(=O)(O)O[C@@H]%14[C@@H](COP(=O)(O)O[C@@H]%15[C@@H](COP(=O)(O)O[C@@H]%16[C@@H](COP(=O)(O)O[C@@H]%17[C@@H](COP(=O)(O)O[C@@H]%18[C@@H](COP(=O)(O)O[C@@H]%19[C@@H](COP(=O)(O)O[C@@H]%20[C@@H](COP(=O)(O)O[C@@H]%21[C@@H](CO)O[C@@H](n%22cnc%23c(N)ncnc%23%22)[C@@H]%21O)O[C@@H](n%21ccc(N)nc%21=O)[C@@H]%20O)O[C@@H](n%20ccc(N)nc%20=O)[C@@H]%19O)O[C@@H](n%19ccc(=O)[nH]c%19=O)[C@@H]%18O)O[C@@H](n%18ccc(N)nc%18=O)[C@@H]%17O)O[C@@H](n%17cnc%18c(N)ncnc%18%17)[C@@H]%16O)O[C@@H](n%16ccc(N)nc%16=O)[C@@H]%15O)O[C@@H](n%15ccc(N)nc%15=O)[C@@H]%14O)O[C@@H](n%14cnc%15c(N)ncnc%15%14)[C@@H]%13O)O[C@@H](n%13cnc%14c(N)ncnc%14%13)[C@@H]%12O)O[C@@H](n%12cnc%13c(=O)[nH]c(N)nc%13%12)[C@@H]%11O)O[C@@H](n%11cnc%12c(=O)[nH]c(N)nc%12%11)[C@@H]%10O)O[C@@H](n%10ccc(N)nc%10=O)[C@@H]9O)O[C@@H](n9ccc(N)nc9=O)[C@@H]8O)O[C@@H](n8cnc9c(N)ncnc98)[C@@H]7O)O[C@@H](n7cnc8c(=O)[nH]c(N)nc87)[C@@H]6O)O[C@@H](n6ccc(N)nc6=O)[C@@H]5O)O[C@@H](n5cnc6c(N)ncnc65)[C@@H]4O)O[C@@H](n4ccc(N)nc4=O)[C@@H]3O)O2)c(=O)[nH]c1=O,0,,_BEVASIRANIB,,Withdrawn,NCT00557791,AGE RELATED MACULAR DEGENERATION,All,"50 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,1,1,0,1,1,1,1,0,1,0
O=S(=O)([O-])CCS.[Na+],0,,_MESNA,,Terminated,NCT00623077,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|KIDNEY CANCER|LIVER CANCER|RETINOBLASTOMA|SARCOMA,All,"up to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])CCS.[Na+],0,,_MESNA,,Withdrawn,NCT03829566,NEUROMYELITIS OPTICA|DEVIC'S DISEASE|NMO SPECTRUM DISORDER,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(=O)O)C[C@H]1NC(=N)N.O.O.O,0,,_PERAMIVIR,,Terminated,NCT00958776,COUGH|SORE THROAT|NASAL CONGESTION|HEADACHE|FEVER|SEASONAL INFLUENZA,All,"12 Years and older   (Child, Adult, Older Adult)",Industry|U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","La Mesa, California, United States|Long Beach, California, United States|Modesto, California, United States|Oceanside, California, United States|Pulmonary Consultants PC Physicians Medical Group, Inc., Orange, California, United States|Orange, California, United States|UC Davis Medical Center, Sacramento, California, United States|Sharp Chula Vista Medical Center, San Diego, California, United States|San Diego, California, United States|Denver, Colorado, United States|Drogue Medical, LLC, Wheat Ridge, Colorado, United States|Washington Hospital Center CAR, Washington, District of Columbia, United States|Washington, District of Columbia, United States|Ft. Lauderdale, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|West Palm Beach, Florida, United States|Florida Hospital, Winter Park, Florida, United States|Columbus, Georgia, United States|DeKalb Medical Center, Decatur, Georgia, United States|Savannah, Georgia, United States|Honolulu, Hawaii, United States|Medical Arts Associates, Ltd., Moline, Illinois, United States|Springfield, Illinois, United States|South Bend, Indiana, United States|Kentucky Lung Clinic, Hazard, Kentucky, United States|Natchitoches, Louisiana, United States|New Orleans, Louisiana, United States|Annapolis, Maryland, United States|Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Wayne State University - Hutzel Hospital, Detroit, Michigan, United States|Wayne State University, Department of Emergency Medicine, Detroit, Michigan, United States|Detroit, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|William Beaumont Hospital, Troy, Michigan, United States|Washington University School of Medicine, St. Louis, Missouri, United States|St. Louis, Missouri, United States|Las Vegas, Nevada, United States|New Brunswick, New Jersey, United States|Bronx, New York, United States|Manhasset, New York, United States|New York, New York, United States|University of North Carolina at Chapel Hill AIDS Clinical Trials Unit, Chapel Hill, North Carolina, United States|Remington-Davis, Inc., Columbus, Ohio, United States|Dayton, Ohio, United States|Kettering, Ohio, United States|Regional Infection Diseases Infusion Center Inc., Lima, Ohio, United States|ID Clinical Research, LTD, Toledo, Ohio, United States|Medical College Of Ohio, Toledo, Ohio, United States|Toledo, Ohio, United States|Allentown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|East Providence, Rhode Island, United States|Charleston, South Carolina, United States|Sioux Falls, South Dakota, United States|San Antonio, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Carilion Infectious Disease, Roanoke, Virginia, United States|VA Medical Center - Salem, Salem, Virginia, United States|Hospital del Torax Dr. Antonio A. Cetrangolo, Buenos Aires, Argentina|Buenos Aires, Argentina|Caba, Argentina|Cordoba, Argentina|Mendoza, Argentina|Merlo, Argentina|Rosario, Argentina|Santa Fe, Argentina|Vicente Lopez, Argentina|Bruxelles, Belgium|Liege, Belgium|Mons, Belgium|Sarajevo, Bosnia and Herzegovina|Tuzla, Bosnia and Herzegovina|Belo Horizonte, MG, Brazil|Curitiba, PR, Brazil|Passo Fundo, RS, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil|Porto Alegre, RS, Brazil|Campinas, SP, Brazil|Santo Andre, SP, Brazil|Santos, SP, Brazil|Sao Paulo, SP, Brazil|Plovdiv, Bulgaria|DDPPDI - Ruse, Ruse, Bulgaria|Fifth MHAT-Sofia, AD, Sofia, Bulgaria|MHAT - Tokuda Hospital Sofia, AD, Sofia, Bulgaria|Military Medical Academy - MHAT, Sofia, Bulgaria|Sofia, Bulgaria|MHAT - Tokuda Hospital Sofia, AD, Stara Zagora, Bulgaria|MHAT 'Dr. St. Cherkezov', AD, Veliko Tarnovo, Bulgaria|Kelowna, British Columbia, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|Kingston, Ontario, Canada|Toronto, Ontario, Canada|Chicoutimi, Quebec, Canada|Sherbrooke, Quebec, Canada|Quebec, Canada|Hospital Clinico Regional Dr. Guillermo Grant Benavente, Concepcion, Chile|Hosp. de Urgencia Asistencia Publica Dr. Alejandro del Rio, Santiago, Chile|Santiago, Chile|Temuco, Chile|Fakultni nemocnice Brno, Brno, Czech Republic|Hradec Kralove, Czech Republic|Praha, Czech Republic|Tabor, Czech Republic|Krajska zdravotni, a.s. - Masarykova nemocnice v Ustinad La, Usti nad Labem, Czech Republic|Berlin, Germany|Erlangen, Germany|Goettingen, Germany|Koeln, Germany|Mainz, Germany|Universitaetsklinikum Regensburg, Regensburg, Germany|Debrecen, Hungary|Fehergyarmat, Hungary|Fejer Megyei Szent Gyorgy Korhaz, Szekesfehervar, Hungary|Principal SMO Dr. Bugyi Istvan Korhaz Szentes, Szentes, Hungary|Zalaegerszeg, Hungary|Hyderabad, Andhra Pradesh, India|Secunderabad, Andhra Pradesh, India|Ahmedabad, Gujarat, India|Karamsad, Gujarat, India|Surat, Gujarat, India|Vadodara, Gujarat, India|Faridabad, Haryana, India|Srinagar, Jammu & Kashmir, India|Bangalore, Karnataka, India|Mangalore, Karnataka, India|Ernakulam, Kerala, India|Thrissur, Kerala, India|Trivandrum, Kerala, India|Cherthala, Maharashtra, India|Mumbai, Maharashtra, India|Nagpur, Maharashtra, India|Nashik, Maharashtra, India|Pune, Maharashtra, India|Mohali, Punjab, India|Bikaner, Rajasthan, India|Fortis Escort Hospital, Jaipur, Rajasthan, India|Apollo First Med Hospitals, Chennai, Tamil Nadu, India|Life Line Multispecialty Hospital, Chennai, Tamil Nadu, India|Chennai, Tamil Nadu, India|Coimbatore, Tamil Nadu, India|Lucknow, Uttar Pradesh, India|Kolkata, West Bengal, India|Delhi, India|Afula, Israel|Haifa, Israel|Holon, Israel|Jerusalem, Israel|Kfar Saba, Israel|Ramat Gan, Israel|Tel Aviv, Israel|Liepaja, Latvia|Rezekne, Latvia|Valmiera, Latvia|Ventspils, Latvia|Beirut, Lebanon|Arequipa, Peru|Cuzco, Peru|Lima, Peru|Bydgoszcz, Poland|Lancut, Poland|Lodz, Poland|Mielec, Poland|Poznan, Poland|Pulawy, Poland|Engels, Russian Federation|Niznhy Novgorod, Russian Federation|Novosibirsk, Russian Federation|St. Petersburg, Russian Federation|Tomsk, Russian Federation|Belgrade, Serbia|Kragujevac, Serbia|Nis, Serbia|Novi Sad, Serbia|Trnava, Slovakia|Middelburg, Mpumalanga, South Africa|Bloemfontein, South Africa|Dundee, South Africa|Durban, South Africa|Krugersdorp, South Africa|Limpopo, South Africa|Port Elizabeth, South Africa|Pretoria, South Africa|Somerset West, South Africa|Worcester, South Africa|Chernivci, Ukraine|Donetsk, Ukraine|Kharkiv, Ukraine|Kyiv, Ukraine|Odesa, Ukraine|Poltava, Ukraine|Sumy, Ukraine|Vinnytsya, Ukraine|Leicester, United Kingdom",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0
OC[C@H]1O[C@@H](O)[C@H](F)[C@@H](O)[C@@H]1O,0,,_FLUDEOXYGLUCOSE,,Terminated,NCT01283178,SALIVARY GLAND SQUAMOUS CELL CARCINOMA|STAGE II SALIVARY GLAND CANCER|STAGE II SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE II SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE II SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE II VERRUCOUS CARCINOMA OF THE ORAL CAVITY|STAGE III SALIVARY GLAND CANCER|STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE III VERRUCOUS CARCINOMA OF THE ORAL CAVITY|STAGE IV SALIVARY GLAND CANCER|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV VERRUCOUS CARCINOMA OF THE ORAL CAVITY,All,"19 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Virginia Commonwealth University, Richmond, Virginia, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O,0,,_FLUDEOXYGLUCOSE_F_18,,Terminated,NCT01283178,SALIVARY GLAND SQUAMOUS CELL CARCINOMA|STAGE II SALIVARY GLAND CANCER|STAGE II SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE II SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE II SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE II VERRUCOUS CARCINOMA OF THE ORAL CAVITY|STAGE III SALIVARY GLAND CANCER|STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE III VERRUCOUS CARCINOMA OF THE ORAL CAVITY|STAGE IV SALIVARY GLAND CANCER|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV VERRUCOUS CARCINOMA OF THE ORAL CAVITY,All,"19 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Virginia Commonwealth University, Richmond, Virginia, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CC1(C)CC(C)(C)CC(C)(N)C1.CS(=O)(=O)O,0,,_NERAMEXANE_MESYLATE,WO-2010118889-A1,Terminated,NCT00799942,"NYSTAGMUS, CONGENITAL|NYSTAGMUS, ACQUIRED|MULTIPLE SCLEROSIS",All,"18 Years to 81 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Leicester, Leicester Royal Infirmary, Ophthalmology Group, Leicester, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,32.7488,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0
CC1(C)CC(C)(C)CC(C)(N)C1.CS(=O)(=O)O,0,,_NERAMEXANE_MESYLATE,WO-2010118889-A1,Terminated,NCT00827008,SUBJECTIVE TINNITUS,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Paradigm Clinical Research, Tucson, Arizona, United States|Providence Clinical Research, Burbank, California, United States|Central California Clinical Research, Fresno, California, United States|UC Davis Health System Department of Otolaryngology, Sacramento, California, United States|Colorado Otolaryngology Associates, Colorado Springs, Colorado, United States|New West Physicians, Golden, Colorado, United States|Visions Clinical Research, Boynton Beach, Florida, United States|Clinical Research of West Florida, Tampa, Florida, United States|Deerpath Physicians Group, Gurnee, Illinois, United States|Knight Center for Integrated Health,, Peoria, Illinois, United States|University of Kansas Department of Otolaryngology Head & Neck Surgery, Kansas City, Kansas, United States|Heartland Research Associates, LLC., Wichita, Kansas, United States|Heartland Research Associates, LLC., Wichita, Kansas, United States|Commonwealth Ear, Nose & Throat, Louisville, Kentucky, United States|Glacier Ear, Nose, and Throat, Head and Neck Surgery, P.C., Kalispell, Montana, United States|Immedicenter, Bloomfield, New Jersey, United States|David L. Bortniker, M.D, FACS, Somerville, New Jersey, United States|Montefiore Medical Center Attn: Anxiety and Depression Center, Bronx, New York, United States|Erie County Medical Center, Department of Rehabilitation Medicine, Buffalo, New York, United States|Cary Medical Research, Cary, North Carolina, United States|Wake Research Associates, LLC, Raleigh, North Carolina, United States|Wilmington Medical Research, Wilmington, North Carolina, United States|Piedmont Medical Research, Winston-Salem, North Carolina, United States|Medical University of South Carolina - Department of Otolaryngology, Department of Otolaryngology - Head & Neck Surgery, Charleston, South Carolina, United States|Future Search Trials of Neurology, Austin, Texas, United States|FutureSearch Trials of Dallas, Dallas, Texas, United States|R/D Clinical Research, Inc., Lake Jackson, Texas, United States|South Texas Research Alliance LLC, Laredo, Texas, United States|Research Across America, Plano, Texas, United States|Advanced Clinical Research, West Jordon, Utah, United States|Health Research of Hampton Roads, Inc., Newport News, Virginia, United States|Krankenhaus der Elisabethinen, Graz, Austria|Bezirkskrankenhaus Kufstein Dr. Christof Pauli (PI: Prim. Dr. Peter Ostertag, Kufstein, Austria|Clin Pharm International GmbH, Zentrum Wien, Vienna, Austria|University Hospital Brussels, Brussels, Belgium|Clinique Universitaire Saint-luc, Bruxelles, Belgium|AZ Sint Lucas, ENT department, Gent, Belgium|University Hospital Leuven, ENT Department, Leuven, Belgium|Consultório Dr. Marcelo Rates, Belo Horizonte/Mimaf Gerais, Brazil|Osmar Clayton Person, Santo André/SP, Brazil|Instituto Ganz Sanchez, São Paulo/SP, Brazil|Clínica OTOSUL, Valenca/RJ, Brazil|Medico, Chodov, Prague, Czech Republic|prof. MUDr. Ivo Šlapák, Brno, Czech Republic|Teaching University Hospital, ORL klinika, Brno, Czech Republic|ORL oddělení, Karlovarská krajská nemocncie a.s., Karlovy Vary, Czech Republic|Oblastní nemocnice Kladno a.s., Nemocnice Středočeského kraje, Kladno, Czech Republic|Pro-audio,s.r.o.-private ENT clinic, Mladá Boleslav, Czech Republic|ORL oddělení, Všeobecná Fakultní Nemocnice v Praze, Praha, Czech Republic|ORL oddělení , Karlovarská krajská nemocnice a. s., Sokolov, Czech Republic|Dr. Ebbo, Issy les moulineaux, France|Dr. Sarfati, La seyne sur Mer, France|Centre Hospitalier de Bretagne Sud Service ORL-B9, Lorient, France|Dr. Bonfils, Paris, France|Dr. Ohresser, Paris, France|Hopital Nord, Saint-etienne, France|Dr. Fraysse, Toulouse cedex, France|Service ORL CHU Bretonneau, Tours, France|Hopital Paul BROUSSE Polyclinique, Villejuif, France|Dr. Kühne, Elisabeth, Halle, Saale, Germany|Dr. med. Norbert Pasch, Aachen, Germany|Charité, Universitätsmedizin Berlin-Tinnituszentrum, Berlin, Germany|Klin. Forschung Berlin Buch GmbH, Berlin, Germany|Dr. med. Frank Reintjes, Braunschweig, Germany|DM Helena Sigal, Chemnitz, Germany|Dr. Klaus Peter Jayme, Darmstadt, Germany|Dr. Christian Dörr, Dresden, Germany|HNO-Praxis im Gesundheitszentrum, Duisburg, Germany|Dr. Gieselmann, Werner, Heiligenhaus, Germany|Dr. Wolfgang Lotte, Iserlohn, Germany|Dr. Dr. med. Hans-Detlev Stahl, Leipzig, Germany|HNO Praxis, Lichtenfels, Germany|Dr. Dannesberger, Lorsch, Germany|ClinPharm International, Magdeburg, Germany|HNO Gemeinschaftpraxis, Meppen, Germany|Martin Canis, MD, Munich, Germany|Dr. Susanne Wiedemann, Nuernberg, Germany|Dr. med. Ulrike Walter, Nürnberg, Germany|Dr. Norbert Staab, Schlüchtern, Germany|Dr. Hannelore Neumaier, Wiesbaden, Germany|Unidad Médica de Especialidades del Noroeste (UMEN), Centro Culiacán Sinaloa, Mexico|Hospital General de Chihuahua. ""Dr. Salvador Anchondo"", Chihuahua C.P. 31000, Mexico|Hospital Christus Muguerza del Parque, Chihuahua CP 3100, Mexico|Internal Medicine Clin Trials (IMED), Col Obispado, Monterrey , N.L. C.P. 64060, Mexico|Hospital Civil de Guadalajara, Col. El Retiro CP 44280 Cuadalajara Jalis, Mexico|Grupo Médico Terranova, CP 44630 Guadalajara Jalisco, Mexico|Clinical Research Instutute S.C., Edo. de México CP 54055, Mexico|Instituto Biomédico de Investigación A.C., Fracc. Bosques del Prado Norte Aguascalientes, Mexico|Unidad de Investigación Clínica Cardiometábolica de Occidente S.C. (UNICAMO), Jalisco, 44150, Mexico|Monterrey International Research Center (MIRC), Nuevo León CP 64000, Mexico|Hospital Universitario Dr. José Eleuterio González. Edificio Elizondo Barragán, Servicio de Otorrinolaringología, Nuevo León CP 64400, Mexico|Hospital Central ""Dr. Ignacio Morones Prieto"" Servicio de Otorrinolaringología, San Luis Potosí, SLP, México, 78240, Mexico|Andromed Zoetermeer, Zoetermeer, EK, Netherlands|Andromed Oost, Velp, ES, Netherlands|Rijnland Ziekenhuis, ENT department, Leiderdorp, GA, Netherlands|Andromed Rotterdam, Rotterdam, HC, Netherlands|Adromed Nijmegen, Nijmegen, HL, Netherlands|Andromed Leiden, Leiderdorp, RA, Netherlands|Andromed Breda, Breda, VL, Netherlands|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Poland|Niepubliczny Zaklad Opieki Zdrowotnej Prywatne Centrum Medyczne PROMEDIS, Gdansk, Poland|Szpital Miejski im. J.Brudzinskiego, Gdynia, Poland|Samodzielny Publiczny Szpital Kliniczny im. Andrzeja Mieleckiego Slaskiego Uniwersytetu Medycznego w Katowicach, Katowice, Poland|NZOZ Specjalistyczne Centrum Medyczne Nowomed, Krakow, Poland|Niepubliczny Zaklad Opieki Zdrowotnej PROMED, Krakow, Poland|Specjalistyczny Gabinet Otolaryngologiczny, Krakow, Poland|Szpital Specjalistyczny im. Stefana Zeromskiego, SP ZOZ w Krakowie, Oddzial Otolaryngologii, Krakow, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi, Lodz, Poland|Wojewodzki Szpital Specjalistyczny im. Stefana Kardynała Wyszynskiego Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Lublin, Poland|Wojewodzki Szpital Specjalistyczny w Olsztynie, Olsztyn, Poland|Instytut Fizjologii i Patologii Sluchu, Warszawa, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 we Wroclawiu, Wroclaw, Poland|Hospital Militar Regional nº 1 Serviço de Otorrinolaringologia, Porto, Portugal|Louis Leipoldt Mediclinic, Bellville, South Africa|Lakeview Hospital, Benoni, South Africa|1007 Louis Pasteur Building, Pretoria, South Africa|GCT Eastmed Clinical Trial centre, Pretoria, South Africa|Constantiaberg Medi Clinic,, Western Cape, South Africa|Prince Alfred House, Wynberg, South Africa|Hospital Sagunto, Sagunto, Valencia, Spain|Fundación Hospital de Alcorcón, Otorhinolaryngology, Alcorcon - Madrid, Spain|Hospital Clínico Barcelona, Dept. Of ORL, Barcelona, Spain|Hospital Puerta del Hierro, Madrid- Servicio de ORL, Madrid, Spain|Hospital Universitario Príncipe de Asturias, Madrid, Spain|Clínica Universitaria de Navarra, Dept. ORL, Pamplona, Navarra, Spain|Hospital Universitario de Salamanca- Hospital Virgen de la Vega, Salamanca, Spain|Oldfield Surgery, Bath, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|Avondale Surgery, Research Office, Chesterfield, United Kingdom|Burbage Surgery, Leicestershire, United Kingdom|The university Hospitals of Leicester, Leicester Royal Infirmary, Leicester, United Kingdom|The Freeman Hospital, Newcastle upon Tyne, United Kingdom|Wansford and Kings Cliffe Practice, Petereborough, United Kingdom|Frome Medical Practice, Somerset, United Kingdom|Sherbourne Medical Centre, Warwickshire, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,32.7488,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0
Cl.Cl.NCCNCCNCCN,0,,_TRIENTINE_HYDROCHLORIDE,5688516,Terminated,NCT01213888,DIABETIC RETINOPATHY,All,"19 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Care Provider)","Eye Care Centre - Vancouver Coastal Health, Vancouver, British Columbia, Canada",A61L29/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,51.0,37.5202776237705,83.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
Cl.Cl.NCCNCCNCCN,0,,_TRIENTINE_HYDROCHLORIDE,5688516,Withdrawn,NCT01295073,MACULAR EDEMA FOLLOWING CATARACT SURGERY,All,"19 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Univeristy of British Columbia/Vancouver Coastal Health Authority - Eye Care Center, Vancouver, British Columbia, Canada",A61L29/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,51.0,37.5202776237705,83.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
C=Cc1c(C)c2cc3nc(c(CC(=O)N[C@@H](CC(=O)[O-])C(=O)[O-])c4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CC)c(C)c4C(=O)[O-])[C@@H](CCC(=O)[O-])[C@@H]3C.[Na+].[Na+].[Na+].[Na+],0,,_TALAPORFIN_SODIUM,,Terminated,NCT00102115,MACULAR DEGENERATION|CHOROIDAL NEOVASCULARIZATION,All,"50 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Texas Retina, Dallas, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0
O.O.O.O.O.O=S([O-])([O-])=S.[Na+].[Na+],0,,_SODIUM_THIOSULFATE,,Terminated,NCT01369641,CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CC[C@H](NCCCNCCCCN)C[C@@H]1C[C@H]3O)OS(=O)(=O)O.C[C@H](O)C(=O)O.O,0,,_SQUALAMINE_LACTATE,,Terminated,NCT00139282,"""WET"" AGE-RELATED MACULAR DEGENERATION",All,"50 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States|Eldorado Retina Associates, Louisville, Colorado, United States|Florida Eye Microsurgical Institute, Boynton Beach, Florida, United States|National Ophthalmic Research Institute, Fort Myers, Florida, United States|University of Florida, Jacksonville, Florida, United States|Magruder Eye Institute, Orlando, Florida, United States|East Florida Eye Institute, Stuart, Florida, United States|Retina Associates of Florida, Tampa, Florida, United States|Center for Retina and Macular Disease, Winter Haven, Florida, United States|Midwest Eye Institute, Indianapolis, Indiana, United States|Retina Associates, PA, Shawnee Mission, Kansas, United States|Cumberland Valley Retina Consultants, PC, Hagerstown, Maryland, United States|Delaware Valley Retina Associates, Lawrenceville, New Jersey, United States|Retina Associates of New Jersey, Teaneck, New Jersey, United States|MaculaCare, New York, New York, United States|Charlotte Eye, Ear, Nose & Throat Associates, Charlotte, North Carolina, United States|Horizon Eye Care, Charlotte, North Carolina, United States|The Ohio State University, Havener Eye Institute, Columbus, Ohio, United States|Penn State Ophthalmology, Hershey, Pennsylvania, United States|Retina Vitreous Consultants, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Genaera Corporation, Plymouth Meeting, Pennsylvania, United States|Carolina Retina Center, Columbia, South Carolina, United States|Black Hills Regional Eye Institute, Rapid City, South Dakota, United States|Southeastern Retina Associates, Kingsport, Tennessee, United States|Retina Research Center, Austin, Texas, United States|Garcia & Associates, MD, PA, Houston, Texas, United States|John Moran Eye Center, Salt Lake City, Utah, United States|Virginia Retina Center, Leesburg, Virginia, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,1,1,0,0,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,0
CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CC[C@H](NCCCNCCCCN)C[C@@H]1C[C@H]3O)OS(=O)(=O)O.C[C@H](O)C(=O)O.O,0,,_SQUALAMINE_LACTATE,,Withdrawn,NCT02511613,AGE-RELATED MACULAR DEGENERATION,All,"50 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Investigational Site, Beverly Hills, California, United States|Investigational Site, Hagerstown, Maryland, United States|Investigational Site, New York, New York, United States|Investigational Site, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,1,1,0,0,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,0
CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CC[C@H](NCCCNCCCCN)C[C@@H]1C[C@H]3O)OS(=O)(=O)O.C[C@H](O)C(=O)O.O,0,,_SQUALAMINE_LACTATE,,Withdrawn,NCT02349516,DIABETIC RETINOPATHY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NJ Retina, New Brunswick, New Jersey, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,1,1,0,0,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,0
CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,0,,_FOSAPREPITANT_DIMEGLUMINE,,Terminated,NCT00895245,NAUSEA AND VOMITING|STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,0,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,1
Cl.O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2,0,,_PALONOSETRON_HYDROCHLORIDE,5202333,Terminated,NCT00895245,NAUSEA AND VOMITING|STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",C07D471/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,50.0,22.7355797860325,44.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0
C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,0,,_FOSAPREPITANT,,Terminated,NCT00895245,NAUSEA AND VOMITING|STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1,1,0,1,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1,0,1
CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[nH]2)C(CCCO)=C4C)C(C)=C3CCCO,0,,_MOTEXAFIN,,Terminated,NCT00080028,HEAD AND NECK CANCER|OROPHARYNX CANCER|LARYNX CANCER|HYPOPHARYNX CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duke University Medical Center, Durham, North Carolina, United States|University of Texas, San Antonio Health Science Center, San Antonio, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,0,,_ERLOTINIB_HYDROCHLORIDE,EP-0817775-B1,Terminated,NCT00573989,HEAD AND NECK CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UNC Linberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,28.0,75.2376845520441,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,0,,_ERLOTINIB_HYDROCHLORIDE,EP-0817775-B1,Terminated,NCT01192815,STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE III VERRUCOUS CARCINOMA OF THE LARYNX|STAGE III VERRUCOUS CARCINOMA OF THE ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV VERRUCOUS CARCINOMA OF THE LARYNX|STAGE IV VERRUCOUS CARCINOMA OF THE ORAL CAVITY,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,28.0,75.2376845520441,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,0,,_ERLOTINIB_HYDROCHLORIDE,EP-0817775-B1,Withdrawn,NCT01332279,RECURRENT METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY|RECURRENT SALIVARY GLAND CANCER|RECURRENT SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|RECURRENT SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|RECURRENT VERRUCOUS CARCINOMA OF THE LARYNX|RECURRENT VERRUCOUS CARCINOMA OF THE ORAL CAVITY|SALIVARY GLAND SQUAMOUS CELL CARCINOMA|TONGUE CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,75.2376845520441,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,0,,_PEMETREXED,WO-2001056575-A1,Terminated,NCT00573989,HEAD AND NECK CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UNC Linberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,20.0,32.7488,392.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)[O-])C(=O)[O-])cc3)c2c(=O)[nH]1.[Na+].[Na+],0,,_PEMETREXED_DISODIUM,WO-2001062760-A2,Terminated,NCT00573989,HEAD AND NECK CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UNC Linberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,11.0,32.7488,6.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Terminated,NCT00482911,INTRAOCULAR MELANOMA|MALIGNANT CONJUNCTIVAL NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Terminated,NCT00006054,IMMUNOLOGIC DEFICIENCY SYNDROMES|CHEDIAK-HIGASHI SYNDROME|COMMON VARIABLE IMMUNODEFICIENCY|GRAFT VERSUS HOST DISEASE|X-LINKED LYMPHOPROLIFERATIVE SYNDROME|FAMILIAL ERYTHROPHAGOCYTIC LYMPHOHISTIOCYTOSIS|HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS|X-LINKED AGAMMAGLOBULINEMIA|WISKOTT-ALDRICH SYNDROME|CHRONIC GRANULOMATOUS DISEASE|X-LINKED HYPER IGM SYNDROME|SEVERE COMBINED IMMUNODEFICIENCY|LEUKOCYTE ADHESION DEFICIENCY SYNDROME|VIRUS-ASSOCIATED HEMOPHAGOCYTIC SYNDROME,All,"up to 35 Years   (Child, Adult)",Other,Primary Purpose: Treatment,"Fairview University Medical Center, Minneapolis, Minnesota, United States",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Terminated,NCT00499733,CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Brady Urological Institute at Johns Hopkins Hospital, Baltimore, Maryland, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Withdrawn,NCT03829566,NEUROMYELITIS OPTICA|DEVIC'S DISEASE|NMO SPECTRUM DISORDER,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Withdrawn,NCT00003273,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|NEUROBLASTOMA|RETINOBLASTOMA|SARCOMA,All,up to 10 Years   (Child),Other,Primary Purpose: Treatment,"Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Maine Children's Cancer Program, Scarborough, Maine, United States|Spectrum Health and DeVos Children's Hospital, Grand Rapids, Michigan, United States|Children's Hospital of Omaha, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Albert Einstein Clinical Cancer Center, Bronx, New York, United States|Winthrop University Hospital, Mineola, New York, United States|NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Beth Israel Hospital North, New York, New York, United States|State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States|State University of New York - Upstate Medical University, Syracuse, New York, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States|Children's Hospital, Buenos Aires, Argentina|British Columbia Children's Hospital, Vancouver, British Columbia, Canada",6,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O,0,,_SUNITINIB_MALATE,EP-2638896-A1,Terminated,NCT00482911,INTRAOCULAR MELANOMA|MALIGNANT CONJUNCTIVAL NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,47.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O,0,,_SUNITINIB_MALATE,EP-2638896-A1,Terminated,NCT00906360,METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY SQUAMOUS CELL CARCINOMA|RECURRENT METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY|RECURRENT SALIVARY GLAND CANCER|RECURRENT SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|RECURRENT SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|RECURRENT VERRUCOUS CARCINOMA OF THE LARYNX|RECURRENT VERRUCOUS CARCINOMA OF THE ORAL CAVITY|SALIVARY GLAND SQUAMOUS CELL CARCINOMA|STAGE III SALIVARY GLAND CANCER|STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|STAGE III VERRUCOUS CARCINOMA OF THE LARYNX|STAGE III VERRUCOUS CARCINOMA OF THE ORAL CAVITY|STAGE IV SALIVARY GLAND CANCER|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|STAGE IV VERRUCOUS CARCINOMA OF THE LARYNX|STAGE IV VERRUCOUS CARCINOMA OF THE ORAL CAVITY|TONGUE CANCER|UNTREATED METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Evanston CCOP-NorthShore University HealthSystem, Evanston, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Fort Wayne Medical Oncology and Hematology Inc - State Boulevard, Fort Wayne, Indiana, United States|University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States|University of Michigan University Hospital, Ann Arbor, Michigan, United States|Saint John's Mercy Medical Center, Saint Louis, Missouri, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,47.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O,0,,_SUNITINIB_MALATE,EP-2638896-A1,Terminated,NCT00673816,VON HIPPEL-LINDAU SYNDROME,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,47.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,0,,_VINCRISTINE,3932417,Terminated,NCT02116959,ADVANCED INTRA-OCULAR RETINOBLASTOMA|RETINOBLASTOMA,All,"3 Months to 18 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, San Francisco, San Francisco, California, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,0,,_VINCRISTINE,3932417,Terminated,NCT00072384,INTRAOCULAR RETINOBLASTOMA,All,up to 17 Years   (Child),Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Oncology Group, Arcadia, California, United States|Southern California Permanente Medical Group, Downey, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Yale University, New Haven, Connecticut, United States|Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|University of Illinois, Chicago, Illinois, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Baylor College of Medicine, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,0,,_VINCRISTINE,3932417,Withdrawn,NCT00003273,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|NEUROBLASTOMA|RETINOBLASTOMA|SARCOMA,All,up to 10 Years   (Child),Other,Primary Purpose: Treatment,"Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Maine Children's Cancer Program, Scarborough, Maine, United States|Spectrum Health and DeVos Children's Hospital, Grand Rapids, Michigan, United States|Children's Hospital of Omaha, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Albert Einstein Clinical Cancer Center, Bronx, New York, United States|Winthrop University Hospital, Mineola, New York, United States|NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Beth Israel Hospital North, New York, New York, United States|State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States|State University of New York - Upstate Medical University, Syracuse, New York, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States|Children's Hospital, Buenos Aires, Argentina|British Columbia Children's Hospital, Vancouver, British Columbia, Canada",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,0,,_VINCRISTINE,3932417,Withdrawn,NCT00980551,RETINOBLASTOMA,All,up to 10 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Terminated,NCT00072384,INTRAOCULAR RETINOBLASTOMA,All,up to 17 Years   (Child),Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Oncology Group, Arcadia, California, United States|Southern California Permanente Medical Group, Downey, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Yale University, New Haven, Connecticut, United States|Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|University of Illinois, Chicago, Illinois, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Baylor College of Medicine, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Withdrawn,NCT00003273,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|NEUROBLASTOMA|RETINOBLASTOMA|SARCOMA,All,up to 10 Years   (Child),Other,Primary Purpose: Treatment,"Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Maine Children's Cancer Program, Scarborough, Maine, United States|Spectrum Health and DeVos Children's Hospital, Grand Rapids, Michigan, United States|Children's Hospital of Omaha, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Albert Einstein Clinical Cancer Center, Bronx, New York, United States|Winthrop University Hospital, Mineola, New York, United States|NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Beth Israel Hospital North, New York, New York, United States|State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States|State University of New York - Upstate Medical University, Syracuse, New York, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States|Children's Hospital, Buenos Aires, Argentina|British Columbia Children's Hospital, Vancouver, British Columbia, Canada",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC(=O)O.C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,0,,_OCTREOTIDE_ACETATE,,Terminated,NCT00248157,DIABETIC RETINOPATHY,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,1,1,0,0
NC(=O)C[S+]([O-])C(c1ccccc1)c1ccccc1,0,,_MODAFINIL,,Terminated,NCT00591019,TINNITUS,All,"20 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Masking: Single (Participant)|Primary Purpose: Treatment,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC.Cl,0,,_VERAPAMIL_HYDROCHLORIDE,4753802,Terminated,NCT03102190,SINUSITIS|NASAL POLYPS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts Eye and Ear, Boston, Massachusetts, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,27.3352635577732,466.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OP(=O)(O)O,0,,_ETOPOSIDE_PHOSPHATE,,Terminated,NCT02137096,RECURRENT NASOPHARYNX CARCINOMA,All,"2 Years to 30 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UF Health Shands Hospital, Gainesville, Florida, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,0,,_CHLORPHENIRAMINE_MALEATE,4256763,Terminated,NCT02722083,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Germantown, Tennessee, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,29.897944516314503,544.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0
CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccc3ccccc3c2)CSSC[C@@H](C(=O)N[C@H](C(N)=O)[C@@H](C)O)NC1=O,0,,_LANREOTIDE,,Terminated,NCT00288522,THYROID-ASSOCIATED OPHTHALMOPATHY,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Hospital General d'Alacant, Alicante, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,0,1,0,1,0,0
Nc1ccc2cc3ccc(N)cc3nc2c1.Nc1ccc2cc3ccc(N)cc3nc2c1.O=S(=O)(O)O,0,,_PROFLAVINE_HEMISULFATE,,Terminated,NCT01456143,SQUAMOUS CELL CARCINOMA|NEOPLASIA|HEAD AND NECK CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)[nH]c(N)nc21,0,,_VALGANCICLOVIR,,Terminated,NCT02606266,CONGENITAL CYTOMEGALOVIRUS (CMV),All,6 Months to 12 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Robert Debré Hospital, Paris, France",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,1,0
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)[nH]c(N)nc21,0,,_VALGANCICLOVIR,,Terminated,NCT01655212,CONGENITAL CYTOMEGALOVIRUS INFECTION|SENSORINEURAL HEARING LOSS,All,up to 12 Weeks   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Department Medical Microbiology, Leiden University Medical Center, Leiden, Zuid Holland, Netherlands",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,1,0
Cl.N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,0,,_MELPHALAN_HYDROCHLORIDE,4997651,Terminated,NCT01293539,RETINOBLASTOMA,All,"up to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Johns Hopkins Hospital, Baltimore, Maryland, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,27.4995379781925,71.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0
NC(=O)C[S@@+]([O-])C(c1ccccc1)c1ccccc1,0,,_ARMODAFINIL,,Terminated,NCT01219673,HEAD AND NECK CANCER,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","UT MD Anderson Cancer Center, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,0,,_LOSARTAN,,Terminated,NCT00467831,HERMANSKY-PUDLAK SYNDROME (HPS)|PULMONARY FIBROSIS|OCULOCUTANEOUS ALBINISM|PLATELET STORAGE POOL DEFICIENCY|METABOLIC DISEASE,All,"18 Years to 70 Years   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
O=C(O)O,0,,_BICARBONATE,,Terminated,NCT01066741,OROPHARYNX CANCER|HYPOPHARYNX CANCER,All,"18 Years to 85 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,"Centre Léon Bérard, Lyon, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C(O)O,0,,_BICARBONATE,,Withdrawn,NCT01471925,GASTROESOPHAGEAL REFLUX,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Instituto Goiano de Gastroenterologia, Goiania, GO, Brazil|Mãe de Deus Center, Porto Alegre, Rio Grande do Sul, Brazil|Centro de pesquisa Clínica do Serviço de gastroenterologia, Rio de janeiro, RJ, Brazil|Hospital Israelita Albert Einstein, São Paulo, SP, Brazil|Centro de Pesquisa Clínica de Campinas, Canpinas, São Paulo, Brazil|Centro de Estudos Clínicos do Interior Paulista, Jaú, São Paulo, Brazil",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl,0,,_OXYMETAZOLINE_HYDROCHLORIDE,4603131,Terminated,NCT00584662,CHRONIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","USF, Tampa, Florida, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,51.0893447504055,258.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,0,,_SILDENAFIL_CITRATE,WO-1999030688-A1,Terminated,NCT01830790,AGE-RELATED MACULAR DEGENERATION,All,65 Years and older   (Older Adult),Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Duke Eye Center, Durham, North Carolina, United States",A61K9/19,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,45.0,32.7488,208.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,1,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0
C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12.C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12.O.O.O=S(=O)(O)O,0,,_QUININE_SULFATE,,Terminated,NCT02630472,RHINITIS|SINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0
Nc1ccn([C@H]2C[C@H](O)[C@@H](COP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)O2)c(=O)n1.[Na+].[Na+].[Na+].[Na+],0,,_DENUFOSOL_TETRASODIUM,,Terminated,NCT00083967,RETINAL DETACHMENT,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Retina Center, P.C., Tucson, Arizona, United States|Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States|Retina Vitreous Associates Medical Group, Los Angeles, California, United States|Retina Consultants San Diego, Poway, California, United States|Danbury Eye Physicians & Surgeons, P.C., Danbury, Connecticut, United States|Retina Group of Florida, Ft. Lauderdale, Florida, United States|Central Florida Retina, Orlando, Florida, United States|The University of Chicago, Chicago, Illinois, United States|Illinois Retina Associates, S.C., Joliet, Illinois, United States|Midwest Eye Institute, Indianapolis, Indiana, United States|University of Kentucky, The Kentucky Clinic, Lexington, Kentucky, United States|Maine Vitreoretinal Consultants, Bangor, Maine, United States|National Retina Institute, Chevy Chase, Maryland, United States|New England Eye Center, Boston, Massachusetts, United States|Kresge Eye Institute/Hutzel Hospital, Detroit, Michigan, United States|Retina Associates, Kansas City, Missouri, United States|Retina Associates of NJ, Millburn, New Jersey, United States|Retina Associates of NJ, Teaneck, New Jersey, United States|Retina Associates of NJ, Wayne, New Jersey, United States|NY Eye and Ear Infirmary, New York, New York, United States|Carolina Eye Associates, Southern Pines, North Carolina, United States|Retina Associates of Cleveland, Beachwood, Ohio, United States|Retina Assocites of Cleveland, Inc., Cleveland, Ohio, United States|Cleveland Clinical Foundation, Cleveland, Ohio, United States|Retina Associates of Cleveland, Lakewood, Ohio, United States|Retina Associates of Cleveland, Lorain, Ohio, United States|Retina Associates of Cleveland, Middleburg Heights, Ohio, United States|Scheie Eye Institute, Philadelphia, Pennsylvania, United States|Austin Retina, Austin, Texas, United States|Vitreoretinal Consultants, Houston, Texas, United States|Wagner Mandell Retina Center, Norfolk, Virginia, United States|Wagner Mandell Retina Center, Virginia Beach, Virginia, United States|Medical College of Wisconsin/The Eye Institute, Milwaukee, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0
Nc1ccn([C@H]2C[C@H](O)[C@@H](COP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)O2)c(=O)n1.[Na+].[Na+].[Na+].[Na+],0,,_DENUFOSOL_TETRASODIUM,,Terminated,NCT00114062,CYSTOID MACULAR EDEMA|UVEITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0
Nc1ccn([C@H]2C[C@H](O)[C@@H](COP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)O2)c(=O)n1.[Na+].[Na+].[Na+].[Na+],0,,_DENUFOSOL_TETRASODIUM,,Withdrawn,NCT00135655,"MACULAR EDEMA, CYSTOID",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0
CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(=N)N)[C@@H](C)CC)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O,0,,_PENETRATIN,,Terminated,NCT01579643,CORNEAL OPACITY,All,"1 Month to 18 Years   (Child, Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital of Los Angeles, Los Angeles, California, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,1,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,0,1,1,1,1,0,0,1,1,0
CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(=N)N)[C@@H](C)CC)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O,0,,_PENETRATIN,,Terminated,NCT02116062,KERATITIS|PTERYGIUM|CORNEAL OPACITY CORNEAL THINNING|CORNEAL PERFORATION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpitaux Universitaires de Strasbourg, Strasbourg, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,1,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,0,1,1,1,1,0,0,1,1,0
O=C([O-])c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)[O-])cc(=O)c34)cccc2o1.[Na+].[Na+],0,,_CROMOLYN_SODIUM,4161516,Terminated,NCT01841307,GASTROESOPHAGEAL REFLUX|RESPIRATORY ASPIRATION|IDIOPATHIC PULMONARY FIBROSIS|LUNG TRANSPLANTATION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"UCSF Airway Clinical Research Center, San Francisco, California, United States",A61K9/1688,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,30.0293640526499,1596.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0
CN[C@]1(C)[C@@H]2CC[C@@H](C2)C1(C)C,0,,_MECAMYLAMINE,4168308,Terminated,NCT00414206,MACULAR DEGENERATION,All,"50 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Hospital de Olhos de Araraquara, Araraquara, Brazil|Centro Brasileiro de Ciências Visuais, Belo Horizonte, Brazil|Instituto da Visão, Belo Horizonte, Brazil|Centro Brasileiro de Cirurgia dos Olhos, Goiânia, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil|Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil|Clínica de Olhos Dr. Suel Abujamra, São Paulo, Brazil|Hospital das Clínicas Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil|Hospital de Olhos de São Paulo, São Paulo, Brazil|Hospital São Paulo - Setor de Pesquisa Clínica, São Paulo, Brazil|University Hospital Brno, Department of Ophthalmology, Brno, Czech Republic|Eye Clinic University Hospital, Hradec Kralove, Czech Republic|Ophthalmology Nemocnice Litomysl, Litomyšl, Czech Republic|University Hospital Olomouc, Department of Ophthalmology, Olomouc, Czech Republic|Faculty Hospital Kralovske Vinohrady, Dept. of Ophthalmology, Prague, Czech Republic|Cornea Lexum Praha, Praha, Czech Republic|Cif Biotec, CP, Mexico|Hospital Conde de Valenciana, CP, Mexico|Fundación Hospital ""Nuestra Sra de la Luz"" I.A.P., Delegación Cuauhtémoc, Mexico|Asociación Para Evitar la Ceguera, Mexico City, Mexico|Hospital General de México, Mexico City, Mexico|Hospital San José Tec de Monterrey, Monterrey, Mexico|Klinika Chorób Oczu, Gdansk, Poland|Oddział Okulistyczny Okręgowy Szpital Kolejowy, Katowice, Poland|Klinika Okulistyczna, Lodz, Poland|Oddział Okulistyki, Samodzielny Publiczny Szpital Kliniczny Nr 1 Przemienienia Pańskiego AM w Poznaniu, Poznań, Poland|Katedra i Klinika Okulistyki, Samodzielny Publiczny Kliniczny Szpital Okulistyczny, Warsaw, Poland|Katedra i Klinika Okulistyki, Akademia Medyczna we Wrocławiu, Wrocław, Poland|Republican Ophthalmologic Hospital of MH of Republic of Tatarstan, Kazan, Russian Federation|IRTC ""Eye Microsurgery"" n. a. S.N. Fyodorov, Moscow, Russian Federation|Moscow Scientific Research Institute of Eye Diseases, Moscow, Russian Federation|CJSC ""Inter Yuna"", Rostov-on Don, Russian Federation|City Consultative Diagnostic Centre # 1 (St. Petersburg), St. Petersburg, Russian Federation|IRTC ""Eye Microsurgery"" n. a. S.N. Fyodorov, St. Petersburg, Russian Federation|Military Medical Academy n.a. S.M.Kirov of Ministry of Defence, St. Petersburg, Russian Federation|St. Petersburg State Medical University n. a. Pavlov, St. Petersburg, Russian Federation|Kyiv City Centre of Eye Vascular and Endocrine Diseases of Organ of Vision, Kyiv, Ukraine|Kyiv City Ophthalmologic Hospital ""Eye Microsurgery Centre"", Kyiv, Ukraine|Kyiv City Ophthalmologic Hospital, Kyiv, Ukraine|V.P. Filatov Institute of Eye Diseases and Tissue Pathology of AMS of Ukraine, Odessa, Ukraine|Zaporizhzhya Center of Vision Rehabilitation, Odessa, Ukraine|S.I. Georgiyevsky Crimean State Medical University, Simferopol, Ukraine",A61K9/1075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,21.8156430316844,250.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0
OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O,0,,_GALACTOSE,3933788,Terminated,NCT00427986,DIABETIC MACULAR OEDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Ophthalmology, Glostrup Hospital, University of Copenhagen, Nordre Ringvej 57,, Glostrup, Denmark",C12P21/005,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,30.817881270662603,12433.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
c1ccc2c(c1)-c1nc-2nc2[nH]c(nc3nc(nc4[nH]c(n1)c1ccccc41)-c1ccccc1-3)c1ccccc21,0,,_PHTHALOCYANINE,3931097,Terminated,NCT00023790,BREAST CANCER|HEAD AND NECK CANCER|LYMPHOMA|METASTATIC CANCER|NON-MELANOMATOUS SKIN CANCER|SARCOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",C08F255/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,13.0762438653771,6019.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0
O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O=S(=O)(OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O)O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O,0,,_SUCRALFATE,,Withdrawn,NCT02039869,GASTROESOPHAGEAL REFLUX DISEASE|NON EROSIVE REFLUX DISEASE|DYSPEPSIA,All,"18 Years to 79 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,"Ochsner Medical Center, Kenner, Louisiana, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Virginia Commonwealth University, Richmond, Virginia, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)[CH]CC2=O)C(C)C)cc1)C(C)C,0,,_VEDOTIN,,Withdrawn,NCT03326258,ADVANCED MALIGNANT SOLID NEOPLASM|ESTROGEN RECEPTOR NEGATIVE|GPNMB POSITIVE|HER2/NEU NEGATIVE|METASTATIC MALIGNANT SOLID NEOPLASM|METASTATIC MELANOMA|PROGESTERONE RECEPTOR NEGATIVE|STAGE III BREAST CANCER AJCC V7|STAGE III CUTANEOUS MELANOMA AJCC V7|STAGE III UVEAL MELANOMA AJCC V7|STAGE IIIA CUTANEOUS MELANOMA AJCC V7|STAGE IIIB CUTANEOUS MELANOMA AJCC V7|STAGE IIIC CUTANEOUS MELANOMA AJCC V7|STAGE IV BREAST CANCER AJCC V6 AND V7|STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7|STAGE IV UVEAL MELANOMA AJCC V7|TRIPLE-NEGATIVE BREAST CARCINOMA|UNRESECTABLE SOLID NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,1,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,0,1,1,1,1,1,0,1
CC(C)CCON=O.CCC(C)CON=O,0,,_AMYL_NITRITE,,Withdrawn,NCT02428959,DYSPHAGIA|ACHALASIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Johns Hopkins Hospital, Baltimore, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1.O=C(O)/C=C\C(=O)O,0,,_CEDIRANIB_MALEATE,EP-1699782-B1,Withdrawn,NCT04184518,UVEAL MELANOMA|METASTATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Instituto Catalá d'Oncología L'Hospitalet, L'Hospitalet De Llobregat, Barcelona, Spain|H. U. Virgen de la Victoria, Málaga, Spain|Clínica Universidad de Navarra, Pamplona, Spain|H.U. Virgen Macarena, Sevilla, Spain|Hospital General Universitario de Valencia, Valencia, Spain",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,66.1368816608144,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1
CCN(CC)CC(=O)Nc1c(C)cccc1C.Cl,0,,_LIDOCAINE_HYDROCHLORIDE,4091090,Withdrawn,NCT02955524,HEMODYNAMIC INSTABILITY,All,"8 Weeks and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,17.380233680363,1165.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
NC(N)=Nc1nc(CSCC/C(N)=N/S(N)(=O)=O)cs1,0,,_FAMOTIDINE,,Withdrawn,NCT02700087,LARYNGOMALACIA|ACID REFLUX|STRIDOR,All,up to 4 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)OC(C)OC(C)=O)=C(COC(N)=O)CS[C@H]12)c1ccco1,0,,_CEFUROXIME_AXETIL,,Withdrawn,NCT00000752,HIV INFECTIONS|SINUSITIS,All,"12 Years and older   (Child, Adult, Older Adult)",NIH|Industry,Masking: Double|Primary Purpose: Treatment,"Univ of California / San Diego Treatment Ctr, San Diego, California, United States|Stanford at Kaiser / Kaiser Permanente Med Ctr, San Francisco, California, United States|Montefiore Drug Treatment Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Family Health Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Samaritan Village Inc / Bronx Municipal Hosp, Bronx, New York, United States|Jack Weiler Hosp / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Med Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Med Ctr Adolescent AIDS Program, Bronx, New York, United States|North Central Bronx Hosp / Bronx Municipal Hosp, Bronx, New York, United States|Thomas Jefferson Univ Hosp, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1
CN[C@@H](C)[C@@H](O)c1ccccc1.Cl,0,,_PSEUDOEPHEDRINE_HYDROCHLORIDE,4181719,Withdrawn,NCT00000752,HIV INFECTIONS|SINUSITIS,All,"12 Years and older   (Child, Adult, Older Adult)",NIH|Industry,Masking: Double|Primary Purpose: Treatment,"Univ of California / San Diego Treatment Ctr, San Diego, California, United States|Stanford at Kaiser / Kaiser Permanente Med Ctr, San Francisco, California, United States|Montefiore Drug Treatment Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Family Health Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Samaritan Village Inc / Bronx Municipal Hosp, Bronx, New York, United States|Jack Weiler Hosp / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Med Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Med Ctr Adolescent AIDS Program, Bronx, New York, United States|North Central Bronx Hosp / Bronx Municipal Hosp, Bronx, New York, United States|Thomas Jefferson Univ Hosp, Philadelphia, Pennsylvania, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,19.220107189059306,39.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN[C@@H](C)[C@@H](O)c1ccccc1.Cl,0,,_PSEUDOEPHEDRINE_HYDROCHLORIDE,4181719,Withdrawn,NCT01177852,INFLAMMATION|COUGH|RHINITIS,All,2 Years to 12 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,19.220107189059306,39.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
Nc1nc(=O)c2c([nH]1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O,0,,_LEUCOVORIN,4148999,Withdrawn,NCT00003273,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|NEUROBLASTOMA|RETINOBLASTOMA|SARCOMA,All,up to 10 Years   (Child),Other,Primary Purpose: Treatment,"Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Maine Children's Cancer Program, Scarborough, Maine, United States|Spectrum Health and DeVos Children's Hospital, Grand Rapids, Michigan, United States|Children's Hospital of Omaha, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Albert Einstein Clinical Cancer Center, Bronx, New York, United States|Winthrop University Hospital, Mineola, New York, United States|NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Beth Israel Hospital North, New York, New York, United States|State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States|State University of New York - Upstate Medical University, Syracuse, New York, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States|Children's Hospital, Buenos Aires, Argentina|British Columbia Children's Hospital, Vancouver, British Columbia, Canada",C07D487/14,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,1,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1
Nc1nc(O)c2c(n1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc1)N2C=O.[Ca+2],0,,_LEUCOVORIN_CALCIUM,4500711,Withdrawn,NCT00003273,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|NEUROBLASTOMA|RETINOBLASTOMA|SARCOMA,All,up to 10 Years   (Child),Other,Primary Purpose: Treatment,"Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Maine Children's Cancer Program, Scarborough, Maine, United States|Spectrum Health and DeVos Children's Hospital, Grand Rapids, Michigan, United States|Children's Hospital of Omaha, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Albert Einstein Clinical Cancer Center, Bronx, New York, United States|Winthrop University Hospital, Mineola, New York, United States|NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Beth Israel Hospital North, New York, New York, United States|State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States|State University of New York - Upstate Medical University, Syracuse, New York, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States|Children's Hospital, Buenos Aires, Argentina|British Columbia Children's Hospital, Vancouver, British Columbia, Canada",C07D475/04,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,49.93942380747029,299.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1
N=S(=O)(O)Cc1noc2ccccc12,0,,_ZONISAMIDE,4172896,Withdrawn,NCT02049073,NOISE-INDUCED HEARING LOSS,All,18 Years to 30 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Washington University School of Medicine, Saint Louis, Missouri, United States",C07D261/20,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,16.8217006509373,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1.Cl,0,,_TOPOTECAN_HYDROCHLORIDE,5962216,Withdrawn,NCT00980551,RETINOBLASTOMA,All,up to 10 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",A61K49/0021,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,43.0,30.1279287049015,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
COc1cc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(O)c(OC)c2)ccc1O,0,,_CURCUMIN,WO-2002069910-A2,Withdrawn,NCT00248053,FAMILIAL ADENOMATOUS POLYPOSIS,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),,A61K8/315,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,32.7488,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0
CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0,,_IMATINIB_MESYLATE,WO-2002018368-A1,Withdrawn,NCT00403156,CHOROIDAL NEOVASCULARIZATION,All,"51 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vitreous Retina Macula Consultants of New York, P.C., New York, New York, United States",A61P35/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,59.0,32.7488,558.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1
CN(C)CCC(c1ccc(Br)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,0,,_BROMPHENIRAMINE_MALEATE,4269835,Withdrawn,NCT01177852,INFLAMMATION|COUGH|RHINITIS,All,2 Years to 12 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,17.4130885644469,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,1,0,1,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1,0,,_BLEOMYCIN,WO-1994008564-A1,Withdrawn,NCT00198328,HEAD NECK CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Inovio Biomedical Corporation, San Diego, California, United States",A61K9/1075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,32.7488,22.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
O.OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,0,,_LACTULOSE,WO-2005016898-A2,Withdrawn,NCT00732108,MIGRAINE|HEADACHE|DIZZINESS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of California, San Francisco, San Francisco, California, United States",A61P25/00 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0
CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1,0,,_SULINDAC,4207340,Withdrawn,NCT01245816,FAMILIAL ADENOMATOUS POLYPOSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,17.7416374052855,1478.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
Oc1cccc(-c2c3nc(c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4nc2CC4)C=C3)c1,0,,_TEMOPORFIN,,Withdrawn,NCT01718223,RECURRENT SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|RECURRENT SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|RECURRENT VERRUCOUS CARCINOMA OF THE ORAL CAVITY|STAGE I SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE I SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE I VERRUCOUS CARCINOMA OF THE ORAL CAVITY|STAGE II SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE II SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE II VERRUCOUS CARCINOMA OF THE ORAL CAVITY|TONGUE CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0
C[C@H]1CCN(C(=O)CC#N)C[C@H]1N(C)c1ncnc2[nH]ccc12,0,,_TASOCITINIB,,Withdrawn,NCT01226680,KERATOCONJUNCTIVITIS SICCA,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O.O,0,,_CARBIDOPA,WO-1999004765-A2,Withdrawn,NCT02873351,AGE-RELATED MACULAR DEGENERATION,All,"50 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Robert W Snyder, MD, PhD, PC, Tucson, Arizona, United States",A61K9/0007,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,32.7488,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0
